Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific nTPM" "RNA single cell type specificity" "RNA single cell type distribution" "RNA single cell type specificity score" "RNA single cell type specific nTPM" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific nTPM" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific nTPM" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific nTPM" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific nTPM" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific nTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific nTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "CCD Protein" "CCD Transcript" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Blood expression cluster" "Tissue expression cluster" "Cell line expression cluster" "Single cell expression cluster" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [nTPM]" "Tissue RNA - adrenal gland [nTPM]" "Tissue RNA - amygdala [nTPM]" "Tissue RNA - appendix [nTPM]" "Tissue RNA - basal ganglia [nTPM]" "Tissue RNA - bone marrow [nTPM]" "Tissue RNA - breast [nTPM]" "Tissue RNA - cerebellum [nTPM]" "Tissue RNA - cerebral cortex [nTPM]" "Tissue RNA - cervix [nTPM]" "Tissue RNA - choroid plexus [nTPM]" "Tissue RNA - colon [nTPM]" "Tissue RNA - duodenum [nTPM]" "Tissue RNA - endometrium 1 [nTPM]" "Tissue RNA - epididymis [nTPM]" "Tissue RNA - esophagus [nTPM]" "Tissue RNA - fallopian tube [nTPM]" "Tissue RNA - gallbladder [nTPM]" "Tissue RNA - heart muscle [nTPM]" "Tissue RNA - hippocampal formation [nTPM]" "Tissue RNA - hypothalamus [nTPM]" "Tissue RNA - kidney [nTPM]" "Tissue RNA - liver [nTPM]" "Tissue RNA - lung [nTPM]" "Tissue RNA - lymph node [nTPM]" "Tissue RNA - medulla oblongata [nTPM]" "Tissue RNA - midbrain [nTPM]" "Tissue RNA - ovary [nTPM]" "Tissue RNA - pancreas [nTPM]" "Tissue RNA - parathyroid gland [nTPM]" "Tissue RNA - pituitary gland [nTPM]" "Tissue RNA - placenta [nTPM]" "Tissue RNA - pons [nTPM]" "Tissue RNA - prostate [nTPM]" "Tissue RNA - rectum [nTPM]" "Tissue RNA - retina [nTPM]" "Tissue RNA - salivary gland [nTPM]" "Tissue RNA - seminal vesicle [nTPM]" "Tissue RNA - skeletal muscle [nTPM]" "Tissue RNA - skin 1 [nTPM]" "Tissue RNA - small intestine [nTPM]" "Tissue RNA - smooth muscle [nTPM]" "Tissue RNA - spinal cord [nTPM]" "Tissue RNA - spleen [nTPM]" "Tissue RNA - stomach 1 [nTPM]" "Tissue RNA - testis [nTPM]" "Tissue RNA - thalamus [nTPM]" "Tissue RNA - thymus [nTPM]" "Tissue RNA - thyroid gland [nTPM]" "Tissue RNA - tongue [nTPM]" "Tissue RNA - tonsil [nTPM]" "Tissue RNA - urinary bladder [nTPM]" "Tissue RNA - vagina [nTPM]" "Tissue RNA - white matter [nTPM]" "Cell RNA - A-431 [nTPM]" "Cell RNA - A549 [nTPM]" "Cell RNA - AF22 [nTPM]" "Cell RNA - AN3-CA [nTPM]" "Cell RNA - ASC diff [nTPM]" "Cell RNA - ASC TERT1 [nTPM]" "Cell RNA - BEWO [nTPM]" "Cell RNA - BJ [nTPM]" "Cell RNA - BJ hTERT+ [nTPM]" "Cell RNA - BJ hTERT+ SV40 Large T+ [nTPM]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [nTPM]" "Cell RNA - CACO-2 [nTPM]" "Cell RNA - CAPAN-2 [nTPM]" "Cell RNA - Daudi [nTPM]" "Cell RNA - EFO-21 [nTPM]" "Cell RNA - fHDF/TERT166 [nTPM]" "Cell RNA - GAMG [nTPM]" "Cell RNA - HaCaT [nTPM]" "Cell RNA - HAP1 [nTPM]" "Cell RNA - HBEC3-KT [nTPM]" "Cell RNA - HBF TERT88 [nTPM]" "Cell RNA - HDLM-2 [nTPM]" "Cell RNA - HEK 293 [nTPM]" "Cell RNA - HEL [nTPM]" "Cell RNA - HeLa [nTPM]" "Cell RNA - Hep G2 [nTPM]" "Cell RNA - HHSteC [nTPM]" "Cell RNA - HL-60 [nTPM]" "Cell RNA - HMC-1 [nTPM]" "Cell RNA - HSkMC [nTPM]" "Cell RNA - hTCEpi [nTPM]" "Cell RNA - hTEC/SVTERT24-B [nTPM]" "Cell RNA - hTERT-HME1 [nTPM]" "Cell RNA - hTERT-RPE1 [nTPM]" "Cell RNA - HUVEC TERT2 [nTPM]" "Cell RNA - JURKAT [nTPM]" "Cell RNA - K-562 [nTPM]" "Cell RNA - Karpas-707 [nTPM]" "Cell RNA - LHCN-M2 [nTPM]" "Cell RNA - MCF7 [nTPM]" "Cell RNA - MOLT-4 [nTPM]" "Cell RNA - NB-4 [nTPM]" "Cell RNA - NTERA-2 [nTPM]" "Cell RNA - OE19 [nTPM]" "Cell RNA - PC-3 [nTPM]" "Cell RNA - REH [nTPM]" "Cell RNA - RH-30 [nTPM]" "Cell RNA - RPMI-8226 [nTPM]" "Cell RNA - RPTEC TERT1 [nTPM]" "Cell RNA - RT4 [nTPM]" "Cell RNA - SCLC-21H [nTPM]" "Cell RNA - SH-SY5Y [nTPM]" "Cell RNA - SiHa [nTPM]" "Cell RNA - SK-BR-3 [nTPM]" "Cell RNA - SK-MEL-30 [nTPM]" "Cell RNA - SuSa [nTPM]" "Cell RNA - T-47d [nTPM]" "Cell RNA - THP-1 [nTPM]" "Cell RNA - TIME [nTPM]" "Cell RNA - U-138 MG [nTPM]" "Cell RNA - U-2 OS [nTPM]" "Cell RNA - U-2197 [nTPM]" "Cell RNA - U-251 MG [nTPM]" "Cell RNA - U-266/70 [nTPM]" "Cell RNA - U-266/84 [nTPM]" "Cell RNA - U-698 [nTPM]" "Cell RNA - U-87 MG [nTPM]" "Cell RNA - U-937 [nTPM]" "Cell RNA - WM-115 [nTPM]" "Blood RNA - basophil [nTPM]" "Blood RNA - classical monocyte [nTPM]" "Blood RNA - eosinophil [nTPM]" "Blood RNA - gdT-cell [nTPM]" "Blood RNA - intermediate monocyte [nTPM]" "Blood RNA - MAIT T-cell [nTPM]" "Blood RNA - memory B-cell [nTPM]" "Blood RNA - memory CD4 T-cell [nTPM]" "Blood RNA - memory CD8 T-cell [nTPM]" "Blood RNA - myeloid DC [nTPM]" "Blood RNA - naive B-cell [nTPM]" "Blood RNA - naive CD4 T-cell [nTPM]" "Blood RNA - naive CD8 T-cell [nTPM]" "Blood RNA - neutrophil [nTPM]" "Blood RNA - NK-cell [nTPM]" "Blood RNA - non-classical monocyte [nTPM]" "Blood RNA - plasmacytoid DC [nTPM]" "Blood RNA - T-reg [nTPM]" "Blood RNA - total PBMC [nTPM]" "Brain RNA - amygdala [nTPM]" "Brain RNA - basal ganglia [nTPM]" "Brain RNA - cerebellum [nTPM]" "Brain RNA - cerebral cortex [nTPM]" "Brain RNA - hippocampal formation [nTPM]" "Brain RNA - hypothalamus [nTPM]" "Brain RNA - medulla oblongata [nTPM]" "Brain RNA - midbrain [nTPM]" "Brain RNA - pons [nTPM]" "Brain RNA - spinal cord [nTPM]" "Brain RNA - thalamus [nTPM]" "Brain RNA - white matter [nTPM]" "Single Cell Type RNA - Adipocytes [nTPM]" "Single Cell Type RNA - Alveolar cells type 1 [nTPM]" "Single Cell Type RNA - Alveolar cells type 2 [nTPM]" "Single Cell Type RNA - Astrocytes [nTPM]" "Single Cell Type RNA - B-cells [nTPM]" "Single Cell Type RNA - Basal keratinocytes [nTPM]" "Single Cell Type RNA - Basal prostatic cells [nTPM]" "Single Cell Type RNA - Basal respiratory cells [nTPM]" "Single Cell Type RNA - Basal squamous epithelial cells [nTPM]" "Single Cell Type RNA - Bipolar cells [nTPM]" "Single Cell Type RNA - Breast glandular cells [nTPM]" "Single Cell Type RNA - Breast myoepithelial cells [nTPM]" "Single Cell Type RNA - Cardiomyocytes [nTPM]" "Single Cell Type RNA - Cholangiocytes [nTPM]" "Single Cell Type RNA - Club cells [nTPM]" "Single Cell Type RNA - Collecting duct cells [nTPM]" "Single Cell Type RNA - Cone photoreceptor cells [nTPM]" "Single Cell Type RNA - Cytotrophoblasts [nTPM]" "Single Cell Type RNA - dendritic cells [nTPM]" "Single Cell Type RNA - Distal enterocytes [nTPM]" "Single Cell Type RNA - Distal tubular cells [nTPM]" "Single Cell Type RNA - Ductal cells [nTPM]" "Single Cell Type RNA - Early spermatids [nTPM]" "Single Cell Type RNA - Endometrial ciliated cells [nTPM]" "Single Cell Type RNA - Endometrial stromal cells [nTPM]" "Single Cell Type RNA - Endothelial cells [nTPM]" "Single Cell Type RNA - Enteroendocrine cells [nTPM]" "Single Cell Type RNA - Erythroid cells [nTPM]" "Single Cell Type RNA - Excitatory neurons [nTPM]" "Single Cell Type RNA - Exocrine glandular cells [nTPM]" "Single Cell Type RNA - Extravillous trophoblasts [nTPM]" "Single Cell Type RNA - Fibroblasts [nTPM]" "Single Cell Type RNA - Gastric mucus-secreting cells [nTPM]" "Single Cell Type RNA - Glandular and luminal cells [nTPM]" "Single Cell Type RNA - granulocytes [nTPM]" "Single Cell Type RNA - Granulosa cells [nTPM]" "Single Cell Type RNA - Hepatic stellate cells [nTPM]" "Single Cell Type RNA - Hepatocytes [nTPM]" "Single Cell Type RNA - Hofbauer cells [nTPM]" "Single Cell Type RNA - Horizontal cells [nTPM]" "Single Cell Type RNA - Inhibitory neurons [nTPM]" "Single Cell Type RNA - Intestinal goblet cells [nTPM]" "Single Cell Type RNA - Ionocytes [nTPM]" "Single Cell Type RNA - Kupffer cells [nTPM]" "Single Cell Type RNA - Langerhans cells [nTPM]" "Single Cell Type RNA - Late spermatids [nTPM]" "Single Cell Type RNA - Leydig cells [nTPM]" "Single Cell Type RNA - Macrophages [nTPM]" "Single Cell Type RNA - Melanocytes [nTPM]" "Single Cell Type RNA - Microglial cells [nTPM]" "Single Cell Type RNA - monocytes [nTPM]" "Single Cell Type RNA - Muller glia cells [nTPM]" "Single Cell Type RNA - NK-cells [nTPM]" "Single Cell Type RNA - Oligodendrocyte precursor cells [nTPM]" "Single Cell Type RNA - Oligodendrocytes [nTPM]" "Single Cell Type RNA - Pancreatic endocrine cells [nTPM]" "Single Cell Type RNA - Paneth cells [nTPM]" "Single Cell Type RNA - Peritubular cells [nTPM]" "Single Cell Type RNA - Plasma cells [nTPM]" "Single Cell Type RNA - Prostatic glandular cells [nTPM]" "Single Cell Type RNA - Proximal enterocytes [nTPM]" "Single Cell Type RNA - Proximal tubular cells [nTPM]" "Single Cell Type RNA - Respiratory ciliated cells [nTPM]" "Single Cell Type RNA - Rod photoreceptor cells [nTPM]" "Single Cell Type RNA - Sertoli cells [nTPM]" "Single Cell Type RNA - Skeletal myocytes [nTPM]" "Single Cell Type RNA - Smooth muscle cells [nTPM]" "Single Cell Type RNA - Spermatocytes [nTPM]" "Single Cell Type RNA - Spermatogonia [nTPM]" "Single Cell Type RNA - Squamous epithelial cells [nTPM]" "Single Cell Type RNA - Suprabasal keratinocytes [nTPM]" "Single Cell Type RNA - Syncytiotrophoblasts [nTPM]" "Single Cell Type RNA - T-cells [nTPM]" "Single Cell Type RNA - Theca cells [nTPM]" "Single Cell Type RNA - Undifferentiated cells [nTPM]" "Single Cell Type RNA - Urothelial cells [nTPM]" ACTB ENSG00000075624 "Actin beta" P60709 7 5526409-5563902 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Deafness, Disease variant, Dystonia, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "monocytes: 22882.9;Pancreatic endocrine cells: 14370.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002621, HPA041264, HPA041271" Supported NA NA 5800000000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 17: WM-115 - Nervous system development" "Cluster 3: Monocytes - Immune response regulation" "CAB002621: , HPA041264: AB_2677383, HPA041271: AB_2677386" "unprognostic (1.66e-1)" "unprognostic (1.15e-1)" "unprognostic (4.20e-2)" "unprognostic (1.15e-2)" "unprognostic (1.01e-2)" "prognostic unfavorable (4.51e-4)" "unprognostic (9.80e-3)" "unprognostic (1.57e-3)" "unprognostic (1.73e-1)" "unprognostic (5.99e-2)" "unprognostic (3.33e-2)" "unprognostic (3.77e-1)" "prognostic unfavorable (3.78e-5)" "unprognostic (2.68e-2)" "unprognostic (3.20e-1)" "unprognostic (1.50e-1)" "unprognostic (4.88e-3)" 2558.1 1235.8 2143.2 4250.8 2321.0 3598.4 2009.8 2400.1 2776.1 2274.6 2183.3 6581.2 1659.0 5033.9 1630.3 2928.9 2943.6 1772.1 817.6 2355.6 2315.8 1313.6 1759.9 2876.0 4394.2 2654.8 2338.9 1711.5 761.9 838.5 731.4 1817.2 2569.2 2027.1 2338.4 488.2 1470.2 2943.2 465.1 1541.7 2825.9 5736.8 2457.9 3009.5 2869.7 558.3 2483.4 3278.4 1317.9 524.0 4602.3 3720.8 2223.5 3045.4 7791.1 5198.8 5604.1 4658.2 2321.1 3120.3 6654.3 6049.6 4853.2 6209.7 4619.4 8249.5 4361.9 4522.7 4557.0 9445.4 4904.8 4820.3 3279.5 9453.9 4507.4 5324.6 1668.7 3974.3 4579.6 4520.6 3538.8 4733.2 9853.8 4098.5 2786.7 6863.0 1738.0 4128.6 5073.2 3561.3 2189.7 3513.0 6603.4 7531.9 4055.1 13162.1 6813.7 2468.5 3490.8 5658.6 3351.4 3419.7 5904.6 3175.8 1633.1 2746.9 5754.7 5822.1 2400.3 5088.3 5859.7 5314.8 7975.3 10437.4 7019.9 7000.1 8802.8 1902.3 2442.5 5082.1 5772.0 6622.6 12412.7 14674.1 18104.2 29636.6 10647.1 19648.6 8327.7 5139.6 7639.4 9512.9 19292.5 4844.1 5592.0 7894.3 18040.6 6233.1 22870.8 7122.2 11463.2 37406.8 2143.2 2321.0 2400.1 2776.1 2355.6 2315.8 2654.8 2338.9 2569.2 2457.9 2483.4 3045.4 2775.4 1150.6 680.4 142.4 4118.9 5737.0 9776.6 5792.0 3110.2 146.7 1564.0 2047.2 145.3 1080.9 2763.3 2144.5 85.5 3647.7 3989.3 3419.3 2277.4 6508.8 101.3 1422.1 2344.0 2768.4 1451.5 3170.9 129.3 6365.4 12480.2 2958.5 3136.1 2041.6 1539.9 2372.0 2163.5 2590.6 13977.7 269.2 101.3 2006.7 3694.5 7392.0 11420.0 199.7 1766.7 8486.4 2995.4 259.5 22882.9 1654.4 5237.9 116.1 302.2 14370.0 2899.8 2680.3 3040.4 4764.9 4968.2 2149.2 1453.8 146.7 3287.0 1398.2 5423.9 133.8 381.9 4376.1 4722.2 3257.7 5961.7 1688.9 1966.6 6941.4 ADA ADA1 ENSG00000196839 "Adenosine deaminase" P00813 20 44619522-44652233 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Nucleotide metabolism" Hydrolase "Disease variant, FDA approved drug targets, Hereditary hemolytic anemia, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "intestine: 507.2;lymphoid tissue: 259.0" "Cell type enhanced" "Detected in many" "dendritic cells: 76.4;Extravillous trophoblasts: 128.2;NK-cells: 56.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "intermediate monocyte: 168.5;NK-cell: 94.5;non-classical monocyte: 362.8;plasmacytoid DC: 218.6" "Group enriched" "Detected in all" 4 "dendritic cells: 218.6;monocytes: 362.8;NK-cells: 94.5" "Group enriched" "Detected in many" 5 "JURKAT: 570.9;MOLT-4: 1915.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001399, CAB004307, HPA023884" Enhanced Supported "Plasma membrane,Cytosol" No No 470000 "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 9: Intestine - Unknown function" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 38: Extravillous trophoblasts - Unknown function" "Plasma membrane" Cytosol "CAB004307: AB_626634, HPA001399: AB_1078099, HPA023884: AB_1844573" "unprognostic (4.30e-2)" "unprognostic (6.89e-2)" "unprognostic (3.96e-2)" "prognostic unfavorable (1.23e-7)" "unprognostic (9.33e-2)" "unprognostic (9.07e-3)" "prognostic unfavorable (6.77e-5)" "prognostic unfavorable (2.20e-4)" "unprognostic (1.59e-1)" "unprognostic (2.16e-1)" "unprognostic (3.66e-2)" "unprognostic (3.48e-1)" "prognostic unfavorable (2.94e-14)" "unprognostic (2.29e-1)" "unprognostic (1.04e-2)" "unprognostic (1.53e-1)" "unprognostic (1.82e-1)" 16.6 6.3 6.9 18.5 8.2 20.2 10.9 6.8 9.4 7.3 5.6 5.7 507.2 3.8 1.7 9.0 5.6 9.2 17.8 6.9 7.0 3.3 4.4 6.2 33.4 7.2 8.2 2.1 5.3 1.5 1.3 4.6 7.2 4.3 3.6 0.3 4.7 2.8 5.3 6.0 17.9 5.7 6.1 17.5 46.0 2.4 8.7 259.0 5.8 6.4 26.4 9.3 5.4 8.8 14.0 37.7 19.2 13.2 35.6 48.7 30.5 13.7 7.8 13.2 9.3 17.5 14.8 38.4 15.8 17.9 24.7 2.2 13.2 55.1 7.3 2.9 17.2 7.8 6.6 13.5 15.0 6.3 20.3 234.3 23.2 5.1 9.0 12.6 50.3 570.9 20.4 30.7 6.0 33.1 1915.5 28.9 5.2 17.2 13.5 102.3 25.8 95.0 2.3 0.0 0.7 9.3 20.2 4.4 24.2 24.0 4.5 19.1 16.9 10.1 18.6 20.5 2.8 40.1 27.3 82.3 3.5 32.5 9.0 0.5 9.8 1.2 43.3 168.5 27.8 7.5 35.5 51.0 35.2 7.6 27.3 38.6 2.5 94.5 362.8 218.6 29.8 57.4 6.9 8.2 6.8 9.4 6.9 7.0 7.2 8.2 7.2 6.1 8.7 8.8 18.2 0.0 1.9 2.9 13.5 12.9 3.4 10.0 13.6 0.0 2.7 3.2 2.1 0.0 4.8 1.8 0.0 2.9 76.4 0.8 0.0 3.7 0.4 0.7 9.1 17.0 0.0 10.7 0.2 19.7 128.2 19.7 14.8 0.8 0.0 3.5 7.1 3.6 28.5 0.0 0.2 1.5 10.2 20.8 25.5 1.8 42.3 27.6 8.8 3.7 37.4 3.8 56.7 0.5 9.4 10.7 0.3 2.6 31.4 6.0 0.7 3.0 2.4 0.0 13.1 1.9 14.1 0.3 6.2 12.9 13.9 3.7 30.9 6.8 4.9 2.7 AICDA "AID, ARP2, CDA2, HIGM2" ENSG00000111732 "Activation induced cytidine deaminase" Q9GZX7 12 8602170-8612867 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins" "mRNA processing" Hydrolase "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "lymphoid tissue: 15.4" "Cell type enhanced" "Detected in single" "Proximal enterocytes: 2.6" "Cancer enhanced" "Detected in single" "testis cancer: 0.8" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 5 "memory B-cell: 1.9;naive B-cell: 3.8" "Lineage enriched" "Detected in single" 6 "B-cells: 3.8" "Group enriched" "Detected in some" 7 "Daudi: 142.5;U-698: 118.4" "Not detected" "Not detected" "Low region specificity" "Detected in some" NA NA "Cluster 19: B-cells - Humoral immune response" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 50: Fibroblasts - ECM organization" "unprognostic (2.71e-2)" "unprognostic (1.39e-2)" "unprognostic (7.76e-2)" "unprognostic (1.68e-1)" "unprognostic (8.73e-3)" "unprognostic (1.11e-1)" "unprognostic (4.05e-2)" "unprognostic (9.69e-2)" "unprognostic (1.96e-2)" "unprognostic (4.04e-6)" "unprognostic (8.82e-2)" "unprognostic (1.28e-1)" "unprognostic (4.21e-1)" "unprognostic (4.65e-1)" 0.2 0.1 0.4 3.7 0.3 0.6 0.0 1.2 0.6 0.0 0.1 0.2 0.2 0.2 0.2 0.2 0.0 0.5 0.3 0.3 0.1 0.0 0.1 0.2 15.4 0.2 0.3 0.0 0.1 0.0 0.0 0.3 0.3 0.0 0.1 0.2 0.3 0.0 1.4 0.3 0.8 0.0 0.0 0.7 0.2 0.2 0.3 0.4 0.2 0.0 12.0 0.1 0.1 0.6 0.1 0.0 0.1 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 142.5 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 5.3 0.2 0.1 0.0 2.0 19.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.2 0.2 0.0 0.2 0.2 0.5 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.1 1.3 0.1 0.1 0.6 0.1 0.4 0.5 0.1 0.0 0.1 118.4 0.0 0.3 0.1 0.5 0.2 0.1 0.1 0.1 0.0 1.9 0.1 0.0 0.1 3.8 0.1 0.1 0.6 0.1 0.1 0.2 0.1 0.2 0.4 0.3 1.2 0.6 0.3 0.1 0.2 0.3 0.3 0.0 0.3 0.6 0.2 0.0 0.6 0.0 0.9 0.3 0.6 0.0 0.0 0.4 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.9 0.0 0.6 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.8 0.1 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 2.6 0.2 0.0 0.7 0.0 0.8 0.1 0.0 0.4 0.0 0.1 0.0 0.3 0.0 0.1 0.3 AIRE "APECED, APS1, PGA1" ENSG00000160224 "Autoimmune regulator" O43918 21 44285838-44298648 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 1.6;lymphoid tissue: 1.3" "Cell type enhanced" "Detected in some" "Cardiomyocytes: 3.1;Excitatory neurons: 1.1;Microglial cells: 1.9" "Cancer enriched" "Detected in single" 14 "testis cancer: 6.7" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" NA NA "Cluster 37: B-cells - Transcription" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 54: Cardiomyocytes - Muscle contraction" "unprognostic (3.24e-2)" "unprognostic (2.37e-2)" "unprognostic (1.77e-2)" "unprognostic (1.56e-1)" "unprognostic (1.86e-2)" "unprognostic (2.47e-2)" "unprognostic (2.68e-1)" "unprognostic (1.37e-2)" "unprognostic (1.43e-1)" "unprognostic (8.53e-3)" "unprognostic (3.69e-3)" "unprognostic (1.79e-1)" "unprognostic (6.29e-7)" "unprognostic (5.04e-2)" "unprognostic (3.18e-1)" "unprognostic (2.27e-1)" "unprognostic (3.57e-2)" 0.0 0.0 0.9 0.1 0.5 0.1 0.1 0.5 0.9 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.6 0.1 0.0 0.0 0.2 0.8 0.9 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.2 0.0 0.1 0.0 0.3 0.1 0.0 0.5 0.0 0.0 0.0 1.5 1.3 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.9 0.5 0.5 0.9 0.6 1.6 0.8 0.9 0.7 0.5 1.5 0.6 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.5 0.1 0.0 0.0 1.1 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.4 0.1 0.1 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 1.9 0.7 0.2 0.0 0.5 0.1 0.0 0.0 0.4 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.3 0.1 0.0 0.2 0.0 AK2 ENSG00000004455 "Adenylate kinase 2" P54819 1 33007940-33080996 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Kinase, Transferase" "Disease variant, SCID" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Proximal tubular cells: 440.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018479, CAB079913" Approved Approved Mitochondria NA NA 1100000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 8: Non-specific - Mitochondria" "Cluster 32: U-937 - Innate immune response" "Cluster 67: Proximal tubular cells - Tubular reabsorption" Mitochondria "CAB079913: AB_2546087, HPA018479: AB_1844676" "prognostic favorable (4.37e-4)" "unprognostic (3.25e-2)" "unprognostic (2.80e-2)" "prognostic unfavorable (8.65e-4)" "unprognostic (3.16e-2)" "unprognostic (8.21e-2)" "prognostic unfavorable (9.32e-4)" "unprognostic (7.86e-3)" "unprognostic (1.85e-2)" "unprognostic (1.28e-1)" "prognostic unfavorable (6.40e-4)" "unprognostic (4.95e-2)" "unprognostic (8.33e-3)" "unprognostic (9.56e-3)" "unprognostic (2.71e-1)" "unprognostic (1.40e-1)" "unprognostic (5.40e-3)" 85.3 88.6 39.9 76.9 45.0 74.3 80.4 44.1 49.0 79.6 49.8 117.2 140.0 58.6 52.1 108.5 65.3 49.0 114.1 38.8 43.8 181.6 172.9 59.3 73.3 48.5 42.8 59.9 78.9 123.6 49.4 68.4 50.4 63.2 114.0 51.0 81.1 55.5 154.2 74.4 139.4 68.1 44.0 57.2 92.7 54.8 44.3 85.9 86.6 122.9 113.4 84.2 76.9 49.3 339.1 153.4 131.6 149.7 94.9 116.6 132.8 185.0 143.5 267.7 280.2 283.2 311.9 602.1 218.4 139.8 204.2 235.4 312.5 327.0 276.6 261.6 229.3 396.2 270.0 219.9 218.2 712.5 222.2 118.1 238.2 232.7 471.2 163.3 190.2 245.7 436.9 230.4 165.0 174.2 273.0 392.8 181.2 337.4 222.4 314.7 222.2 415.6 286.2 205.1 190.8 114.8 205.4 235.0 584.8 151.4 194.5 517.2 138.9 165.5 194.3 259.4 357.5 238.0 324.7 565.7 232.4 664.6 195.5 49.2 158.8 198.0 77.1 145.5 81.8 122.3 72.7 74.0 195.8 105.8 72.9 67.9 42.1 115.3 130.4 154.2 96.8 188.1 39.9 45.0 44.1 49.0 38.8 43.8 48.5 42.8 50.4 44.0 44.3 49.3 60.5 51.3 79.0 19.6 44.0 125.2 101.4 228.1 63.7 21.1 66.5 72.6 106.9 71.4 142.8 112.2 83.4 158.0 37.0 109.6 256.3 120.2 108.3 50.0 42.1 70.7 50.4 50.9 16.2 123.7 164.6 58.0 66.3 47.0 40.0 38.8 41.4 135.5 96.1 8.4 19.7 84.7 89.5 44.8 60.1 42.8 46.9 48.4 87.2 12.2 67.3 22.1 48.4 14.1 22.0 110.5 67.2 44.0 55.7 109.0 236.9 440.0 67.0 41.8 52.6 34.1 108.4 91.0 31.6 88.6 122.7 216.6 40.7 72.2 122.6 120.5 ATM "ATA, ATC, ATD, ATDC, TEL1, TELO1" ENSG00000149311 "ATM serine/threonine kinase" Q13315 11 108222832-108369102 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle, DNA damage" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease variant, Neurodegeneration, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cone photoreceptor cells: 210.6;NK-cells: 339.8;Oligodendrocytes: 217.6;Rod photoreceptor cells: 200.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 78.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000102, HPA067142" Supported Supported Nucleoplasm,Vesicles NA NA "Cluster 44: Non-specific - Transcription" "Cluster 20: Retina & Lymphoid tissues - Unknown function" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" Nucleoplasm Vesicles "CAB000102: , HPA067142: AB_2685789" "unprognostic (9.77e-2)" "unprognostic (1.47e-1)" "unprognostic (3.04e-1)" "unprognostic (2.36e-1)" "unprognostic (5.70e-2)" "unprognostic (2.86e-2)" "unprognostic (6.32e-3)" "unprognostic (1.05e-1)" "unprognostic (8.19e-2)" "unprognostic (1.63e-1)" "unprognostic (7.68e-2)" "unprognostic (6.16e-2)" "unprognostic (2.17e-3)" "unprognostic (3.10e-1)" "unprognostic (7.87e-2)" "unprognostic (1.21e-1)" "unprognostic (2.81e-1)" 6.2 7.4 8.2 17.5 15.0 16.2 8.5 17.0 12.3 8.7 16.1 6.7 5.2 10.0 9.9 4.0 7.5 8.2 7.0 7.3 11.3 5.8 7.8 7.6 33.7 15.8 13.1 15.8 14.8 9.3 12.1 8.0 17.0 6.3 7.0 20.6 11.4 6.1 4.4 7.5 12.6 6.9 10.3 22.2 8.6 5.2 12.7 18.2 8.8 6.0 25.9 7.1 6.9 28.8 4.3 6.8 14.8 7.6 20.2 29.1 3.1 10.9 13.5 6.4 11.3 7.1 10.3 18.3 14.0 10.2 9.6 7.7 11.6 10.8 9.0 12.3 5.7 15.2 8.7 10.2 10.5 16.4 17.0 18.3 6.3 10.0 21.2 15.2 14.1 16.5 12.4 9.9 14.3 3.4 10.6 18.5 9.8 8.6 7.4 9.7 9.7 24.9 8.1 7.5 9.0 10.5 11.1 4.7 20.6 13.2 9.3 10.1 23.7 15.8 8.4 7.3 9.0 6.2 7.0 78.3 7.0 19.0 18.8 21.3 5.5 4.0 16.5 5.7 11.1 11.6 11.7 12.5 2.6 13.0 21.1 20.4 9.9 9.7 13.3 6.2 6.1 5.3 8.2 15.0 17.0 12.3 7.3 11.3 15.8 13.1 17.0 10.3 12.7 28.8 23.7 38.5 20.8 62.7 146.4 12.6 17.5 21.1 28.5 111.0 19.6 14.2 39.9 12.8 19.5 22.0 210.6 16.9 140.2 4.2 5.9 9.9 19.2 14.4 52.1 25.9 20.4 39.1 70.2 12.3 13.2 39.0 12.8 20.9 13.3 45.9 32.9 23.3 29.1 60.6 82.8 14.9 26.4 96.4 34.0 5.1 39.4 69.2 26.6 178.9 63.2 27.3 339.8 85.5 217.6 7.6 7.6 27.8 96.5 9.1 8.9 11.1 16.0 200.1 26.3 41.4 29.2 31.5 37.4 15.8 12.4 4.2 147.7 52.3 11.5 10.2 BCL10 "c-E10, CARMEN, CIPER, CLAP, mE10" ENSG00000142867 "BCL10 immune signaling adaptor" O95999 1 85265776-85276632 "Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins" "Adaptive immunity, Apoptosis, Immunity, Innate immunity" "Cancer-related genes, Disease variant, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 194.1;Paneth cells: 210.2;Urothelial cells: 297.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HUVEC TERT2: 97.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001944, HPA017925" Approved NA NA "Cluster 34: Basophils - Unknown function" "Cluster 37: Intestine - Unknown function" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 22: Epithelial cell types - Mixed function" "CAB001944: , HPA017925: AB_1845312" "unprognostic (3.78e-3)" "unprognostic (2.53e-1)" "prognostic favorable (2.51e-4)" "unprognostic (1.61e-1)" "unprognostic (3.47e-1)" "unprognostic (2.61e-2)" "prognostic unfavorable (7.21e-7)" "unprognostic (7.06e-2)" "unprognostic (2.36e-1)" "unprognostic (9.46e-2)" "unprognostic (1.27e-2)" "unprognostic (1.73e-1)" "unprognostic (4.92e-3)" "unprognostic (3.18e-2)" "unprognostic (1.06e-1)" "unprognostic (1.63e-1)" "unprognostic (1.07e-1)" 10.1 7.4 4.3 13.8 4.6 24.3 10.6 5.3 6.8 14.7 6.0 26.7 14.7 8.1 7.9 18.1 9.0 18.9 5.5 5.3 4.4 8.7 9.8 9.2 13.7 4.8 4.6 7.2 8.9 6.2 2.6 9.3 4.4 7.8 23.5 2.7 8.5 5.1 6.7 9.4 16.5 11.8 4.7 11.6 14.9 6.5 5.8 9.4 9.0 5.7 16.4 23.1 11.3 5.5 38.5 7.6 11.6 11.8 13.7 23.7 16.9 26.8 27.6 20.9 27.8 8.1 14.5 14.5 19.1 22.5 39.3 19.6 12.8 32.4 28.7 14.8 8.2 16.9 6.5 11.9 24.0 16.7 15.4 18.6 31.7 31.4 25.6 24.5 97.9 10.0 11.7 14.1 33.2 6.8 16.4 13.5 19.0 22.1 25.0 12.2 21.8 9.8 71.2 29.2 6.3 8.5 8.2 28.6 23.2 14.8 9.6 10.2 47.3 19.0 13.2 24.1 27.5 11.7 6.5 16.6 9.9 13.1 14.7 78.4 34.1 48.2 20.8 41.8 23.5 46.7 27.0 24.4 33.7 41.4 24.7 23.5 85.0 24.6 33.1 26.3 31.1 22.9 4.3 4.6 5.3 6.8 5.3 4.4 4.8 4.6 4.4 4.7 5.8 5.5 40.6 22.4 18.1 3.3 49.6 194.1 167.2 75.4 48.3 5.7 29.2 19.8 4.6 17.2 54.9 23.9 0.0 16.0 24.1 174.3 17.6 71.5 85.1 97.7 36.1 48.2 49.0 9.1 8.8 44.7 28.4 24.9 57.1 152.2 39.3 17.9 28.2 19.8 21.2 10.1 6.1 79.7 38.7 31.8 68.8 13.4 11.1 41.7 16.0 2.8 21.7 11.1 11.3 9.5 6.1 74.1 210.2 11.3 25.0 80.0 45.2 25.4 32.9 6.3 0.0 19.9 21.8 9.7 12.9 76.7 171.3 23.7 31.3 21.5 77.2 297.4 BLM "BS, RECQ2, RECQL3" ENSG00000197299 "BLM RecQ like helicase" P54132 15 90717346-90816166 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease variant, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "bone marrow: 5.7;lymphoid tissue: 7.9;salivary gland: 7.8" "Cell type enhanced" "Detected in many" "Erythroid cells: 18.3;Oligodendrocyte precursor cells: 58.3;Plasma cells: 20.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005689 Approved Supported Nucleoplasm,Cytosol NA NA "Cluster 46: Basophils - DNA binding" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Nucleoplasm Cytosol "HPA005689: AB_1845372" "unprognostic (2.77e-1)" "unprognostic (3.82e-3)" "unprognostic (4.03e-2)" "unprognostic (2.98e-2)" "unprognostic (4.75e-2)" "unprognostic (9.89e-2)" "unprognostic (6.12e-5)" "unprognostic (2.82e-2)" "unprognostic (4.55e-3)" "unprognostic (5.24e-3)" "unprognostic (1.80e-3)" "unprognostic (9.12e-2)" "unprognostic (1.55e-15)" "unprognostic (6.53e-3)" "unprognostic (6.55e-2)" "unprognostic (2.43e-1)" "unprognostic (1.83e-2)" 0.3 0.2 0.9 3.6 1.1 5.7 0.5 2.3 0.9 0.1 0.3 1.4 1.0 0.4 0.4 0.6 0.3 0.3 0.3 0.8 1.1 0.1 0.1 0.4 6.4 1.2 1.4 0.1 0.2 0.0 0.6 1.2 1.1 0.1 1.7 2.4 7.8 0.0 0.5 0.4 1.6 0.4 1.0 1.6 1.1 2.2 0.9 7.9 0.3 0.1 6.2 1.0 0.2 1.0 13.0 14.4 20.4 12.6 0.1 0.9 14.6 9.4 3.2 11.1 13.4 11.7 10.1 35.1 5.9 2.6 14.1 20.4 25.7 7.1 15.1 19.1 20.5 36.4 14.8 3.9 0.0 33.7 17.3 0.3 0.1 10.6 4.7 1.3 7.9 16.9 32.7 9.9 11.0 7.4 28.3 14.5 22.2 24.9 4.2 25.4 39.1 14.7 2.3 18.9 14.6 14.7 8.5 11.5 4.8 18.1 7.2 23.4 3.7 8.6 13.6 9.6 21.0 6.4 30.4 39.5 5.6 25.8 15.7 1.7 0.6 2.6 1.6 0.8 2.6 4.6 1.4 2.1 0.7 2.3 1.0 1.1 0.7 3.1 1.0 0.7 3.2 0.9 0.9 1.1 2.3 0.9 0.8 1.1 1.2 1.4 1.1 1.0 0.9 1.0 0.9 3.2 8.9 1.0 12.9 0.3 0.5 0.5 0.6 3.6 1.3 1.0 7.9 0.0 4.2 0.0 2.1 5.5 6.9 2.2 1.9 1.0 2.7 1.3 1.3 2.0 0.0 18.3 0.7 0.7 6.8 1.8 3.6 1.7 13.3 8.1 2.2 0.6 5.7 0.0 8.6 1.3 0.0 7.7 1.3 1.6 0.0 7.7 0.0 7.5 2.7 1.7 10.3 58.3 2.6 1.2 0.3 0.4 20.6 0.7 0.2 0.0 5.4 7.1 0.0 0.9 1.7 17.1 12.9 2.2 0.6 1.0 10.2 0.7 4.0 0.4 BLNK "BASH, bca, BLNK-s, Ly57, SLP-65, SLP65" ENSG00000095585 "B cell linker" Q8WV28 10 96189171-96271587 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "B-cell activation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 70.5" "Cell type enhanced" "Detected in many" "B-cells: 94.2;dendritic cells: 64.0;Microglial cells: 157.4;Plasma cells: 80.4;Proximal enterocytes: 64.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 9 "memory B-cell: 161.2;naive B-cell: 140.5;plasmacytoid DC: 231.5" "Group enriched" "Detected in many" 101 "B-cells: 161.2;dendritic cells: 231.5" "Group enriched" "Detected in some" 6 "Daudi: 68.7;REH: 168.4;RPMI-8226: 94.4;U-698: 251.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB009333, CAB016291, HPA038309, HPA038310" Enhanced Supported "Vesicles,Plasma membrane" NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "Plasma membrane" Vesicles "CAB009333: AB_2290422, CAB016291: AB_626752, HPA038309: AB_2675945, HPA038310: AB_2675946" "unprognostic (4.86e-2)" "unprognostic (6.05e-3)" "unprognostic (1.00e-2)" "unprognostic (2.73e-2)" "unprognostic (2.29e-1)" "unprognostic (1.63e-3)" "unprognostic (1.08e-2)" "unprognostic (5.19e-2)" "unprognostic (2.97e-1)" "unprognostic (1.02e-1)" "unprognostic (8.94e-2)" "unprognostic (3.73e-1)" "unprognostic (1.84e-2)" "unprognostic (5.23e-2)" "unprognostic (9.76e-2)" "unprognostic (1.46e-3)" "prognostic favorable (2.67e-6)" 2.2 3.2 3.8 27.5 3.4 10.1 6.3 2.4 4.1 7.1 13.9 16.9 38.9 2.4 30.1 39.9 6.1 10.8 1.0 3.5 5.1 28.5 39.2 6.6 57.6 4.7 4.0 1.5 12.1 17.4 1.8 6.4 5.0 7.3 18.2 1.4 10.9 13.2 0.5 8.0 34.0 3.0 3.8 54.0 29.2 1.3 4.9 10.6 11.6 1.1 70.5 9.9 15.8 5.2 0.3 0.1 0.1 0.2 0.0 0.1 0.8 0.1 0.0 0.0 0.0 0.2 0.2 68.7 0.4 0.0 0.3 0.6 0.1 0.8 0.1 5.5 0.2 0.3 0.3 0.1 0.0 0.1 1.4 0.1 8.7 0.0 0.0 0.1 0.0 0.8 0.3 6.4 0.0 0.7 0.4 0.2 0.2 0.2 0.0 168.4 0.3 94.4 0.9 13.0 0.3 0.3 0.2 15.1 0.1 0.2 23.7 1.1 0.2 0.2 0.8 0.1 0.2 5.4 0.4 251.4 0.1 0.5 0.1 0.3 1.6 0.2 0.3 1.3 0.1 161.2 0.3 0.2 20.6 140.5 0.1 0.1 1.1 1.9 0.1 231.5 0.6 8.1 3.8 3.4 2.4 4.1 3.5 5.1 4.7 4.0 5.0 3.8 4.9 5.2 0.4 6.4 7.7 0.7 94.2 1.1 21.0 13.1 21.1 0.0 4.1 3.4 1.2 30.0 7.3 40.5 0.0 23.0 64.0 9.2 27.4 14.6 3.1 14.4 1.9 0.3 4.9 5.3 1.0 13.8 17.5 0.7 35.7 22.9 1.3 0.0 2.9 27.8 22.8 0.0 1.3 19.4 30.5 9.0 13.8 1.1 0.3 18.2 1.8 157.4 4.8 0.0 0.0 2.5 0.9 4.4 22.4 0.0 80.4 5.1 64.6 2.3 3.4 0.0 6.6 0.3 0.7 1.6 0.1 34.7 1.4 41.5 3.6 0.5 22.5 23.8 BTK "AGMX1, ATK, IMD1, PSCTK1, XLA" ENSG00000010671 "Bruton tyrosine kinase" Q06187 X 101349447-101390796 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 32.6;lymphoid tissue: 78.0" "Cell type enhanced" "Detected in some" "B-cells: 84.7;granulocytes: 211.4;Hofbauer cells: 56.6;Kupffer cells: 63.5;Macrophages: 61.1;monocytes: 71.1;Plasma cells: 43.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 4 "basophil: 557.5" "Lineage enriched" "Detected in many" 4 "granulocytes: 557.5" "Cell line enhanced" "Detected in some" "Daudi: 206.7;HEL: 287.4;HMC-1: 990.3;U-937: 149.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001198, HPA002028, CAB016689" Enhanced Supported "Plasma membrane,Cytosol" NA NA 2300000 "Cluster 38: Basophils - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 57: B-cells - Immune response" "Plasma membrane, Cytosol" "CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306" "unprognostic (3.19e-2)" "unprognostic (2.51e-3)" "unprognostic (1.06e-2)" "unprognostic (3.66e-2)" "unprognostic (5.69e-2)" "unprognostic (3.76e-3)" "unprognostic (6.55e-2)" "unprognostic (3.58e-3)" "unprognostic (6.02e-2)" "unprognostic (3.12e-1)" "unprognostic (1.02e-1)" "unprognostic (1.41e-1)" "unprognostic (2.08e-3)" "unprognostic (7.80e-2)" "unprognostic (1.29e-2)" "unprognostic (1.56e-2)" "unprognostic (8.14e-2)" 6.3 2.9 2.3 30.7 2.6 32.6 4.4 2.8 3.4 3.9 3.1 6.6 4.8 2.5 1.5 3.6 1.9 7.6 1.6 2.3 3.1 1.3 5.4 19.6 55.5 4.7 3.6 0.8 1.2 0.9 0.9 7.0 4.7 1.9 9.1 0.3 2.8 2.3 0.6 2.9 14.7 7.1 3.8 38.4 7.0 1.4 3.9 9.3 1.3 2.0 78.0 9.3 1.5 6.5 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 206.7 0.0 0.0 0.1 0.5 0.0 0.0 0.1 0.0 0.3 287.4 0.0 0.0 0.0 116.7 990.3 0.0 0.0 0.1 0.0 0.0 0.0 0.2 61.9 2.3 0.0 0.0 0.6 81.5 1.6 0.0 0.0 87.2 0.1 13.2 0.0 0.0 0.2 0.0 0.3 0.1 0.5 1.0 0.0 68.5 0.4 0.0 0.3 0.2 0.1 2.6 1.4 98.3 0.5 149.8 0.3 557.5 62.2 110.5 0.2 99.9 0.2 72.4 0.2 0.1 72.7 73.0 0.4 0.1 24.7 0.2 123.9 33.1 0.1 38.4 2.3 2.6 2.8 3.4 2.3 3.1 4.7 3.6 4.7 3.8 3.9 6.5 1.5 3.2 8.9 0.3 84.7 1.0 0.2 0.0 0.6 0.0 0.9 1.4 0.6 0.0 0.6 0.0 0.0 1.4 30.1 0.1 0.0 0.0 0.2 1.3 0.3 0.8 0.0 27.1 0.5 0.0 0.5 0.9 1.1 2.3 211.4 0.0 0.7 0.3 56.6 0.0 0.3 0.3 0.0 63.5 31.0 0.1 0.3 61.1 3.6 10.3 71.1 0.0 2.1 0.0 0.1 0.1 0.5 0.0 43.8 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.5 0.7 1.7 0.5 0.3 1.9 5.7 0.2 0.1 0.1 C1QA ENSG00000173372 "Complement C1q A chain" P02745 1 22636628-22639678 "Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement pathway, Host-virus interaction, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 1092.6" "Group enriched" "Detected in many" 9 "Hofbauer cells: 1663.2;Kupffer cells: 5007.4;Macrophages: 1874.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 39 "intermediate monocyte: 226.1;non-classical monocyte: 181.7" "Lineage enriched" "Detected in many" 60 "monocytes: 226.1" "Cell line enhanced" "Detected in some" "HMC-1: 2.3;NB-4: 1.4;RPMI-8226: 7.1;SCLC-21H: 3.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002350, CAB009823" Supported "Secreted to blood" NA NA 2700000000 "Cluster 51: Monocytes - Innate immune response" "Cluster 64: Macrophages - Immune response" "Cluster 25: RPMI-8226 - Immune response" "Cluster 4: Macrophages - Innate immune response" "CAB009823: AB_2228238, HPA002350: AB_1078552" "unprognostic (1.97e-1)" "unprognostic (1.14e-2)" "unprognostic (1.98e-3)" "unprognostic (3.07e-2)" "unprognostic (6.10e-2)" "unprognostic (2.60e-1)" "unprognostic (1.16e-1)" "unprognostic (2.13e-1)" "unprognostic (1.67e-2)" "unprognostic (1.99e-1)" "unprognostic (4.42e-2)" "unprognostic (1.86e-1)" "prognostic unfavorable (1.58e-6)" "unprognostic (1.54e-1)" "unprognostic (2.11e-3)" "unprognostic (2.75e-2)" "unprognostic (7.30e-2)" 375.1 235.6 86.6 134.0 85.6 53.9 95.9 85.8 135.3 75.8 120.0 142.8 172.3 43.1 26.0 58.3 75.6 172.4 74.8 82.9 93.7 56.2 208.8 404.3 532.3 126.7 110.1 37.5 34.3 26.2 46.3 256.3 110.3 47.1 120.2 4.1 48.1 54.6 14.8 21.8 190.1 195.0 107.5 1092.6 90.8 38.2 109.4 100.3 36.5 49.3 68.0 257.5 30.4 131.6 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 1.4 0.3 0.0 0.0 0.5 0.2 7.1 0.0 0.0 3.0 0.9 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.1 0.4 0.1 0.8 0.0 0.0 0.1 0.1 0.0 0.1 5.2 0.1 0.1 226.1 0.0 0.0 0.1 0.1 3.7 0.0 0.0 0.0 0.5 0.3 181.7 0.0 0.0 9.7 86.6 85.6 85.8 135.3 82.9 93.7 126.7 110.1 110.3 107.5 109.4 131.6 17.4 35.3 55.8 0.0 19.0 18.4 2.3 0.0 2.2 0.4 5.1 24.6 8.9 37.1 18.0 0.0 0.0 8.7 2.7 0.5 0.0 0.0 4.5 0.2 0.5 46.0 1.8 41.0 0.0 0.2 11.3 9.6 0.0 0.2 21.5 0.2 76.1 26.2 1663.2 0.0 0.0 0.1 0.0 5007.4 291.4 9.9 13.1 1874.2 26.6 20.6 16.7 0.3 0.0 0.0 0.1 0.0 0.1 0.4 2.8 1.3 0.1 1.1 15.3 0.8 78.9 7.4 4.6 0.7 2.1 4.2 16.8 18.2 11.8 0.0 0.2 1.3 C1QB ENSG00000173369 "Complement C1q B chain" 1 22652762-22661637 "Human disease related genes, Predicted secreted proteins" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in all" "lung: 546.4;lymphoid tissue: 990.2" "Group enriched" "Detected in many" 28 "Hofbauer cells: 1451.0;Kupffer cells: 4559.7;Macrophages: 1747.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 71 "intermediate monocyte: 140.6;non-classical monocyte: 101.2" "Lineage enriched" "Detected in many" 85 "monocytes: 140.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA052116 Approved "Secreted to blood" NA NA "Cluster 51: Monocytes - Innate immune response" "Cluster 64: Macrophages - Immune response" "Cluster 4: Macrophages - Innate immune response" "HPA052116: AB_2681735" "unprognostic (1.42e-1)" "unprognostic (3.36e-2)" "unprognostic (5.61e-3)" "unprognostic (8.20e-2)" "unprognostic (5.93e-2)" "unprognostic (4.09e-1)" "unprognostic (1.25e-1)" "unprognostic (2.35e-1)" "unprognostic (2.87e-2)" "unprognostic (2.21e-1)" "unprognostic (2.63e-2)" "unprognostic (1.57e-1)" "prognostic unfavorable (9.58e-6)" "unprognostic (4.14e-2)" "unprognostic (7.76e-3)" "unprognostic (4.83e-2)" "unprognostic (2.35e-2)" 439.2 229.0 95.8 149.4 94.2 53.5 87.1 97.2 148.7 65.4 132.6 162.0 186.0 27.7 26.4 63.0 50.5 194.9 62.6 89.8 107.7 18.3 243.4 546.4 514.6 161.0 143.3 39.6 40.0 28.5 1.8 249.2 138.4 28.0 146.0 7.8 44.9 51.2 5.3 6.1 186.1 261.4 138.2 990.2 88.0 39.9 142.2 72.0 23.6 38.6 58.4 255.8 1.1 185.8 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.8 0.4 0.0 0.0 0.5 0.3 0.6 0.0 0.0 0.5 0.8 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.1 0.8 0.0 0.1 0.1 0.0 0.2 0.0 1.7 0.0 0.0 140.6 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.4 0.8 101.2 0.0 0.0 5.3 95.8 94.2 97.2 148.7 89.8 107.7 161.0 143.3 138.4 138.2 142.2 185.8 13.8 12.8 22.1 0.0 17.1 6.2 2.1 0.0 1.8 1.2 4.9 23.1 5.5 24.3 10.5 3.7 0.0 6.6 2.7 0.6 0.0 0.0 3.3 0.1 0.2 65.9 0.0 32.8 0.1 0.0 9.6 5.9 0.0 0.1 11.4 0.1 52.1 26.0 1451.0 0.0 0.1 0.0 0.0 4559.7 92.1 7.8 8.4 1747.2 0.0 34.7 5.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 2.3 1.0 0.3 1.1 3.6 3.9 59.2 4.0 3.2 0.4 0.9 5.7 4.5 9.6 6.1 0.2 0.0 1.5 C1QC C1QG ENSG00000159189 "Complement C1q C chain" P02747 1 22643633-22648110 "Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement pathway, Immunity, Innate immunity" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 950.7" "Group enriched" "Detected in many" 7 "Hofbauer cells: 1356.5;Kupffer cells: 2134.6;Macrophages: 1040.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in some" 5 "intermediate monocyte: 57.2" "Lineage enriched" "Detected in single" 541 "monocytes: 57.2" "Cell line enhanced" "Detected in some" "NB-4: 1.0;RPMI-8226: 2.6;U-266/70: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001471, CAB009828" Supported "Secreted to blood" NA NA 513000000 2100000000 "Cluster 7: Monocytes - Unknown function" "Cluster 64: Macrophages - Immune response" "Cluster 25: RPMI-8226 - Immune response" "Cluster 4: Macrophages - Innate immune response" "CAB009828: AB_2067541, HPA001471: AB_1078553" "unprognostic (2.97e-1)" "unprognostic (6.80e-2)" "unprognostic (2.40e-2)" "unprognostic (1.84e-1)" "unprognostic (7.40e-2)" "unprognostic (2.38e-1)" "unprognostic (1.98e-1)" "unprognostic (1.40e-1)" "unprognostic (1.66e-2)" "unprognostic (7.44e-2)" "unprognostic (2.75e-2)" "unprognostic (1.32e-1)" "prognostic unfavorable (1.17e-5)" "unprognostic (1.06e-1)" "unprognostic (1.63e-3)" "unprognostic (2.21e-2)" "unprognostic (3.73e-2)" 285.2 196.0 60.1 159.7 58.6 43.5 70.5 64.8 97.1 51.9 90.6 133.2 179.9 36.3 13.5 55.3 67.4 155.4 58.6 54.9 75.5 41.2 169.6 290.8 370.2 124.7 105.4 32.1 37.5 22.1 39.6 204.9 105.0 37.8 91.3 3.9 51.6 44.5 12.9 18.3 195.7 164.7 100.4 950.7 94.8 33.9 106.0 75.7 29.2 31.8 50.7 191.8 24.6 159.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.7 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.3 1.0 0.2 0.0 0.0 0.6 0.2 2.6 0.0 0.0 0.4 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.1 1.0 0.0 0.1 0.1 0.1 0.0 0.0 1.3 0.0 0.0 57.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 10.4 0.0 0.0 1.2 60.1 58.6 64.8 97.1 54.9 75.5 124.7 105.4 105.0 100.4 106.0 159.3 13.4 6.4 5.2 0.3 13.7 8.9 1.1 0.0 2.8 0.6 4.9 24.5 1.6 15.7 3.1 0.0 0.0 5.8 2.3 0.4 0.0 0.0 3.2 0.0 0.1 34.5 0.0 27.2 0.0 0.2 9.5 4.4 0.0 0.1 5.1 0.1 25.4 6.6 1356.5 0.0 0.1 0.1 0.0 2134.6 202.4 3.6 6.2 1040.7 7.2 29.0 23.6 0.4 0.0 0.0 0.0 0.0 1.1 1.2 0.9 0.4 0.0 0.4 0.7 0.6 46.0 2.5 1.8 0.4 0.8 3.3 6.5 9.9 3.5 0.0 0.0 0.7 C1R ENSG00000159403 "Complement C1r" 12 7080214-7092540 "Human disease related genes, Predicted intracellular proteins" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in all" "liver: 1425.6" "Cell type enhanced" "Detected in many" "Endometrial stromal cells: 442.3;Fibroblasts: 684.4;Hepatocytes: 1444.2;Leydig cells: 1142.6;Peritubular cells: 388.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 1089.8;ASC TERT1: 546.0;BJ hTERT+: 461.9;BJ hTERT+ SV40 Large T+ RasG12V: 303.4;HSkMC: 672.1" "Low region specificity" "Detected in many" "HPA001251, HPA001551" Uncertain Uncertain Nucleoplasm,Cytosol NA NA "Cluster 49: Eosinophils - Unknown function" "Cluster 85: Liver - Metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" "Nucleoplasm, Cytosol" "HPA001251: AB_2666252, HPA001551: AB_10754818" "unprognostic (1.55e-2)" "unprognostic (8.97e-2)" "unprognostic (3.46e-2)" "unprognostic (1.92e-1)" "unprognostic (1.47e-2)" "unprognostic (2.66e-2)" "unprognostic (1.94e-2)" "unprognostic (2.05e-1)" "unprognostic (2.50e-1)" "unprognostic (1.72e-1)" "unprognostic (1.21e-1)" "unprognostic (4.16e-2)" "prognostic unfavorable (1.94e-14)" "unprognostic (3.54e-2)" "unprognostic (2.25e-2)" "unprognostic (6.13e-2)" "unprognostic (2.59e-2)" 540.6 203.6 15.8 122.4 15.9 1.1 400.6 15.9 23.3 470.5 21.7 277.3 38.3 353.8 80.8 119.0 526.3 279.1 458.7 15.4 19.6 148.9 1425.6 340.3 72.4 23.4 19.9 644.3 88.0 11.0 63.9 52.4 18.4 205.2 100.9 5.8 158.3 87.0 69.4 177.7 228.1 157.7 18.1 192.1 242.7 46.7 18.1 34.7 223.4 74.2 75.3 468.4 394.3 18.0 1.2 8.9 0.9 9.1 1089.8 546.0 0.4 108.9 461.9 143.0 303.4 1.4 2.4 0.5 4.5 108.8 11.8 2.3 11.8 5.5 18.3 18.3 1.1 0.5 4.1 3.6 226.5 0.8 2.3 672.1 3.2 74.7 4.7 121.0 2.9 0.5 0.3 20.5 21.2 0.1 8.0 0.8 3.1 0.1 0.9 8.6 3.8 0.8 0.9 5.5 0.4 2.3 95.1 3.7 2.8 1.3 0.2 0.2 0.4 38.3 6.3 152.1 0.8 1.1 3.0 0.2 53.1 1.0 5.4 0.0 0.0 0.6 0.3 0.0 0.5 0.0 0.2 0.7 0.0 0.0 0.6 0.6 0.5 0.8 0.0 0.0 0.3 0.1 15.8 15.9 15.9 23.3 15.4 19.6 23.4 19.9 18.4 18.1 18.1 18.0 45.4 22.4 90.5 3.6 7.1 54.7 58.8 76.6 33.6 0.3 5.9 30.9 20.8 183.0 22.9 18.4 2.1 4.1 1.8 0.7 3.9 280.8 4.6 13.3 442.3 45.4 0.0 40.6 0.9 44.5 3.7 684.4 16.3 11.6 10.1 24.9 114.9 1444.2 11.2 0.0 0.3 0.7 0.0 40.9 66.9 29.2 1142.6 7.0 53.4 13.1 1.6 16.0 0.0 2.5 0.1 51.1 1.3 388.1 6.2 17.7 0.3 6.1 5.3 1.4 170.9 87.5 140.4 6.8 6.7 5.6 40.1 5.2 11.5 15.2 0.7 11.2 C1S ENSG00000182326 "Complement C1s" P09871 12 6988259-7071032 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Complement pathway, Immunity, Innate immunity" "Hydrolase, Protease, Serine protease" "Disease variant, Ehlers-Danlos syndrome, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "liver: 2915.2" "Cell type enhanced" "Detected in many" "Fibroblasts: 687.0;Hepatocytes: 2795.1;Leydig cells: 1193.2;Peritubular cells: 640.1" "Cancer enhanced" "Detected in all" "liver cancer: 276.7" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 7 "neutrophil: 2.2" "Lineage enriched" "Detected in single" 18 "granulocytes: 2.2" "Cell line enhanced" "Detected in many" "ASC diff: 769.5;ASC TERT1: 1012.7;BJ hTERT+: 336.1;HSkMC: 540.2" "Not detected" "Not detected" "CAB016722, HPA018852" Supported Approved Nucleoplasm,Cytosol "Secreted to blood" NA NA 93000000000 14000000000 "Cluster 1: Neutrophils - Mixed function" "Cluster 62: Liver - Hemostasis" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 2: Hepatocytes - Metabolism" Nucleoplasm Cytosol "CAB016722: , HPA018852: AB_1847112" "unprognostic (2.72e-3)" "unprognostic (7.31e-2)" "unprognostic (9.37e-2)" "unprognostic (1.39e-2)" "unprognostic (1.05e-2)" "unprognostic (9.63e-2)" "prognostic favorable (7.73e-4)" "unprognostic (6.38e-2)" "unprognostic (1.16e-1)" "unprognostic (6.14e-2)" "unprognostic (1.57e-1)" "unprognostic (1.85e-2)" "prognostic unfavorable (7.44e-15)" "unprognostic (2.02e-2)" "unprognostic (5.68e-3)" "unprognostic (1.19e-2)" "unprognostic (5.39e-2)" 416.4 136.1 26.4 207.7 28.5 1.7 252.5 27.1 43.1 309.2 36.7 192.4 84.6 209.0 147.2 152.9 315.4 543.8 191.5 25.4 34.8 60.2 2915.2 224.9 209.2 44.3 31.7 485.9 62.1 21.8 33.1 52.9 31.2 174.4 215.2 9.7 96.9 139.1 57.0 104.1 154.2 251.8 30.9 168.5 150.1 90.0 30.9 88.1 139.0 154.7 192.5 455.7 189.8 31.3 0.2 18.6 1.2 10.2 769.5 1012.7 4.5 143.3 336.1 74.7 135.7 0.9 2.0 0.5 19.7 179.6 20.2 1.1 0.3 2.1 6.7 0.7 0.7 0.5 5.6 48.2 230.3 1.8 0.9 540.2 2.8 60.2 4.4 94.2 0.1 0.2 0.4 0.1 9.9 0.0 0.4 1.6 10.3 0.0 0.6 0.2 1.1 1.5 3.1 2.5 0.8 0.9 86.6 1.8 2.1 17.4 0.1 0.0 0.5 34.2 2.6 133.8 0.2 0.6 0.5 0.8 73.6 1.2 2.5 0.3 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 26.4 28.5 27.1 43.1 25.4 34.8 44.3 31.7 31.2 30.9 30.9 31.3 37.6 16.0 41.0 9.4 5.7 76.2 18.9 22.2 23.9 0.9 4.5 15.4 21.5 171.6 15.5 3.7 0.0 3.7 0.7 0.1 1.9 285.2 6.6 8.7 272.4 30.6 0.0 112.2 2.9 42.9 2.5 687.0 11.2 7.3 5.1 25.7 93.5 2795.1 8.1 5.0 1.7 0.0 2.0 62.8 103.7 29.9 1193.2 6.4 88.9 19.7 1.0 15.2 0.0 1.5 0.6 31.7 0.1 640.1 1.8 9.7 0.0 7.1 4.6 1.1 138.1 34.9 127.6 6.3 5.3 6.3 53.8 2.6 12.8 30.7 0.2 5.2 C2 ENSG00000166278 "Complement C2" P06681 6 31897785-31945672 "Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Complement pathway, Immunity, Innate immunity" "Hydrolase, Protease, Serine protease" "Age-related macular degeneration, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "liver: 477.9" "Group enriched" "Detected in many" 4 "Alveolar cells type 2: 142.4;Hepatocytes: 380.3;Hofbauer cells: 282.7;Kupffer cells: 99.3" "Cancer enriched" "Detected in all" 9 "liver cancer: 100.2" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 4 "intermediate monocyte: 21.1;non-classical monocyte: 25.9" "Lineage enriched" "Detected in single" 35 "monocytes: 25.9" "Cell line enriched" "Detected in some" 5 "Karpas-707: 284.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" CAB016775 Supported "Secreted to blood" NA NA 34000000000 "Cluster 51: Monocytes - Innate immune response" "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 2: Karpas-707 - Immune response" "Cluster 15: Hepatocytes - Hemostasis" "CAB016775: " "unprognostic (2.05e-1)" "unprognostic (1.22e-1)" "unprognostic (7.68e-2)" "unprognostic (1.49e-3)" "unprognostic (7.40e-2)" "unprognostic (3.34e-2)" "unprognostic (1.36e-2)" "unprognostic (8.88e-3)" "unprognostic (3.02e-1)" "unprognostic (2.59e-3)" "unprognostic (3.27e-2)" "unprognostic (3.15e-3)" "prognostic unfavorable (2.64e-7)" "unprognostic (2.05e-1)" "unprognostic (4.42e-2)" "unprognostic (7.37e-2)" "unprognostic (2.55e-2)" 42.6 12.1 0.8 27.6 1.0 3.2 11.7 0.9 1.4 8.1 1.7 14.3 16.7 7.0 1.3 7.6 12.0 23.0 8.5 0.7 1.1 23.2 477.9 80.0 27.8 3.0 2.6 5.3 1.9 0.9 3.8 48.4 3.0 5.4 13.0 0.4 9.1 0.9 2.1 5.8 30.2 23.6 2.1 46.3 12.0 4.1 3.7 5.5 3.3 2.7 12.5 23.6 5.3 2.1 0.3 0.1 0.1 0.6 0.1 0.0 6.8 0.5 0.3 0.4 0.3 0.4 0.3 0.6 3.5 1.0 0.6 0.5 0.1 0.0 0.3 0.2 0.4 0.3 0.4 52.8 1.1 0.1 0.7 2.7 0.3 0.6 0.1 0.6 0.0 0.7 0.5 284.0 0.0 0.0 0.4 0.5 0.3 0.1 0.0 0.2 16.5 3.0 0.0 0.1 0.3 0.3 2.6 0.3 0.2 0.3 0.2 9.5 0.2 0.2 0.7 0.5 0.1 0.9 31.6 2.7 0.8 0.9 0.1 0.1 5.6 0.0 0.1 21.1 0.1 0.0 0.0 0.0 0.7 0.1 0.1 0.1 0.5 0.1 25.9 0.0 0.0 2.2 0.8 1.0 0.9 1.4 0.7 1.1 3.0 2.6 3.0 2.1 3.7 2.1 2.1 25.6 142.4 2.6 1.9 3.3 1.1 2.0 0.6 1.4 1.3 1.3 0.6 25.8 11.2 1.8 0.0 2.1 0.1 1.8 0.0 0.6 0.3 1.5 18.7 1.9 2.4 10.7 6.6 2.7 2.7 19.8 3.1 1.3 3.8 0.2 21.0 380.3 282.7 1.7 6.3 11.3 0.0 99.3 5.0 1.3 6.8 32.6 3.6 7.5 7.3 0.1 0.0 1.0 1.7 4.5 33.1 1.2 0.4 4.0 55.2 35.7 9.4 0.9 0.0 5.6 3.5 0.8 1.4 0.7 2.8 4.0 2.0 0.5 15.8 4.5 C3 "ARMD9, C3a, C3b, CPAMD1" ENSG00000125730 "Complement C3" P01024 19 6677704-6730562 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Complement alternate pathway, Complement pathway, Fatty acid metabolism, Immunity, Inflammatory response, Innate immunity, Lipid metabolism" "Age-related macular degeneration, Disease variant, FDA approved drug targets, Hemolytic uremic syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 8 "liver: 4761.3" "Cell type enriched" "Detected in many" 5 "Hepatocytes: 4512.2" "Cancer enriched" "Detected in all" 5 "liver cancer: 1213.6" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 4 "non-classical monocyte: 13.3" "Lineage enriched" "Detected in many" 4 "monocytes: 13.3" "Group enriched" "Detected in many" 7 "BJ hTERT+: 357.8;EFO-21: 738.6;Hep G2: 795.3;HSkMC: 534.8;SiHa: 209.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003563, CAB004209, HPA020432" Enhanced "Secreted to blood" NA NA 1260000000000 200000000000 "Cluster 51: Monocytes - Innate immune response" "Cluster 62: Liver - Hemostasis" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" "CAB004209: AB_627277, HPA003563: AB_1847117, HPA020432: AB_1847118" "unprognostic (3.26e-3)" "unprognostic (3.91e-1)" "unprognostic (3.92e-1)" "unprognostic (5.98e-3)" "unprognostic (3.31e-1)" "unprognostic (1.04e-1)" "prognostic favorable (8.11e-4)" "unprognostic (1.99e-1)" "unprognostic (9.26e-2)" "unprognostic (5.80e-2)" "unprognostic (8.12e-3)" "unprognostic (5.48e-2)" "prognostic unfavorable (1.09e-5)" "unprognostic (2.63e-2)" "unprognostic (2.49e-2)" "unprognostic (6.03e-3)" "unprognostic (3.88e-1)" 585.2 286.5 46.0 194.3 53.7 1.5 213.9 47.8 46.0 237.5 31.5 128.9 22.9 82.9 41.1 76.4 350.3 354.9 221.6 36.5 81.8 51.4 4761.3 176.0 68.2 143.3 99.2 228.1 182.7 17.9 21.8 17.7 116.4 35.4 76.5 11.7 155.6 57.4 36.6 51.4 156.4 123.0 89.9 7.1 107.9 41.1 103.4 34.1 92.4 52.0 126.4 363.3 101.3 121.9 65.0 23.0 0.0 0.1 10.8 36.0 74.7 5.2 357.8 6.8 12.6 3.6 49.5 1.9 738.6 0.3 54.2 46.6 0.2 43.1 6.9 24.0 0.5 3.1 31.2 795.3 16.3 6.2 9.1 534.8 12.8 60.8 27.3 9.5 0.0 0.0 2.1 0.8 0.2 1.0 0.6 1.6 1.5 0.7 0.1 0.4 5.0 0.3 32.1 6.2 0.5 0.5 209.5 0.1 0.5 0.1 17.2 8.8 3.5 5.7 7.4 4.8 3.6 1.6 4.8 4.5 75.1 4.5 0.3 1.7 1.3 0.6 0.3 2.5 0.2 0.5 0.2 0.1 0.7 0.5 0.2 0.2 3.0 1.3 13.3 0.5 0.1 0.9 46.0 53.7 47.8 46.0 36.5 81.8 143.3 99.2 116.4 89.9 103.4 121.9 36.4 76.9 473.9 0.7 29.4 27.5 14.7 141.5 0.6 0.7 19.5 23.4 14.5 783.5 422.5 16.5 0.0 1.4 2.0 0.2 5.9 494.1 45.9 23.0 63.5 26.2 0.0 209.9 0.4 136.7 1.4 482.2 17.9 57.7 5.1 0.1 124.9 4512.2 34.4 0.0 0.5 0.9 20.3 164.5 44.8 97.5 226.2 45.1 35.6 70.3 14.6 1.2 0.0 0.5 0.6 376.4 0.2 10.9 3.9 13.3 1.9 53.6 177.5 4.6 6.6 20.1 49.1 4.0 7.7 5.2 21.9 2.7 15.0 0.1 0.4 38.2 C4A "C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG" ENSG00000244731 "Complement C4A (Rodgers blood group)" P0C0L4 6 31982057-32002681 "Blood group antigen proteins, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement pathway, Immunity, Inflammatory response, Innate immunity" "Blood group antigen" "Disease variant, FDA approved drug targets, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 115.8;liver: 336.8" "Cell type enhanced" "Detected in some" "Alveolar cells type 1: 9.6;Alveolar cells type 2: 46.4;Cardiomyocytes: 8.3;Club cells: 13.6;Fibroblasts: 19.1" "Cancer enhanced" "Detected in many" "liver cancer: 27.8" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HDLM-2: 58.5;HSkMC: 72.8;U-266/70: 17.1;U-266/84: 33.9" "CAB009811, CAB032603, HPA046356, HPA048287, HPA050103" Supported "Secreted to blood" NA NA 342000000 120000000000 "Cluster 85: Liver - Metabolism" "Cluster 44: HDLM-2 - Immune response" "Cluster 11: Alveolar cells - Smell perception" "CAB009811: AB_2066891, CAB032603: AB_2290613, HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016" "unprognostic (2.13e-1)" "unprognostic (3.02e-2)" "unprognostic (3.74e-2)" "unprognostic (3.10e-1)" "unprognostic (5.29e-2)" "unprognostic (3.09e-2)" "unprognostic (2.48e-2)" "unprognostic (1.02e-1)" "unprognostic (2.00e-1)" "unprognostic (1.44e-1)" "unprognostic (3.70e-1)" "unprognostic (3.15e-1)" "unprognostic (4.47e-2)" "unprognostic (3.20e-2)" "unprognostic (5.20e-2)" "unprognostic (3.97e-2)" "unprognostic (8.63e-2)" 27.9 115.8 0.2 10.6 1.6 0.4 15.7 0.3 2.2 12.6 0.2 31.3 7.5 16.9 11.8 2.6 29.9 2.3 21.8 0.5 1.2 43.1 336.8 14.9 4.5 5.8 1.9 57.5 23.0 0.6 20.6 0.5 2.3 11.1 3.7 5.5 14.2 0.0 1.7 1.7 17.0 0.0 0.5 15.3 11.7 4.1 1.7 4.2 44.5 0.0 2.9 23.1 4.1 1.4 0.0 0.3 0.0 0.0 1.0 5.2 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.6 0.7 0.2 0.1 0.1 0.4 0.0 58.5 0.5 0.0 0.3 1.0 0.0 0.0 0.0 72.8 0.0 0.0 0.0 0.5 0.0 0.6 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 3.9 0.0 0.1 0.5 0.0 0.0 0.0 0.0 1.1 0.0 0.2 17.1 33.9 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.6 0.3 2.2 0.5 1.2 5.8 1.9 2.3 0.5 1.7 1.4 0.0 9.6 46.4 0.3 0.0 0.0 0.0 0.0 0.6 0.0 0.3 0.0 8.3 2.8 13.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 19.1 0.0 0.0 0.0 0.0 0.4 6.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.1 0.0 0.5 4.4 0.0 0.0 0.0 2.6 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 C4B "C4B1, C4B3, C4F, CH, CO4, CPAMD3" ENSG00000224389 "Complement C4B (Chido blood group)" P0C0L5 6 32014795-32035418 "Blood group antigen proteins, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Complement pathway, Immunity, Inflammatory response, Innate immunity" "Blood group antigen" "FDA approved drug targets, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 221.5;liver: 385.2" "Cell type enhanced" "Detected in some" "Alveolar cells type 2: 103.9;Cardiomyocytes: 71.8;Club cells: 22.9;Fibroblasts: 53.9" "Cancer enhanced" "Detected in many" "liver cancer: 33.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "Karpas-707: 129.8" "HPA046356, HPA048287, HPA050103" Approved "Secreted to blood" NA NA 120000000000 "Cluster 85: Liver - Metabolism" "Cluster 2: Karpas-707 - Immune response" "Cluster 11: Alveolar cells - Smell perception" "HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016" "unprognostic (1.29e-1)" "unprognostic (2.99e-2)" "unprognostic (5.50e-3)" "unprognostic (1.30e-1)" "unprognostic (8.09e-2)" "unprognostic (6.24e-2)" "unprognostic (6.09e-2)" "unprognostic (1.05e-1)" "unprognostic (4.81e-2)" "unprognostic (1.12e-1)" "unprognostic (6.24e-2)" "unprognostic (6.86e-2)" "unprognostic (1.04e-1)" "unprognostic (3.12e-2)" "unprognostic (1.30e-1)" "unprognostic (3.99e-3)" "unprognostic (1.11e-2)" 29.7 221.5 4.0 0.4 2.5 0.6 15.9 2.5 2.3 10.3 2.4 27.3 2.0 16.6 0.0 2.2 24.0 5.9 22.7 3.2 13.3 39.8 385.2 13.6 2.7 7.1 12.4 56.5 25.1 1.1 20.1 1.6 7.7 10.2 6.0 2.5 21.0 1.2 1.3 1.1 16.6 9.7 9.9 16.3 10.3 3.1 11.8 7.5 49.1 0.2 4.3 18.5 3.7 11.6 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.8 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.0 21.0 7.8 0.5 0.0 26.2 0.1 0.0 0.0 2.6 0.0 0.0 0.0 129.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 2.5 2.5 2.3 3.2 13.3 7.1 12.4 7.7 9.9 11.8 11.6 0.0 3.2 103.9 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 71.8 1.5 22.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.5 0.6 0.0 0.0 0.0 0.2 0.0 53.9 0.0 0.0 1.3 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.6 0.1 0.0 0.5 8.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 C4BPA C4BP ENSG00000123838 "Complement component 4 binding protein alpha" P04003 1 207104233-207144972 "Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement pathway, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 11 "liver: 1918.6" "Group enriched" "Detected in many" 14 "Alveolar cells type 1: 493.6;Alveolar cells type 2: 660.8;Hepatocytes: 1020.8" "Cancer enriched" "Detected in many" 7 "liver cancer: 434.8" "Not detected" "Not detected" "Immune cell enriched" "Detected in single" 137 "neutrophil: 29.5" "Lineage enriched" "Detected in single" 137 "granulocytes: 29.5" "Cell line enriched" "Detected in some" 5 "Hep G2: 37.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA000926, HPA001578" Enhanced "Secreted to blood" NA NA 30800000000 28000000000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" "HPA000926: AB_1078355, HPA001578: AB_1078354" "unprognostic (3.85e-4)" "unprognostic (9.07e-2)" "unprognostic (2.06e-1)" "prognostic favorable (6.37e-5)" "unprognostic (3.58e-2)" "unprognostic (2.41e-1)" "prognostic favorable (2.24e-4)" "unprognostic (3.64e-2)" "unprognostic (1.94e-1)" "unprognostic (5.90e-4)" "unprognostic (4.47e-2)" "unprognostic (2.58e-1)" "unprognostic (5.51e-7)" "unprognostic (9.74e-2)" "unprognostic (2.52e-2)" "unprognostic (6.92e-2)" "unprognostic (2.66e-1)" 1.4 0.7 0.4 2.5 0.2 0.1 4.5 0.7 0.2 6.3 0.0 1.7 0.0 4.5 0.0 0.1 1.0 3.2 0.2 0.1 0.7 0.6 1918.6 173.3 0.3 0.4 0.2 1.5 9.6 0.2 0.1 0.7 0.5 0.1 0.8 0.0 1.1 0.0 0.0 0.0 0.8 0.1 0.1 1.2 0.4 0.3 0.3 0.0 0.1 0.0 1.1 0.1 0.0 0.4 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 37.4 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 7.8 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.5 0.0 0.2 0.0 0.0 0.0 0.4 0.2 0.7 0.2 0.1 0.7 0.4 0.2 0.5 0.1 0.3 0.4 0.0 493.6 660.8 0.0 3.7 0.0 0.0 0.2 0.0 0.0 2.7 0.4 0.2 41.5 22.5 0.0 0.0 0.0 0.0 3.2 0.0 11.2 0.3 18.0 7.6 1.9 0.0 21.5 0.7 18.7 0.0 1.1 0.0 48.8 3.8 0.0 22.1 1020.8 0.2 0.0 1.4 0.3 0.0 39.2 0.0 0.2 0.0 1.0 0.0 0.0 0.0 0.0 0.0 1.0 0.9 5.6 32.0 0.0 0.0 0.3 0.1 0.1 3.6 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.1 3.9 16.7 0.2 1.4 C4BPB C4BP ENSG00000123843 "Complement component 4 binding protein beta" P20851 1 207088860-207099993 "Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement pathway, Immunity, Innate immunity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 11 "liver: 471.3" "Cell type enriched" "Detected in many" 4 "Hepatocytes: 597.6" "Cancer enriched" "Detected in many" 19 "liver cancer: 83.7" "Not detected" "Not detected" "Immune cell enhanced" "Detected in single" "plasmacytoid DC: 1.1" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in some" 16 "CACO-2: 116.4;HeLa: 46.2;Hep G2: 151.6;OE19: 57.1" "Not detected" "Not detected" "HPA000925, HPA051620" Approved Uncertain "Golgi apparatus" "Secreted to blood" NA NA 265000000000 1100000000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 62: Liver - Hemostasis" "Cluster 39: CACO-2 - Unknown function" "Cluster 15: Hepatocytes - Hemostasis" "Golgi apparatus" "HPA000925: , HPA051620: AB_2681554" "unprognostic (1.73e-1)" "unprognostic (2.62e-1)" "unprognostic (3.26e-1)" "unprognostic (2.07e-3)" "unprognostic (1.72e-1)" "unprognostic (2.54e-2)" "unprognostic (4.58e-3)" "unprognostic (9.49e-2)" "unprognostic (1.37e-1)" "unprognostic (4.25e-1)" "unprognostic (6.39e-2)" "unprognostic (2.64e-2)" "unprognostic (1.21e-2)" "unprognostic (1.55e-1)" "unprognostic (1.03e-1)" "unprognostic (1.05e-2)" "unprognostic (8.25e-2)" 3.0 0.1 0.0 3.4 0.0 0.0 1.8 0.0 0.1 2.8 0.0 3.6 3.8 0.1 0.0 0.2 0.5 3.1 0.1 0.0 0.0 0.4 471.3 1.5 0.4 0.0 0.0 44.2 9.1 0.0 0.0 6.2 0.1 0.0 1.8 0.0 0.5 0.0 0.1 0.2 4.4 0.6 0.0 0.4 8.4 0.7 0.0 0.1 0.0 0.1 0.2 0.4 0.0 0.1 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 116.4 5.8 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 46.2 151.6 0.9 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 57.1 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.6 0.3 0.0 0.0 2.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 12.8 2.0 0.0 1.2 0.0 0.0 0.1 0.0 0.0 7.3 2.2 0.5 54.3 3.2 0.0 0.0 1.0 0.2 10.2 1.9 11.4 4.1 0.7 0.1 0.8 1.8 8.0 0.1 88.8 0.3 3.4 5.6 0.8 0.0 0.3 9.7 597.6 2.1 0.0 0.2 5.6 0.0 13.1 0.3 2.8 0.0 0.6 0.0 0.0 0.7 0.0 0.0 0.0 0.1 69.2 15.9 0.0 0.1 0.2 4.3 0.0 2.2 0.0 0.0 1.1 0.4 0.1 0.4 0.0 0.0 0.1 1.1 143.8 4.8 0.1 C5 "C5a, C5b, CPAMD4" ENSG00000106804 "Complement C5" P01031 9 120952335-121050275 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Inflammatory response, Innate immunity" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 29 "liver: 433.7" "Cell type enriched" "Detected in many" 16 "Hepatocytes: 538.3" "Cancer enriched" "Detected in many" 17 "liver cancer: 73.0" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "A549: 28.4;Hep G2: 30.4" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA029339 Supported "Secreted to blood" NA NA 113000000000 39000000000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 62: Liver - Hemostasis" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" "HPA029339: AB_10601125" "unprognostic (2.51e-1)" "unprognostic (5.88e-3)" "unprognostic (2.50e-3)" "unprognostic (1.57e-2)" "unprognostic (5.05e-2)" "unprognostic (9.52e-3)" "prognostic favorable (9.43e-4)" "unprognostic (1.83e-1)" "unprognostic (3.19e-2)" "unprognostic (1.55e-1)" "unprognostic (2.35e-2)" "unprognostic (4.41e-2)" "unprognostic (1.46e-5)" "unprognostic (5.91e-2)" "unprognostic (1.20e-1)" "unprognostic (3.67e-2)" "unprognostic (2.75e-1)" 2.9 1.7 2.5 1.1 3.4 2.2 2.5 2.4 2.6 3.0 3.5 2.8 3.9 2.7 2.7 1.6 3.0 1.5 1.3 2.2 2.6 4.8 433.7 7.0 2.1 2.9 2.9 3.3 14.9 2.6 3.1 0.9 3.2 3.2 1.6 3.5 1.4 2.2 0.5 3.8 3.9 1.9 2.8 1.5 5.8 1.6 2.8 1.2 2.0 1.2 1.7 2.6 2.1 4.5 1.6 28.4 6.4 11.3 8.0 9.2 0.2 3.4 3.5 0.9 2.0 0.8 2.8 4.1 0.1 1.8 3.8 11.0 0.3 0.3 1.5 0.9 0.0 1.8 1.5 30.4 1.5 1.0 0.7 4.1 0.5 2.0 3.7 1.8 1.0 1.6 0.7 3.8 2.2 5.6 0.4 0.2 1.7 7.0 10.9 2.5 2.8 0.4 1.7 0.8 1.6 6.5 1.6 0.0 2.7 4.4 2.2 3.7 1.3 2.8 0.2 7.5 3.4 2.3 1.8 1.7 2.2 3.8 6.8 0.0 0.3 0.4 0.0 0.0 0.2 0.3 0.1 0.1 0.4 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.5 3.4 2.4 2.6 2.2 2.6 2.9 2.9 3.2 2.8 2.8 4.5 0.8 6.4 28.6 30.0 3.5 1.0 1.0 0.5 1.8 4.8 2.2 1.3 0.8 32.9 7.1 1.8 0.0 0.1 0.1 0.4 1.9 0.2 1.8 1.1 2.2 1.4 0.0 12.0 7.3 0.4 0.0 2.9 2.0 0.8 0.0 3.1 7.5 538.3 1.9 6.7 9.4 1.0 0.0 16.3 1.0 2.8 3.1 3.5 0.0 6.5 2.3 3.2 2.1 25.6 25.4 0.7 3.8 9.1 0.1 0.7 1.0 6.8 3.8 2.6 0.0 4.0 1.6 7.5 2.5 2.0 1.3 0.0 1.4 2.8 2.0 0.6 C6 ENSG00000039537 "Complement C6" P13671 5 41142116-41261438 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters" "Complement pathway, Cytolysis, Immunity, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "liver: 665.9" "Cell type enhanced" "Detected in some" "Cholangiocytes: 127.2;Hepatocytes: 376.9;Late spermatids: 54.8;Leydig cells: 120.2;Respiratory ciliated cells: 58.0" "Group enriched" "Detected in many" 7 "liver cancer: 49.0;pancreatic cancer: 12.5" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 13 "ASC diff: 4.5;ASC TERT1: 6.2;HSkMC: 16.8" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA043823, CAB069427" Enhanced "Secreted to blood" NA NA 45000000000 9200000000 "Cluster 62: Liver - Hemostasis" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 15: Hepatocytes - Hemostasis" "CAB069427: AB_1614336, HPA043823: AB_10960262" "unprognostic (9.79e-2)" "unprognostic (1.96e-2)" "unprognostic (5.94e-3)" "unprognostic (3.02e-2)" "unprognostic (1.67e-1)" "unprognostic (1.18e-1)" "unprognostic (1.12e-3)" "unprognostic (4.66e-2)" "unprognostic (3.72e-2)" "unprognostic (1.53e-1)" "unprognostic (2.34e-1)" "unprognostic (3.04e-3)" "prognostic favorable (4.31e-4)" "unprognostic (2.69e-4)" "unprognostic (1.61e-1)" "unprognostic (1.40e-2)" "unprognostic (3.51e-2)" 12.8 1.1 0.2 0.0 0.2 0.0 5.4 0.2 0.1 0.8 1.6 0.8 0.9 0.4 0.9 0.3 43.9 12.0 57.1 0.2 0.6 4.4 665.9 3.2 0.4 0.0 1.7 6.2 42.7 0.1 0.7 2.8 0.2 0.9 0.6 0.0 0.9 0.6 0.6 0.6 1.4 0.9 0.1 0.3 2.2 4.2 0.8 0.6 2.0 0.7 0.5 0.9 0.6 0.6 0.0 0.0 0.0 0.0 4.5 6.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.2 0.0 16.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.1 0.2 0.6 0.0 1.7 0.2 0.1 0.8 0.6 0.8 0.0 0.0 0.7 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 20.9 127.2 7.5 0.0 0.0 0.0 0.1 0.3 0.0 9.3 11.3 37.5 0.8 0.9 0.0 8.0 1.4 0.4 0.0 6.7 0.0 0.7 0.0 0.1 5.0 376.9 0.0 0.0 2.7 1.0 0.0 9.7 0.3 54.8 120.2 0.2 0.0 0.0 0.0 0.0 0.0 1.0 1.3 0.5 1.3 0.4 0.0 0.0 11.6 0.8 58.0 0.0 0.0 0.2 0.4 0.4 0.1 0.0 0.0 0.0 0.4 0.5 0.6 0.0 C7 ENSG00000112936 "Complement C7" P10643 5 40909497-40984643 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 735.4" "Group enriched" "Detected in many" 4 "Fibroblasts: 578.4;Hepatic stellate cells: 662.5;Leydig cells: 1058.5;Sertoli cells: 309.0;Theca cells: 503.1" "Cancer enriched" "Detected in all" 4 "pancreatic cancer: 73.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "ASC diff: 116.5;HHSteC: 155.1;HSkMC: 212.1;SH-SY5Y: 146.7" "Not detected" "Not detected" "Region enhanced" "Detected in many" "spinal cord: 13.7" HPA001465 Approved "Secreted to blood" NA NA 48000000000 "Cluster 46: Fibroblasts - ECM organization" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" "HPA001465: AB_1078554" "unprognostic (5.01e-2)" "unprognostic (3.74e-2)" "unprognostic (7.40e-2)" "unprognostic (4.68e-3)" "unprognostic (5.35e-2)" "unprognostic (1.43e-3)" "prognostic favorable (5.89e-4)" "unprognostic (6.67e-2)" "unprognostic (3.45e-1)" "unprognostic (2.21e-2)" "unprognostic (1.33e-1)" "unprognostic (1.93e-3)" "unprognostic (2.24e-2)" "unprognostic (6.10e-3)" "unprognostic (1.12e-1)" "unprognostic (2.14e-1)" "unprognostic (2.06e-3)" 470.9 607.7 2.6 21.7 3.5 0.2 46.4 2.6 9.6 118.5 13.6 165.3 19.3 124.6 163.6 52.9 377.3 211.7 558.7 2.8 2.5 298.1 110.6 206.7 99.2 4.4 2.7 735.4 149.8 15.0 23.1 359.2 3.0 101.6 32.5 1.5 18.0 105.7 4.3 12.6 139.8 256.3 4.3 138.2 120.2 28.0 3.0 32.2 105.1 1.6 22.5 122.1 118.3 3.0 0.0 0.0 0.0 0.0 116.5 16.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 155.1 0.0 0.0 212.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.0 0.0 0.0 0.0 0.2 0.0 0.0 1.2 146.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 2.6 3.5 2.6 9.6 2.8 2.5 4.4 2.7 3.0 4.3 3.0 3.0 7.9 6.4 4.1 0.0 1.4 0.6 0.5 0.0 1.8 2.1 1.2 0.3 56.7 7.2 2.5 0.0 0.0 0.2 0.1 0.4 0.0 0.2 4.7 0.5 7.9 127.6 54.8 26.7 0.1 1.3 0.1 578.4 0.0 0.2 1.3 2.7 662.5 8.3 0.5 43.7 0.3 1.3 0.0 14.5 4.2 29.8 1058.5 1.5 0.0 58.1 0.6 3.7 0.0 0.0 0.0 0.9 0.9 18.0 1.0 1.3 0.2 0.1 0.0 0.9 309.0 2.2 23.7 2.6 2.5 6.5 0.6 0.3 1.2 503.1 3.0 0.8 C8A ENSG00000157131 "Complement C8 alpha chain" P07357 1 56854797-56918223 "Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters" "Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 195 "liver: 635.7" "Cell type enriched" "Detected in some" 36 "Hepatocytes: 296.4" "Cancer enriched" "Detected in single" 279 "liver cancer: 85.3" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 5 "Hep G2: 1.4" "Not detected" "Not detected" "Not detected" "Not detected" "Secreted to blood" NA NA 6400000000 "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" "unprognostic (3.73e-3)" "unprognostic (2.44e-1)" "unprognostic (1.28e-1)" "unprognostic (6.40e-2)" "unprognostic (9.82e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.1 635.7 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.0 0.1 0.0 5.3 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 5.3 296.4 0.0 0.0 0.1 0.0 0.0 8.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 C8B ENSG00000021852 "Complement C8 beta chain" P07358 1 56929207-56966140 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 156 "liver: 840.0" "Cell type enriched" "Detected in some" 18 "Hepatocytes: 295.1" "Cancer enriched" "Detected in some" 181 "liver cancer: 107.0" "Not detected" "Not detected" "Immune cell enriched" "Detected in single" 22 "basophil: 2.1" "Lineage enriched" "Detected in single" 22 "granulocytes: 2.1" "Cell line enriched" "Detected in single" 4 "Hep G2: 1.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA023694 Supported "Secreted to blood" NA NA 6700000000 "Cluster 41: Basophils - Cellular respiration" "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" "HPA023694: AB_1847128" "unprognostic (6.65e-2)" "prognostic favorable (9.31e-5)" "unprognostic (2.37e-1)" "unprognostic (2.37e-1)" "unprognostic (1.29e-2)" "unprognostic (6.57e-2)" "unprognostic (5.12e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 840.0 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.3 15.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.2 1.0 0.0 0.1 0.0 5.3 0.0 0.7 0.0 0.0 0.0 0.3 0.0 0.0 7.1 295.1 0.1 0.0 0.1 0.0 0.0 7.6 0.0 11.6 0.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.7 0.0 0.0 0.0 C8G ENSG00000176919 "Complement C8 gamma chain" P07360 9 136945185-136946975 "Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 18 "liver: 564.4" "Cell type enriched" "Detected in some" 9 "Hepatocytes: 1134.7" "Cancer enriched" "Detected in all" 58 "liver cancer: 260.0" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 12 "HMC-1: 41.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA046269 Approved "Secreted to blood" NA NA 2800000000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 62: Liver - Hemostasis" "Cluster 3: HMC-1 - Innate immune response" "Cluster 15: Hepatocytes - Hemostasis" "HPA046269: AB_2679606" "unprognostic (5.00e-2)" "unprognostic (4.05e-3)" "prognostic unfavorable (2.99e-4)" "unprognostic (3.94e-1)" "unprognostic (4.53e-1)" "unprognostic (2.75e-2)" "unprognostic (1.71e-3)" "unprognostic (2.79e-1)" "unprognostic (1.88e-1)" "unprognostic (3.67e-1)" "unprognostic (2.96e-2)" "unprognostic (3.00e-1)" "unprognostic (5.02e-3)" "unprognostic (2.16e-1)" "unprognostic (7.67e-2)" "unprognostic (1.65e-1)" "unprognostic (1.05e-2)" 0.3 1.5 0.1 0.0 0.1 0.0 0.3 0.1 0.3 0.3 0.0 1.2 31.2 0.4 0.9 0.5 0.4 2.5 1.3 0.1 0.1 2.3 564.4 0.3 0.1 0.1 0.1 0.1 0.3 0.0 0.6 0.0 0.2 0.4 0.3 0.0 0.4 0.1 3.1 0.3 17.8 0.0 0.1 2.1 1.3 2.3 0.1 0.2 0.7 0.0 0.1 0.2 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.4 0.0 0.0 41.8 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 1.0 0.0 0.0 0.3 2.3 0.4 0.2 0.4 0.0 0.0 0.4 0.9 0.7 28.6 0.3 0.0 2.1 0.4 1.1 25.0 0.0 0.2 0.9 0.1 0.1 0.7 1.8 8.0 0.2 0.8 1.0 0.1 0.0 0.3 8.9 1.2 17.5 1134.7 0.3 0.0 0.2 5.0 0.0 25.3 0.2 1.5 0.0 0.2 0.0 0.0 0.0 1.1 4.1 0.5 0.1 0.5 4.7 0.7 0.0 0.4 122.3 6.7 0.1 0.5 0.0 0.3 0.3 0.7 0.6 0.5 0.4 3.4 1.8 0.2 2.0 0.2 C9 ENSG00000113600 "Complement C9" P02748 5 39284140-39424868 "Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity" "Age-related macular degeneration, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 288 "liver: 1397.0" "Cell type enriched" "Detected in some" 37 "Hepatocytes: 1962.3" "Cancer enriched" "Detected in single" 244 "liver cancer: 90.4" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "JURKAT: 9.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002151, HPA029577" Uncertain "Secreted to blood" NA NA 69600000000 64000000000 "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 15: Hepatocytes - Hemostasis" "CAB002151: AB_563670, HPA029577: AB_10603779" "unprognostic (1.00e-1)" "unprognostic (1.57e-1)" "unprognostic (1.50e-1)" "unprognostic (2.01e-1)" "unprognostic (6.58e-2)" "unprognostic (1.30e-1)" "unprognostic (2.91e-1)" "unprognostic (5.49e-3)" "unprognostic (1.91e-2)" "unprognostic (1.29e-2)" "unprognostic (2.19e-2)" "unprognostic (9.43e-5)" "unprognostic (1.36e-1)" "unprognostic (1.80e-1)" "unprognostic (2.04e-1)" 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.8 1397.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.5 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.7 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.3 6.6 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.3 20.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.6 0.0 0.8 2.0 0.0 18.7 0.1 0.0 0.0 0.5 0.0 0.1 0.0 0.0 42.5 1962.3 1.2 0.0 0.1 0.2 0.0 52.6 0.0 0.3 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.4 0.1 3.7 1.7 0.0 0.0 0.3 3.0 0.0 0.0 0.1 CARD11 "BIMP3, CARMA1" ENSG00000198286 "Caspase recruitment domain family member 11" Q9BXL7 7 2906142-3043867 "Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins" Immunity "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 47.3" "Cell type enhanced" "Detected in many" "B-cells: 34.9;dendritic cells: 47.2;Microglial cells: 49.6;NK-cells: 28.8;Pancreatic endocrine cells: 24.9;Plasma cells: 26.7;T-cells: 28.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 4 "plasmacytoid DC: 31.4" "Lineage enriched" "Detected in many" 4 "dendritic cells: 31.4" "Cell line enhanced" "Detected in many" "Daudi: 122.7;K-562: 50.1;RT4: 91.4;U-698: 108.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA052984 Approved NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "HPA052984: AB_2682005" "unprognostic (3.12e-2)" "unprognostic (1.75e-1)" "unprognostic (2.17e-1)" "unprognostic (8.46e-3)" "unprognostic (4.81e-1)" "unprognostic (3.44e-2)" "unprognostic (1.71e-1)" "unprognostic (2.31e-1)" "unprognostic (5.65e-2)" "unprognostic (5.11e-2)" "unprognostic (2.09e-2)" "unprognostic (3.09e-1)" "prognostic unfavorable (6.68e-8)" "unprognostic (3.74e-2)" "unprognostic (4.75e-2)" "unprognostic (1.31e-1)" "prognostic favorable (1.10e-4)" 1.3 3.1 6.9 21.8 1.5 18.5 1.2 1.8 1.5 2.3 1.0 2.4 3.7 1.3 0.2 1.3 2.2 8.8 1.0 1.3 4.9 1.6 1.6 4.7 47.3 4.2 8.4 1.3 1.4 0.7 0.9 0.5 3.7 1.4 2.3 0.2 3.3 1.6 0.6 0.7 18.3 0.6 3.0 31.5 7.5 1.7 14.0 20.9 1.5 0.2 29.5 17.1 1.3 4.6 16.7 2.6 0.1 0.1 0.0 0.0 12.2 0.1 0.0 0.5 0.0 32.4 35.5 122.7 29.2 0.0 0.0 27.2 0.0 0.4 0.3 42.1 1.1 0.1 3.1 0.3 0.6 0.4 0.0 0.0 0.0 0.2 0.0 0.8 23.1 13.3 50.1 0.0 0.0 0.3 4.7 0.0 44.9 20.6 0.1 5.9 0.1 30.7 11.4 91.4 0.3 1.5 0.1 0.2 0.1 17.7 0.2 2.5 15.4 0.2 11.8 0.1 0.1 12.3 0.1 108.0 0.0 0.0 0.2 0.5 0.0 0.0 7.7 0.0 7.2 5.4 4.4 5.2 0.9 6.2 2.9 5.3 0.2 5.5 0.0 31.4 3.5 2.9 6.9 1.5 1.8 1.5 1.3 4.9 4.2 8.4 3.7 3.0 14.0 4.6 0.5 0.0 0.0 0.7 34.9 0.0 0.3 0.3 0.6 0.6 0.3 0.4 2.0 0.0 0.3 1.8 0.0 0.0 47.2 0.7 0.0 4.6 0.2 0.4 0.3 0.6 0.0 0.8 2.1 5.3 0.0 1.6 14.3 0.7 5.7 8.6 0.4 0.2 1.5 0.0 1.6 0.3 0.0 2.4 1.8 0.4 0.3 5.4 3.6 49.6 1.0 0.1 28.8 1.0 0.6 24.9 0.0 0.0 26.7 0.3 0.0 0.1 1.0 0.2 0.0 0.3 0.9 1.5 0.2 0.0 0.3 0.0 28.6 4.5 0.4 8.1 CASP10 "FLICE-2, MCH4" ENSG00000003400 "Caspase 10" Q92851 2 201182898-201229406 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Distal enterocytes: 71.3;NK-cells: 44.3;Paneth cells: 44.5;Plasma cells: 49.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 25.3" "Low region specificity" "Detected in all" "CAB003780, HPA017059" Approved Approved "Golgi apparatus,Vesicles" NA NA "Cluster 24: B-cells - Unknown function" "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 1: K-562 - Erythropoiesis" "Cluster 53: Intestinal epithelial cells - Unknown function" "Golgi apparatus" Vesicles "CAB003780: AB_289592, HPA017059: AB_1846040" "unprognostic (4.01e-2)" "unprognostic (8.24e-2)" "unprognostic (4.80e-1)" "unprognostic (1.28e-3)" "unprognostic (4.74e-2)" "unprognostic (2.25e-1)" "prognostic unfavorable (8.54e-4)" "unprognostic (1.73e-2)" "unprognostic (1.48e-2)" "unprognostic (3.68e-2)" "unprognostic (1.91e-1)" "unprognostic (1.04e-1)" "prognostic unfavorable (6.05e-7)" "unprognostic (3.23e-2)" "unprognostic (2.19e-2)" "unprognostic (4.49e-2)" "unprognostic (1.38e-2)" 8.8 2.4 5.7 9.2 5.5 19.5 6.5 4.5 5.8 4.0 4.4 13.2 21.8 3.3 6.2 8.8 5.4 7.4 6.7 4.7 5.1 8.1 6.2 11.5 8.9 6.0 5.0 1.6 4.8 2.3 1.3 9.6 5.8 3.9 13.4 1.3 5.4 3.1 4.9 5.7 18.4 5.1 5.6 22.6 10.2 1.2 7.3 8.7 5.3 2.8 10.4 9.0 5.1 5.4 4.4 3.5 0.3 0.4 0.1 0.3 7.5 0.7 4.6 0.4 1.8 4.6 9.8 0.5 7.0 2.5 1.7 2.9 0.2 2.3 1.3 2.1 4.8 12.2 4.0 15.1 1.6 8.3 12.7 0.5 2.0 5.3 0.4 0.3 25.3 5.1 14.9 17.4 0.4 0.3 15.9 7.8 0.6 6.0 2.4 8.8 0.5 18.4 8.7 6.2 0.2 0.1 4.1 0.2 1.9 3.0 0.2 7.8 10.0 0.4 0.8 3.4 0.2 18.7 12.1 0.5 4.5 6.3 0.2 5.9 11.7 0.7 6.4 16.5 5.6 8.2 5.2 3.6 6.5 7.7 7.2 6.4 2.1 8.5 19.3 6.6 1.2 7.2 5.7 5.5 4.5 5.8 4.7 5.1 6.0 5.0 5.8 5.6 7.3 5.4 20.7 19.2 10.0 0.3 15.8 6.0 2.7 10.6 5.2 0.0 1.3 0.9 1.8 8.6 9.4 9.2 0.0 1.1 20.5 71.3 1.9 16.2 1.2 7.7 7.4 29.7 2.4 14.9 0.3 10.4 0.7 4.2 26.5 12.0 7.6 0.8 26.4 7.1 9.4 0.0 0.5 21.6 4.1 26.6 17.5 0.0 0.6 16.2 7.2 33.7 22.0 0.5 44.3 0.0 0.9 8.6 44.5 0.0 49.7 2.5 26.1 8.7 24.4 0.4 0.0 2.9 2.2 0.1 0.1 6.6 4.5 0.4 12.9 4.1 16.4 10.3 CASP8 "Casp-8, FLICE, MACH, MCH5" ENSG00000064012 "Caspase 8" Q14790 2 201233443-201287711 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Host-virus interaction" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 66.6" "Cell type enhanced" "Detected in many" "dendritic cells: 107.4;NK-cells: 132.8;Plasma cells: 73.4;T-cells: 86.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA001302, CAB002047, HPA005688, HPA006191" Approved Supported Nucleoplasm,Cytosol No No "Cluster 5: Granulocytes - Unknown function" "Cluster 2: Immune cells - Immune response" "Cluster 29: U-266 - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" Cytosol Nucleoplasm "CAB002047: AB_563465, HPA001302: AB_1846057, HPA005688: AB_1846056, HPA006191: AB_2667535" "unprognostic (5.21e-3)" "unprognostic (2.10e-1)" "unprognostic (1.83e-2)" "unprognostic (9.69e-3)" "unprognostic (2.09e-1)" "unprognostic (5.60e-2)" "prognostic unfavorable (3.02e-4)" "unprognostic (2.10e-1)" "unprognostic (4.79e-2)" "prognostic favorable (1.25e-4)" "unprognostic (7.75e-2)" "unprognostic (5.11e-2)" "prognostic unfavorable (1.27e-6)" "unprognostic (7.67e-3)" "unprognostic (2.43e-1)" "unprognostic (2.53e-1)" "unprognostic (4.53e-3)" 11.5 10.2 1.7 28.6 2.0 66.6 13.9 1.3 2.1 9.6 4.2 16.1 20.5 8.5 13.2 12.9 14.1 13.2 5.2 2.1 1.8 10.7 14.1 19.6 37.7 3.4 3.0 7.7 7.8 2.9 3.4 9.9 2.7 6.9 17.6 4.6 8.4 7.3 3.3 12.1 26.0 9.9 2.4 37.1 15.9 4.3 2.6 24.4 7.9 3.0 29.7 18.0 8.6 2.4 33.6 26.6 7.7 22.2 20.7 29.7 12.0 13.8 13.2 16.0 26.2 36.1 54.9 3.7 29.6 10.7 28.7 16.2 17.2 16.1 31.3 21.1 15.4 31.0 21.9 35.1 17.1 25.6 33.8 25.9 38.0 30.1 23.9 13.4 15.1 26.9 28.6 69.1 14.7 13.1 32.1 25.9 12.6 17.5 23.7 24.7 15.9 55.4 30.8 35.3 2.3 1.1 17.9 29.8 18.0 7.0 8.0 19.1 19.6 17.3 18.0 9.0 10.9 63.1 30.2 21.2 25.3 33.1 16.6 76.1 39.5 77.1 70.7 51.2 66.0 40.9 57.8 75.9 41.6 24.0 37.0 47.2 153.6 70.6 51.5 18.6 75.0 40.6 1.7 2.0 1.3 2.1 2.1 1.8 3.4 3.0 2.7 2.4 2.6 2.4 8.5 25.6 26.7 0.7 50.0 7.5 13.0 6.1 10.2 2.1 12.9 9.3 2.5 10.0 13.0 5.5 10.4 8.5 107.4 37.0 15.6 12.3 5.9 25.6 8.1 10.1 4.2 10.5 2.5 8.4 12.1 9.5 19.4 27.2 24.6 10.4 5.3 11.7 11.9 0.0 1.3 15.2 4.1 25.3 15.7 1.9 2.5 25.0 7.2 10.3 35.6 0.2 132.8 1.0 0.5 11.2 30.1 0.7 73.4 9.7 22.3 23.6 14.2 0.4 0.0 4.5 3.7 0.8 0.4 13.1 7.7 3.4 86.9 10.6 17.4 12.7 CD19 ENSG00000177455 "CD19 molecule" P15391 16 28931965-28939342 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "intestine: 33.0;lymphoid tissue: 75.3" "Cell type enhanced" "Detected in some" "B-cells: 135.3;Early spermatids: 38.2;Plasma cells: 30.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 80 "memory B-cell: 138.2;naive B-cell: 172.1" "Lineage enriched" "Detected in many" 89 "B-cells: 172.1" "Cell line enhanced" "Detected in some" "Daudi: 143.3;REH: 77.1;U-698: 33.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB016110 Enhanced NA NA "Cluster 21: B-cells - Adaptive immune response" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "CAB016110: AB_626952" "unprognostic (3.27e-3)" "unprognostic (1.19e-3)" "unprognostic (6.63e-2)" "unprognostic (1.09e-2)" "unprognostic (8.68e-3)" "unprognostic (3.11e-5)" "unprognostic (2.61e-1)" "unprognostic (6.96e-3)" "unprognostic (1.29e-2)" "unprognostic (4.29e-3)" "unprognostic (1.12e-1)" "unprognostic (1.30e-1)" "unprognostic (5.41e-6)" "unprognostic (2.06e-1)" "unprognostic (1.83e-1)" "unprognostic (1.36e-1)" "unprognostic (2.07e-1)" 0.6 0.1 0.0 28.5 0.1 6.2 0.1 0.9 0.4 0.1 0.0 2.0 0.9 0.2 0.1 0.9 0.2 0.9 0.1 0.0 0.0 0.7 0.3 0.5 72.1 0.2 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.5 1.6 0.1 1.2 0.1 0.0 0.0 33.0 0.2 0.0 72.7 3.9 3.8 0.2 5.7 1.2 0.0 75.3 2.8 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 143.3 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 77.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.3 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 33.0 0.0 0.1 0.0 1.9 0.2 0.2 0.0 0.3 0.0 138.2 0.1 0.0 0.3 172.1 0.4 0.1 1.3 0.3 0.4 0.2 0.0 7.2 0.0 0.1 0.9 0.4 0.0 0.0 0.2 0.1 0.0 0.0 0.2 0.3 0.2 0.0 0.6 0.0 135.3 0.0 0.1 0.1 0.6 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.2 1.5 0.2 0.0 0.0 38.2 1.5 0.0 1.0 0.0 0.8 0.0 0.0 0.8 0.8 0.5 0.1 0.0 0.4 1.4 0.3 1.7 0.0 0.0 0.1 0.0 0.8 0.6 7.9 0.3 1.1 3.6 0.0 0.2 0.5 0.0 0.0 0.0 0.1 0.1 0.7 30.5 0.2 0.3 0.1 0.5 0.1 0.0 0.1 0.1 7.4 4.2 0.0 0.0 0.7 2.4 0.6 0.5 0.1 CD247 "CD3H, CD3Q, CD3Z" ENSG00000198821 "CD247 molecule" P20963 1 167430640-167518610 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Adaptive immunity, Host-virus interaction, Immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "bone marrow: 49.0;lymphoid tissue: 179.4" "Group enriched" "Detected in many" 9 "dendritic cells: 492.1;NK-cells: 727.1;T-cells: 247.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 25 "gdT-cell: 376.4;MAIT T-cell: 208.9;memory CD4 T-cell: 190.0;memory CD8 T-cell: 219.7;naive CD4 T-cell: 237.8;naive CD8 T-cell: 195.1;NK-cell: 225.3;T-reg: 254.5" "Group enriched" "Detected in all" 32 "NK-cells: 225.3;T-cells: 376.4" "Group enriched" "Detected in some" 25 "HDLM-2: 155.9;JURKAT: 113.1;MOLT-4: 167.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB004651, HPA008750" Enhanced NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 3: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" "CAB004651: AB_425347, HPA008750: AB_1857863" "prognostic favorable (9.12e-4)" "unprognostic (3.21e-3)" "unprognostic (7.09e-3)" "prognostic favorable (8.63e-6)" "unprognostic (1.99e-2)" "prognostic favorable (3.98e-4)" "unprognostic (1.79e-2)" "unprognostic (1.11e-2)" "unprognostic (5.46e-3)" "unprognostic (9.73e-3)" "unprognostic (1.33e-2)" "unprognostic (2.50e-1)" "prognostic unfavorable (9.94e-6)" "unprognostic (1.60e-1)" "unprognostic (5.33e-2)" "unprognostic (4.02e-2)" "unprognostic (5.94e-3)" 3.2 1.7 2.3 25.3 2.3 49.0 1.9 2.2 2.5 1.9 1.9 4.3 7.1 2.3 3.1 2.1 1.8 5.5 1.3 2.3 2.3 2.0 5.4 10.9 57.7 2.3 2.2 0.8 0.8 0.5 0.8 1.4 2.2 1.8 4.6 0.2 2.4 1.6 1.4 1.1 14.3 1.5 2.1 40.2 7.0 0.4 2.9 179.4 2.5 0.9 36.4 7.3 1.9 2.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 155.9 0.3 0.0 0.1 0.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 113.1 0.0 0.1 0.0 0.0 167.1 0.0 0.1 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.2 0.3 0.8 0.0 0.0 0.0 8.3 1.0 0.4 376.4 1.4 208.9 9.3 190.0 219.7 1.5 4.9 237.8 195.1 8.7 225.3 1.2 2.8 254.5 231.2 2.3 2.3 2.2 2.5 2.3 2.3 2.3 2.2 2.2 2.1 2.9 2.5 3.4 3.2 16.0 3.3 8.2 1.5 0.1 0.0 0.6 0.4 3.5 3.2 0.6 1.5 1.3 0.0 0.0 0.1 492.1 0.4 0.0 0.5 0.2 0.7 0.8 1.8 0.0 14.7 8.8 0.0 0.1 2.2 6.1 1.1 6.3 0.4 7.1 1.4 0.3 3.3 9.4 0.5 0.0 7.8 1.4 0.2 0.0 5.9 3.6 14.0 7.6 0.1 727.1 0.5 3.7 0.0 1.2 0.0 51.9 0.1 0.2 1.3 2.2 0.2 0.0 0.9 1.2 0.1 2.5 1.4 0.6 0.1 247.2 0.0 0.1 0.1 CD3D T3D ENSG00000167286 "CD3d molecule" P04234 11 118339075-118342705 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 30 "lymphoid tissue: 906.7" "Group enriched" "Detected in many" 14 "dendritic cells: 231.0;T-cells: 665.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Group enriched" "Detected in all" 52 "gdT-cell: 1462.4;MAIT T-cell: 990.0;memory CD4 T-cell: 1206.1;memory CD8 T-cell: 1368.7;naive CD4 T-cell: 1091.4;naive CD8 T-cell: 1338.9;T-reg: 1660.4" "Lineage enriched" "Detected in all" 66 "T-cells: 1660.4" "Group enriched" "Detected in some" 4 "JURKAT: 621.5;MOLT-4: 1299.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB013055, HPA071778" Enhanced Uncertain "Endoplasmic reticulum" NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 63: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" "Endoplasmic reticulum" "CAB013055: , HPA071778: " "prognostic favorable (3.00e-4)" "prognostic favorable (8.46e-5)" "unprognostic (1.05e-2)" "prognostic favorable (1.73e-7)" "unprognostic (6.00e-2)" "prognostic favorable (1.70e-4)" "unprognostic (3.82e-1)" "unprognostic (2.40e-2)" "unprognostic (2.24e-3)" "unprognostic (1.01e-2)" "unprognostic (5.69e-2)" "unprognostic (2.55e-1)" "prognostic unfavorable (3.07e-5)" "unprognostic (9.00e-2)" "unprognostic (2.02e-1)" "unprognostic (3.66e-2)" "prognostic favorable (6.16e-4)" 4.1 3.8 0.3 77.5 0.4 28.6 9.9 0.4 1.4 5.2 0.7 18.8 21.7 3.6 5.7 7.6 4.5 15.7 3.7 0.3 0.6 2.3 7.9 20.6 222.7 1.1 0.4 3.2 1.3 0.9 0.8 1.2 0.6 5.9 22.4 0.3 8.3 3.1 2.5 4.0 30.1 3.9 0.7 60.9 23.8 2.4 0.5 906.7 3.8 1.4 166.9 26.7 3.6 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 1.0 0.2 0.0 0.0 0.0 0.0 0.6 0.0 621.5 49.8 0.0 0.0 0.0 1299.8 237.2 1.2 0.0 0.0 0.7 0.1 0.5 0.0 0.0 0.4 0.0 0.0 1.9 0.0 0.2 0.8 0.0 0.5 0.0 1.5 1.1 0.0 0.9 1.1 0.4 0.0 0.1 0.0 10.1 5.3 4.6 1462.4 3.3 990.0 9.6 1206.1 1368.7 5.0 3.7 1091.4 1338.9 25.1 4.2 5.3 6.0 1660.4 1138.7 0.3 0.4 0.4 1.4 0.3 0.6 1.1 0.4 0.6 0.7 0.5 0.8 5.9 6.4 29.6 0.0 18.6 15.3 0.3 0.0 1.8 0.0 5.4 6.7 2.8 7.2 2.6 3.7 0.0 0.4 231.0 0.9 0.0 1.3 0.4 0.8 0.8 5.0 1.2 16.8 0.0 0.0 0.0 8.3 21.4 0.9 12.6 0.0 7.9 3.1 0.6 0.0 0.0 0.2 0.0 14.9 28.4 0.7 0.0 14.2 12.4 1.0 25.0 0.0 32.0 0.0 0.0 0.1 0.2 0.0 21.0 0.3 0.0 3.4 1.5 0.0 0.0 2.5 5.8 0.1 1.2 1.4 11.8 0.3 665.7 0.0 1.1 0.2 CD3E ENSG00000198851 "CD3e molecule" P07766 11 118304730-118316175 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Adaptive immunity, Immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 17 "lymphoid tissue: 640.4" "Group enriched" "Detected in many" 7 "dendritic cells: 213.6;NK-cells: 154.5;T-cells: 601.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in all" 26 "gdT-cell: 490.6;MAIT T-cell: 420.8;memory CD4 T-cell: 414.4;memory CD8 T-cell: 463.5;naive CD4 T-cell: 491.7;naive CD8 T-cell: 501.3;NK-cell: 202.2;T-reg: 426.3" "Group enriched" "Detected in all" 21 "NK-cells: 202.2;T-cells: 501.3" "Group enriched" "Detected in some" 67 "JURKAT: 544.9;MOLT-4: 764.9" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB000010, HPA040957, HPA043955, CAB072863, CAB072864" Enhanced Supported "Endoplasmic reticulum,Golgi apparatus,Plasma membrane" NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 63: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 58: T-cells - T-cell receptor" "Endoplasmic reticulum, Plasma membrane" "Golgi apparatus" "CAB000010: AB_2631163, CAB072863: AB_2665707, CAB072864: AB_2665708, HPA040957: AB_2677222, HPA043955: AB_2678747" "prognostic favorable (1.72e-4)" "prognostic favorable (1.62e-4)" "unprognostic (1.51e-2)" "prognostic favorable (2.30e-6)" "unprognostic (4.31e-2)" "prognostic favorable (1.32e-4)" "unprognostic (3.60e-3)" "unprognostic (3.85e-2)" "prognostic favorable (1.18e-4)" "unprognostic (6.11e-3)" "unprognostic (1.59e-1)" "unprognostic (3.59e-1)" "prognostic unfavorable (1.12e-5)" "unprognostic (5.46e-2)" "unprognostic (9.28e-2)" "unprognostic (3.13e-2)" "unprognostic (1.12e-2)" 6.4 5.6 0.9 85.8 1.1 36.7 6.7 0.9 1.2 7.1 1.3 15.3 22.0 5.8 4.6 9.5 5.4 20.1 3.8 0.7 1.0 3.5 9.7 23.0 209.6 1.8 0.9 3.8 2.2 0.7 1.0 1.6 1.4 6.6 19.3 0.0 11.6 3.0 1.9 5.4 36.4 5.1 1.2 78.9 24.4 1.7 1.3 640.4 5.3 1.6 147.0 24.8 4.9 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 544.9 0.9 2.0 0.0 0.0 764.9 0.6 0.3 0.0 0.0 0.2 0.1 1.0 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.2 0.0 1.6 8.0 9.8 0.0 0.6 0.0 16.4 1.8 2.4 490.6 1.3 420.8 1.6 414.4 463.5 1.5 2.1 491.7 501.3 12.2 202.2 2.0 8.6 426.3 333.0 0.9 1.1 0.9 1.2 0.7 1.0 1.8 0.9 1.4 1.2 1.3 1.6 4.9 0.0 8.6 0.0 12.9 5.2 0.3 0.0 0.0 0.0 3.8 4.8 0.3 0.0 0.6 1.8 0.0 0.2 213.6 0.4 0.0 0.2 7.0 0.5 0.9 2.5 0.0 6.9 0.1 0.0 0.0 5.3 24.5 0.9 7.6 0.0 8.9 2.4 0.3 0.0 0.1 0.0 0.0 7.6 8.3 0.2 0.0 12.6 12.4 1.0 8.4 0.0 154.5 0.0 0.1 0.0 1.1 0.0 41.4 0.1 0.2 2.1 0.0 0.0 0.0 1.3 2.7 0.0 0.0 1.6 5.4 0.3 601.4 0.0 0.6 0.3 CD3G ENSG00000160654 "CD3g molecule" P09693 11 118344344-118355161 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 9 "lymphoid tissue: 94.7" "Group enriched" "Detected in many" 11 "dendritic cells: 139.6;T-cells: 294.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 21 "gdT-cell: 229.0;MAIT T-cell: 135.6;memory CD4 T-cell: 187.3;memory CD8 T-cell: 197.3;naive CD4 T-cell: 192.6;naive CD8 T-cell: 241.7;T-reg: 200.0" "Lineage enriched" "Detected in many" 26 "T-cells: 241.7" "Group enriched" "Detected in some" 52 "JURKAT: 70.9;MOLT-4: 193.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB017520, HPA038494" Enhanced Supported "Plasma membrane,Cytosol" NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 3: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" "Plasma membrane, Cytosol" "CAB017520: AB_831094, HPA038494: AB_2676044" "prognostic favorable (6.33e-4)" "prognostic favorable (2.61e-4)" "unprognostic (4.58e-3)" "unprognostic (3.12e-5)" "unprognostic (6.30e-2)" "prognostic favorable (3.00e-4)" "unprognostic (1.98e-2)" "unprognostic (1.54e-2)" "unprognostic (8.25e-3)" "unprognostic (1.08e-3)" "unprognostic (1.54e-2)" "unprognostic (2.19e-1)" "prognostic unfavorable (9.33e-5)" "unprognostic (1.60e-1)" "unprognostic (2.37e-2)" "unprognostic (4.13e-2)" "unprognostic (2.10e-3)" 0.7 0.8 0.6 10.5 0.8 1.3 1.0 1.1 0.8 0.7 1.1 2.3 3.3 0.5 0.6 1.4 0.9 2.5 0.5 0.5 0.4 0.6 1.6 2.8 27.9 0.9 0.6 0.4 0.5 0.2 0.0 0.3 0.8 0.9 2.7 0.4 1.6 0.3 10.5 0.9 4.6 0.6 0.3 11.5 4.1 0.4 0.8 94.7 0.6 0.3 20.4 3.0 0.4 1.9 0.2 0.2 0.1 0.2 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.2 0.2 0.7 0.2 0.0 0.3 0.2 0.0 0.0 0.0 0.6 0.6 0.0 0.4 0.2 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.0 70.9 2.5 0.3 0.0 0.6 193.8 1.3 0.2 0.0 0.1 0.2 0.0 0.3 0.0 0.1 0.5 0.2 0.0 1.1 0.1 0.0 0.6 0.2 0.0 0.2 0.2 0.2 0.1 0.2 0.7 0.3 0.2 0.2 0.1 9.2 1.2 1.2 229.0 0.6 135.6 0.8 187.3 197.3 0.6 0.9 192.6 241.7 6.4 1.4 1.2 1.5 200.0 90.4 0.6 0.8 1.1 0.8 0.5 0.4 0.9 0.6 0.8 0.3 0.8 1.9 3.2 3.2 6.9 0.0 7.8 2.3 0.1 0.0 1.8 0.2 2.0 2.9 0.8 1.5 1.9 0.0 0.0 0.1 139.6 0.4 0.0 0.3 1.0 0.4 0.4 1.4 0.0 3.4 0.1 0.0 0.0 2.3 13.7 0.4 6.3 0.0 4.2 1.7 0.1 0.0 0.1 0.2 0.0 3.8 5.8 1.4 0.0 7.7 5.4 1.0 8.1 0.0 14.4 0.0 0.3 0.0 0.1 0.0 18.5 0.0 0.0 0.6 0.7 0.8 0.0 1.3 1.6 0.2 0.4 0.6 2.4 0.3 294.0 0.1 0.3 0.0 CD40 "Bp50, p50, TNFRSF5" ENSG00000101017 "CD40 molecule" P25942 20 46118278-46129863 "Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins, Predicted secreted proteins" Immunity Receptor "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "B-cells: 127.5;Basal respiratory cells: 126.0;Langerhans cells: 191.4;monocytes: 242.0;Prostatic glandular cells: 130.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "memory B-cell: 139.4;naive B-cell: 157.9" "Group enriched" "Detected in all" 6 "B-cells: 157.9;monocytes: 43.3" "Cell line enhanced" "Detected in many" "CAPAN-2: 76.0;Daudi: 42.1;EFO-21: 131.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002495, HPA031567, HPA031568, CAB072868" Enhanced "Secreted to blood" NA NA 705000 "Cluster 19: B-cells - Humoral immune response" "Cluster 16: Immune cells - Immune response" "Cluster 38: EFO-21 - Unknown function" "Cluster 3: Monocytes - Immune response regulation" "CAB002495: AB_563562, CAB072868: AB_2665719, HPA031567: AB_2673936, HPA031568: AB_2673937" "unprognostic (6.41e-2)" "unprognostic (1.55e-2)" "unprognostic (7.08e-3)" "unprognostic (6.21e-2)" "unprognostic (4.23e-3)" "unprognostic (1.25e-1)" "unprognostic (7.64e-3)" "unprognostic (1.34e-1)" "unprognostic (4.15e-2)" "unprognostic (7.16e-2)" "unprognostic (2.48e-2)" "unprognostic (7.04e-2)" "prognostic unfavorable (4.48e-4)" "unprognostic (1.22e-1)" "unprognostic (4.95e-2)" "unprognostic (1.60e-2)" "unprognostic (2.28e-2)" 25.9 8.4 6.7 34.9 7.0 2.7 20.5 7.6 7.7 19.4 9.4 11.8 12.6 14.4 7.6 12.4 19.7 14.3 16.3 6.6 7.2 26.1 18.3 34.4 57.8 8.0 7.1 24.5 21.9 46.5 9.9 12.4 7.6 23.6 9.6 1.1 24.5 15.4 8.6 17.0 21.8 14.0 7.8 35.1 15.6 3.8 7.3 17.3 20.4 7.1 57.7 32.9 21.0 8.0 26.6 4.1 0.0 12.8 4.7 2.7 5.0 4.9 1.4 3.8 3.6 0.0 76.0 42.1 131.8 0.8 18.7 3.1 2.3 16.2 3.9 29.0 0.0 10.0 0.0 7.5 36.6 0.0 13.0 16.2 6.2 15.3 0.0 0.0 28.3 0.0 3.5 0.0 0.8 0.0 0.0 0.2 1.8 9.3 0.1 1.1 1.0 4.5 32.7 0.3 0.0 0.0 23.1 12.6 0.0 0.0 2.7 14.5 0.0 0.0 41.2 0.0 0.1 0.1 0.1 29.2 9.6 5.0 0.1 4.0 28.0 0.4 4.8 43.3 3.5 139.4 2.6 2.0 16.1 157.9 5.0 3.7 2.8 2.9 32.1 8.3 4.1 20.0 6.7 7.0 7.6 7.7 6.6 7.2 8.0 7.1 7.6 7.8 7.3 8.0 68.8 12.8 15.0 6.5 127.5 43.6 63.3 126.0 30.1 1.2 3.8 10.0 3.9 30.0 32.9 14.7 0.0 0.4 7.3 1.5 0.0 68.4 9.0 1.3 2.4 61.5 1.2 5.2 0.9 29.7 3.2 37.9 11.7 3.3 3.8 0.6 55.3 17.0 40.5 0.0 0.9 6.2 14.2 13.0 191.4 14.6 25.7 48.1 28.4 12.2 242.0 9.0 6.2 0.5 0.2 37.9 8.8 22.6 25.1 130.2 6.1 4.3 12.2 0.4 32.9 28.0 31.6 1.9 5.7 13.2 34.1 0.4 4.8 2.3 6.8 64.4 CD40LG "CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP" ENSG00000102245 "CD40 ligand" P29965 X 136648158-136660390 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins, Predicted secreted proteins" Cytokine "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 15.5" "Cell type enriched" "Detected in some" 8 "T-cells: 76.6" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 26.3;MAIT T-cell: 64.1;memory CD4 T-cell: 80.5;naive CD4 T-cell: 76.1" "Lineage enriched" "Detected in many" 39 "T-cells: 80.5" "Cell line enriched" "Detected in some" 15 "MOLT-4: 23.5" "Not detected" "Not detected" "Not detected" "Not detected" "HPA045827, HPA072480" Enhanced Approved "Golgi apparatus,Plasma membrane" "Secreted to blood" NA NA 776000 20000 "Cluster 32: T-cells - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" "Golgi apparatus, Plasma membrane" "HPA045827: AB_10959606, HPA072480: " "unprognostic (1.94e-5)" "unprognostic (1.24e-2)" "unprognostic (3.26e-1)" "unprognostic (1.27e-3)" "unprognostic (4.71e-2)" "unprognostic (3.56e-5)" "unprognostic (3.66e-2)" "unprognostic (5.48e-3)" "unprognostic (2.77e-1)" "unprognostic (2.14e-4)" "unprognostic (1.87e-1)" "unprognostic (1.55e-1)" "unprognostic (6.70e-4)" "unprognostic (2.15e-1)" "unprognostic (5.19e-2)" "unprognostic (2.36e-3)" "unprognostic (2.92e-2)" 0.8 0.3 0.1 7.9 0.0 1.9 1.1 0.2 0.2 0.9 0.2 1.9 1.8 0.3 0.2 1.0 0.4 2.0 0.2 0.1 0.2 0.4 1.0 2.4 15.5 0.1 0.1 0.3 0.0 0.0 0.0 0.1 0.2 0.8 3.1 0.0 0.6 0.3 0.1 0.6 3.8 0.6 0.0 4.9 2.0 0.3 0.1 15.5 0.5 0.2 14.8 2.5 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 23.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.1 0.3 26.3 0.1 64.1 0.1 80.5 11.7 0.2 0.0 76.1 0.7 1.3 0.8 0.1 0.1 10.5 13.6 0.1 0.0 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.0 0.1 0.2 0.6 0.0 2.4 0.0 2.4 1.3 0.0 0.0 0.0 0.0 0.4 0.5 0.3 0.0 0.6 0.0 0.0 0.0 4.5 0.0 0.0 0.0 3.9 0.0 0.0 0.6 0.0 1.7 0.0 0.0 0.0 0.6 2.6 0.0 1.3 0.0 1.1 0.3 0.1 0.0 0.0 0.0 0.0 0.6 4.0 8.9 0.0 2.9 1.8 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.4 0.0 0.0 0.0 0.6 0.7 0.0 0.0 0.1 2.0 0.0 76.6 0.0 0.0 0.1 CD55 "CR, CROM, DAF, TC" ENSG00000196352 "CD55 molecule (Cromer blood group)" P08174 1 207321532-207386804 "Blood group antigen proteins, CD markers, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Complement pathway, Host-virus interaction, Immunity, Innate immunity" "Blood group antigen, Host cell receptor for virus entry, Receptor" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 2227.6;Syncytiotrophoblasts: 847.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "neutrophil: 662.2" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 472.3;HMC-1: 665.7;PC-3: 395.0;U-2197: 405.3" "Low region specificity" "Detected in many" "HPA002190, CAB010454, HPA024386" Enhanced "Secreted to blood" NA No 32300000 360000000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 20: HeLa - Mitochondria" "Cluster 41: Macrophages - Immune response" "CAB010454: AB_2075970, HPA002190: AB_1078472, HPA024386: AB_1846319" "unprognostic (4.08e-2)" "unprognostic (3.22e-1)" "unprognostic (3.41e-1)" "unprognostic (1.63e-1)" "unprognostic (9.05e-2)" "unprognostic (1.08e-2)" "unprognostic (1.05e-1)" "unprognostic (1.22e-1)" "unprognostic (1.06e-1)" "unprognostic (3.57e-2)" "unprognostic (1.55e-2)" "unprognostic (1.86e-1)" "prognostic unfavorable (9.36e-4)" "unprognostic (3.41e-2)" "unprognostic (2.04e-1)" "unprognostic (9.70e-2)" "unprognostic (2.33e-2)" 64.9 161.5 13.8 99.6 23.3 134.0 59.0 15.8 28.3 103.3 19.0 47.7 47.7 58.3 17.3 58.3 28.0 49.4 48.4 15.7 29.4 20.5 28.0 224.1 26.7 21.1 20.0 67.7 24.5 28.9 26.3 92.5 26.2 16.1 42.9 9.2 126.1 18.1 108.9 85.9 50.7 46.6 15.2 43.1 44.0 36.0 20.8 15.8 47.6 59.5 41.3 183.2 41.8 34.4 33.2 43.6 0.1 14.6 54.2 55.1 220.7 62.5 100.1 31.3 33.1 139.5 44.3 60.8 50.3 35.8 123.3 17.4 65.2 12.9 29.1 29.0 26.4 79.9 472.3 23.3 162.3 50.5 665.7 25.9 150.5 40.8 171.8 133.8 169.7 9.6 89.6 29.3 19.4 35.6 5.3 37.8 43.2 78.9 395.0 7.4 42.3 50.7 54.3 30.7 17.7 0.4 321.2 64.3 53.9 95.1 54.4 41.5 80.4 17.6 33.2 405.3 23.8 24.7 31.4 42.7 44.8 19.6 78.9 317.7 181.2 247.6 35.0 174.4 51.8 108.2 46.0 36.4 121.7 115.2 102.6 101.9 662.2 134.5 223.7 64.8 34.6 159.3 13.8 23.3 15.8 28.3 15.7 29.4 21.1 20.0 26.2 15.2 20.8 34.4 95.9 2227.6 405.3 2.3 529.8 705.1 214.1 143.6 59.2 3.1 69.9 53.8 72.7 7.2 542.6 23.9 0.0 217.5 201.7 196.1 3.9 98.6 324.6 345.6 101.9 143.4 17.3 79.8 7.6 180.2 411.7 244.7 387.9 709.3 146.9 88.9 46.8 9.1 70.0 1.7 10.7 155.7 77.3 177.5 449.2 66.3 32.6 377.3 160.1 7.5 122.6 4.8 69.0 6.0 54.3 388.9 241.2 9.1 305.4 334.9 138.4 3.2 259.5 3.3 6.6 56.1 98.0 8.9 13.7 273.4 765.9 847.7 215.4 281.5 145.1 578.6 CD59 "16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20" ENSG00000085063 "CD59 molecule (CD59 blood group)" P13987 11 33703010-33736479 "Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes, Disease variant, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Ductal cells: 1445.2;Prostatic glandular cells: 1678.0;Urothelial cells: 1531.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "TIME: 3747.5;U-2197: 3049.9" "CAB001448, HPA026494" Supported Uncertain "Golgi apparatus,Vesicles" "Intracellular and membrane" NA NA 58000000 "Cluster 4: T-regs - Cell cycle regulation" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 22: Epithelial cell types - Mixed function" "Golgi apparatus, Vesicles" "CAB001448: AB_563604, HPA026494: AB_1846321" "unprognostic (2.07e-2)" "prognostic unfavorable (3.81e-5)" "unprognostic (7.40e-2)" "unprognostic (1.14e-2)" "unprognostic (2.11e-2)" "prognostic unfavorable (3.10e-5)" "unprognostic (5.65e-2)" "unprognostic (1.46e-1)" "unprognostic (4.47e-2)" "unprognostic (2.98e-1)" "prognostic unfavorable (2.92e-5)" "unprognostic (1.66e-2)" "prognostic favorable (1.39e-10)" "prognostic unfavorable (9.03e-4)" "unprognostic (1.31e-1)" "unprognostic (1.03e-2)" "unprognostic (3.09e-1)" 517.4 248.3 284.5 209.6 310.8 198.8 555.9 329.0 365.1 305.5 542.2 255.1 120.7 290.7 971.7 478.9 368.1 475.3 608.3 288.2 359.7 577.4 339.8 553.5 148.8 327.9 340.2 228.5 353.6 706.1 250.3 485.6 340.9 256.8 271.4 130.7 693.6 443.2 529.3 282.8 167.9 380.0 330.5 131.8 422.7 127.7 337.0 167.7 308.1 915.0 288.6 550.5 325.5 315.6 297.2 278.4 77.6 212.0 1697.1 1314.9 46.8 1765.7 1778.5 408.9 451.9 129.7 822.1 23.9 291.5 1802.5 475.5 314.0 141.0 1589.9 561.1 475.5 218.2 31.3 846.7 193.1 483.2 183.4 94.8 631.8 387.2 343.3 1550.6 1104.9 2475.5 109.3 207.9 585.9 2575.4 282.7 79.9 70.3 43.5 541.8 1421.8 30.1 232.1 227.8 1304.4 510.0 54.3 79.5 576.2 243.7 298.2 218.0 187.5 18.1 3747.5 838.6 235.5 3049.9 595.9 273.8 558.8 30.4 734.2 1.3 1556.9 164.9 22.3 209.6 50.9 7.9 64.8 63.9 104.9 56.6 95.4 59.6 68.2 41.4 134.3 92.5 4.8 49.9 298.2 53.5 284.5 310.8 329.0 365.1 288.2 359.7 327.9 340.2 340.9 330.5 337.0 315.6 728.0 272.4 247.2 32.3 39.1 286.0 1103.2 951.4 82.0 51.3 434.9 270.0 315.5 444.7 569.7 242.8 33.3 553.5 29.2 344.6 164.4 1445.2 129.4 94.3 91.6 792.6 166.6 206.0 25.1 618.3 407.2 303.5 109.6 115.6 139.4 88.2 585.0 185.7 486.7 47.1 29.9 112.8 722.2 139.4 374.2 61.6 237.3 88.2 1270.0 54.4 161.7 198.3 26.8 32.6 22.2 1195.7 392.2 204.7 149.7 1678.0 41.7 208.2 1042.5 56.2 276.1 159.1 410.7 130.6 31.2 83.7 284.4 836.6 52.4 139.5 104.9 1531.0 CD79A "IGA, MB-1" ENSG00000105369 "CD79a molecule" P11912 19 41877279-41881372 "Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "intestine: 152.3;lymphoid tissue: 545.2" "Group enriched" "Detected in some" 5 "B-cells: 1186.4;Plasma cells: 956.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 38 "memory B-cell: 1273.8;naive B-cell: 1457.5" "Lineage enriched" "Detected in all" 40 "B-cells: 1457.5" "Group enriched" "Detected in some" 22 "Daudi: 1598.7;REH: 491.0;U-698: 1366.7" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB000019, HPA056444" Enhanced NA NA "Cluster 21: B-cells - Adaptive immune response" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "CAB000019: AB_2244527, HPA056444: " "prognostic favorable (8.45e-5)" "unprognostic (1.63e-3)" "unprognostic (4.13e-3)" "unprognostic (1.31e-3)" "unprognostic (2.02e-1)" "prognostic favorable (1.18e-5)" "unprognostic (1.23e-2)" "unprognostic (8.11e-3)" "unprognostic (9.41e-3)" "unprognostic (1.12e-2)" "unprognostic (2.53e-1)" "unprognostic (2.32e-1)" "prognostic unfavorable (2.15e-5)" "unprognostic (6.08e-2)" "unprognostic (3.39e-1)" "unprognostic (1.17e-1)" "unprognostic (1.46e-1)" 4.8 4.9 0.2 213.4 0.2 47.2 9.5 0.2 0.4 3.6 0.1 47.3 37.9 2.4 1.4 9.9 1.8 13.0 2.9 0.1 0.1 3.4 2.6 8.9 482.4 0.3 0.2 3.7 0.6 0.1 0.3 1.2 0.2 4.3 28.9 0.0 28.5 2.2 0.7 0.4 152.3 2.2 0.6 286.5 76.9 2.4 0.2 93.7 8.1 0.4 545.2 32.3 1.9 0.3 1.1 0.8 0.3 0.1 0.2 0.7 0.2 0.2 0.0 0.3 0.0 0.0 0.1 1598.7 1.2 0.0 0.1 0.0 0.2 0.2 0.0 0.5 0.7 2.7 0.0 1.7 0.2 2.6 1.8 0.5 0.6 0.2 0.0 0.0 0.0 8.0 3.1 0.4 0.1 1.1 1.6 9.9 0.1 0.1 0.4 491.0 0.8 2.5 0.1 0.0 0.5 0.5 0.8 0.5 1.3 0.0 0.0 4.8 1.6 0.1 4.3 0.3 0.8 7.8 1.4 1366.7 0.0 52.1 0.1 12.4 1.5 6.9 1.7 1.8 0.7 1273.8 4.1 2.1 2.5 1457.5 4.9 26.3 4.6 2.6 4.3 36.3 10.4 62.7 0.2 0.2 0.2 0.4 0.1 0.1 0.3 0.2 0.2 0.6 0.2 0.3 0.2 0.0 2.4 0.0 1186.4 1.8 0.5 0.5 0.6 0.0 0.7 0.9 0.2 1.5 0.2 0.0 0.0 0.2 18.2 0.7 0.0 1.8 0.2 0.1 0.3 0.5 0.0 10.5 0.0 25.6 0.4 2.2 6.6 0.2 0.0 0.4 2.2 1.0 0.8 0.0 0.0 0.4 0.0 4.1 1.4 0.0 0.3 5.3 138.7 0.0 6.3 0.0 15.5 0.0 0.0 181.7 0.4 0.4 956.7 0.3 0.2 0.9 0.0 0.0 0.0 0.2 0.7 0.3 0.6 0.9 1.4 0.1 23.5 0.2 5.3 0.2 CD79B "B29, IGB" ENSG00000007312 "CD79b molecule" P40259 17 63928740-63932336 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 266.7" "Cell type enriched" "Detected in many" 4 "B-cells: 491.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in all" 4 "memory B-cell: 1132.1;naive B-cell: 1505.8" "Lineage enriched" "Detected in all" 5 "B-cells: 1505.8" "Cell line enhanced" "Detected in some" "Daudi: 1060.0;REH: 350.2;U-698: 1475.5" "Not detected" "Not detected" "Not detected" "Not detected" "HPA009178, CAB009751, HPA044107" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Cluster 21: B-cells - Adaptive immune response" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "Plasma membrane" "Nucleoplasm, Cytosol" "CAB009751: AB_2275844, HPA009178: AB_1078483, HPA044107: " "unprognostic (3.90e-3)" "unprognostic (1.61e-3)" "unprognostic (5.21e-2)" "unprognostic (3.45e-3)" "unprognostic (4.22e-3)" "prognostic favorable (2.35e-4)" "unprognostic (1.82e-1)" "unprognostic (9.25e-3)" "unprognostic (3.89e-2)" "unprognostic (1.48e-1)" "unprognostic (1.04e-1)" "unprognostic (2.87e-2)" "unprognostic (2.50e-3)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (4.28e-2)" "unprognostic (2.75e-1)" 5.0 1.7 0.9 70.5 0.9 54.6 3.4 0.9 1.4 1.9 1.7 7.7 4.7 1.4 1.6 2.6 1.5 6.8 12.3 0.9 0.9 4.7 3.4 4.9 266.7 1.0 0.9 0.6 0.7 0.7 25.3 3.8 0.9 2.5 7.2 0.0 7.8 0.8 3.4 2.4 66.2 2.6 0.9 147.7 10.7 1.0 1.0 27.1 4.1 5.8 208.4 13.4 2.2 1.0 1.8 0.0 0.5 0.0 0.0 0.0 0.0 0.6 0.0 0.2 0.4 0.0 0.0 1060.0 7.8 0.0 0.4 0.3 0.0 0.0 0.0 0.5 0.0 2.7 0.0 0.4 0.6 0.6 0.5 0.0 0.0 0.1 0.0 0.0 1.2 0.4 1.2 56.9 0.0 0.0 0.6 23.0 0.3 0.0 0.0 350.2 0.9 4.4 0.0 0.0 0.5 0.0 1.7 0.0 0.7 5.8 0.0 16.2 1.7 0.1 3.7 0.3 0.6 51.3 54.4 1475.5 0.0 2.2 0.0 6.2 13.0 1.1 44.9 192.2 51.3 1132.1 57.1 30.1 47.0 1505.8 38.4 23.2 5.8 42.4 304.3 6.7 107.9 112.1 0.9 0.9 0.9 1.4 0.9 0.9 1.0 0.9 0.9 0.9 1.0 1.0 24.9 0.0 1.3 0.0 491.9 4.5 0.4 0.0 1.8 0.0 1.1 4.4 1.4 1.5 0.0 0.0 0.0 0.2 24.2 0.3 0.0 0.1 0.6 0.3 1.0 25.2 1.2 8.6 0.0 0.0 0.4 3.3 0.5 0.3 15.2 0.0 51.4 1.3 5.8 0.0 0.0 0.4 0.0 14.8 5.1 1.4 1.2 13.4 21.4 0.0 14.3 0.0 36.0 0.0 0.0 0.0 0.1 1.9 99.6 0.4 0.0 1.0 0.0 0.0 0.0 4.4 5.4 1.2 0.3 0.7 3.1 0.4 27.0 0.5 0.8 0.2 CD81 "TAPA-1, TAPA1, TSPAN28" ENSG00000110651 "CD81 molecule" P60033 11 2376177-2397397 "CD markers, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Adaptive immunity, Host-virus interaction, Immunity" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Adipocytes: 1003.1;Endometrial stromal cells: 1050.9;Muller glia cells: 809.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "memory B-cell: 148.9;naive B-cell: 137.2" "Lineage enriched" "Detected in all" 4 "B-cells: 148.9" "Cell line enhanced" "Detected in many" "ASC diff: 2960.6;fHDF/TERT166: 1752.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002507, HPA007234" Supported Supported "Plasma membrane,Cytosol" NA NA 400000 "Cluster 43: B-cells - Humoral immune response" "Cluster 89: Fibroblasts - ECM organization" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" "Plasma membrane" Cytosol "CAB002507: AB_563639, HPA007234: AB_1846333" "unprognostic (2.96e-1)" "unprognostic (3.40e-1)" "prognostic unfavorable (7.56e-4)" "unprognostic (1.84e-2)" "prognostic unfavorable (8.21e-5)" "unprognostic (6.03e-2)" "unprognostic (1.75e-1)" "unprognostic (1.31e-1)" "unprognostic (2.09e-1)" "unprognostic (1.24e-1)" "prognostic favorable (3.86e-4)" "unprognostic (3.07e-3)" "unprognostic (2.08e-1)" "unprognostic (3.55e-2)" "unprognostic (1.67e-1)" "unprognostic (2.06e-1)" "unprognostic (2.06e-1)" 892.1 299.1 560.6 270.7 598.4 77.8 773.6 614.8 590.2 952.7 498.9 992.0 150.7 1384.0 960.5 364.3 853.1 534.5 937.9 511.1 615.8 636.6 1175.7 768.4 429.0 665.7 640.8 656.8 449.5 258.3 409.1 441.0 651.1 634.0 234.4 75.9 531.1 1602.0 214.3 511.1 423.1 978.5 694.1 631.3 494.3 316.9 655.1 158.9 564.6 227.6 278.6 749.2 763.4 734.4 337.0 342.0 268.5 413.4 2960.6 1668.4 224.8 621.0 1361.6 490.3 492.2 322.8 1.8 285.4 218.3 1752.6 312.5 430.5 167.3 442.2 199.9 135.6 517.8 43.7 117.1 0.3 976.4 188.2 359.8 1222.3 619.9 201.1 302.1 757.9 476.6 204.0 198.7 484.9 696.4 257.2 160.7 239.1 324.4 304.7 274.2 324.7 135.5 183.3 529.1 223.3 288.8 319.2 198.4 514.4 383.8 214.3 171.0 337.8 641.3 249.0 181.6 471.2 216.6 356.9 88.1 529.1 361.3 111.0 435.0 0.9 3.3 22.9 21.1 5.8 34.4 148.9 14.9 33.0 2.6 137.2 9.2 16.9 1.0 14.7 7.3 7.7 12.0 10.7 560.6 598.4 614.8 590.2 511.1 615.8 665.7 640.8 651.1 694.1 655.1 734.4 1003.1 243.6 270.0 95.0 88.2 179.8 391.8 89.7 26.2 82.7 325.6 452.0 277.4 167.3 102.3 207.8 27.1 21.8 267.1 20.0 35.2 105.7 15.9 365.4 1050.9 344.5 71.9 30.7 19.0 55.1 31.7 560.4 21.4 462.7 81.7 204.0 293.4 603.9 251.5 148.0 32.4 48.2 50.8 232.7 179.7 50.2 389.2 277.6 151.2 60.0 23.0 809.2 45.3 145.8 93.6 61.3 14.7 251.3 50.7 147.6 5.0 29.9 85.8 76.1 118.3 356.9 423.6 15.6 19.4 30.6 164.9 20.1 136.8 379.0 41.5 298.1 CD8A CD8 ENSG00000153563 "CD8a molecule" P01732 2 86784610-86808396 "CD markers, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 16 "lymphoid tissue: 369.0" "Group enriched" "Detected in many" 4 "dendritic cells: 111.7;T-cells: 242.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 14 "MAIT T-cell: 234.4;memory CD8 T-cell: 523.0;naive CD8 T-cell: 476.8" "Lineage enriched" "Detected in many" 19 "T-cells: 523.0" "Cell line enhanced" "Detected in some" "JURKAT: 4.0;MOLT-4: 15.2;RPMI-8226: 3.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB000012, HPA037756, CAB075722" Enhanced Supported "Plasma membrane" "Intracellular and membrane" NA NA 490000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 63: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 58: T-cells - T-cell receptor" "Plasma membrane" "CAB000012: AB_2075537, CAB075722: AB_2665709, HPA037756: AB_2675648" "unprognostic (1.29e-3)" "prognostic favorable (4.54e-4)" "unprognostic (9.26e-3)" "prognostic favorable (6.15e-6)" "unprognostic (7.28e-2)" "unprognostic (2.79e-3)" "unprognostic (1.03e-2)" "unprognostic (2.00e-2)" "unprognostic (1.35e-2)" "unprognostic (4.50e-3)" "unprognostic (1.09e-1)" "unprognostic (1.14e-1)" "prognostic unfavorable (1.91e-5)" "unprognostic (1.36e-1)" "unprognostic (1.48e-1)" "unprognostic (6.74e-2)" "unprognostic (1.56e-2)" 5.3 4.6 2.1 21.2 2.8 22.5 4.7 1.9 3.0 3.8 1.4 4.9 11.8 3.0 3.6 4.4 4.0 9.8 2.3 2.1 2.1 1.8 7.4 10.5 45.0 2.8 2.1 2.5 2.6 1.1 1.5 0.6 2.5 3.4 5.9 0.2 8.3 1.9 0.8 1.3 20.7 2.4 2.2 117.1 16.4 1.0 2.3 369.0 4.4 0.4 21.4 9.1 4.0 2.1 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.3 0.0 1.4 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 4.0 0.0 0.2 0.0 0.6 15.2 0.9 0.5 0.1 0.2 0.1 0.7 3.3 0.0 0.3 0.7 1.9 0.1 0.0 0.0 0.0 0.3 0.4 0.0 0.0 0.5 0.1 0.0 0.1 0.2 0.7 0.0 0.0 0.0 1.4 0.8 0.3 30.0 0.3 234.4 0.6 2.3 523.0 0.4 0.6 2.2 476.8 4.3 27.9 0.9 1.2 0.8 152.4 2.1 2.8 1.9 3.0 2.1 2.1 2.8 2.1 2.5 2.2 2.3 2.1 2.2 0.0 4.6 0.0 5.7 2.0 0.2 0.0 0.0 0.3 1.5 1.5 3.4 1.5 0.6 0.0 0.0 0.0 111.7 0.2 0.0 0.2 0.3 0.5 0.3 1.3 0.0 7.8 4.2 0.0 0.0 2.6 8.2 0.4 2.5 0.0 6.4 2.3 0.1 0.0 3.1 0.3 0.0 1.9 11.5 0.2 0.0 6.6 0.0 1.0 5.9 0.1 38.1 0.0 0.2 0.0 0.0 0.0 30.8 0.2 0.0 0.4 1.5 0.4 0.0 1.1 1.4 0.4 0.4 1.1 1.8 0.1 242.4 0.0 0.6 0.1 CDCA7 "FLJ14736, JPO1" ENSG00000144354 "Cell division cycle associated 7" Q9BWT1 2 173354820-173368997 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 32.4;lymphoid tissue: 50.1" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 45.7;Intestinal goblet cells: 40.7;Leydig cells: 53.7;Undifferentiated cells: 124.2" "Cancer enhanced" "Detected in all" "colorectal cancer: 43.3" "Low region specificity" "Detected in some" "Immune cell enhanced" "Detected in many" "T-reg: 7.9" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "MOLT-4: 279.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA005565 Supported Nucleoplasm,Cytosol No Yes "Cluster 4: T-regs - Cell cycle regulation" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 53: Intestinal epithelial cells - Unknown function" "Nucleoplasm, Cytosol" "HPA005565: AB_2078680" "unprognostic (1.67e-3)" "unprognostic (2.26e-1)" "unprognostic (1.21e-1)" "unprognostic (1.54e-2)" "unprognostic (2.16e-1)" "unprognostic (1.44e-2)" "prognostic unfavorable (4.20e-4)" "unprognostic (7.54e-2)" "prognostic unfavorable (5.50e-4)" "unprognostic (4.96e-2)" "unprognostic (2.83e-1)" "unprognostic (8.97e-3)" "unprognostic (0.00e+0)" "unprognostic (4.53e-3)" "unprognostic (1.96e-1)" "unprognostic (2.04e-1)" "unprognostic (2.47e-2)" 1.7 0.3 0.7 13.1 0.6 23.0 2.4 0.5 0.7 12.6 6.5 25.5 30.7 13.8 3.3 10.1 3.8 1.5 0.8 0.7 1.2 0.5 0.3 1.6 37.5 0.7 0.9 1.1 1.7 0.3 0.1 7.4 0.7 3.0 29.5 0.4 2.5 1.2 3.1 11.7 32.4 3.4 0.7 2.4 14.3 6.0 1.2 50.1 0.5 0.8 41.2 2.8 6.7 1.0 44.2 33.3 76.4 83.3 3.6 14.0 79.9 26.0 9.2 60.3 67.2 51.6 54.4 122.1 32.2 15.8 23.5 45.0 122.4 46.6 87.0 59.2 67.4 27.6 24.6 66.0 3.8 181.2 25.1 11.4 3.9 32.8 27.3 7.8 28.0 158.1 67.4 27.2 17.7 35.4 279.7 181.7 90.4 103.4 22.7 194.4 58.2 77.3 29.5 38.2 22.3 39.2 40.8 13.4 22.0 67.9 0.3 70.5 13.0 39.3 16.8 12.9 48.5 7.4 17.1 173.0 24.4 99.8 34.0 0.0 0.5 0.0 1.1 0.0 0.4 1.9 3.0 5.9 3.5 0.3 0.2 1.0 0.2 3.2 0.0 0.5 7.9 2.3 0.7 0.6 0.5 0.7 0.7 1.2 0.7 0.9 0.7 0.7 1.2 1.0 1.0 0.0 0.6 0.7 3.0 20.3 14.9 3.3 14.8 0.0 2.6 6.5 1.1 0.0 0.3 0.0 0.0 45.7 1.6 17.1 0.0 0.2 0.9 3.2 33.0 3.4 12.2 33.6 0.1 0.2 29.9 4.1 22.4 6.8 0.0 18.5 0.0 0.2 10.4 0.0 10.5 40.7 4.1 1.0 4.4 2.2 53.7 2.3 3.6 0.0 1.2 0.7 0.0 0.5 0.1 1.0 11.1 34.6 3.8 5.3 11.9 0.0 0.1 0.0 0.0 1.1 7.2 13.8 28.9 21.8 15.9 10.1 9.1 2.7 124.2 3.8 CEBPE CRP1 ENSG00000092067 "CCAAT enhancer binding protein epsilon" Q15744 14 23117306-23119255 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 15 "bone marrow: 51.8" "Cell type enhanced" "Detected in some" "Hofbauer cells: 6.6;Kupffer cells: 1.4;Macrophages: 2.3;monocytes: 2.3" "Not detected" "Not detected" "Not detected" "Not detected" "Immune cell enriched" "Detected in many" 218 "eosinophil: 750.4" "Lineage enriched" "Detected in many" 250 "granulocytes: 750.4" "Group enriched" "Detected in some" 4 "HL-60: 233.8;NB-4: 122.5" "Not detected" "Not detected" "Not detected" "Not detected" "HPA002928, CAB005113" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 24: NB-4 - Immune response" "Cluster 4: Macrophages - Innate immune response" Nucleoplasm "Plasma membrane, Cytosol" "CAB005113: AB_631240, HPA002928: AB_1078494" "unprognostic (1.33e-2)" "unprognostic (4.76e-2)" "unprognostic (4.19e-2)" "unprognostic (2.04e-1)" "unprognostic (5.01e-2)" "unprognostic (1.66e-3)" "unprognostic (2.84e-1)" "unprognostic (1.49e-2)" "unprognostic (3.33e-2)" "unprognostic (5.69e-2)" "unprognostic (9.03e-2)" "unprognostic (2.22e-1)" "unprognostic (3.80e-3)" "unprognostic (1.42e-1)" "unprognostic (1.12e-2)" "unprognostic (2.57e-2)" "unprognostic (8.19e-2)" 0.1 0.0 0.1 1.6 0.1 51.8 0.0 0.0 0.2 0.0 0.0 0.2 2.4 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.5 0.4 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.2 0.0 0.0 0.0 0.2 0.1 3.2 0.3 0.1 3.4 0.8 0.0 0.3 0.5 0.0 0.0 0.1 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 233.8 39.6 0.0 0.0 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 0.9 122.5 0.0 0.0 0.0 10.4 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 18.3 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.2 0.0 26.3 0.0 0.5 3.0 750.4 0.0 0.6 0.1 0.5 1.0 0.4 1.5 0.5 1.8 1.5 3.4 0.0 0.3 1.5 0.0 1.8 0.1 0.1 0.0 0.2 0.0 0.1 0.1 0.1 0.2 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.0 0.3 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 6.6 0.0 0.0 0.0 0.0 1.4 0.6 0.1 0.0 2.3 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.6 0.1 0.0 0.0 CFB "BF, BFD, H2-Bf" ENSG00000243649 "Complement factor B" P00751 6 31945650-31952084 "Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Complement alternate pathway, Immunity, Innate immunity" "Hydrolase, Protease, Serine protease" "Age-related macular degeneration, Disease variant, Hemolytic uremic syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 18 "liver: 2613.2" "Cell type enhanced" "Detected in many" "Ductal cells: 873.6;Exocrine glandular cells: 197.3;Hepatocytes: 284.0;Pancreatic endocrine cells: 318.0;Proximal enterocytes: 139.7" "Cancer enhanced" "Detected in all" "liver cancer: 78.3" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 15.0;ASC TERT1: 23.0;EFO-21: 25.1;fHDF/TERT166: 14.1;HSkMC: 19.1;U-87 MG: 10.1" "Low region specificity" "Detected in all" "HPA000951, HPA001817, HPA001832, CAB016381" Supported Approved "Endoplasmic reticulum,Vesicles,Cell Junctions" "Secreted to blood" NA NA 879000000 120000000000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 62: Liver - Hemostasis" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 1: Pancreatic cells - Digestion" "Endoplasmic reticulum, Vesicles" "Cell Junctions" "CAB016381: AB_627562, HPA000951: AB_2797216, HPA001817: AB_1078779, HPA001832: AB_1078778" "prognostic favorable (2.76e-5)" "unprognostic (1.02e-1)" "unprognostic (1.44e-1)" "unprognostic (7.94e-2)" "unprognostic (1.82e-2)" "unprognostic (8.56e-2)" "unprognostic (8.08e-3)" "unprognostic (8.81e-2)" "unprognostic (3.51e-1)" "unprognostic (2.26e-2)" "unprognostic (1.32e-2)" "unprognostic (6.57e-2)" "prognostic unfavorable (1.53e-5)" "unprognostic (1.36e-1)" "unprognostic (5.13e-2)" "unprognostic (1.05e-2)" "unprognostic (3.68e-2)" 143.7 18.0 3.6 32.8 3.6 0.1 28.5 3.4 9.9 16.3 3.9 22.3 28.1 8.2 14.2 24.1 53.7 0.8 42.6 3.7 3.4 58.7 2613.2 39.2 4.2 4.1 3.7 9.9 51.8 0.2 17.7 5.0 3.8 60.3 14.5 1.4 43.3 0.0 3.0 7.7 73.1 48.3 3.4 12.9 54.5 2.1 3.7 1.9 15.5 0.7 6.7 17.8 9.2 3.6 0.5 1.9 0.1 0.0 15.0 23.0 0.1 0.0 0.2 1.1 0.0 0.1 8.6 0.1 25.1 14.1 0.6 6.0 0.0 1.8 1.2 1.0 0.3 0.7 0.4 0.5 0.0 1.0 0.4 19.1 0.4 0.6 0.5 1.3 0.2 0.1 0.3 0.7 0.1 0.2 0.1 0.3 0.4 0.0 0.4 0.3 0.3 1.3 1.7 0.5 0.0 0.1 0.0 1.3 0.0 0.0 0.0 0.2 0.0 3.4 1.2 0.4 0.4 0.7 2.1 1.0 10.1 0.6 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 3.6 3.6 3.4 9.9 3.7 3.4 4.1 3.7 3.8 3.4 3.7 3.6 1.0 0.0 16.9 0.0 2.6 0.8 0.9 64.8 11.4 0.3 4.9 0.9 0.4 44.3 127.3 5.5 0.0 0.1 0.0 3.7 3.9 873.6 0.0 1.9 0.4 3.9 2.4 16.0 0.2 197.3 0.2 34.6 20.9 1.2 0.0 0.0 11.7 284.0 1.0 0.0 0.2 8.5 18.3 19.7 1.0 0.0 2.8 1.1 0.0 5.6 18.1 0.4 0.0 0.0 0.0 318.0 10.6 0.0 0.1 8.6 139.7 17.1 75.4 0.7 0.0 1.0 12.6 0.1 0.1 3.9 1.8 1.6 1.6 0.0 12.4 4.5 CFD "ADN, DF, PFD" ENSG00000197766 "Complement factor D" P00746 19 859664-863641 "Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins" "Complement alternate pathway, Immunity, Innate immunity" "Hydrolase, Protease, Serine protease" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 1496.7;breast: 993.2" "Group enriched" "Detected in many" 6 "Fibroblasts: 9365.5;Leydig cells: 5032.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "basophil: 297.6" "Lineage enriched" "Detected in all" 5 "granulocytes: 297.6" "Group enriched" "Detected in many" 5 "ASC diff: 197.4;THP-1: 342.2" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Secreted to blood" NA NA 732000000 4400000000 "Cluster 2: Granulocytes - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 43: THP-1 - Innate immune response" "Cluster 50: Fibroblasts - ECM organization" "unprognostic (3.00e-2)" "unprognostic (6.09e-2)" "unprognostic (2.44e-1)" "unprognostic (1.22e-3)" "unprognostic (6.92e-2)" "unprognostic (5.28e-2)" "unprognostic (8.11e-3)" "unprognostic (2.48e-1)" "unprognostic (1.46e-2)" "unprognostic (8.10e-2)" "prognostic favorable (1.77e-4)" "unprognostic (9.53e-2)" "prognostic unfavorable (7.09e-4)" "unprognostic (1.23e-1)" "unprognostic (4.55e-2)" "unprognostic (1.92e-2)" "unprognostic (9.75e-2)" 1496.7 33.3 1.5 9.6 1.6 10.7 993.2 1.2 2.4 597.4 3.7 324.8 23.5 58.4 2.4 212.8 258.0 9.6 854.2 1.7 2.3 18.1 8.7 363.3 2.1 3.3 2.3 74.3 41.4 1.7 9.0 14.5 3.6 277.8 10.9 0.6 247.3 6.3 197.0 488.6 248.4 4.0 2.6 28.6 263.8 51.8 2.9 3.6 332.3 26.9 0.8 848.3 729.8 5.8 3.9 5.2 0.6 2.2 197.4 26.2 9.5 0.8 0.0 0.0 0.0 0.8 0.4 0.2 5.7 0.0 0.5 3.0 1.8 0.5 0.0 5.7 14.5 0.5 12.3 3.8 3.6 2.5 4.9 8.7 0.2 0.1 0.0 0.8 0.0 4.5 11.9 0.9 0.0 2.6 0.6 49.2 1.0 4.5 16.1 1.3 0.5 5.2 0.3 1.2 1.8 1.8 5.5 1.9 0.5 0.6 7.5 342.2 0.4 0.2 5.1 2.9 0.6 7.8 4.7 0.4 0.2 20.8 0.2 297.6 41.2 127.8 8.4 55.5 13.2 5.7 4.2 10.2 14.5 1.4 9.7 9.7 112.0 1.3 57.3 1.8 4.7 37.8 1.5 1.6 1.2 2.4 1.7 2.3 3.3 2.3 3.6 2.6 2.9 5.8 857.8 9.6 23.3 0.0 19.2 785.5 49.0 10.1 17.1 2.9 107.3 120.1 55.5 21.5 30.9 18.4 2.1 36.6 40.0 33.1 11.7 7.7 27.1 23.1 593.3 114.8 4.2 8.2 0.2 0.0 32.9 9365.5 113.6 15.9 17.1 0.9 30.4 2.6 272.4 1.7 0.4 8.7 0.0 424.7 1145.2 89.6 5032.4 442.5 642.1 4.7 303.6 1.3 21.6 0.0 0.1 2.9 64.8 283.2 41.0 19.7 4.3 3.4 28.4 6.5 0.0 414.3 530.2 11.4 21.3 28.6 735.9 34.3 82.8 1.2 21.0 233.2 CFH "ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS" ENSG00000000971 "Complement factor H" P08603 1 196652043-196747504 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement alternate pathway, Host-virus interaction, Immunity, Innate immunity" "Age-related macular degeneration, Cancer-related genes, Disease variant, Hemolytic uremic syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 6 "liver: 1676.3" "Group enriched" "Detected in many" 4 "Fibroblasts: 448.0;Hepatocytes: 1114.8;Leydig cells: 283.9" "Cancer enriched" "Detected in all" 9 "liver cancer: 151.1" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "MAIT T-cell: 18.7" "Lineage enriched" "Detected in single" 26 "T-cells: 18.7" "Cell line enhanced" "Detected in many" "HHSteC: 123.1;HSkMC: 119.5;hTERT-RPE1: 374.9;RT4: 227.0" "CAB016385, CAB016769, HPA038922, HPA049176, HPA053326" Supported Approved Vesicles "Secreted to blood" NA NA 396000000000 100000000000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 85: Liver - Metabolism" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 50: Fibroblasts - ECM organization" Vesicles "CAB016385: AB_627572, CAB016769: , HPA038922: AB_2676271, HPA049176: AB_2680663, HPA053326: AB_2682113" "unprognostic (2.40e-1)" "unprognostic (9.86e-2)" "unprognostic (1.22e-1)" "unprognostic (8.39e-2)" "unprognostic (5.40e-3)" "unprognostic (1.80e-1)" "unprognostic (3.75e-3)" "unprognostic (7.40e-2)" "unprognostic (1.06e-1)" "unprognostic (1.04e-1)" "unprognostic (9.08e-2)" "unprognostic (2.08e-1)" "prognostic unfavorable (1.92e-6)" "unprognostic (6.50e-3)" "unprognostic (4.49e-3)" "unprognostic (1.73e-1)" "unprognostic (1.37e-1)" 125.3 42.1 18.1 32.7 21.5 1.3 66.9 20.0 29.6 76.8 43.0 51.0 30.5 12.8 15.9 63.8 24.2 133.6 301.5 18.1 18.6 25.5 1676.3 70.8 27.4 19.3 19.0 165.1 14.0 6.4 16.0 26.1 19.9 23.0 80.2 4.3 126.7 24.0 21.1 74.5 52.1 32.5 19.5 13.9 46.9 14.3 21.6 12.1 102.5 84.0 25.9 149.9 27.0 21.1 0.0 64.9 0.0 0.0 96.5 54.7 0.1 25.8 63.1 3.5 13.5 0.1 11.9 0.3 9.6 0.1 0.2 2.2 0.0 23.6 2.6 1.3 0.0 20.0 74.7 0.0 123.1 0.9 0.3 119.5 0.3 18.4 7.9 374.9 79.2 0.0 74.4 2.7 89.4 0.1 0.5 0.1 0.4 0.0 0.1 0.2 89.8 21.0 0.0 227.0 0.0 0.1 0.4 0.0 0.1 0.6 0.1 0.0 5.6 73.6 0.9 0.8 0.8 0.8 0.0 0.3 13.1 0.2 5.8 0.0 0.1 0.0 2.0 0.0 18.7 0.0 6.6 4.0 0.2 0.0 0.4 1.5 0.7 0.0 0.0 0.0 0.0 1.1 18.1 21.5 20.0 29.6 18.1 18.6 19.3 19.0 19.9 19.5 21.6 21.1 73.9 9.6 17.6 0.7 4.2 44.2 63.6 140.6 14.2 2.4 1.3 3.4 10.9 35.8 141.1 5.5 0.0 0.0 3.1 0.1 0.0 6.2 2.6 2.3 3.8 49.8 0.0 52.6 0.6 0.8 0.0 448.0 8.6 1.9 3.8 6.9 47.8 1114.8 1.1 0.0 1.0 0.0 14.2 43.8 62.1 7.4 283.9 5.7 44.4 38.4 0.3 0.3 0.0 0.0 0.2 5.3 0.0 138.8 2.6 13.0 0.0 0.5 115.6 1.4 6.6 94.2 59.6 1.4 1.0 10.9 38.2 0.1 13.2 26.3 0.0 61.5 CFI "C3b-INA, FI, IF, KAF" ENSG00000205403 "Complement factor I" P05156 4 109740694-109801999 "Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins" "Complement pathway, Host-virus interaction, Immunity, Innate immunity" "Hydrolase, Protease, Serine protease" "Age-related macular degeneration, Disease variant, Hemolytic uremic syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "liver: 1098.8" "Cell type enhanced" "Detected in many" "Cholangiocytes: 108.7;Hepatocytes: 592.5;Muller glia cells: 147.8;Proximal tubular cells: 223.6" "Cancer enhanced" "Detected in all" "liver cancer: 90.2" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CAPAN-2: 106.1;Hep G2: 179.8;HSkMC: 67.4;RPTEC TERT1: 190.6" "HPA001143, CAB016777, HPA024061" Supported "Secreted to blood" NA NA 12000000000 "Cluster 85: Liver - Metabolism" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "CAB016777: , HPA001143: AB_1078555, HPA024061: AB_1847129" "unprognostic (1.04e-1)" "unprognostic (5.79e-2)" "unprognostic (1.68e-1)" "unprognostic (6.32e-2)" "unprognostic (1.55e-2)" "unprognostic (8.58e-2)" "unprognostic (2.95e-2)" "unprognostic (3.00e-1)" "unprognostic (2.00e-2)" "unprognostic (5.42e-3)" "unprognostic (1.41e-1)" "unprognostic (3.61e-1)" "unprognostic (8.63e-2)" "unprognostic (1.29e-1)" "unprognostic (3.42e-2)" "unprognostic (1.74e-1)" "prognostic unfavorable (6.06e-4)" 45.1 50.2 8.1 12.6 8.2 0.1 17.4 7.7 13.2 36.8 10.4 7.4 38.0 39.2 80.3 9.3 74.0 73.0 25.0 8.3 9.6 224.9 1098.8 50.7 8.9 15.6 10.2 32.1 26.0 3.1 8.4 24.1 10.7 8.3 6.4 53.0 15.0 26.7 3.9 2.7 22.3 24.3 10.5 33.1 14.4 8.8 9.2 2.3 14.5 4.6 7.5 34.1 8.3 10.6 0.0 0.6 0.0 0.3 0.0 0.2 0.1 1.5 1.4 0.1 0.2 0.0 106.1 0.0 32.9 0.0 0.5 0.0 0.0 0.0 0.0 34.8 0.7 0.0 0.4 179.8 6.2 0.3 0.0 67.4 0.0 0.1 0.0 3.6 4.8 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 190.6 0.5 0.0 0.3 1.6 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.4 0.6 0.0 0.0 0.0 0.1 18.8 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.1 8.2 7.7 13.2 8.3 9.6 15.6 10.2 10.7 10.5 9.2 10.6 48.1 12.8 50.9 3.6 4.0 1.0 12.2 15.2 0.6 3.4 2.1 5.6 2.3 108.7 36.2 64.4 2.1 0.1 0.3 1.7 31.3 69.3 0.2 34.1 46.4 57.7 0.0 2.7 0.3 30.9 0.2 34.3 8.2 33.6 3.8 72.1 55.0 592.5 0.7 1.7 0.2 1.9 0.0 16.7 1.5 0.8 16.8 2.0 0.0 4.7 1.6 147.8 0.0 0.0 0.3 30.8 2.4 0.0 0.0 3.8 17.0 223.6 8.4 7.3 0.0 1.3 9.4 1.6 0.5 1.9 1.1 0.3 3.4 18.5 4.1 12.6 CFP PFC ENSG00000126759 "Complement factor properdin" P27918 X 47623172-47630305 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Complement alternate pathway, Immunity, Innate immunity" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "bone marrow: 83.9;lymphoid tissue: 58.4" "Cell type enhanced" "Detected in many" "Hepatic stellate cells: 108.1;Kupffer cells: 356.7;Langerhans cells: 164.1;Macrophages: 177.3;monocytes: 473.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in all" 8 "classical monocyte: 1167.5;intermediate monocyte: 1273.6;myeloid DC: 994.5;neutrophil: 730.3;non-classical monocyte: 868.9" "Group enriched" "Detected in all" 46 "dendritic cells: 994.5;granulocytes: 730.3;monocytes: 1273.6" "Cell line enhanced" "Detected in some" "EFO-21: 20.7;HEL: 5.0;HMC-1: 5.5;NB-4: 10.7;U-937: 7.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA072644 Approved Vesicles "Secreted to blood" NA NA 6200000000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 38: EFO-21 - Unknown function" "Cluster 19: Monocytes & Neutrophils - Innate immune response" Vesicles "HPA072644: " "unprognostic (2.77e-3)" "unprognostic (2.21e-3)" "unprognostic (1.00e-1)" "unprognostic (2.15e-2)" "unprognostic (4.15e-2)" "unprognostic (9.66e-5)" "unprognostic (9.90e-3)" "unprognostic (1.30e-2)" "unprognostic (5.37e-2)" "unprognostic (1.20e-1)" "unprognostic (1.08e-2)" "unprognostic (2.70e-1)" "unprognostic (1.97e-2)" "unprognostic (2.58e-1)" "unprognostic (1.32e-1)" "unprognostic (4.62e-2)" "unprognostic (2.17e-1)" 6.0 1.9 0.3 20.5 0.3 83.9 2.1 0.3 0.6 0.6 0.2 2.1 1.2 0.9 0.2 1.6 3.4 2.1 2.6 0.4 0.1 0.8 12.0 9.3 11.7 0.1 0.0 0.7 0.8 0.1 0.8 0.9 0.0 0.7 0.9 0.2 1.0 0.2 1.0 1.5 3.7 5.2 0.0 58.4 1.5 0.6 0.0 5.1 0.9 0.7 4.4 4.9 0.7 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 20.7 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.2 5.0 0.2 0.0 0.1 1.1 5.5 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.2 0.0 0.2 0.0 10.7 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 3.2 1.0 0.0 0.1 0.5 0.1 0.4 0.4 0.1 0.1 7.2 0.0 131.5 1167.5 39.9 3.0 1273.6 2.3 6.7 15.1 1.8 994.5 2.6 21.8 8.1 730.3 12.3 868.9 30.9 14.1 1071.9 0.3 0.3 0.3 0.6 0.4 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 9.1 1.0 5.8 4.0 0.1 0.3 1.2 3.4 0.7 0.4 0.9 1.5 2.8 0.0 0.0 0.3 1.7 0.3 0.0 0.2 0.2 0.4 0.4 7.4 0.0 2.5 1.4 0.7 0.5 2.0 1.1 0.6 1.3 4.0 108.1 2.0 17.3 1.7 1.1 0.0 0.0 356.7 164.1 0.3 0.9 177.3 5.4 0.0 473.7 0.3 4.1 2.0 0.3 0.3 0.1 1.2 1.2 0.3 0.1 0.5 7.5 1.9 0.0 1.5 1.2 0.0 0.2 0.5 3.0 0.4 4.8 3.1 0.6 0.0 CIITA "C2TA, MHC2TA, NLRA" ENSG00000179583 "Class II major histocompatibility complex transactivator" P33076 16 10866222-10943021 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Acyltransferase, Kinase, Transferase" "Cancer-related genes, Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 57.3" "Cell type enhanced" "Detected in many" "B-cells: 48.8;Langerhans cells: 51.8;Macrophages: 43.8;Microglial cells: 42.2;monocytes: 51.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "classical monocyte: 29.1;eosinophil: 17.5;intermediate monocyte: 23.5;memory B-cell: 47.3;myeloid DC: 46.2;naive B-cell: 63.3;non-classical monocyte: 29.0;plasmacytoid DC: 48.3" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 51.1;REH: 89.5;U-266/70: 18.0;U-698: 25.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB016084, HPA054757" Enhanced Supported Nucleoplasm NA NA "Cluster 23: Antigen presenting cells - Antigen presentation" "Cluster 16: Immune cells - Immune response" "Cluster 14: REH - Unknown function" "Cluster 41: Macrophages - Immune response" Nucleoplasm "CAB016084: AB_627261, HPA054757: " "unprognostic (1.45e-3)" "unprognostic (1.38e-2)" "unprognostic (8.22e-3)" "unprognostic (1.12e-2)" "unprognostic (5.66e-2)" "unprognostic (2.88e-3)" "unprognostic (2.92e-2)" "unprognostic (1.55e-2)" "unprognostic (1.15e-2)" "unprognostic (1.85e-1)" "unprognostic (1.23e-1)" "unprognostic (3.72e-1)" "unprognostic (1.64e-2)" "unprognostic (2.72e-2)" "unprognostic (6.33e-3)" "unprognostic (2.74e-1)" "unprognostic (1.05e-2)" 9.4 6.5 6.4 39.2 5.9 9.2 7.8 7.3 7.9 10.7 8.9 6.7 20.5 7.3 2.6 5.5 7.4 15.0 5.4 5.4 11.5 7.2 4.7 24.1 57.3 15.0 8.3 3.6 3.9 2.6 3.0 2.6 11.9 4.8 8.2 1.4 12.1 6.9 5.0 8.7 24.8 7.3 11.5 51.2 12.9 2.1 13.0 15.9 5.2 2.4 57.0 9.0 4.1 16.4 0.4 0.4 0.7 0.6 0.1 0.0 0.5 0.2 0.0 0.3 0.4 0.6 12.0 11.2 1.6 0.0 1.7 1.8 0.0 0.0 0.2 51.1 0.6 6.3 2.6 1.3 0.0 0.9 0.9 2.1 0.0 0.2 0.0 1.8 0.0 0.7 0.8 4.1 0.2 0.7 0.6 1.0 0.3 0.4 0.3 89.5 0.6 7.9 0.1 3.6 1.8 0.3 2.1 0.6 2.1 0.6 1.0 3.8 0.5 4.3 0.7 1.2 0.5 18.0 1.4 25.8 16.0 1.1 14.7 0.7 29.1 17.5 0.8 23.5 0.4 47.3 0.3 1.4 46.2 63.3 0.2 0.4 6.8 1.8 29.0 48.3 1.2 5.4 6.4 5.9 7.3 7.9 5.4 11.5 15.0 8.3 11.9 11.5 13.0 16.4 14.5 6.4 19.5 0.3 48.8 2.3 0.3 1.3 1.2 0.8 1.7 2.0 5.3 1.5 1.5 3.7 0.0 0.2 17.9 2.0 0.0 5.5 0.8 1.5 0.4 7.3 2.4 6.9 1.4 2.0 0.3 1.2 4.6 1.4 10.8 7.7 1.4 0.7 8.7 0.0 1.8 1.9 0.0 16.1 51.8 0.0 0.6 43.8 7.2 42.2 51.8 0.2 2.1 0.0 0.3 1.1 0.1 0.0 1.1 0.4 12.3 4.8 5.6 1.6 0.0 1.0 1.2 0.0 0.0 1.0 2.8 0.1 3.0 0.4 1.5 0.5 CORO1A "coronin-1, HCORO1, p57" ENSG00000102879 "Coronin 1A" P31146 16 30182827-30189076 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" Actin-binding "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "bone marrow: 568.8;lymphoid tissue: 583.8" "Cell type enhanced" "Detected in many" "B-cells: 523.9;dendritic cells: 588.7;Hofbauer cells: 494.4;Kupffer cells: 395.8;Macrophages: 342.7;monocytes: 583.7;NK-cells: 968.1;T-cells: 663.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 924.0;HL-60: 645.7;HMC-1: 1086.7;JURKAT: 603.0;MOLT-4: 632.5;NB-4: 771.8;RPMI-8226: 980.9;U-698: 618.2;U-937: 829.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB046473, HPA051132" Enhanced Approved Cytosol NA NA 45000000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 3: HMC-1 - Innate immune response" "Cluster 63: NK-cells & T-cells - Immune response" Cytosol "CAB046473: AB_10602363, HPA051132: AB_2681355" "unprognostic (4.17e-3)" "unprognostic (3.64e-3)" "unprognostic (3.86e-2)" "prognostic favorable (6.91e-4)" "unprognostic (2.41e-1)" "prognostic favorable (4.42e-4)" "unprognostic (1.99e-2)" "unprognostic (8.27e-3)" "unprognostic (8.26e-3)" "unprognostic (4.30e-1)" "unprognostic (1.54e-1)" "unprognostic (2.25e-1)" "prognostic unfavorable (5.74e-7)" "unprognostic (2.55e-1)" "unprognostic (2.37e-2)" "unprognostic (7.16e-2)" "unprognostic (2.01e-1)" 29.1 20.8 34.4 306.4 37.1 568.8 11.2 24.9 52.0 10.6 23.6 26.8 44.3 10.0 3.1 22.5 17.9 45.0 11.3 36.9 31.9 11.5 13.1 49.5 583.8 37.6 32.0 6.4 8.4 4.3 9.3 18.4 32.2 11.4 15.3 0.9 32.9 7.3 6.7 17.6 111.0 22.2 35.8 321.4 49.0 4.8 33.9 257.6 12.7 8.8 309.1 57.6 10.4 50.0 3.1 3.6 10.9 21.5 0.1 0.1 6.1 2.6 0.7 5.4 3.0 0.7 6.9 924.0 6.1 0.9 1.5 4.4 5.2 10.8 1.3 302.3 2.5 97.9 0.5 15.0 1.7 645.7 1086.7 2.8 0.0 4.3 0.5 0.4 2.0 603.0 1.5 467.6 3.4 80.7 632.5 771.8 4.0 3.1 6.4 340.0 17.5 980.9 1.3 5.1 17.3 13.0 2.2 110.7 2.0 0.2 1.9 373.0 1.6 4.0 9.0 2.7 3.1 348.5 497.7 618.2 3.0 829.6 6.3 797.2 773.6 2671.1 637.5 859.7 597.8 505.5 567.3 625.6 843.2 512.0 537.1 566.2 1318.9 531.0 898.0 482.1 858.7 1647.2 34.4 37.1 24.9 52.0 36.9 31.9 37.6 32.0 32.2 35.8 33.9 50.0 6.3 22.4 32.5 0.3 523.9 11.3 1.2 3.2 2.2 1.2 4.7 5.5 1.5 17.2 6.0 1.8 0.0 4.6 588.7 2.3 0.0 3.5 0.5 1.1 2.0 12.3 6.0 60.2 3.3 0.9 17.4 9.5 18.8 1.3 83.7 0.6 21.8 4.8 494.4 0.0 1.7 2.2 6.1 395.8 197.9 1.2 0.6 342.7 32.0 4.7 583.7 0.8 968.1 1.5 0.4 11.1 47.5 0.0 201.4 0.8 1.0 4.8 3.5 0.9 6.6 2.9 5.1 0.1 0.9 2.4 9.1 4.9 663.0 2.7 3.3 0.9 CR2 "C3DR, CD21" ENSG00000117322 "Complement C3d receptor 2" P20023 1 207454230-207489895 "CD markers, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Complement pathway, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "lymphoid tissue: 174.0" "Group enriched" "Detected in some" 17 "B-cells: 54.9;Plasma cells: 14.9" "Cancer enhanced" "Detected in many" "pancreatic cancer: 7.1;stomach cancer: 5.9" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "memory B-cell: 17.5;naive B-cell: 20.3" "Lineage enriched" "Detected in many" 8 "B-cells: 20.3" "Cell line enhanced" "Detected in some" "Daudi: 24.0;JURKAT: 4.0;MOLT-4: 13.4;RPMI-8226: 4.7" "Not detected" "Not detected" "CAB002659, HPA052942, HPA060715" Enhanced NA NA 220000000 "Cluster 21: B-cells - Adaptive immune response" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "CAB002659: , HPA052942: AB_2681994, HPA060715: AB_2684349" "prognostic favorable (6.90e-4)" "unprognostic (1.22e-1)" "unprognostic (9.95e-2)" "unprognostic (3.64e-2)" "unprognostic (2.65e-1)" "unprognostic (1.27e-3)" "unprognostic (1.18e-1)" "unprognostic (6.62e-3)" "unprognostic (1.91e-2)" "unprognostic (1.79e-1)" "unprognostic (1.20e-1)" "unprognostic (7.95e-2)" "unprognostic (2.14e-1)" "unprognostic (1.12e-1)" "unprognostic (2.19e-1)" "unprognostic (2.09e-2)" "unprognostic (3.35e-2)" 2.0 0.0 0.1 53.1 0.1 0.8 0.6 0.0 0.2 0.0 0.0 5.1 0.9 0.4 0.0 0.7 0.1 2.0 0.1 0.2 0.0 6.2 0.4 1.1 174.0 0.1 0.2 0.0 0.2 0.1 0.0 0.2 0.1 1.1 4.0 0.0 4.3 0.0 0.2 0.0 16.7 0.4 0.0 73.2 6.9 0.5 0.1 15.2 0.8 0.0 171.0 1.9 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 24.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.4 0.0 0.0 0.1 13.4 0.0 2.1 0.0 0.3 0.0 0.2 4.7 0.0 0.0 1.1 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.7 17.5 1.0 0.6 0.0 20.3 2.4 2.2 0.3 0.0 0.0 0.0 0.0 1.4 0.1 0.1 0.0 0.2 0.2 0.0 0.1 0.2 0.1 0.0 0.1 0.2 0.0 0.0 0.0 0.0 54.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.1 0.0 0.0 0.0 0.4 0.3 0.0 0.0 0.2 1.1 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.0 0.0 0.0 1.6 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 14.9 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.1 0.0 0.0 1.0 0.1 0.0 0.0 CTLA4 "CD, CD152, CELIAC3, CTLA-4, GSE, IDDM12" ENSG00000163599 "Cytotoxic T-lymphocyte associated protein 4" P16410 2 203867771-203873965 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Diabetes mellitus, Disease variant, FDA approved drug targets, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "lymphoid tissue: 37.4" "Cell type enriched" "Detected in some" 8 "T-cells: 41.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Immune cell enriched" "Detected in some" 7 "T-reg: 44.5" "Lineage enriched" "Detected in single" 445 "T-cells: 44.5" "Cell line enhanced" "Detected in some" "Karpas-707: 1.5;SK-MEL-30: 3.0;U-266/70: 4.3;U-266/84: 13.5" "Not detected" "Not detected" "Not detected" "Not detected" "Intracellular and membrane" NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 16: Immune cells - Immune response" "Cluster 16: U-266 - Nucleosome" "Cluster 24: Non-specific - Transcription regulation" "unprognostic (1.92e-2)" "unprognostic (9.13e-3)" "unprognostic (1.47e-3)" "unprognostic (9.89e-6)" "unprognostic (1.86e-1)" "prognostic favorable (4.48e-5)" "unprognostic (1.02e-1)" "unprognostic (1.75e-2)" "unprognostic (1.84e-3)" "unprognostic (2.65e-3)" "unprognostic (2.77e-1)" "unprognostic (3.76e-1)" "unprognostic (9.86e-10)" "unprognostic (4.13e-2)" "unprognostic (7.45e-2)" "unprognostic (4.94e-2)" "unprognostic (1.19e-2)" 1.1 0.2 0.4 18.5 0.4 6.1 1.0 0.4 0.7 0.6 0.5 1.3 0.3 0.3 0.0 1.6 0.6 5.2 0.5 0.5 0.5 0.6 0.7 2.9 37.4 1.3 0.7 0.1 0.4 0.5 0.3 0.3 1.1 1.5 3.2 0.0 0.5 1.0 0.1 0.7 6.2 0.8 0.6 3.9 2.9 1.1 0.5 10.1 1.1 0.2 17.0 5.8 0.8 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.0 4.3 13.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.5 0.0 6.2 0.8 0.0 0.0 1.4 0.3 0.0 0.0 0.0 0.0 44.5 0.6 0.4 0.4 0.4 0.7 0.5 0.5 1.3 0.7 1.1 0.6 0.5 0.5 0.4 0.0 3.2 0.0 1.6 0.5 0.0 0.0 0.0 0.0 0.3 0.3 0.2 0.0 0.0 0.0 0.0 0.3 0.8 0.0 0.0 0.0 0.4 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.2 4.1 0.0 1.3 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.1 0.2 0.0 3.3 0.0 2.8 0.2 0.0 1.0 0.0 0.0 0.0 0.0 0.0 5.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.3 1.0 0.2 0.9 0.1 41.9 0.0 0.0 0.1 CTPS1 "CTPS, GATD5" ENSG00000171793 "CTP synthase 1" P17812 1 40979688-41012565 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins" "Immunity, Pyrimidine biosynthesis" Ligase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 73.4" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017111, HPA051322" Enhanced Approved "Actin filaments,Cytosol" NA Yes 150000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 29: Non-specific - Vesicular transport" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 20: Spermatogonia & Spermatocytes - Spermatogenesis" Cytosol "Actin filaments" "CAB017111: , HPA051322: AB_2681441" "unprognostic (6.60e-2)" "unprognostic (4.44e-2)" "unprognostic (3.21e-2)" "unprognostic (2.00e-3)" "unprognostic (2.14e-1)" "unprognostic (8.37e-2)" "unprognostic (1.42e-2)" "unprognostic (9.72e-3)" "unprognostic (1.94e-3)" "unprognostic (1.01e-1)" "unprognostic (2.04e-2)" "unprognostic (8.93e-3)" "unprognostic (1.09e-1)" "unprognostic (8.21e-3)" "unprognostic (1.34e-1)" "unprognostic (4.49e-1)" "unprognostic (1.89e-2)" 9.1 8.1 4.8 11.1 4.7 6.8 6.7 4.0 5.8 9.3 7.9 8.7 4.4 23.6 5.7 14.9 11.1 10.6 5.3 4.9 5.3 12.4 73.4 7.6 12.4 4.6 4.9 3.4 4.7 47.6 0.0 7.8 5.8 13.5 12.0 2.4 50.6 24.8 7.7 4.6 8.4 51.9 4.7 5.0 4.1 14.7 4.9 17.3 4.8 7.6 17.8 17.7 0.3 5.0 77.8 68.5 95.3 60.5 22.9 30.9 138.5 138.8 57.0 141.2 92.0 131.5 66.6 149.8 55.6 61.7 39.4 38.6 91.5 97.0 139.5 66.5 78.0 87.3 72.3 43.3 87.8 128.0 56.8 34.0 49.2 148.5 103.0 23.0 64.1 102.2 84.7 51.5 99.4 42.9 125.0 38.1 126.8 66.4 81.3 100.9 120.0 93.7 71.4 69.4 118.4 61.7 79.2 77.7 33.9 90.8 30.1 152.9 53.5 78.2 119.6 61.7 167.2 36.8 50.8 134.5 59.8 84.5 97.4 0.0 3.5 0.0 3.6 6.5 5.7 5.2 4.1 4.3 11.0 4.0 3.7 6.1 0.0 6.9 5.9 11.9 6.3 3.4 4.8 4.7 4.0 5.8 4.9 5.3 4.6 4.9 5.8 4.7 4.9 5.0 5.4 6.4 18.4 4.9 10.9 8.0 14.3 9.1 9.6 12.5 4.6 4.7 5.7 21.5 7.0 5.5 6.2 15.4 26.4 2.2 1.9 19.2 32.4 4.7 10.8 8.5 3.0 22.5 14.1 17.2 26.4 8.7 7.1 7.3 1.3 15.8 2.2 29.0 11.0 11.8 18.7 3.4 6.1 2.8 6.2 27.9 10.8 6.8 1.8 7.5 8.7 5.4 7.2 7.1 10.3 19.3 1.1 24.8 15.1 19.3 25.2 12.8 2.8 4.3 39.5 9.3 17.5 11.1 40.6 11.8 7.4 5.6 9.9 20.7 5.8 7.3 CXCR4 "CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R" ENSG00000121966 "C-X-C motif chemokine receptor 4" P61073 2 136114349-136118149 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 1175.1;lymphoid tissue: 549.3" "Cell type enhanced" "Detected in many" "B-cells: 1446.9;dendritic cells: 1015.1;Langerhans cells: 486.2;Macrophages: 513.6;Plasma cells: 534.2;T-cells: 1436.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 580.8;JURKAT: 323.6;Karpas-707: 302.1;MOLT-4: 538.9;REH: 281.0;U-266/70: 648.5;U-698: 677.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 21: B-cells - Adaptive immune response" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" "unprognostic (1.19e-1)" "unprognostic (1.46e-2)" "unprognostic (2.69e-1)" "unprognostic (5.97e-2)" "unprognostic (1.29e-2)" "unprognostic (1.12e-2)" "unprognostic (4.99e-2)" "unprognostic (9.25e-2)" "unprognostic (6.06e-2)" "prognostic favorable (2.05e-4)" "unprognostic (1.23e-1)" "unprognostic (2.66e-1)" "prognostic unfavorable (1.41e-7)" "prognostic unfavorable (5.67e-4)" "unprognostic (1.57e-1)" "unprognostic (3.47e-2)" "unprognostic (9.33e-2)" 51.8 184.5 11.8 297.9 11.4 1175.1 39.6 14.6 23.8 36.1 20.1 33.2 12.6 35.2 5.5 34.9 64.9 84.5 21.8 10.6 19.7 29.0 52.4 95.5 383.8 24.3 12.8 12.9 10.0 12.3 32.6 57.5 18.2 34.1 48.6 7.8 30.2 11.8 5.2 9.8 246.5 28.1 16.7 346.5 64.0 4.0 15.2 491.2 36.7 12.0 549.3 99.3 26.9 32.3 0.8 0.3 9.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.9 0.0 580.8 1.8 0.0 0.4 0.7 1.7 0.0 0.0 29.6 6.9 35.1 84.3 0.0 0.0 81.5 60.7 0.0 0.0 0.0 0.0 0.0 54.5 323.6 1.0 302.1 0.0 1.5 538.9 72.8 9.3 45.4 2.9 281.0 62.6 102.5 4.5 0.0 30.9 26.1 0.6 2.0 0.3 2.9 0.7 156.7 8.1 0.0 2.0 0.5 0.4 648.5 116.7 677.4 0.1 131.8 0.1 87.0 28.5 117.8 83.8 15.6 67.3 115.6 76.5 79.6 25.7 166.2 113.1 109.5 143.3 17.2 9.1 63.7 76.1 51.9 11.8 11.4 14.6 23.8 10.6 19.7 24.3 12.8 18.2 16.7 15.2 32.3 32.0 16.0 42.2 8.5 1446.9 41.0 5.7 0.3 9.6 8.6 46.1 42.2 5.2 11.5 4.4 3.7 0.0 1.5 1015.1 1.1 13.7 5.1 1.2 20.0 8.9 67.6 1.8 67.5 0.0 0.9 4.2 28.9 52.0 71.0 12.6 9.0 29.6 9.1 159.9 0.0 0.2 2.0 10.2 270.0 486.2 2.9 1.5 513.6 113.8 3.7 189.2 1.0 153.5 0.0 2.0 2.3 1.1 2.6 534.2 3.2 0.0 3.2 2.4 0.8 46.0 99.1 23.1 0.5 7.8 8.5 35.7 6.3 1436.5 4.6 1.8 4.5 CYBA p22-PHOX ENSG00000051523 "Cytochrome b-245 alpha chain" P13498 16 88643289-88651054 "Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Electron transport, Transport" Oxidoreductase "Chronic granulomatous disease, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 742.0;lymphoid tissue: 693.1" "Cell type enhanced" "Detected in many" "dendritic cells: 1632.1;Hofbauer cells: 2171.9;Kupffer cells: 1734.2;Macrophages: 1682.8;monocytes: 1688.5;NK-cells: 1805.4;Plasma cells: 1990.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "eosinophil: 733.7" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "MCF7: 1058.3;RPMI-8226: 1631.2;THP-1: 1231.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009492 Enhanced NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 2: Immune cells - Immune response" "Cluster 25: RPMI-8226 - Immune response" "Cluster 4: Macrophages - Innate immune response" "CAB009492: AB_2090309" "prognostic favorable (8.19e-4)" "unprognostic (1.05e-1)" "unprognostic (8.32e-2)" "prognostic favorable (4.75e-5)" "unprognostic (2.42e-1)" "unprognostic (4.77e-2)" "unprognostic (4.88e-2)" "unprognostic (9.16e-2)" "unprognostic (1.72e-1)" "unprognostic (1.11e-1)" "unprognostic (3.08e-2)" "unprognostic (2.68e-1)" "prognostic unfavorable (1.83e-4)" "unprognostic (1.91e-1)" "unprognostic (5.22e-2)" "unprognostic (2.57e-2)" "unprognostic (1.63e-2)" 149.9 68.0 40.3 344.4 41.8 742.0 93.3 46.0 58.0 81.9 62.4 200.9 196.6 60.8 38.5 80.9 95.4 122.5 93.2 38.6 55.0 187.7 71.5 234.6 333.8 73.8 49.3 40.0 108.6 13.4 40.6 54.9 64.1 75.2 79.9 1.8 116.7 26.6 41.8 39.4 245.3 51.3 65.4 693.1 236.0 10.4 62.4 87.1 136.5 19.9 192.8 144.6 74.1 92.2 2.5 663.0 2.6 1.5 1.3 0.4 329.5 155.7 77.3 39.3 24.1 447.2 819.6 510.5 420.7 56.4 0.0 250.5 21.4 0.9 5.8 146.1 564.1 99.0 217.7 694.9 75.7 156.3 397.6 80.7 0.0 1.6 0.3 1.9 23.9 103.6 278.5 567.5 3.2 1058.3 147.9 822.3 106.2 248.7 1.5 437.9 1.6 1631.2 324.9 490.9 84.2 76.5 482.7 78.8 138.5 60.8 1.4 1231.3 129.8 1.5 6.1 1.8 2.2 362.9 459.9 543.6 195.5 464.9 53.4 120.2 103.8 733.7 76.7 150.1 55.8 109.8 36.7 70.4 107.0 110.7 28.9 36.7 192.3 36.4 143.3 196.3 41.2 47.3 40.3 41.8 46.0 58.0 38.6 55.0 73.8 49.3 64.1 65.4 62.4 92.2 157.8 16.0 12.4 0.0 1290.9 119.4 233.4 420.8 53.5 0.4 131.7 133.2 12.8 368.9 487.1 285.1 2.1 45.3 1632.1 807.2 127.2 636.8 4.2 219.5 137.5 137.1 230.5 162.7 0.2 155.3 299.0 184.8 285.4 312.5 279.0 104.3 317.0 23.9 2171.9 0.0 0.2 540.3 233.9 1734.2 1370.8 14.0 50.1 1682.8 1152.6 32.8 1688.5 1.6 1805.4 1.0 0.2 682.8 1045.8 21.4 1990.6 191.8 390.4 1057.4 529.7 2.7 59.2 44.0 164.3 0.9 15.6 75.2 85.7 118.2 838.6 20.5 805.2 436.9 CYBB "CGD, GP91-PHOX, NOX2" ENSG00000165168 "Cytochrome b-245 beta chain" P04839 X 37780059-37813461 "Disease related genes, Human disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Electron transport, Ion transport, Transport" "Ion channel, Oxidoreductase, Voltage-gated channel" "Chronic granulomatous disease, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 160.9;lymphoid tissue: 158.9" "Cell type enhanced" "Detected in many" "Hofbauer cells: 157.2;Kupffer cells: 456.0;Macrophages: 469.3;monocytes: 396.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "classical monocyte: 276.3;intermediate monocyte: 261.6" "Group enriched" "Detected in many" 4 "dendritic cells: 90.9;granulocytes: 110.5;monocytes: 276.3" "Group enriched" "Detected in some" 5 "Daudi: 52.8;NB-4: 64.2;REH: 54.6;RPMI-8226: 210.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA051227 Enhanced NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 25: RPMI-8226 - Immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" "HPA051227: AB_2681395" "unprognostic (5.83e-2)" "unprognostic (1.77e-2)" "unprognostic (2.15e-3)" "unprognostic (1.48e-2)" "unprognostic (1.27e-1)" "unprognostic (5.65e-2)" "unprognostic (2.29e-2)" "unprognostic (4.45e-2)" "unprognostic (9.14e-2)" "unprognostic (2.32e-2)" "unprognostic (5.73e-2)" "unprognostic (5.18e-2)" "unprognostic (5.92e-2)" "unprognostic (3.02e-1)" "unprognostic (2.48e-2)" "unprognostic (1.32e-1)" "unprognostic (9.72e-2)" 40.5 28.4 5.5 158.9 5.3 160.9 15.2 6.5 5.5 12.3 12.4 22.3 19.3 9.3 4.3 8.9 9.9 26.2 8.0 4.7 9.1 8.0 27.5 91.5 97.1 15.1 9.6 6.9 4.0 4.4 2.5 54.6 13.3 6.7 30.6 1.7 7.0 9.7 3.7 2.2 22.3 55.5 12.5 89.0 17.2 4.7 11.1 18.3 5.3 5.5 73.2 46.8 2.3 24.0 1.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.2 52.8 0.0 0.0 0.0 0.1 1.2 0.0 0.0 0.0 0.4 3.6 0.6 0.0 0.0 3.6 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.5 0.0 0.0 0.1 64.2 0.2 0.0 0.3 54.6 0.0 210.4 0.0 0.1 0.4 0.1 0.0 0.4 0.0 0.0 0.1 20.0 0.0 0.0 0.1 0.1 0.2 0.6 1.6 3.4 0.0 8.9 0.0 2.2 276.3 110.5 0.4 261.6 0.5 39.6 0.3 0.4 62.8 32.8 0.3 0.2 19.2 0.6 237.1 90.9 0.9 162.5 5.5 5.3 6.5 5.5 4.7 9.1 15.1 9.6 13.3 12.5 11.1 24.0 2.4 25.6 25.4 0.7 99.9 1.0 0.1 0.0 0.6 0.1 1.0 3.0 11.0 2.8 13.0 1.8 0.0 0.9 82.7 2.0 0.0 0.0 0.6 0.2 0.1 8.1 0.0 5.2 1.6 0.4 1.1 4.4 4.1 0.1 7.6 0.1 5.0 3.2 157.2 1.7 1.6 0.7 0.0 456.0 25.0 0.7 0.6 469.3 1.8 76.8 396.6 0.1 14.4 0.0 0.1 0.1 0.5 0.0 13.6 0.0 0.6 0.5 7.3 0.7 13.1 1.6 1.2 0.0 0.6 1.9 1.3 1.8 7.5 0.0 1.3 0.1 DCLRE1C "A-SCID, ARTEMIS, FLJ11360, SCIDA, SNM1C" ENSG00000152457 "DNA cross-link repair 1C" Q96SD1 10 14897359-14954432 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Adaptive immunity, DNA damage, DNA recombination, DNA repair, Immunity" "Endonuclease, Exonuclease, Hydrolase, Nuclease" "Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cone photoreceptor cells: 62.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA069295 Supported "Nucleoplasm,Golgi apparatus" NA NA "Cluster 46: Basophils - DNA binding" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 52: Non-specific - Transcription" Nucleoplasm "Golgi apparatus" "HPA069295: AB_2686112" "unprognostic (8.42e-2)" "unprognostic (1.69e-2)" "unprognostic (2.66e-2)" "unprognostic (2.40e-2)" "unprognostic (1.36e-2)" "prognostic favorable (1.30e-4)" "unprognostic (8.02e-4)" "unprognostic (1.23e-1)" "unprognostic (1.24e-1)" "prognostic favorable (7.98e-4)" "unprognostic (1.91e-1)" "unprognostic (4.20e-2)" "prognostic unfavorable (9.03e-8)" "unprognostic (2.43e-2)" "unprognostic (2.32e-1)" "unprognostic (2.51e-1)" "unprognostic (5.45e-3)" 4.2 3.3 2.2 8.0 3.2 14.0 6.1 5.7 3.4 4.5 3.7 4.3 5.2 4.4 3.8 7.1 3.7 4.0 2.3 2.2 2.2 3.5 2.6 4.9 14.1 2.8 2.7 4.5 3.1 3.8 2.2 4.4 3.1 4.0 5.2 4.9 4.5 3.7 3.0 6.9 5.4 3.9 2.5 10.4 5.9 1.9 2.9 12.3 5.5 2.7 12.8 5.4 5.1 3.7 16.2 7.8 6.9 13.8 6.4 8.2 6.6 9.7 5.3 13.0 13.5 8.9 13.4 21.7 3.8 7.6 9.2 13.7 7.6 5.1 10.9 13.4 8.0 16.7 8.9 6.0 5.1 10.0 18.4 6.6 4.8 12.7 5.3 8.2 7.4 13.9 10.5 17.4 8.6 7.4 14.9 9.9 4.7 14.4 3.5 17.2 9.2 12.1 6.5 6.0 3.6 6.9 10.7 10.2 27.5 5.3 12.8 18.5 6.0 8.3 11.6 17.1 10.8 9.9 19.1 21.5 8.1 10.5 11.8 27.4 13.9 20.0 12.1 18.9 14.5 25.1 14.1 15.0 20.9 28.1 12.2 13.2 13.2 11.0 17.5 22.4 11.9 8.9 2.2 3.2 5.7 3.4 2.2 2.2 2.8 2.7 3.1 2.5 2.9 3.7 6.6 3.2 6.9 17.9 27.6 17.3 20.8 10.9 5.7 24.8 7.8 4.3 4.4 11.5 26.1 14.7 62.6 15.1 21.8 10.9 3.9 9.9 26.8 8.5 8.6 8.2 6.7 22.7 12.4 11.1 21.9 10.2 7.1 13.1 6.3 14.1 10.4 1.9 10.2 32.0 10.6 7.3 10.2 19.8 20.6 2.3 12.5 13.3 19.6 16.9 21.8 10.4 35.0 12.5 11.9 14.9 15.5 11.3 13.4 21.5 12.3 2.7 22.3 47.9 19.7 18.1 11.9 13.9 18.5 7.3 21.2 5.1 14.8 12.4 8.6 41.4 DNMT3B ENSG00000088305 "DNA methyltransferase 3 beta" Q9UBC3 20 32762385-32809356 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Activator, DNA-binding, Methyltransferase, Repressor, Transferase" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 5.3;Extravillous trophoblasts: 5.2;Horizontal cells: 5.0;Inhibitory neurons: 6.8;Sertoli cells: 6.6" "Cancer enriched" "Detected in all" 25 "testis cancer: 111.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BEWO: 245.7;CACO-2: 95.8;HEL: 100.7;K-562: 98.6;NTERA-2: 333.9;SuSa: 174.4" "Not detected" "Not detected" "Not detected" "Not detected" "HPA001595, HPA001803, CAB069896" Enhanced Supported Nucleoplasm NA Yes "Cluster 23: Testis - Cell cycle regulation" "Cluster 5: NTERA-2 - Transcription" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Nucleoplasm "CAB069896: AB_2094115, HPA001595: AB_1847814, HPA001803: " "unprognostic (7.65e-3)" "unprognostic (3.52e-3)" "unprognostic (1.17e-1)" "prognostic unfavorable (5.04e-4)" "unprognostic (3.42e-1)" "unprognostic (7.27e-2)" "unprognostic (4.39e-4)" "unprognostic (4.18e-3)" "unprognostic (8.60e-3)" "unprognostic (8.48e-2)" "unprognostic (6.79e-2)" "unprognostic (4.65e-2)" "prognostic unfavorable (1.87e-7)" "unprognostic (6.62e-2)" "unprognostic (1.00e-1)" "unprognostic (1.50e-1)" "unprognostic (6.55e-2)" 0.8 0.6 1.2 0.8 1.5 3.6 1.3 2.4 1.6 1.3 1.0 0.7 0.8 1.0 3.1 0.8 0.7 0.8 1.0 1.2 1.6 1.7 1.2 0.7 0.9 1.4 1.3 0.8 6.0 1.1 0.6 2.0 1.3 0.8 0.7 3.0 1.2 0.6 0.5 3.8 0.8 0.9 1.0 1.0 0.9 5.8 1.4 3.7 1.7 0.2 0.9 1.3 1.1 1.4 3.9 5.3 27.0 6.2 0.5 2.1 245.7 3.5 2.4 3.6 3.8 95.8 4.3 10.0 9.7 1.7 4.3 2.2 17.6 1.7 3.0 1.2 14.0 100.7 3.3 18.5 0.9 4.6 9.7 2.3 1.9 5.5 1.1 1.8 6.6 6.2 98.6 2.7 1.4 15.7 15.6 86.1 333.9 8.8 3.2 15.4 4.5 2.3 9.1 4.2 8.6 5.7 5.9 8.5 2.5 174.4 5.8 5.5 1.6 5.5 12.3 2.8 2.6 5.9 2.8 3.8 2.6 27.4 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 1.2 1.5 2.4 1.6 1.2 1.6 1.4 1.3 1.3 1.0 1.4 1.4 1.6 0.0 1.5 3.9 0.1 0.9 0.2 0.3 0.6 2.1 1.5 1.3 1.3 0.0 0.8 0.0 2.1 5.3 0.3 0.2 0.0 1.3 0.1 0.8 0.9 1.6 0.0 4.6 1.1 0.6 5.2 1.2 0.5 2.2 0.0 1.3 0.7 0.6 0.8 5.0 6.8 0.3 0.0 0.3 0.3 1.0 0.0 0.7 0.0 1.9 0.1 0.8 0.0 1.5 1.3 1.0 0.1 0.4 1.3 0.3 0.1 1.3 0.1 2.5 6.6 0.3 0.9 0.1 2.6 0.9 1.3 4.8 0.3 0.8 0.6 0.1 DOCK2 KIAA0209 ENSG00000134516 "Dedicator of cytokinesis 2" Q92608 5 169637268-170083382 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Guanine-nucleotide releasing factor" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "bone marrow: 61.6;lung: 16.4;lymphoid tissue: 51.4" "Cell type enhanced" "Detected in many" "B-cells: 53.3;dendritic cells: 78.1;Kupffer cells: 93.2;Macrophages: 78.0;Microglial cells: 173.3;monocytes: 72.5;T-cells: 50.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 123.4;HDLM-2: 172.7;HL-60: 132.7;HMC-1: 135.8;MOLT-4: 94.5;U-698: 112.4;U-937: 85.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA036469 Enhanced NA NA 46000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 3: HMC-1 - Innate immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" "HPA036469: AB_2675140" "unprognostic (3.45e-2)" "unprognostic (1.84e-2)" "unprognostic (3.90e-3)" "unprognostic (2.04e-2)" "unprognostic (1.03e-1)" "unprognostic (5.92e-3)" "unprognostic (3.47e-1)" "unprognostic (1.61e-2)" "unprognostic (1.34e-1)" "unprognostic (2.10e-1)" "unprognostic (1.15e-1)" "unprognostic (1.31e-1)" "unprognostic (2.03e-3)" "unprognostic (1.47e-1)" "unprognostic (2.22e-2)" "unprognostic (6.95e-2)" "unprognostic (7.24e-2)" 7.7 3.6 1.4 34.4 2.4 61.6 3.6 1.9 2.6 3.1 2.8 7.6 5.0 2.3 1.3 3.3 2.4 9.6 1.6 1.8 2.5 1.2 5.5 16.4 42.5 6.4 3.7 1.6 1.9 1.5 0.8 7.3 4.6 1.8 7.8 0.2 2.6 1.9 0.9 1.2 9.6 7.0 4.6 36.5 8.1 1.7 6.3 51.4 1.5 1.4 46.9 9.9 1.1 8.4 0.4 0.3 0.0 0.0 0.0 0.4 0.0 3.3 0.0 8.2 14.3 0.0 0.0 123.4 4.5 13.0 3.9 0.1 0.1 0.6 19.5 172.7 0.3 71.0 3.4 0.0 0.2 132.7 135.8 0.4 0.0 6.3 0.0 5.5 0.5 65.1 1.4 60.3 8.7 0.0 94.5 27.0 0.2 0.0 0.0 59.9 4.8 49.3 3.0 0.0 0.4 0.0 0.5 0.1 0.0 0.0 0.1 64.8 0.4 5.9 6.8 4.1 9.1 18.6 40.9 112.4 7.3 85.1 0.2 19.7 28.6 22.0 12.3 48.6 12.6 13.2 11.3 12.6 29.8 9.7 7.8 9.5 29.4 13.5 72.1 10.9 11.7 24.0 1.4 2.4 1.9 2.6 1.8 2.5 6.4 3.7 4.6 4.6 6.3 8.4 1.4 0.0 3.9 2.0 53.3 0.9 0.2 0.0 0.0 0.0 0.7 2.3 1.7 0.0 2.5 0.0 0.0 0.3 78.1 0.2 0.0 0.0 5.9 0.3 0.3 1.5 0.0 15.1 9.6 0.0 0.3 1.3 1.5 0.3 33.6 0.8 1.8 1.3 42.6 0.0 4.9 0.0 0.0 93.2 31.1 5.6 0.3 78.0 5.4 173.3 72.5 0.0 47.4 4.0 21.7 0.2 0.1 0.0 39.6 0.1 0.0 0.2 0.7 0.1 6.6 0.7 0.6 2.8 1.4 0.2 2.0 0.8 50.8 0.3 0.1 0.1 DOCK8 "FLJ00026, FLJ00152, FLJ00346, ZIR8" ENSG00000107099 "Dedicator of cytokinesis 8" Q8NF50 9 214854-465259 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Guanine-nucleotide releasing factor" "Disease variant, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "choroid plexus: 45.0;lymphoid tissue: 64.8" "Cell type enhanced" "Detected in many" "Microglial cells: 506.8;monocytes: 134.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "neutrophil: 173.6" "Group enriched" "Detected in all" 4 "dendritic cells: 53.0;granulocytes: 173.6;monocytes: 84.2" "Cell line enhanced" "Detected in many" "Daudi: 52.9;HL-60: 53.3;MOLT-4: 50.1;NB-4: 83.7;REH: 61.9;RT4: 54.3;THP-1: 158.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003218, HPA073349" Enhanced Approved Nucleoplasm,Centrosome,Mitochondria,Cytosol NA NA "Cluster 14: Monocytes - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 43: THP-1 - Innate immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" Centrosome "Nucleoplasm, Mitochondria, Cytosol" "HPA003218: AB_1078695, HPA073349: " "unprognostic (1.56e-1)" "unprognostic (5.90e-2)" "unprognostic (7.75e-2)" "unprognostic (7.55e-3)" "unprognostic (3.31e-1)" "unprognostic (6.28e-3)" "unprognostic (1.79e-1)" "unprognostic (8.12e-2)" "unprognostic (2.72e-2)" "unprognostic (6.72e-2)" "unprognostic (1.90e-1)" "unprognostic (3.89e-2)" "prognostic favorable (9.21e-6)" "unprognostic (2.91e-1)" "unprognostic (3.91e-2)" "unprognostic (3.91e-1)" "prognostic favorable (6.89e-6)" 11.0 13.3 4.3 35.7 4.4 42.2 7.3 5.2 3.9 4.3 45.0 7.3 7.3 3.0 2.9 7.2 4.3 14.6 2.0 4.0 5.9 16.5 6.1 19.7 51.1 8.8 7.6 2.0 4.2 7.7 2.6 15.3 9.1 5.1 7.3 4.5 4.6 2.8 1.0 3.0 15.4 6.2 9.3 45.6 9.5 7.5 8.8 64.8 4.9 2.5 49.6 14.8 3.3 12.8 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.0 0.0 0.0 1.6 1.4 52.9 3.9 0.0 0.0 2.3 0.8 0.3 0.0 18.2 2.3 0.1 0.0 0.2 0.0 53.3 7.1 0.2 9.3 0.0 0.2 0.0 0.0 0.0 11.8 25.9 0.0 3.2 50.1 83.7 0.2 0.2 0.7 61.9 0.1 21.3 0.2 54.3 0.1 0.0 0.0 0.6 3.6 1.0 1.4 158.0 10.2 0.0 0.4 0.7 0.1 10.3 0.1 0.0 0.1 33.3 0.9 65.1 56.9 73.5 12.2 52.0 10.2 25.2 15.7 13.8 53.0 23.2 11.3 11.1 173.6 24.1 84.2 13.8 15.6 22.6 4.3 4.4 5.2 3.9 4.0 5.9 8.8 7.6 9.1 9.3 8.8 12.8 5.0 9.6 33.5 2.3 112.6 6.4 2.5 1.2 45.5 3.6 12.3 10.8 2.3 18.6 4.9 7.3 77.2 70.9 101.9 1.5 1.9 1.0 33.4 1.9 0.7 9.8 8.4 35.1 1.9 6.5 4.3 5.3 12.8 3.2 24.6 12.7 2.9 2.6 58.4 0.0 4.2 12.9 2.0 115.0 49.4 14.8 3.1 107.7 8.8 506.8 134.3 1.1 74.2 4.5 2.2 1.4 24.9 0.4 94.6 1.5 1.2 12.8 8.0 4.2 13.1 30.2 20.6 22.1 13.3 9.4 3.8 42.7 111.6 1.1 1.3 3.4 ELANE "ELA2, HLE, HNE, NE" ENSG00000197561 "Elastase, neutrophil expressed" P08246 19 851014-856247 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 91 "bone marrow: 3894.9" "Cell type enhanced" "Detected in some" "Basal keratinocytes: 8.7;Fibroblasts: 16.2;Langerhans cells: 11.1;Leydig cells: 6.2;Melanocytes: 7.2;Suprabasal keratinocytes: 7.4" "Group enriched" "Detected in some" 7 "pancreatic cancer: 3.5;stomach cancer: 3.7" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "classical monocyte: 4.0;neutrophil: 12.1" "Group enriched" "Detected in many" 9 "granulocytes: 12.1;monocytes: 4.0" "Cell line enriched" "Detected in some" 91 "THP-1: 3105.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB015409, HPA066836, HPA073774" Enhanced "Secreted to blood" NA NA 370000 "Cluster 1: Neutrophils - Mixed function" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 43: THP-1 - Innate immune response" "Cluster 50: Fibroblasts - ECM organization" "CAB015409: AB_831596, HPA066836: AB_2685733, HPA073774: " "unprognostic (3.46e-2)" "unprognostic (1.10e-1)" "unprognostic (1.42e-3)" "unprognostic (2.09e-2)" "unprognostic (1.80e-3)" "unprognostic (3.43e-2)" "unprognostic (3.92e-1)" "unprognostic (6.38e-3)" "unprognostic (5.80e-1)" "unprognostic (2.54e-2)" "unprognostic (4.06e-2)" "unprognostic (3.48e-2)" "unprognostic (1.19e-10)" "unprognostic (6.27e-3)" "unprognostic (4.00e-2)" "unprognostic (2.76e-2)" "unprognostic (4.75e-3)" 3.4 1.0 0.3 0.0 0.3 3894.9 3.4 0.1 0.7 0.5 0.2 2.0 0.4 1.0 0.0 1.1 1.4 0.1 4.0 0.3 0.2 0.7 3.3 19.4 0.6 0.1 0.2 0.5 0.5 0.0 1.2 0.8 0.1 2.9 0.0 0.0 2.4 0.1 1.5 5.4 1.8 0.1 0.1 42.6 1.4 0.4 0.2 6.3 3.1 0.0 0.0 2.1 1.0 0.2 2.0 0.1 0.0 0.0 1.0 1.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.4 0.0 0.0 1.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 3105.0 0.0 0.0 0.1 0.0 1.3 0.0 0.2 0.8 0.0 34.0 0.0 0.0 4.0 0.0 0.9 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.0 27.2 0.3 0.3 0.1 0.7 0.3 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.9 0.0 0.0 0.0 0.3 8.7 0.0 0.0 0.0 0.0 0.2 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.7 0.0 4.2 0.1 0.0 1.3 16.2 0.0 0.1 0.0 0.0 0.7 0.9 0.2 0.0 0.1 0.0 0.0 3.4 11.1 0.0 6.2 1.1 7.2 0.0 0.9 0.0 1.0 0.0 0.1 0.0 0.0 1.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.0 0.2 0.0 0.0 7.4 0.0 0.7 0.2 0.0 0.0 FAS "APO-1, APT1, CD95, FAS1, TNFRSF6" ENSG00000026103 "Fas cell surface death receptor" P25445 10 88990531-89017059 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Predicted secreted proteins" Apoptosis "Calmodulin-binding, Receptor" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Basal prostatic cells: 109.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 114.7" "Group enriched" "Detected in all" 5 "granulocytes: 114.7;T-cells: 96.2" "Cell line enhanced" "Detected in many" "HDLM-2: 83.4;Karpas-707: 109.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA027444 Uncertain Supported "Nuclear bodies,Plasma membrane,Cytosol" "Secreted to blood" NA NA 11900000 420000 "Cluster 31: Non-specific - Inflammatory response" "Cluster 85: Liver - Metabolism" "Cluster 2: Karpas-707 - Immune response" "Cluster 24: Non-specific - Transcription regulation" "Plasma membrane" "Nuclear bodies, Cytosol" "HPA027444: AB_10601378" "unprognostic (6.84e-2)" "unprognostic (2.88e-3)" "unprognostic (8.38e-3)" "unprognostic (1.94e-1)" "unprognostic (2.35e-2)" "unprognostic (9.56e-2)" "unprognostic (7.00e-2)" "unprognostic (2.05e-1)" "unprognostic (3.01e-1)" "unprognostic (7.70e-2)" "unprognostic (1.26e-2)" "unprognostic (1.98e-1)" "unprognostic (1.52e-3)" "unprognostic (2.10e-1)" "unprognostic (2.32e-2)" "unprognostic (4.95e-3)" "unprognostic (1.65e-1)" 14.1 26.3 3.6 17.0 3.6 20.8 10.9 2.9 4.7 12.7 2.8 16.4 7.0 12.8 10.3 10.8 14.8 15.7 7.5 3.6 3.7 7.2 23.3 21.7 18.9 4.6 3.1 20.1 3.7 2.7 3.7 10.4 4.0 8.9 23.3 3.3 6.5 9.3 2.3 9.4 9.2 15.0 3.5 11.2 4.4 2.6 3.9 14.4 7.3 2.6 15.6 12.9 10.2 4.3 22.7 8.2 5.4 13.9 37.0 51.3 0.0 51.8 50.2 1.7 9.1 0.1 23.4 4.7 19.0 52.1 9.6 4.0 1.0 44.8 3.2 83.4 8.7 0.4 5.2 14.7 31.6 3.4 1.6 69.2 38.7 31.4 66.0 24.5 4.7 17.8 0.0 109.0 44.0 1.4 6.4 3.4 0.6 0.2 1.8 1.4 0.5 5.0 60.7 7.3 0.4 0.2 7.7 0.0 0.8 7.0 13.9 1.0 9.5 15.8 9.0 15.2 12.3 45.3 5.3 0.4 11.8 10.2 4.5 43.1 9.4 30.9 9.9 12.3 13.8 7.5 27.6 19.6 11.5 4.0 3.1 10.0 114.7 3.1 22.1 0.2 96.2 12.8 3.6 3.6 2.9 4.7 3.6 3.7 4.6 3.1 4.0 3.5 3.9 4.3 10.3 57.7 13.8 40.1 12.8 45.9 109.7 53.1 39.9 0.0 5.5 9.5 3.5 12.8 27.5 9.2 0.0 0.4 16.3 24.9 0.0 6.3 11.3 9.2 22.3 8.9 8.4 9.5 8.8 4.3 0.2 35.4 8.6 15.5 3.8 4.9 2.2 19.3 5.5 1.7 2.8 14.4 8.2 7.0 31.7 4.9 19.0 17.7 12.4 17.8 20.9 14.5 10.3 8.0 0.7 6.5 8.7 13.9 32.2 46.0 15.6 14.4 26.3 0.7 6.6 26.8 29.1 11.3 1.1 28.5 43.9 0.4 48.4 11.8 24.4 30.0 FASLG "APT1LG1, CD178, FasL, TNFSF6" ENSG00000117560 "Fas ligand" P48023 1 172659103-172666876 "Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Apoptosis, Transcription, Transcription regulation" "Cytokine, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 5.7" "Group enriched" "Detected in some" 14 "dendritic cells: 43.4;NK-cells: 79.3;T-cells: 28.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Immune cell enhanced" "Detected in many" "gdT-cell: 58.1" "Group enriched" "Detected in many" 9 "NK-cells: 41.5;T-cells: 58.1" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA054959 Approved "Secreted to blood" NA NA 73600 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 2: Immune cells - Immune response" "Cluster 63: NK-cells & T-cells - Immune response" "HPA054959: AB_2682650" "unprognostic (1.09e-3)" "unprognostic (1.41e-2)" "unprognostic (8.69e-2)" "unprognostic (1.54e-7)" "unprognostic (3.29e-1)" "unprognostic (2.23e-3)" "unprognostic (5.44e-2)" "unprognostic (1.84e-2)" "unprognostic (4.67e-2)" "unprognostic (4.76e-2)" "unprognostic (8.88e-2)" "unprognostic (1.07e-1)" "prognostic unfavorable (1.59e-6)" "unprognostic (3.49e-2)" "unprognostic (1.22e-1)" "unprognostic (1.15e-2)" "unprognostic (3.82e-3)" 0.3 0.8 0.1 1.0 0.2 2.8 0.6 0.1 0.2 0.4 0.1 0.8 1.9 0.5 0.7 0.3 0.3 1.1 0.3 0.2 0.1 0.3 1.1 2.0 5.7 0.3 0.2 0.3 0.1 0.0 0.1 0.2 0.2 0.5 0.9 0.0 0.9 0.3 0.1 0.4 1.4 0.3 0.0 4.1 1.5 0.2 0.1 0.6 0.2 0.0 1.8 0.8 0.2 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 5.5 0.1 0.0 58.1 0.2 35.5 0.0 11.5 31.4 0.1 0.0 2.2 25.0 1.9 41.5 0.1 0.0 0.2 14.9 0.1 0.2 0.1 0.2 0.2 0.1 0.3 0.2 0.2 0.0 0.1 0.4 0.4 0.0 2.5 0.0 0.6 0.9 0.0 0.0 0.0 0.0 0.2 0.3 0.2 0.0 0.0 0.0 0.0 0.0 43.4 0.1 0.0 0.1 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 1.3 0.0 0.4 0.0 0.1 0.0 0.0 0.2 0.0 0.3 1.2 0.0 0.0 0.6 1.8 0.0 0.9 0.0 79.3 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 28.8 0.0 0.0 0.1 FCGR3A "CD16, CD16a, FCG3, FCGR3" ENSG00000203747 "Fc fragment of IgG receptor IIIa" P08637 1 161541759-161550737 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "IgG-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lung: 206.3;lymphoid tissue: 306.8" "Cell type enhanced" "Detected in many" "dendritic cells: 333.4;Hofbauer cells: 193.1;Kupffer cells: 807.9;Macrophages: 300.0;NK-cells: 579.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "intermediate monocyte: 1763.5;neutrophil: 1169.8;non-classical monocyte: 3948.7" "Group enriched" "Detected in all" 5 "granulocytes: 1169.8;monocytes: 3948.7" "Not detected" "Not detected" "CAB032435, HPA055431" Supported "Secreted to blood" NA NA "Cluster 51: Monocytes - Innate immune response" "Cluster 64: Macrophages - Immune response" "Cluster 63: NK-cells & T-cells - Immune response" "CAB032435: AB_626925, HPA055431: AB_2682815" "unprognostic (5.27e-2)" "unprognostic (9.95e-2)" "unprognostic (2.37e-2)" "unprognostic (1.66e-1)" "unprognostic (1.39e-1)" "unprognostic (1.82e-1)" "unprognostic (2.24e-2)" "unprognostic (6.06e-2)" "unprognostic (2.41e-1)" "unprognostic (1.64e-1)" "unprognostic (1.98e-2)" "unprognostic (7.52e-2)" "prognostic unfavorable (3.22e-6)" "unprognostic (1.14e-1)" "unprognostic (4.66e-2)" "unprognostic (1.03e-2)" "unprognostic (7.51e-2)" 52.9 41.9 18.4 99.8 20.4 27.3 14.7 19.3 27.2 8.2 26.5 12.5 5.8 5.9 5.9 4.9 9.1 24.5 22.3 16.9 22.0 7.9 111.5 206.3 37.1 37.7 27.9 6.6 7.8 13.6 11.3 71.0 30.6 6.9 12.6 6.9 14.7 7.6 3.3 2.2 5.7 68.4 31.7 306.8 6.8 7.7 28.8 9.3 7.0 4.3 3.9 32.5 3.5 39.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 6.5 26.2 9.6 513.6 1763.5 4.9 3.7 4.7 205.9 175.8 1.4 3.0 184.0 1169.8 136.2 3948.7 4.6 2.6 734.1 18.4 20.4 19.3 27.2 16.9 22.0 37.7 27.9 30.6 31.7 28.8 39.8 2.7 22.4 24.6 0.7 6.5 0.5 0.1 0.0 0.0 0.2 1.4 3.4 0.7 8.6 10.5 3.7 2.1 1.2 333.4 0.0 0.0 0.2 1.4 0.1 0.0 18.9 0.0 16.4 0.0 0.0 1.4 3.9 0.0 0.1 18.9 0.1 8.6 5.3 193.1 0.0 0.1 0.1 0.0 807.9 7.4 3.7 0.3 300.0 0.0 20.6 77.2 0.1 579.9 0.0 0.1 0.0 0.0 0.0 22.1 0.0 0.0 0.8 5.8 1.5 19.7 1.1 0.4 0.0 0.5 0.2 0.0 2.1 88.0 0.0 0.0 0.3 FERMT3 "KIND3, MGC10966, MIG-2, MIG2B, UNC112C, URP2" ENSG00000149781 "Fermitin family member 3" Q86UX7 11 64206678-64223891 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 180.6;lymphoid tissue: 130.1" "Cell type enhanced" "Detected in many" "dendritic cells: 118.3;granulocytes: 96.4;Hofbauer cells: 193.1;Kupffer cells: 95.8;Langerhans cells: 88.0;Macrophages: 232.9;monocytes: 142.9;NK-cells: 93.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 306.9;HL-60: 135.9;HMC-1: 314.2;Karpas-707: 127.6;MOLT-4: 121.8;NB-4: 174.1;U-937: 138.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA065231 Approved Vesicles NA NA 160000000 "Cluster 31: Non-specific - Inflammatory response" "Cluster 2: Immune cells - Immune response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 51: Myeloid cells - Hemostasis" Vesicles "HPA065231: AB_2685439" "unprognostic (1.96e-2)" "unprognostic (1.07e-2)" "unprognostic (3.38e-3)" "prognostic favorable (9.89e-4)" "unprognostic (8.77e-2)" "unprognostic (1.83e-2)" "unprognostic (3.56e-2)" "unprognostic (2.46e-1)" "unprognostic (4.20e-1)" "unprognostic (3.98e-1)" "unprognostic (2.70e-1)" "unprognostic (3.88e-1)" "prognostic unfavorable (2.12e-5)" "unprognostic (3.08e-3)" "unprognostic (5.25e-2)" "unprognostic (4.97e-2)" "unprognostic (1.75e-1)" 25.1 14.5 9.4 63.3 11.6 180.6 13.0 11.2 18.1 8.5 12.2 17.3 22.0 8.4 0.7 6.4 13.6 15.6 12.0 9.8 11.6 11.1 12.5 46.2 89.2 17.9 12.2 5.1 7.0 1.3 5.9 15.0 13.2 8.2 8.1 0.6 10.7 4.4 6.0 7.1 34.1 9.4 13.3 130.1 29.6 4.5 17.1 48.7 10.0 4.6 41.8 19.8 7.3 15.3 1.2 1.6 0.5 0.9 0.3 0.8 2.0 1.4 0.2 0.4 0.3 2.6 2.3 32.6 3.2 6.3 0.7 2.4 1.0 0.5 0.5 83.9 0.6 306.9 1.6 0.1 10.8 135.9 314.2 1.2 1.1 5.2 0.0 0.5 81.2 77.0 7.3 127.6 8.6 3.5 121.8 174.1 1.2 1.0 2.3 72.4 8.8 0.7 0.3 0.7 1.9 0.5 0.7 4.5 1.7 0.7 2.0 92.6 7.8 1.1 2.5 1.9 0.9 1.5 3.3 59.4 19.5 138.9 86.6 204.1 207.0 236.5 120.0 192.6 114.9 54.5 94.1 112.0 162.0 53.1 60.9 80.6 184.6 102.4 151.2 195.7 120.9 292.6 9.4 11.6 11.2 18.1 9.8 11.6 17.9 12.2 13.2 13.3 17.1 15.3 3.8 9.6 14.7 0.7 52.1 4.7 0.9 0.3 3.4 0.5 3.3 5.2 2.4 4.3 3.9 0.0 0.0 1.2 118.3 6.1 0.0 0.8 0.4 4.3 5.6 7.9 0.0 62.5 1.2 2.4 1.4 5.4 19.9 7.3 96.4 0.4 19.6 1.4 193.1 0.0 1.5 32.1 0.0 95.8 88.0 0.9 0.9 232.9 17.8 5.6 142.9 0.3 93.7 1.0 1.5 4.3 10.9 2.6 35.2 0.9 8.2 0.4 1.0 0.3 6.6 13.7 6.6 1.2 0.8 1.9 4.5 2.6 78.5 1.4 15.0 0.7 FOXN1 "FKHL20, RONU, WHN" ENSG00000109101 "Forkhead box N1" O15353 17 28506243-28538900 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "esophagus: 18.4;lymphoid tissue: 10.7;skin 1: 41.1;vagina: 10.9" "Cell type enhanced" "Detected in some" "Basal keratinocytes: 4.0;Prostatic glandular cells: 5.9;Squamous epithelial cells: 15.9;Suprabasal keratinocytes: 12.4;Urothelial cells: 15.4" "Cancer enhanced" "Detected in many" "cervical cancer: 7.0;head and neck cancer: 8.0" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "HaCaT: 10.9" "Not detected" "Not detected" "Low region specificity" "Detected in some" NA NA "Cluster 31: Skin - Epidermis development" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 61: Squamous epithelial cells - Keratinization" "unprognostic (1.60e-1)" "prognostic favorable (6.43e-4)" "unprognostic (2.68e-3)" "unprognostic (5.98e-6)" "prognostic favorable (5.00e-4)" "unprognostic (2.85e-1)" "unprognostic (2.56e-1)" "unprognostic (3.89e-2)" "unprognostic (7.08e-3)" "unprognostic (1.26e-2)" "unprognostic (1.90e-3)" "unprognostic (4.68e-2)" "unprognostic (3.96e-1)" "unprognostic (1.34e-1)" "unprognostic (9.69e-2)" 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 4.3 0.0 0.1 0.0 0.0 0.0 18.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.0 2.4 0.1 0.1 41.1 0.0 0.0 0.0 0.0 0.1 0.3 0.0 10.7 0.1 0.0 5.6 0.8 10.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.9 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 2.9 1.8 1.2 0.0 0.4 0.6 0.4 0.0 0.3 0.0 0.0 0.8 0.0 2.2 0.0 0.0 0.8 0.3 0.0 0.0 1.2 0.0 0.0 0.2 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 5.9 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.2 15.9 12.4 1.1 0.1 0.0 0.4 15.4 FOXP3 "AIID, DIETER, IPEX, JM2, PIDX, SCURFIN, XPID" ENSG00000049768 "Forkhead box P3" Q9BZS1 X 49250438-49270477 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Diabetes mellitus, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "epididymis: 7.2;lymphoid tissue: 7.4" "Cell type enhanced" "Detected in some" "granulocytes: 1.3;Hepatocytes: 1.4;Horizontal cells: 3.3;Melanocytes: 1.8;T-cells: 5.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Immune cell enriched" "Detected in some" 11 "T-reg: 53.3" "Lineage enriched" "Detected in single" 394 "T-cells: 53.3" "Cell line enhanced" "Detected in some" "HDLM-2: 2.9;MCF7: 5.2;SiHa: 4.7" "Not detected" "Not detected" "Not detected" "Not detected" "CAB026301, HPA045943" Enhanced Supported Nucleoplasm NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 16: Immune cells - Immune response" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 24: Non-specific - Transcription regulation" Nucleoplasm "CAB026301: , HPA045943: AB_2679508" "unprognostic (2.46e-2)" "prognostic favorable (1.91e-4)" "unprognostic (4.95e-3)" "prognostic favorable (7.02e-4)" "unprognostic (2.55e-4)" "prognostic favorable (4.90e-4)" "unprognostic (2.42e-2)" "unprognostic (3.46e-1)" "unprognostic (1.04e-2)" "unprognostic (1.99e-3)" "unprognostic (8.77e-3)" "unprognostic (1.94e-1)" "unprognostic (2.73e-14)" "unprognostic (5.93e-2)" "unprognostic (4.55e-2)" "unprognostic (1.98e-1)" "unprognostic (1.39e-1)" 0.2 0.2 0.9 7.4 0.7 1.3 0.7 1.5 0.8 0.4 0.0 0.6 0.7 0.2 7.2 1.2 0.2 1.6 0.2 0.8 0.6 0.3 2.4 0.9 6.1 0.7 0.7 0.4 0.2 0.4 0.5 0.1 0.8 0.6 0.7 0.7 1.1 0.8 0.3 2.3 1.9 0.3 0.5 2.4 1.6 1.3 0.8 7.2 0.6 0.1 5.2 2.8 0.3 0.7 0.1 0.3 0.2 0.9 0.1 0.0 1.1 0.2 0.2 0.1 0.4 0.8 0.2 0.6 0.3 0.5 0.6 0.3 0.8 0.0 0.1 2.9 0.5 0.2 0.3 0.2 0.4 0.3 0.4 0.1 0.8 0.9 1.7 0.0 0.0 0.9 0.9 0.7 0.0 5.2 0.1 0.3 0.8 0.1 0.7 0.4 0.3 0.2 0.2 0.2 0.6 0.5 4.7 0.5 2.0 0.5 1.5 0.8 0.8 0.3 1.4 0.5 0.1 0.4 1.1 0.4 0.2 0.8 0.7 0.0 0.0 0.0 0.0 0.1 0.2 0.0 4.7 0.2 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 53.3 1.3 0.9 0.7 1.5 0.8 0.8 0.6 0.7 0.7 0.8 0.5 0.8 0.7 0.1 0.0 0.6 0.3 0.4 0.5 0.0 0.0 0.0 0.2 0.3 0.3 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.1 1.3 0.1 0.0 1.4 0.1 3.3 0.2 0.0 0.0 0.0 0.6 0.0 0.0 0.3 1.8 0.0 0.2 0.2 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.8 0.9 0.0 0.4 0.0 5.3 0.2 0.0 0.0 G6PC3 UGRP ENSG00000141349 "Glucose-6-phosphatase catalytic subunit 3" Q9BUM1 17 44070735-44076344 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Gluconeogenesis Hydrolase "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067052 Supported "Endoplasmic reticulum" NA NA "Cluster 28: Myeloid DCs - Unknown function" "Cluster 35: Non-specific - Unknown function" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 47: Cytotrophoblasts - Unknown function" "Endoplasmic reticulum" "HPA067052: AB_2685771" "unprognostic (9.13e-2)" "unprognostic (2.28e-1)" "unprognostic (3.61e-1)" "prognostic favorable (1.11e-4)" "unprognostic (1.88e-3)" "unprognostic (3.16e-1)" "prognostic unfavorable (9.61e-4)" "unprognostic (2.79e-1)" "unprognostic (2.43e-1)" "unprognostic (1.15e-2)" "unprognostic (2.59e-2)" "unprognostic (1.85e-3)" "unprognostic (1.87e-3)" "unprognostic (4.53e-2)" "unprognostic (3.06e-2)" "unprognostic (2.35e-1)" "unprognostic (4.49e-2)" 56.7 97.2 64.8 22.5 67.8 16.0 55.6 70.5 79.3 47.6 88.8 42.1 28.7 55.4 63.9 37.1 45.6 23.9 61.9 65.3 77.5 75.2 26.4 42.9 19.3 74.9 86.9 44.3 56.5 66.7 95.1 25.8 96.1 59.5 18.2 17.1 48.7 40.6 54.3 26.8 39.6 23.0 67.9 45.2 51.4 55.1 72.7 15.2 71.1 26.4 12.0 48.7 37.7 72.4 40.0 231.7 73.7 128.5 77.9 58.3 55.3 45.0 86.9 96.2 64.4 97.1 62.3 88.9 62.8 95.1 65.4 67.4 53.5 92.1 44.5 46.4 86.0 49.3 142.5 182.4 84.1 46.1 59.8 77.3 44.3 93.1 62.3 59.6 79.3 35.9 51.5 109.6 72.5 112.1 22.4 71.4 99.3 48.7 133.5 45.6 48.4 207.5 137.6 93.6 92.7 83.0 49.1 57.4 59.3 82.9 158.6 45.1 87.6 98.8 53.1 26.8 63.5 74.0 56.2 26.1 110.3 38.2 128.9 3.0 33.1 7.9 9.9 43.4 12.1 12.1 8.0 9.1 54.2 13.9 9.7 12.9 1.4 17.5 26.3 74.5 8.5 16.9 64.8 67.8 70.5 79.3 65.3 77.5 74.9 86.9 96.1 67.9 72.7 72.4 22.3 3.2 12.9 5.2 10.4 2.5 17.3 31.8 8.0 10.5 20.7 21.5 6.4 21.5 25.2 40.5 12.5 64.3 17.1 12.4 13.7 59.3 5.0 18.9 22.1 26.0 22.9 9.7 2.8 49.4 41.1 25.0 16.8 20.1 18.3 20.2 18.5 7.1 58.7 5.0 4.5 14.1 24.4 21.6 12.2 6.2 20.2 20.9 14.2 0.0 21.8 30.7 10.3 8.0 5.5 33.6 13.6 23.0 27.2 19.5 20.5 36.0 24.6 8.3 13.1 15.3 21.4 31.5 26.7 14.3 2.6 42.5 7.0 43.9 19.7 17.2 G6PD G6PD1 ENSG00000160211 "Glucose-6-phosphate dehydrogenase" P11413 X 154531391-154547572 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Carbohydrate metabolism, Glucose metabolism" Oxidoreductase "Cancer-related genes, Disease variant, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 105.9" "Cell type enhanced" "Detected in many" "monocytes: 112.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "eosinophil: 412.7" "Lineage enriched" "Detected in all" 5 "granulocytes: 412.7" "Cell line enhanced" "Detected in all" "A549: 2333.8;MCF7: 883.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000247, HPA000834" Enhanced Enhanced "Centriolar satellite,Cytosol" No No 2400000 "Cluster 49: Eosinophils - Unknown function" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 3: Monocytes - Immune response regulation" Cytosol "Centriolar satellite" "HPA000247: AB_1078978, HPA000834: AB_1078977" "unprognostic (1.73e-2)" "unprognostic (1.53e-3)" "unprognostic (1.13e-2)" "unprognostic (1.02e-1)" "unprognostic (7.78e-2)" "unprognostic (4.34e-2)" "prognostic unfavorable (9.45e-13)" "unprognostic (2.78e-2)" "unprognostic (1.66e-1)" "unprognostic (1.76e-2)" "unprognostic (1.09e-1)" "unprognostic (3.66e-1)" "unprognostic (2.89e-3)" "unprognostic (2.83e-1)" "unprognostic (1.94e-1)" "unprognostic (1.47e-1)" "unprognostic (7.25e-2)" 40.7 39.1 19.9 30.2 21.8 105.9 31.9 20.5 28.3 20.6 20.0 13.9 13.1 21.6 13.3 54.3 19.3 46.5 14.3 21.3 22.7 12.7 6.5 29.4 28.9 25.4 22.2 24.1 13.0 9.6 27.5 13.7 24.5 12.2 13.1 26.1 21.2 14.4 4.2 21.3 12.4 25.6 19.7 26.9 18.1 54.0 26.1 26.2 45.9 5.1 37.2 33.8 22.4 21.9 168.5 2333.8 49.7 189.7 207.2 281.7 43.5 116.0 341.7 120.0 205.8 111.2 61.9 110.9 174.1 274.3 475.9 146.3 79.3 202.5 60.3 111.4 55.0 116.8 517.2 244.6 401.6 117.8 373.5 136.6 58.5 233.9 49.8 185.6 252.5 79.8 69.6 46.3 218.4 883.9 77.5 93.0 35.3 549.5 172.2 74.9 28.4 120.5 357.1 210.9 49.6 62.0 115.9 444.5 99.9 65.0 67.1 99.4 289.8 73.1 250.0 102.5 181.8 58.2 80.0 189.8 200.6 77.5 150.9 166.1 84.9 412.7 50.3 72.1 32.1 16.0 13.7 36.7 40.1 17.0 16.5 28.2 137.4 69.3 63.5 18.9 18.7 72.8 19.9 21.8 20.5 28.3 21.3 22.7 25.4 22.2 24.5 19.7 26.1 21.9 7.9 0.0 17.0 4.6 21.5 12.5 24.3 46.6 8.6 6.2 14.6 8.6 1.1 14.3 22.9 11.0 18.8 29.6 58.9 25.5 29.4 39.3 10.3 7.7 13.7 13.2 9.5 37.7 2.9 29.3 41.2 19.6 23.4 10.7 37.5 26.1 18.2 1.6 45.6 33.7 2.3 11.5 24.4 58.2 26.0 20.8 26.1 56.6 19.6 5.6 112.3 13.6 83.4 3.5 3.7 31.0 11.4 16.1 21.6 23.9 18.5 18.3 10.9 32.5 6.6 7.5 23.6 10.9 32.8 34.4 13.8 36.3 33.8 11.6 13.5 30.5 GFI1 "GFI-1, GFI1A, ZNF163" ENSG00000162676 "Growth factor independent 1 transcriptional repressor" Q99684 1 92473043-92486925 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "bone marrow: 53.7;lymphoid tissue: 31.2" "Cell type enhanced" "Detected in some" "dendritic cells: 14.2;Intestinal goblet cells: 12.4;NK-cells: 11.3;Plasma cells: 8.6;T-cells: 16.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Immune cell enhanced" "Detected in some" "gdT-cell: 2.1" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "HL-60: 61.9;HMC-1: 47.5;NB-4: 64.7;THP-1: 127.7;U-937: 261.3" "Not detected" "Not detected" "Not detected" "Not detected" CAB011197 Uncertain NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 32: U-937 - Innate immune response" "Cluster 63: NK-cells & T-cells - Immune response" "CAB011197: AB_532302" "unprognostic (5.67e-4)" "unprognostic (8.67e-3)" "prognostic favorable (5.68e-5)" "unprognostic (4.88e-3)" "unprognostic (3.57e-2)" "unprognostic (5.86e-3)" "unprognostic (2.06e-1)" "unprognostic (3.87e-3)" "unprognostic (1.26e-3)" "unprognostic (4.47e-3)" "unprognostic (5.20e-2)" "unprognostic (1.72e-1)" "unprognostic (6.80e-6)" "unprognostic (2.63e-1)" "unprognostic (8.27e-2)" "unprognostic (3.97e-1)" "unprognostic (4.37e-2)" 1.0 0.5 0.1 5.1 0.2 53.7 0.9 0.1 0.1 0.6 0.3 3.6 4.7 0.6 0.5 0.5 0.7 1.9 0.3 0.1 0.1 0.5 1.0 2.8 6.9 0.3 0.1 0.5 9.4 0.2 0.5 0.2 0.2 0.8 4.5 0.0 1.0 0.3 0.2 0.3 5.7 0.4 0.2 7.0 3.2 0.9 0.2 31.2 0.9 0.0 4.4 1.7 0.6 0.2 1.4 0.1 0.1 0.1 0.1 0.0 0.4 0.0 0.1 0.1 0.1 1.0 10.3 0.1 0.7 0.0 0.5 0.4 1.2 0.0 0.2 0.0 2.5 1.6 0.2 5.3 0.1 61.9 47.5 0.0 0.0 0.1 0.1 0.3 0.1 17.1 0.4 15.3 0.1 2.1 39.5 64.7 0.0 0.1 0.2 7.8 2.7 3.4 0.0 0.7 0.1 0.1 0.3 0.1 0.3 0.1 0.0 127.7 0.0 0.0 1.5 0.1 0.2 22.2 1.6 4.0 0.0 261.3 0.0 0.0 0.0 0.4 2.1 0.0 1.0 0.0 0.9 1.4 0.0 0.0 0.3 1.9 0.0 0.1 0.0 0.8 0.3 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.2 0.2 0.2 0.3 0.0 0.0 0.0 1.1 0.1 0.0 0.0 0.0 0.0 0.3 0.3 0.7 0.0 0.0 0.0 0.0 0.0 14.2 1.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.9 0.0 0.1 1.1 0.2 0.0 0.1 1.4 0.0 0.1 0.0 0.1 12.4 0.0 0.8 0.2 0.2 0.0 0.8 0.0 0.0 0.1 0.0 11.3 0.0 0.1 0.4 0.0 0.0 8.6 0.0 0.7 0.1 0.1 0.0 0.0 0.1 0.2 0.5 3.9 0.0 0.0 0.0 16.4 0.1 0.4 0.0 HAX1 "HAX-1, HCLSBP1, HS1BP1" ENSG00000143575 "HCLS1 associated protein X-1" O00165 1 154272589-154275875 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055141, HPA075289" Approved Supported Mitochondria NA NA "Cluster 44: Non-specific - Transcription" "Cluster 39: Non-specific - Mitochondria" "Cluster 43: THP-1 - Innate immune response" "Cluster 39: Non-specific - Basic cellular processes" Mitochondria "HPA055141: AB_2682714, HPA075289: AB_2686742" "unprognostic (1.32e-1)" "unprognostic (2.68e-1)" "unprognostic (9.50e-2)" "unprognostic (6.93e-2)" "unprognostic (2.88e-2)" "unprognostic (1.73e-2)" "unprognostic (1.55e-3)" "unprognostic (2.34e-1)" "unprognostic (2.20e-1)" "unprognostic (9.09e-3)" "unprognostic (3.09e-2)" "unprognostic (8.91e-2)" "prognostic unfavorable (1.34e-5)" "unprognostic (1.52e-1)" "unprognostic (1.59e-1)" "unprognostic (1.69e-1)" "unprognostic (3.96e-1)" 58.6 63.0 100.0 43.6 105.5 36.8 74.4 105.2 124.1 60.0 100.6 62.0 48.0 46.2 100.1 53.7 61.7 40.4 168.6 100.5 107.9 76.1 104.0 45.2 58.3 102.1 99.9 72.9 85.5 84.9 88.6 40.5 102.9 55.5 63.3 54.1 85.8 63.8 256.7 48.8 43.2 64.1 105.1 47.1 66.3 69.5 105.0 67.4 69.2 242.7 77.3 58.5 48.9 103.3 115.3 100.7 84.2 178.0 100.3 111.8 132.1 109.8 178.7 227.0 207.5 126.6 125.7 170.9 150.7 188.0 105.9 100.0 190.7 151.3 172.3 171.0 140.8 81.8 76.5 104.4 221.5 172.5 167.0 104.4 274.2 172.8 206.3 82.2 129.7 246.1 166.1 244.8 145.6 260.9 169.9 136.1 88.7 277.4 213.2 121.3 59.7 326.7 115.4 60.8 123.2 121.7 96.4 228.2 326.7 137.5 190.0 454.8 64.5 92.7 122.7 97.7 148.8 284.8 315.9 315.3 139.0 158.4 153.4 266.5 97.6 215.4 113.7 121.9 129.3 136.1 139.2 128.3 118.6 142.2 166.5 132.6 61.1 116.7 150.1 122.8 183.3 163.9 100.0 105.5 105.2 124.1 100.5 107.9 102.1 99.9 102.9 105.1 105.0 103.3 69.9 28.9 37.6 7.2 125.2 74.6 112.2 118.8 60.9 57.0 92.8 123.1 106.9 62.9 71.6 46.0 47.9 84.8 76.1 54.1 181.9 93.3 147.6 41.3 36.6 65.6 57.6 66.0 12.0 106.4 132.1 62.2 36.7 34.0 99.6 80.6 61.4 90.3 98.7 40.4 12.9 67.1 91.6 63.9 79.3 104.6 61.2 66.8 87.2 9.4 128.5 91.1 91.6 7.5 17.1 84.6 63.6 62.1 192.9 92.5 128.7 141.8 59.3 97.5 59.2 58.2 76.0 223.8 112.0 71.0 76.4 88.8 97.7 74.3 71.7 101.7 HELLS "LSH, Nbla10143, PASG, SMARCA6" ENSG00000119969 "Helicase, lymphoid specific" Q9NRZ9 10 94501434-94613905 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, Transcription, Transcription regulation" "Developmental protein, Helicase, Hydrolase" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 16.3;lymphoid tissue: 15.9" "Cell type enhanced" "Detected in many" "Spermatocytes: 182.0;Spermatogonia: 173.9" "Cancer enhanced" "Detected in all" "testis cancer: 16.1" "Region enhanced" "Detected in many" "cerebellum: 5.5" "Immune cell enhanced" "Detected in many" "plasmacytoid DC: 36.8" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004491, HPA063242" Enhanced Approved "Nucleoplasm,Golgi apparatus,Vesicles" No Yes "Cluster 35: T-regs - Unknown function" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Nucleoplasm "Golgi apparatus, Vesicles" "CAB004491: AB_627895, HPA063242: AB_2684968" "unprognostic (1.94e-1)" "prognostic favorable (1.36e-4)" "unprognostic (9.85e-2)" "unprognostic (3.38e-2)" "unprognostic (8.65e-2)" "unprognostic (4.85e-3)" "unprognostic (1.76e-5)" "unprognostic (7.59e-3)" "unprognostic (7.03e-3)" "unprognostic (6.49e-2)" "unprognostic (2.05e-2)" "unprognostic (9.45e-5)" "unprognostic (9.93e-13)" "unprognostic (2.25e-2)" "unprognostic (1.72e-1)" "unprognostic (6.24e-2)" "unprognostic (3.03e-2)" 1.1 1.2 0.8 6.4 0.3 16.3 3.0 5.5 1.2 3.2 1.3 4.3 2.9 2.9 1.4 5.9 1.7 2.0 0.7 0.4 1.3 2.5 1.8 1.7 12.4 0.8 0.8 2.6 1.2 1.4 3.0 4.1 1.0 2.1 5.1 1.1 1.9 1.0 0.3 5.3 3.9 2.2 0.9 4.3 3.7 12.8 0.9 15.9 1.1 0.2 12.6 3.6 3.2 1.5 57.7 55.4 70.6 90.1 2.9 6.4 37.4 42.9 27.8 34.4 54.6 70.3 45.5 70.0 16.7 15.5 29.1 56.3 40.9 34.9 50.7 68.5 45.5 37.3 56.3 58.0 1.7 71.2 31.6 3.6 2.0 42.1 20.0 9.4 24.0 46.0 20.7 43.5 43.1 54.9 75.2 35.6 73.4 42.3 24.1 70.3 62.1 16.3 24.2 72.2 28.4 22.8 50.3 14.5 7.8 59.0 60.9 23.1 17.2 38.4 19.4 35.4 52.4 22.3 47.6 74.5 19.0 42.8 17.9 0.3 0.7 0.0 7.0 1.5 2.4 18.8 11.4 9.4 2.3 23.2 5.2 7.7 1.0 10.2 1.0 36.8 19.7 2.3 0.8 0.3 5.5 1.2 0.4 1.3 0.8 0.8 1.0 0.9 0.9 1.5 4.7 9.6 3.9 0.0 19.7 21.5 11.5 12.6 13.1 16.4 10.0 15.0 1.0 12.8 12.6 22.0 0.0 46.3 13.2 26.2 3.9 9.0 2.0 9.3 16.4 8.1 10.8 50.5 3.3 6.2 43.4 13.0 17.9 16.3 5.7 60.6 5.7 3.6 15.1 6.7 5.4 17.8 8.2 2.2 10.3 5.3 9.0 7.3 1.8 9.4 5.7 4.3 1.0 4.5 6.6 4.7 1.8 5.7 37.5 3.7 1.7 1.6 6.3 11.4 19.7 10.5 16.4 182.0 173.9 22.9 9.9 11.1 15.7 16.5 30.9 11.7 ICOS "AILIM, CD278" ENSG00000163600 "Inducible T cell costimulator" Q9Y6W8 2 203936763-203961577 "CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "bone marrow: 16.5;lymphoid tissue: 20.2" "Cell type enriched" "Detected in some" 12 "T-cells: 81.2" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Immune cell enhanced" "Detected in many" "T-reg: 29.1" "Lineage enriched" "Detected in single" 54 "T-cells: 29.1" "Group enriched" "Detected in some" 8 "HEL: 4.6;MOLT-4: 12.1" "Not detected" "Not detected" "Not detected" "Not detected" "CAB032575, HPA034865" Approved Approved "Plasma membrane,Actin filaments" "Intracellular and membrane" NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" "Plasma membrane" "Actin filaments" "CAB032575: AB_2122593, HPA034865: " "unprognostic (2.66e-2)" "unprognostic (2.13e-3)" "unprognostic (4.19e-4)" "unprognostic (2.35e-5)" "unprognostic (1.07e-1)" "prognostic favorable (1.80e-4)" "unprognostic (9.38e-2)" "unprognostic (2.89e-2)" "unprognostic (1.49e-2)" "unprognostic (3.51e-4)" "unprognostic (7.50e-2)" "unprognostic (2.12e-1)" "unprognostic (2.86e-5)" "unprognostic (7.05e-2)" "unprognostic (2.48e-2)" "unprognostic (1.93e-1)" "unprognostic (8.82e-3)" 0.5 0.1 0.0 7.7 0.0 16.5 0.3 0.0 0.0 0.2 0.0 0.7 0.7 0.2 0.1 0.5 0.3 1.4 0.2 0.0 0.0 0.2 0.4 2.6 14.3 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.5 1.3 0.0 0.4 0.0 0.0 0.2 2.3 0.4 0.0 3.3 1.3 0.2 0.0 20.2 0.4 0.0 16.2 2.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 4.2 0.0 15.1 6.8 0.0 0.0 15.7 7.2 0.1 0.5 0.0 0.0 29.1 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.0 0.0 1.3 0.0 3.1 2.9 0.0 0.0 0.0 0.0 1.0 1.5 0.2 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.1 0.2 0.1 0.5 0.0 0.0 0.0 0.0 0.0 1.1 2.0 0.2 6.3 0.0 0.4 0.1 0.1 0.0 0.0 0.2 0.0 0.8 4.7 0.1 0.0 3.1 3.6 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.7 0.0 0.3 0.0 1.8 0.1 81.2 0.0 0.0 0.1 IFNGR1 "CD119, IFNGR" ENSG00000027697 "Interferon gamma receptor 1" P15260 6 137197485-137219449 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Basal respiratory cells: 867.1;Club cells: 405.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025889, HPA029213, HPA063871" Approved Supported "Plasma membrane" NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 2: Immune cells - Immune response" "Cluster 21: OE19 - Mitochondria" "Cluster 26: Respiratory epithelial cells - Mucosal defense" "Plasma membrane" "CAB025889: , HPA029213: AB_10601023, HPA063871: AB_2685138" "unprognostic (1.73e-1)" "unprognostic (8.86e-2)" "unprognostic (9.85e-3)" "unprognostic (1.71e-1)" "unprognostic (6.55e-2)" "unprognostic (1.25e-1)" "unprognostic (4.05e-1)" "unprognostic (6.97e-2)" "unprognostic (9.86e-2)" "unprognostic (1.57e-2)" "unprognostic (4.09e-2)" "unprognostic (2.85e-1)" "prognostic unfavorable (5.48e-4)" "unprognostic (1.58e-1)" "unprognostic (2.87e-2)" "unprognostic (1.81e-2)" "unprognostic (5.38e-3)" 155.5 59.3 54.6 131.5 57.8 146.2 121.4 64.5 72.1 74.1 56.8 74.7 97.9 58.1 67.4 65.0 55.7 88.4 103.7 53.1 59.9 44.4 104.0 153.8 140.2 71.9 60.3 43.3 44.5 47.4 26.3 86.1 75.9 53.2 74.4 40.4 57.7 57.4 58.3 66.2 101.2 75.9 69.2 165.9 51.3 27.9 59.9 69.2 58.3 75.5 135.2 112.6 58.0 85.0 23.2 23.4 25.1 33.4 166.8 86.7 23.0 67.0 90.0 38.0 53.3 148.7 39.8 24.5 99.2 36.1 55.1 130.0 24.1 62.6 51.5 49.4 37.4 36.1 23.3 192.9 97.3 112.9 46.6 195.9 232.6 33.3 51.4 36.1 48.7 29.1 32.0 34.9 29.2 27.7 17.7 47.0 22.0 191.9 18.6 51.3 28.4 32.1 65.5 104.4 27.4 39.5 77.3 41.9 57.5 47.8 15.5 68.7 71.1 36.2 27.7 48.5 31.8 25.3 25.5 23.8 19.4 69.2 36.5 158.6 518.4 356.3 106.9 502.6 224.7 91.3 60.0 90.0 309.4 98.3 39.2 43.1 736.0 48.4 375.6 85.1 48.0 519.3 54.6 57.8 64.5 72.1 53.1 59.9 71.9 60.3 75.9 69.2 59.9 85.0 298.7 80.1 59.9 21.5 76.4 127.6 177.6 867.1 84.2 15.4 49.8 37.3 49.6 37.1 405.7 27.6 12.5 78.5 240.8 111.0 7.9 74.2 11.6 91.4 52.7 110.7 13.1 25.7 21.4 101.4 67.1 94.7 33.6 112.8 63.3 10.3 62.8 56.5 149.8 10.1 24.2 25.5 270.6 326.2 220.0 6.1 44.1 261.7 49.8 147.1 138.4 23.5 52.5 25.1 44.9 76.0 57.6 49.2 74.5 129.6 82.0 17.2 150.6 28.1 13.1 45.7 75.7 14.6 22.4 47.3 113.2 209.9 121.5 48.3 33.9 140.2 IFNGR2 "AF-1, IFNGT1" ENSG00000159128 "Interferon gamma receptor 2" P38484 21 33403413-33479348 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins" Receptor "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Prostatic glandular cells: 433.1;Urothelial cells: 602.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 661.8" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 76.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001535 Approved Approved "Nucleoplasm,Golgi apparatus" NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 72: Non-specific - Transcription" "Cluster 44: HDLM-2 - Immune response" "Cluster 22: Epithelial cell types - Mixed function" "Nucleoplasm, Golgi apparatus" "HPA001535: AB_1078432" "unprognostic (9.58e-2)" "unprognostic (5.18e-3)" "unprognostic (1.53e-1)" "unprognostic (5.03e-2)" "unprognostic (1.37e-1)" "unprognostic (1.17e-1)" "prognostic unfavorable (3.25e-4)" "unprognostic (3.29e-1)" "unprognostic (1.54e-1)" "unprognostic (3.53e-2)" "unprognostic (3.25e-2)" "unprognostic (9.49e-2)" "prognostic unfavorable (1.13e-10)" "unprognostic (6.74e-3)" "unprognostic (2.49e-1)" "unprognostic (8.02e-2)" "unprognostic (2.15e-3)" 72.9 41.1 5.9 8.6 7.0 46.6 65.6 2.4 8.2 48.3 7.9 46.8 14.2 31.2 3.4 67.4 37.8 11.6 46.4 7.0 11.2 53.1 43.1 61.8 10.6 8.8 6.4 38.8 32.0 5.6 37.8 18.6 7.6 48.2 7.9 1.0 64.5 6.3 30.0 53.3 51.6 8.6 10.0 80.8 35.8 29.5 12.2 8.1 52.3 10.3 11.9 46.4 56.8 14.0 10.1 10.2 5.9 9.7 16.6 28.2 13.1 30.4 30.0 8.9 13.8 11.3 7.7 15.6 19.8 23.8 24.2 8.6 10.9 25.6 3.1 76.3 44.9 6.0 5.0 12.2 11.0 19.5 17.7 21.4 17.0 14.7 16.6 15.9 20.1 9.9 33.4 11.9 10.2 4.4 5.0 23.2 18.1 15.8 48.0 20.2 14.1 19.6 8.5 10.8 7.9 15.5 19.3 1.9 38.4 1.5 7.1 17.7 30.8 10.1 22.0 8.9 8.8 24.6 28.2 25.4 8.5 23.3 44.7 221.7 283.8 181.7 0.9 281.2 1.2 145.6 16.4 1.7 104.0 158.2 37.7 16.3 661.8 3.5 314.8 31.9 19.2 198.5 5.9 7.0 2.4 8.2 7.0 11.2 8.8 6.4 7.6 10.0 12.2 14.0 72.2 41.7 20.5 9.1 101.4 72.0 225.1 164.8 147.4 9.0 69.3 39.2 18.4 38.6 58.2 27.6 8.4 33.6 11.2 185.3 27.4 117.8 44.6 32.1 51.0 55.1 51.6 17.7 18.7 55.7 86.1 66.8 62.7 50.4 60.3 52.1 40.0 29.6 167.6 15.2 18.9 56.2 57.0 154.5 146.7 60.8 42.0 190.8 56.9 45.0 246.6 8.7 6.2 15.6 5.0 138.6 150.3 32.7 67.9 433.1 151.9 50.1 25.4 8.4 13.1 61.3 33.7 13.4 2.8 90.5 70.0 17.4 16.9 3.4 41.3 602.7 IGLL1 "14.1, CD179B, IGL5, IGLL, IGVPB" ENSG00000128322 "Immunoglobulin lambda like polypeptide 1" P15814 22 23573125-23580302 "CD markers, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "bone marrow: 70.0;testis: 25.2" "Group enriched" "Detected in some" 6 "Early spermatids: 78.0;Late spermatids: 140.7;Melanocytes: 119.2" "Group enriched" "Detected in some" 5 "endometrial cancer: 0.5;lung cancer: 0.5;stomach cancer: 2.1" "Not detected" "Not detected" "Group enriched" "Detected in some" 10 "memory B-cell: 12.0;naive B-cell: 14.8" "Lineage enriched" "Detected in many" 11 "B-cells: 14.8" "Cell line enriched" "Detected in some" 32 "REH: 787.7" "HPA051134, HPA071406" Enhanced Approved "Endoplasmic reticulum" "Secreted to blood" NA NA 48000000000 "Cluster 24: B-cells - Unknown function" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 14: REH - Unknown function" "Cluster 25: Spermatids - Spermatogenesis" "Endoplasmic reticulum" "HPA051134: AB_2681356, HPA071406: AB_2686393" "unprognostic (6.21e-2)" "unprognostic (5.12e-2)" "unprognostic (7.31e-2)" "unprognostic (4.75e-2)" "unprognostic (1.56e-1)" "unprognostic (5.91e-6)" "unprognostic (1.08e-1)" "unprognostic (5.27e-2)" "unprognostic (6.17e-3)" "unprognostic (5.89e-2)" "unprognostic (9.07e-2)" "unprognostic (1.99e-4)" "unprognostic (2.35e-2)" "unprognostic (5.16e-1)" "unprognostic (2.28e-2)" "unprognostic (1.21e-2)" 0.0 0.0 0.3 0.3 0.3 70.0 0.0 0.3 0.4 0.0 0.4 0.1 0.3 0.1 0.2 0.0 0.0 0.0 0.0 0.4 0.3 0.2 0.0 0.1 1.4 0.3 0.2 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.4 0.2 25.2 0.2 10.1 0.0 0.0 1.9 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 24.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.4 0.0 0.0 14.3 2.6 0.0 0.0 0.0 787.7 0.3 17.3 0.0 0.0 0.4 0.0 0.0 0.9 0.0 0.0 0.1 6.2 0.0 0.0 0.3 0.3 0.0 0.6 0.1 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.0 0.0 0.0 0.0 14.8 0.0 0.0 0.0 0.0 0.0 1.3 0.0 1.8 0.3 0.3 0.3 0.4 0.4 0.3 0.3 0.2 0.3 0.2 0.2 0.3 0.4 0.0 0.0 0.0 0.8 0.3 0.2 0.0 0.0 0.0 0.2 0.3 0.2 0.0 0.0 0.0 0.0 0.1 0.2 0.0 3.9 0.0 78.0 0.2 0.3 0.3 0.0 10.5 0.3 0.0 0.4 0.6 0.0 0.5 0.0 0.2 0.7 0.0 0.2 0.0 0.3 0.1 0.0 0.0 0.0 140.7 1.2 0.4 119.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.4 0.3 0.0 6.2 0.0 0.0 0.0 1.5 0.3 17.1 0.6 0.0 0.3 0.0 17.9 0.1 0.0 0.2 IKBKB "IKK-beta, IKK2, IKKB, NFKBIKB" ENSG00000104365 "Inhibitor of nuclear factor kappa B kinase subunit beta" O14920 8 42271302-42332460 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease variant, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cone photoreceptor cells: 135.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001249, CAB004447" Enhanced Supported Cytosol NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 80: Striated muscle - Unknown function" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 9: Photoreceptor cells - Phototransduction" Cytosol "CAB004447: AB_627785, HPA001249: AB_1079126" "unprognostic (1.04e-1)" "unprognostic (2.30e-2)" "unprognostic (1.31e-1)" "unprognostic (1.73e-3)" "unprognostic (1.26e-1)" "unprognostic (1.27e-3)" "unprognostic (1.95e-1)" "unprognostic (1.25e-3)" "unprognostic (1.75e-1)" "unprognostic (1.55e-1)" "unprognostic (3.27e-1)" "unprognostic (1.73e-1)" "unprognostic (1.20e-2)" "unprognostic (1.89e-2)" "unprognostic (9.20e-2)" "unprognostic (3.02e-1)" "prognostic favorable (1.46e-6)" 9.4 8.2 9.1 4.7 9.8 4.8 8.3 9.2 10.9 7.2 11.7 6.8 4.8 8.1 7.3 10.2 11.6 8.6 5.6 9.2 9.5 6.8 6.6 11.3 12.2 10.5 9.9 6.1 6.2 13.5 4.0 8.2 10.0 7.9 6.8 12.3 8.9 9.3 13.7 11.4 4.9 12.7 9.7 10.5 5.5 3.2 10.1 10.8 9.4 24.3 11.6 11.1 6.8 10.2 6.2 15.7 8.0 13.6 17.3 18.9 5.8 9.2 18.2 15.2 17.2 3.1 13.9 14.1 10.0 16.5 12.5 5.6 8.4 18.3 17.8 9.8 10.8 17.8 7.8 5.9 20.9 6.1 24.0 12.3 13.7 15.0 19.1 36.1 20.7 11.6 12.8 6.9 34.6 5.1 13.9 11.3 6.1 18.9 6.0 11.1 15.3 10.0 19.6 5.7 1.3 4.7 6.4 6.4 11.7 10.0 8.7 23.6 13.6 7.2 3.9 13.9 6.1 2.8 4.0 10.3 13.8 7.6 16.7 7.4 5.0 5.6 4.6 4.1 4.3 4.4 5.1 5.5 3.7 4.8 4.8 4.7 5.2 5.1 5.5 8.5 5.9 2.9 9.1 9.8 9.2 10.9 9.2 9.5 10.5 9.9 10.0 9.7 10.1 10.2 31.3 12.8 26.9 19.2 28.4 24.3 34.1 13.9 25.6 12.7 20.6 15.5 8.8 14.3 15.4 16.5 135.5 10.4 34.1 15.9 1.9 13.4 2.3 13.9 15.6 27.4 11.4 10.1 19.7 13.6 5.3 12.4 21.9 16.5 38.0 24.0 19.6 12.0 18.6 18.5 20.6 16.4 8.2 32.3 24.0 3.4 16.4 23.4 19.6 58.1 33.7 8.7 47.4 17.1 30.2 16.6 15.0 12.8 18.2 31.9 13.2 5.5 20.2 47.9 6.6 13.1 11.4 4.8 7.0 17.8 29.1 15.2 24.3 6.2 14.1 30.8 IKBKG "FIP-3, FIP3, Fip3p, IKK-gamma, IP1, IP2, NEMO, ZC2HC9" ENSG00000269335 "Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma" Q9Y6K9 X 154541199-154565046 "Disease related genes, Human disease related genes, Predicted intracellular proteins, RAS pathway related proteins" "DNA damage, Host-virus interaction, Transcription, Transcription regulation" "Disease variant, Ectodermal dysplasia, Osteopetrosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000426, CAB010373" Uncertain Enhanced Cytosol NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 85: Liver - Metabolism" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 51: Myeloid cells - Hemostasis" Cytosol "CAB010373: AB_2124846, HPA000426: AB_1851572" "unprognostic (7.53e-2)" "unprognostic (2.76e-3)" "unprognostic (1.09e-1)" "unprognostic (3.37e-3)" "unprognostic (9.77e-2)" "unprognostic (3.68e-1)" "unprognostic (9.22e-2)" "unprognostic (1.47e-1)" "unprognostic (9.16e-2)" "unprognostic (1.59e-1)" "unprognostic (4.18e-2)" "unprognostic (9.87e-2)" "unprognostic (3.57e-2)" "unprognostic (4.41e-2)" "unprognostic (2.78e-1)" "unprognostic (7.07e-2)" "unprognostic (1.36e-2)" 24.4 32.1 18.0 27.6 19.2 42.5 21.7 18.1 23.8 18.9 16.6 22.1 21.2 24.3 6.2 25.5 19.4 16.0 21.5 17.9 17.3 20.7 62.5 29.7 29.0 22.7 19.3 18.3 18.7 10.8 20.2 11.9 21.6 19.9 10.7 6.3 19.8 13.3 20.0 28.4 26.6 14.1 17.9 41.8 22.6 18.8 20.6 19.7 22.9 9.8 18.7 24.8 21.1 23.6 45.8 46.6 11.2 37.1 22.2 18.2 29.7 28.2 35.1 29.4 43.9 32.2 26.5 35.6 73.5 32.6 79.6 39.8 15.0 27.3 12.0 39.6 25.2 27.5 65.4 54.9 37.4 29.3 92.7 23.4 25.6 39.9 15.8 19.4 33.2 34.6 16.6 34.3 23.5 43.1 29.7 52.9 10.4 32.5 69.2 35.4 16.7 38.4 27.6 27.4 19.5 19.9 32.7 32.9 23.0 8.7 19.4 33.4 36.4 29.8 33.9 70.6 69.9 67.5 49.0 69.2 41.4 50.6 41.3 24.9 34.2 61.3 35.3 42.2 24.1 21.3 21.4 26.5 29.8 20.9 17.1 21.3 50.4 30.7 51.1 25.4 26.8 31.0 18.0 19.2 18.1 23.8 17.9 17.3 22.7 19.3 21.6 17.9 20.6 23.6 16.0 3.2 14.3 8.5 22.3 12.4 12.1 20.6 6.2 6.1 8.0 9.8 6.9 10.0 13.6 12.9 10.4 23.3 27.3 14.0 1.9 18.7 0.9 8.0 10.8 15.3 4.9 9.9 5.5 16.9 16.8 12.6 12.8 9.5 29.2 12.0 10.8 36.4 28.3 25.2 4.8 7.7 14.2 17.2 15.9 2.0 14.3 29.4 12.4 4.7 44.5 11.1 48.4 3.0 11.4 23.4 12.8 13.9 13.7 12.5 10.9 7.6 8.3 10.2 6.6 9.6 13.7 4.6 12.8 10.6 10.5 38.0 24.6 10.2 8.5 14.2 IKZF1 "hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1" ENSG00000185811 "IKAROS family zinc finger 1" Q13422 7 50304068-50405101 "Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Cell cycle, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "bone marrow: 173.0;lymphoid tissue: 112.5" "Cell type enhanced" "Detected in many" "B-cells: 120.5;dendritic cells: 221.4;Erythroid cells: 89.8;Microglial cells: 91.8;monocytes: 106.6;NK-cells: 150.4;Plasma cells: 128.9;T-cells: 182.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 140.4;HDLM-2: 258.6;HMC-1: 220.4;JURKAT: 128.9;MOLT-4: 184.3;REH: 192.3;U-698: 342.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB009247, HPA035221, HPA035222" Enhanced Supported Nucleoplasm,Cytosol NA NA "Cluster 12: Non-specific - Basic cellular processes" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 65: Plasmacytoid DCs - Unknown function" Nucleoplasm Cytosol "CAB009247: AB_2124699, HPA035221: AB_2674524, HPA035222: AB_2674525" "prognostic favorable (4.28e-4)" "prognostic favorable (2.02e-4)" "unprognostic (2.49e-3)" "unprognostic (2.41e-3)" "unprognostic (5.59e-1)" "prognostic favorable (8.63e-4)" "unprognostic (1.45e-2)" "unprognostic (1.37e-2)" "unprognostic (1.15e-2)" "unprognostic (2.43e-1)" "unprognostic (6.63e-2)" "unprognostic (2.95e-1)" "unprognostic (1.69e-3)" "unprognostic (1.71e-1)" "unprognostic (2.84e-2)" "unprognostic (6.77e-2)" "unprognostic (4.67e-2)" 5.0 3.2 3.5 53.0 3.4 173.0 4.4 4.0 3.9 3.6 3.3 7.6 7.0 2.5 2.3 4.8 2.2 7.7 1.5 3.0 4.0 1.4 4.9 11.6 87.1 7.7 5.2 1.6 0.8 0.8 0.6 3.6 7.5 2.3 6.8 0.2 4.6 1.9 1.0 2.0 15.6 4.0 7.3 48.6 12.0 1.7 8.7 112.5 2.1 1.2 73.8 9.6 1.8 10.3 0.4 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 140.4 0.4 0.0 0.0 0.2 0.0 0.0 0.0 258.6 0.2 52.1 0.0 0.0 0.0 84.5 220.4 0.0 0.0 0.0 0.0 0.0 0.0 128.9 72.4 15.4 0.0 0.0 184.3 80.9 2.4 0.0 0.0 192.3 0.3 39.6 0.0 0.0 1.6 2.0 0.8 1.0 0.8 0.4 0.2 112.1 0.2 0.0 1.9 0.2 0.4 80.8 49.4 342.7 0.5 89.5 0.5 21.2 14.2 25.0 35.4 43.9 29.1 46.7 36.3 35.0 15.1 40.7 48.2 35.7 20.2 24.3 43.3 23.4 32.6 26.4 3.5 3.4 4.0 3.9 3.0 4.0 7.7 5.2 7.5 7.3 8.7 10.3 2.8 3.2 12.2 0.7 120.5 2.8 0.1 0.0 0.0 0.0 2.8 1.9 1.5 2.8 1.8 1.8 0.0 0.4 221.4 0.3 0.0 0.4 3.8 0.5 0.4 2.6 0.0 89.8 0.2 0.0 0.4 2.5 4.6 0.6 23.4 0.2 3.9 2.0 30.6 0.0 0.3 0.0 0.0 64.3 61.0 5.3 0.0 72.1 19.6 91.8 106.6 0.0 150.4 1.0 0.3 0.1 0.4 0.0 128.9 0.1 0.0 1.0 1.5 0.1 0.0 1.5 1.6 0.1 2.1 0.5 2.7 0.7 182.8 0.1 0.1 0.1 IL12B "CLMF, CLMF2, IL-12B, NKSF, NKSF2" ENSG00000113302 "Interleukin 12B" P29460 5 159314780-159330487 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" Cytokine "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in single" "lymphoid tissue: 1.4" "Cell type enriched" "Detected in some" 4 "monocytes: 6.7" "Cancer enriched" "Detected in single" 20 "testis cancer: 3.4" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "SCLC-21H: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" HPA040970 Supported "Secreted to blood" NA NA 140000 "Cluster 11: Basophils - Unknown function" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 3: Monocytes - Immune response regulation" "HPA040970: AB_10796234" "unprognostic (5.96e-5)" "unprognostic (4.59e-5)" "unprognostic (1.05e-1)" "unprognostic (3.40e-1)" "unprognostic (9.13e-4)" "unprognostic (6.89e-2)" "unprognostic (2.58e-4)" "unprognostic (6.69e-3)" "unprognostic (3.83e-2)" "unprognostic (4.50e-2)" "unprognostic (2.53e-1)" "unprognostic (7.15e-3)" "unprognostic (9.25e-2)" "unprognostic (1.87e-1)" "unprognostic (1.07e-1)" "unprognostic (1.02e-2)" 0.1 0.0 0.0 0.2 0.1 0.3 0.0 0.6 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.3 0.1 0.0 0.0 0.4 0.2 0.1 0.1 1.4 0.1 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.1 0.4 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.3 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 IL12RB1 "CD212, IL12RB" ENSG00000096996 "Interleukin 12 receptor subunit beta 1" P42701 19 18058995-18098944 "CD markers, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 24.6" "Cell type enhanced" "Detected in some" "dendritic cells: 35.1;Kupffer cells: 13.9;NK-cells: 69.0;Plasma cells: 15.3;T-cells: 31.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 18.8;HDLM-2: 35.2;Karpas-707: 57.8;U-698: 15.2" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" HPA074414 Approved "Plasma membrane" "Intracellular and membrane" NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 63: NK-cells & T-cells - Immune response" "Plasma membrane" "HPA074414: AB_2686687" "unprognostic (7.70e-3)" "prognostic favorable (3.41e-4)" "unprognostic (9.08e-3)" "unprognostic (1.18e-4)" "unprognostic (2.91e-1)" "unprognostic (1.33e-3)" "unprognostic (2.27e-1)" "unprognostic (8.99e-2)" "unprognostic (1.65e-2)" "unprognostic (1.35e-1)" "unprognostic (1.51e-1)" "unprognostic (2.94e-1)" "prognostic unfavorable (5.90e-5)" "unprognostic (1.49e-1)" "unprognostic (2.21e-2)" "unprognostic (4.34e-2)" "unprognostic (2.93e-2)" 2.1 1.2 1.0 15.2 1.8 9.3 0.9 1.0 2.1 1.0 1.7 3.1 4.5 0.7 0.8 1.6 0.8 3.5 0.7 1.1 1.1 0.9 2.2 5.8 24.6 2.5 1.5 0.6 0.5 1.3 0.5 1.6 2.3 0.8 2.9 0.5 1.7 0.6 0.7 1.6 7.0 1.9 1.1 16.2 4.1 0.8 2.3 6.6 0.7 0.2 14.1 4.0 0.5 3.7 0.3 0.1 0.1 0.2 0.0 0.1 0.8 0.1 0.1 0.5 1.0 0.3 2.2 18.8 0.1 0.2 0.7 0.3 0.0 0.0 0.0 35.2 0.2 2.2 0.6 0.3 1.0 0.9 3.1 0.1 0.0 0.5 0.0 0.2 0.1 5.1 0.3 57.8 0.0 0.2 9.7 0.3 0.1 0.1 0.0 6.7 0.1 0.8 0.0 0.1 0.4 0.0 0.2 0.2 0.2 0.1 0.4 9.7 0.4 0.5 0.4 0.2 0.2 6.6 11.0 15.2 0.6 12.1 1.1 8.5 12.5 9.2 50.9 34.7 64.0 11.5 34.8 41.7 14.7 9.1 19.3 34.0 14.7 40.9 34.0 8.1 53.0 24.3 1.0 1.8 1.0 2.1 1.1 1.1 2.5 1.5 2.3 1.1 2.3 3.7 0.5 0.0 3.0 0.3 9.6 0.3 2.1 0.1 0.6 0.0 0.3 0.5 1.0 1.5 0.6 0.0 0.0 0.2 35.1 0.1 0.0 0.0 0.5 0.5 0.2 0.5 0.0 5.2 0.8 0.0 0.8 0.7 3.1 0.7 4.5 0.0 0.4 0.1 6.4 0.0 0.4 0.0 0.0 13.9 4.0 0.0 0.0 11.7 0.0 3.7 11.9 0.0 69.0 0.0 2.6 0.1 0.0 0.0 15.3 0.5 0.4 0.2 0.2 0.0 0.0 0.7 0.3 0.4 0.1 0.0 0.9 0.1 31.5 0.0 0.2 1.3 IL21 "IL-21, Za11" ENSG00000138684 "Interleukin 21" Q9HBE4 4 122610108-122621066 "Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins" Cytokine "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 7 "lymphoid tissue: 5.9" "Group enriched" "Detected in some" 18 "Early spermatids: 13.7;Late spermatids: 8.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Secreted to blood" NA NA 55700 "Cluster 16: Immune cells - Immune response" "Cluster 34: Spermatids - Unknown function" "unprognostic (2.42e-1)" "unprognostic (2.12e-1)" "unprognostic (6.80e-2)" 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.8 0.0 0.1 0.0 0.0 2.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.6 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 IL2RA "CD25, IDDM10, IL2R" ENSG00000134460 "Interleukin 2 receptor subunit alpha" P01589 10 6010689-6062370 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Immunity Receptor "Cancer-related genes, Diabetes mellitus, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 18.9;lymphoid tissue: 17.4;urinary bladder: 11.2" "Group enriched" "Detected in some" 6 "granulocytes: 80.8;monocytes: 177.6" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 8 "basophil: 175.9;T-reg: 248.0" "Group enriched" "Detected in many" 14 "granulocytes: 175.9;T-cells: 248.0" "Cell line enriched" "Detected in some" 59 "HDLM-2: 1113.3" "Not detected" "Not detected" "Low region specificity" "Detected in some" "CAB002419, HPA054622" Enhanced NA NA 410000 "Cluster 4: T-regs - Cell cycle regulation" "Cluster 16: Immune cells - Immune response" "Cluster 44: HDLM-2 - Immune response" "Cluster 3: Monocytes - Immune response regulation" "CAB002419: AB_563538, HPA054622: AB_2682546" "unprognostic (2.82e-1)" "unprognostic (8.10e-3)" "unprognostic (1.75e-2)" "unprognostic (5.86e-2)" "unprognostic (1.50e-1)" "unprognostic (1.45e-3)" "unprognostic (2.78e-2)" "unprognostic (2.73e-1)" "unprognostic (5.03e-2)" "unprognostic (6.32e-2)" "unprognostic (7.21e-2)" "unprognostic (2.07e-1)" "prognostic unfavorable (2.08e-9)" "unprognostic (2.10e-2)" "unprognostic (4.66e-2)" "unprognostic (2.22e-1)" "unprognostic (5.10e-2)" 18.9 1.9 0.0 14.2 0.0 0.4 1.4 0.1 0.2 0.5 1.1 3.3 1.9 0.5 0.2 2.6 0.3 2.9 0.8 0.1 0.1 0.7 0.5 2.4 17.4 0.5 0.1 0.1 0.5 0.3 0.9 2.5 0.4 0.4 2.1 0.0 0.5 0.8 0.1 0.4 6.5 4.7 0.1 7.5 1.2 0.2 0.2 5.2 1.3 0.6 12.9 11.2 0.2 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1113.3 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.9 0.0 0.4 18.9 0.0 0.3 0.0 175.9 0.1 20.1 0.6 0.0 2.2 14.7 27.3 3.1 0.2 7.3 2.0 0.2 0.9 13.4 0.3 0.2 248.0 3.2 0.0 0.0 0.1 0.2 0.1 0.1 0.5 0.1 0.4 0.1 0.2 0.2 0.4 0.0 1.8 1.0 13.0 0.9 0.1 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.6 0.0 0.0 0.0 8.3 0.0 0.0 0.1 0.2 0.2 0.6 0.4 0.0 0.8 0.2 0.6 0.0 0.7 1.1 0.1 80.8 0.0 0.4 0.2 0.3 0.0 0.2 0.0 0.0 7.7 4.8 0.1 0.0 19.3 3.6 1.9 177.6 0.0 2.1 0.0 0.3 0.1 0.0 0.0 1.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.2 0.1 0.6 0.0 19.6 0.0 0.1 0.2 IL2RG "CD132, CIDX, IMD4, SCIDX1" ENSG00000147168 "Interleukin 2 receptor subunit gamma" P31785 X 71107404-71112108 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" Receptor "Cancer-related genes, Disease variant, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 118.0;lymphoid tissue: 346.4" "Cell type enhanced" "Detected in many" "B-cells: 186.1;dendritic cells: 199.0;Distal enterocytes: 202.0;NK-cells: 310.0;Paneth cells: 133.2;Plasma cells: 221.2;T-cells: 289.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enriched" "Detected in many" 6 "Karpas-707: 2316.2" "HPA046641, HPA049691" Enhanced Approved Vesicles NA NA 13000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 58: T-cells - T-cell receptor" Vesicles "HPA046641: AB_2679733, HPA049691: AB_2680851" "unprognostic (2.97e-3)" "unprognostic (4.24e-2)" "unprognostic (1.23e-1)" "prognostic favorable (1.73e-4)" "unprognostic (8.25e-2)" "unprognostic (1.93e-3)" "unprognostic (1.37e-1)" "unprognostic (1.53e-1)" "unprognostic (1.91e-3)" "unprognostic (1.23e-2)" "unprognostic (4.36e-1)" "unprognostic (1.45e-1)" "prognostic unfavorable (2.28e-7)" "unprognostic (1.73e-1)" "unprognostic (4.69e-2)" "unprognostic (4.89e-2)" "unprognostic (9.54e-2)" 12.8 6.2 2.7 132.2 2.4 87.3 14.1 2.5 6.3 10.2 4.0 98.9 50.4 7.5 7.5 15.1 6.8 28.2 4.6 2.3 2.8 7.1 20.6 51.7 235.6 3.6 2.7 4.9 4.1 1.9 1.5 16.9 4.2 7.8 118.0 0.5 19.0 5.9 2.6 15.4 82.8 12.3 3.1 119.4 41.4 2.2 3.0 346.4 5.8 6.3 306.9 46.4 5.5 3.8 1.2 0.5 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.2 0.0 4.7 9.1 187.3 13.5 0.0 0.7 1.7 0.4 0.0 0.0 160.3 0.2 23.6 0.3 0.3 0.2 99.3 4.0 0.0 0.0 0.0 0.1 0.1 0.0 220.5 43.3 2316.2 0.0 0.0 356.4 193.7 0.4 0.9 0.1 79.5 0.8 20.0 0.0 0.7 0.2 0.3 2.3 0.1 0.5 0.0 0.0 3.5 0.4 0.0 1.0 0.0 0.5 132.1 242.2 119.6 2.1 397.4 0.9 540.5 102.2 169.7 1204.7 239.5 1179.9 604.7 1086.3 1250.7 243.5 603.0 742.0 943.1 773.0 1190.3 177.0 368.9 1422.2 1494.0 2.7 2.4 2.5 6.3 2.3 2.8 3.6 2.7 4.2 3.1 3.0 3.8 3.3 3.2 11.2 0.0 186.1 8.2 8.1 13.1 1.2 0.0 1.5 1.7 0.9 4.3 4.2 0.0 0.0 0.5 199.0 202.0 0.0 1.2 0.1 0.8 0.7 5.8 77.7 27.1 0.0 2.3 0.3 4.2 13.7 0.7 39.3 0.4 6.1 2.1 31.1 0.0 0.0 24.5 4.1 25.2 116.7 0.0 0.0 45.4 42.7 1.0 91.1 0.1 310.0 0.0 0.1 28.0 133.2 0.4 221.2 4.3 88.8 1.1 2.3 0.4 0.0 1.3 2.6 0.0 0.1 1.8 6.8 0.3 289.5 0.0 18.6 8.9 IL6ST "CD130, GP130, sGP130" ENSG00000134352 "Interleukin 6 signal transducer" P40189 5 55935095-55995022 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Human disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Host-virus interaction" Receptor "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Glandular and luminal cells: 580.3;Hepatic stellate cells: 808.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "naive CD4 T-cell: 16.7" "Lineage enriched" "Detected in many" 4 "T-cells: 16.7" "Cell line enhanced" "Detected in many" "ASC TERT1: 151.3;BJ hTERT+: 175.2;HHSteC: 155.1;HSkMC: 135.1;TIME: 147.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010558, CAB025784" Approved Supported "Golgi apparatus,Plasma membrane" "Secreted to blood" NA NA 160000000 "Cluster 32: T-cells - Unknown function" "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 44: Endometrium - Transcription" "Plasma membrane" "Golgi apparatus" "CAB025784: , HPA010558: AB_1078439" "unprognostic (1.81e-2)" "unprognostic (1.25e-1)" "unprognostic (7.61e-2)" "unprognostic (3.95e-2)" "unprognostic (8.93e-2)" "unprognostic (3.99e-2)" "unprognostic (5.18e-2)" "unprognostic (9.53e-3)" "unprognostic (1.89e-2)" "unprognostic (2.29e-1)" "unprognostic (4.78e-2)" "unprognostic (1.59e-1)" "prognostic unfavorable (5.05e-4)" "unprognostic (3.69e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (1.25e-1)" 67.1 46.0 26.8 14.1 31.0 9.6 51.3 30.9 36.7 43.0 21.3 33.9 4.2 35.2 18.5 18.4 34.2 23.6 35.1 23.5 31.4 30.0 77.6 53.3 15.9 32.1 27.0 36.9 21.9 39.6 22.5 101.7 35.9 32.6 14.3 28.6 31.9 29.9 41.0 17.8 31.1 28.7 35.1 34.7 27.8 8.9 25.3 23.6 40.4 34.7 16.2 37.7 35.1 42.9 14.4 35.6 9.4 18.8 75.5 151.3 22.3 54.5 175.2 44.1 62.4 40.5 16.3 1.1 33.7 52.5 71.6 7.8 9.8 19.2 84.1 1.6 8.5 4.6 20.1 14.2 155.1 0.4 6.2 135.1 11.1 103.1 42.7 43.6 101.8 1.9 3.7 51.0 47.0 2.9 0.7 0.8 1.5 1.8 10.1 1.1 22.5 14.4 22.5 12.1 3.8 5.9 26.6 5.7 19.7 13.7 29.5 3.1 147.8 12.4 10.1 44.5 24.6 14.6 8.2 0.5 28.9 1.1 31.1 0.0 3.9 0.1 0.7 3.4 0.3 0.8 3.7 0.8 2.1 0.4 16.7 4.8 0.6 0.8 0.5 1.9 4.1 4.0 26.8 31.0 30.9 36.7 23.5 31.4 32.1 27.0 35.9 35.1 25.3 42.9 221.6 134.6 149.8 59.4 30.0 103.9 98.0 60.6 71.2 56.5 202.4 81.3 81.5 124.4 105.4 68.0 35.5 77.9 33.1 34.5 7.9 85.3 12.3 76.4 227.6 256.2 19.8 41.1 25.7 62.0 75.5 285.5 59.1 580.3 32.9 58.6 808.5 219.8 56.0 16.8 70.0 34.1 46.8 93.7 99.1 16.7 105.9 60.3 80.0 188.3 45.8 190.8 7.2 75.4 64.2 80.8 35.6 130.5 100.6 163.9 33.6 52.2 80.3 39.3 98.6 158.7 150.3 54.4 38.6 44.9 83.5 101.8 75.5 228.7 17.1 106.1 IL7R "CD127, IL7RA" ENSG00000168685 "Interleukin 7 receptor" P16871 5 35852695-35879603 "Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 183.7" "Group enriched" "Detected in many" 4 "monocytes: 271.8;T-cells: 973.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "gdT-cell: 102.1;MAIT T-cell: 369.5;memory CD4 T-cell: 213.8;memory CD8 T-cell: 151.1;naive CD4 T-cell: 179.5;naive CD8 T-cell: 124.6;NK-cell: 113.2" "Group enriched" "Detected in all" 33 "NK-cells: 113.2;T-cells: 369.5" "Cell line enhanced" "Detected in many" "BJ: 99.8;BJ hTERT+ SV40 Large T+: 87.7;fHDF/TERT166: 187.7;HBF TERT88: 168.3;REH: 406.2" "Not detected" "Not detected" "Low region specificity" "Detected in single" "CAB010215, HPA067550" Supported "Plasma membrane" "Intracellular and membrane" NA NA 610000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 14: REH - Unknown function" "Cluster 24: Non-specific - Transcription regulation" "Plasma membrane" "CAB010215: AB_673727, HPA067550: " "unprognostic (2.93e-3)" "unprognostic (3.38e-2)" "unprognostic (3.82e-3)" "unprognostic (5.58e-3)" "unprognostic (3.06e-2)" "unprognostic (1.74e-1)" "unprognostic (2.51e-3)" "unprognostic (5.53e-2)" "unprognostic (1.12e-1)" "unprognostic (9.29e-3)" "unprognostic (1.43e-1)" "unprognostic (2.69e-1)" "unprognostic (1.76e-2)" "unprognostic (5.64e-2)" "unprognostic (3.27e-3)" "unprognostic (2.22e-1)" "unprognostic (1.78e-1)" 11.2 14.4 1.5 137.6 1.8 14.0 20.4 7.4 2.7 12.0 1.0 17.3 15.0 3.9 1.6 11.0 5.7 32.4 2.2 2.0 2.5 4.5 12.5 63.9 139.4 1.8 0.5 2.2 5.3 0.8 1.7 2.9 1.6 8.7 20.4 0.9 3.3 3.1 4.1 3.8 56.8 5.6 0.6 70.1 34.1 4.7 4.4 183.7 7.6 1.7 123.0 48.0 7.1 6.2 0.6 0.4 0.7 0.4 0.7 0.6 0.6 99.8 50.6 87.7 51.3 0.5 0.6 9.6 0.3 187.7 15.9 16.0 0.2 6.0 168.3 8.6 1.1 3.2 10.3 0.0 1.5 0.6 7.2 1.6 0.0 18.7 4.3 2.4 2.6 0.7 0.7 0.9 71.3 0.2 2.3 1.0 0.3 0.3 4.6 406.2 5.2 0.6 0.0 5.3 0.4 0.2 15.9 1.7 0.2 0.3 0.6 0.4 7.0 34.5 58.4 14.8 13.4 0.6 0.2 10.4 17.4 9.2 27.8 4.3 1.6 1.0 102.1 1.2 369.5 1.5 213.8 151.1 0.7 2.1 179.5 124.6 7.3 113.2 1.5 1.8 39.7 87.7 1.5 1.8 7.4 2.7 2.0 2.5 1.8 0.5 1.6 0.6 4.4 6.2 8.9 16.0 16.0 0.0 47.4 11.6 2.7 0.0 5.2 0.0 8.6 6.1 4.9 0.0 2.5 0.0 0.0 0.2 136.0 0.6 0.0 1.0 0.1 1.1 0.4 13.2 0.0 16.4 0.0 2.0 0.2 11.6 53.5 1.2 19.6 0.2 13.2 4.4 10.6 0.0 0.0 0.5 0.0 10.6 98.5 0.8 0.0 58.8 21.4 2.8 271.8 0.0 11.3 0.0 0.0 0.1 1.4 0.0 93.5 1.4 0.0 0.8 5.8 0.0 0.0 5.5 7.9 0.2 0.1 1.5 10.4 0.3 973.8 0.4 0.4 3.5 IRAK4 NY-REN-64 ENSG00000198001 "Interleukin 1 receptor associated kinase 4" Q9NWZ3 12 43758944-43789543 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Immunity, Innate immunity" "Kinase, Serine/threonine-protein kinase, Transferase" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-937: 56.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB016685, CAB022077" Uncertain Approved Nucleoli,Microtubules,Cytosol NA NA "Cluster 41: Basophils - Cellular respiration" "Cluster 20: Retina & Lymphoid tissues - Unknown function" "Cluster 32: U-937 - Innate immune response" "Cluster 63: NK-cells & T-cells - Immune response" Microtubules "Nucleoli, Cytosol" "CAB016685: AB_1618505, CAB022077: " "unprognostic (2.76e-2)" "unprognostic (5.63e-2)" "unprognostic (1.47e-2)" "prognostic favorable (3.46e-5)" "unprognostic (6.15e-2)" "unprognostic (3.50e-3)" "unprognostic (1.44e-2)" "unprognostic (8.49e-2)" "unprognostic (6.44e-3)" "unprognostic (7.50e-2)" "unprognostic (4.00e-3)" "unprognostic (6.29e-2)" "unprognostic (4.52e-2)" "unprognostic (2.95e-1)" "unprognostic (2.31e-1)" "unprognostic (1.84e-1)" "prognostic favorable (4.42e-5)" 8.6 6.5 4.0 13.6 4.6 10.0 8.9 4.5 5.1 7.9 5.1 7.9 9.1 6.8 7.0 10.5 7.0 8.8 5.4 3.9 4.6 8.0 9.2 8.5 17.5 5.5 4.7 5.6 15.1 6.9 6.2 8.3 5.4 7.5 8.4 12.3 8.4 7.0 3.0 13.3 11.9 7.2 4.8 18.6 10.5 5.8 4.9 18.5 10.9 3.2 16.3 7.8 7.9 5.3 9.3 6.8 4.7 6.2 16.5 27.6 6.7 12.9 9.1 10.0 9.1 5.8 8.7 15.8 12.4 10.7 6.6 7.5 5.3 8.3 14.2 22.8 4.9 15.2 5.2 3.7 9.4 21.2 17.7 14.7 12.7 12.7 7.4 17.4 15.0 15.1 14.4 11.6 27.8 5.1 18.6 11.7 1.7 0.0 7.9 12.2 5.8 8.4 7.8 8.8 3.4 3.3 6.3 7.9 6.2 6.4 9.9 18.5 13.4 12.2 2.3 15.1 9.0 14.0 19.4 13.7 12.7 56.2 6.9 20.8 4.0 8.7 6.1 4.6 6.3 3.3 4.9 5.3 3.7 4.4 4.4 4.8 7.9 7.9 5.9 5.1 6.7 4.6 4.0 4.6 4.5 5.1 3.9 4.6 5.5 4.7 5.4 4.8 4.9 5.3 24.1 19.2 15.6 5.2 36.5 10.8 11.3 10.7 17.1 5.8 15.2 11.2 4.5 17.2 11.3 33.1 20.9 14.9 52.1 15.7 21.5 12.7 18.4 14.1 12.4 17.3 3.6 12.0 2.9 17.8 8.4 13.7 33.6 15.2 22.1 10.7 16.1 8.7 16.9 8.4 3.4 11.9 14.2 24.7 20.2 23.2 12.5 25.1 10.6 20.6 28.2 9.9 60.8 2.5 14.7 13.3 7.2 11.3 33.2 8.9 18.6 13.8 9.5 27.2 6.6 9.5 11.0 28.2 12.5 17.2 11.8 27.9 41.1 15.0 9.2 13.5 IRF2BP2 IRF-2BP2 ENSG00000168264 "Interferon regulatory factor 2 binding protein 2" Q7Z5L9 1 234604269-234610178 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Repressor" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Basal prostatic cells: 440.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "THP-1: 277.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA027815, HPA062269" Approved Enhanced Nucleoplasm NA NA 13000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 43: THP-1 - Innate immune response" "Cluster 65: Plasmacytoid DCs - Unknown function" Nucleoplasm "HPA027815: AB_10609994, HPA062269: AB_2684732" "unprognostic (1.15e-3)" "unprognostic (1.02e-1)" "unprognostic (3.90e-1)" "unprognostic (2.13e-1)" "unprognostic (3.41e-3)" "unprognostic (1.69e-1)" "unprognostic (1.74e-3)" "unprognostic (1.97e-2)" "unprognostic (8.77e-2)" "unprognostic (2.19e-1)" "unprognostic (3.69e-2)" "unprognostic (2.83e-1)" "prognostic unfavorable (6.42e-4)" "unprognostic (1.25e-1)" "unprognostic (2.70e-1)" "unprognostic (3.14e-1)" "unprognostic (3.77e-1)" 35.6 39.6 43.3 25.6 50.2 157.2 45.0 48.5 49.1 50.0 43.3 42.5 39.6 55.8 26.5 47.0 45.1 40.7 45.0 40.5 45.4 34.2 53.6 43.7 36.3 55.2 49.0 54.8 49.5 45.5 24.1 29.6 51.1 39.2 49.3 26.9 55.0 33.5 47.4 64.2 42.2 31.7 48.9 28.4 44.4 18.0 44.7 29.6 57.3 40.5 30.3 38.7 43.7 61.1 28.0 41.5 29.8 45.7 61.2 48.1 35.1 21.8 18.4 12.7 14.2 24.5 33.5 0.0 49.4 21.2 43.3 37.4 16.2 28.3 20.2 45.2 36.8 26.7 32.9 72.3 49.4 101.0 91.0 57.0 65.8 28.3 53.4 74.4 33.0 24.5 23.0 55.6 33.2 8.4 25.5 107.2 27.1 65.1 15.7 49.6 13.8 66.8 25.1 22.9 58.8 41.8 35.2 46.7 72.7 29.8 45.1 277.5 36.8 45.5 19.0 34.7 41.6 122.9 33.8 9.1 23.1 89.6 63.4 10.1 4.5 8.5 3.9 3.6 4.0 4.3 4.8 4.6 4.7 4.0 4.9 4.1 2.3 3.0 1.9 17.8 4.0 2.5 43.3 50.2 48.5 49.1 40.5 45.4 55.2 49.0 51.1 48.9 44.7 61.1 96.0 134.6 191.3 28.1 75.6 325.9 440.4 142.3 139.5 34.6 126.6 109.7 63.6 133.0 143.8 51.5 10.4 44.6 168.3 84.2 13.7 65.8 24.9 180.8 126.2 101.9 145.5 76.6 14.3 50.0 58.0 97.3 47.4 285.2 107.5 39.6 117.4 185.7 88.9 58.9 22.9 117.1 71.2 131.8 271.2 27.1 69.6 159.7 110.3 30.9 83.2 87.7 38.1 20.6 64.2 68.9 92.0 81.3 39.2 138.2 81.7 40.2 95.1 19.5 78.9 117.1 102.9 29.5 24.1 182.1 396.2 79.4 91.3 15.5 162.7 370.6 IRF8 "ICSBP, ICSBP1, IRF-8" ENSG00000140968 "Interferon regulatory factor 8" Q02556 16 85899162-85922606 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Autophagy, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 85.5;lymphoid tissue: 244.1" "Cell type enhanced" "Detected in many" "B-cells: 225.8;dendritic cells: 492.3;Kupffer cells: 105.1;Langerhans cells: 366.0;Macrophages: 122.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 7 "plasmacytoid DC: 2477.4" "Lineage enriched" "Detected in all" 7 "dendritic cells: 2477.4" "Group enriched" "Detected in some" 4 "Daudi: 240.7;THP-1: 382.3;U-698: 928.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002267, HPA002531, CAB013480" Enhanced Enhanced Nucleoplasm NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 65: Plasmacytoid DCs - Unknown function" Nucleoplasm "CAB013480: AB_2533439, HPA002267: AB_1079143, HPA002531: AB_1851904" "unprognostic (2.09e-3)" "unprognostic (7.51e-2)" "unprognostic (5.16e-2)" "unprognostic (1.19e-1)" "unprognostic (7.54e-2)" "unprognostic (3.46e-3)" "unprognostic (3.19e-2)" "unprognostic (5.31e-3)" "unprognostic (1.23e-1)" "unprognostic (1.20e-1)" "unprognostic (1.66e-1)" "unprognostic (5.31e-2)" "unprognostic (3.14e-3)" "unprognostic (3.97e-2)" "unprognostic (9.66e-3)" "unprognostic (4.04e-1)" "unprognostic (1.10e-2)" 25.9 7.6 4.7 81.4 5.6 85.5 9.3 7.0 6.2 5.6 5.4 27.1 47.1 8.0 3.1 6.7 6.5 19.7 3.8 6.3 5.4 6.1 36.9 27.4 244.1 9.5 8.5 2.5 3.4 1.7 1.7 10.1 10.0 7.7 33.5 0.8 7.1 8.9 2.0 5.0 56.2 13.5 11.3 137.3 22.9 4.8 12.6 61.5 4.1 1.7 224.9 21.8 1.6 14.0 0.9 0.0 0.0 0.0 0.0 0.0 16.9 0.0 0.0 0.0 0.0 26.0 0.0 240.7 1.5 0.0 0.0 0.1 1.4 0.0 0.2 0.2 2.7 0.1 0.0 0.0 1.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.3 0.5 0.0 0.0 0.6 21.3 0.2 20.6 0.0 7.5 1.1 27.2 0.0 0.0 0.1 0.1 1.0 0.0 0.2 1.4 0.0 382.3 0.6 0.0 10.9 0.2 0.9 0.3 0.3 928.2 0.0 128.4 0.0 9.1 137.1 3.4 3.3 134.3 4.5 347.0 1.8 2.1 291.2 361.3 3.5 2.8 8.4 111.5 97.3 2477.4 0.7 150.1 4.7 5.6 7.0 6.2 6.3 5.4 9.5 8.5 10.0 11.3 12.6 14.0 3.7 0.0 4.2 0.0 225.8 10.5 0.8 0.0 0.6 0.0 2.4 3.4 1.5 2.8 1.3 0.0 0.0 0.8 492.3 13.0 1.9 0.5 1.5 7.3 7.6 7.6 28.7 7.4 0.6 1.4 5.7 10.8 15.3 12.5 2.5 0.4 1.8 6.5 64.1 0.0 0.2 11.8 0.0 105.1 366.0 4.6 0.3 122.2 44.4 33.7 35.3 0.4 23.7 1.0 0.4 0.1 10.7 0.0 14.1 2.3 34.2 3.5 0.0 0.2 6.6 0.7 6.7 0.7 6.7 0.4 9.2 1.1 23.1 48.8 25.6 2.5 ISG15 "G1P2, IFI15, UCRP" ENSG00000187608 "ISG15 ubiquitin like modifier" P05161 1 1001138-1014540 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Antiviral defense, Host-virus interaction, Immunity, Innate immunity, Ubl conjugation pathway" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "salivary gland: 320.4" "Cell type enhanced" "Detected in many" "Extravillous trophoblasts: 497.1;Paneth cells: 403.1;Proximal enterocytes: 461.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "BJ hTERT+ SV40 Large T+: 1460.2;BJ hTERT+ SV40 Large T+ RasG12V: 1466.7;HeLa: 501.4;SK-MEL-30: 487.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004627 Approved "Secreted to blood" NA NA 5000000 "Cluster 49: Eosinophils - Unknown function" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 53: Intestinal epithelial cells - Unknown function" "HPA004627: AB_1079152" "unprognostic (3.65e-1)" "unprognostic (1.06e-1)" "unprognostic (1.12e-2)" "unprognostic (4.62e-2)" "unprognostic (3.96e-3)" "unprognostic (1.38e-1)" "unprognostic (4.08e-2)" "unprognostic (1.02e-1)" "unprognostic (1.48e-2)" "unprognostic (3.78e-3)" "unprognostic (2.07e-3)" "unprognostic (2.25e-1)" "prognostic unfavorable (5.11e-10)" "unprognostic (4.55e-2)" "unprognostic (4.13e-2)" "unprognostic (1.12e-2)" "unprognostic (7.46e-2)" 46.8 24.3 42.9 36.9 39.8 136.1 39.0 42.0 49.9 79.0 32.6 47.0 42.5 29.6 3.9 24.0 19.9 31.3 55.4 38.3 36.8 73.2 113.5 59.9 29.7 63.2 42.7 17.6 18.9 8.8 40.3 44.8 63.8 28.1 6.9 1.1 320.4 14.1 15.9 13.4 34.8 18.2 134.8 75.3 31.3 10.5 48.7 48.5 34.7 8.1 11.6 29.2 25.7 38.3 58.1 8.5 4.4 38.2 6.0 11.8 33.2 39.5 95.7 1460.2 1466.7 95.6 91.7 51.4 282.0 33.4 248.2 36.1 4.5 17.3 22.7 58.2 23.7 24.3 501.4 65.2 53.8 15.4 94.5 24.6 5.6 92.7 1.8 4.8 46.1 67.7 14.1 27.4 12.0 282.3 50.0 253.5 4.7 36.3 315.3 85.7 11.0 26.1 19.2 18.0 2.0 1.8 77.1 12.6 487.0 1.9 2.9 29.8 25.8 28.5 27.4 13.2 8.7 35.5 19.6 39.6 27.9 60.2 2.7 508.7 278.6 871.3 228.3 425.4 295.5 259.1 258.6 251.7 174.8 215.7 165.2 191.1 663.3 276.7 381.1 59.4 509.7 217.6 42.9 39.8 42.0 49.9 38.3 36.8 63.2 42.7 63.8 134.8 48.7 38.3 240.1 38.5 17.5 1.6 71.8 44.6 47.9 83.7 9.1 2.0 29.3 21.5 24.3 25.8 61.8 46.0 0.0 24.2 213.7 289.1 5.9 134.1 3.5 65.5 66.1 200.5 35.2 8.0 0.6 280.4 497.1 84.5 25.0 95.4 60.9 113.8 70.6 58.2 273.6 0.0 2.2 104.9 63.1 62.0 273.8 14.0 32.9 170.4 88.9 13.1 132.5 21.2 134.9 2.5 0.3 192.0 403.1 41.3 48.7 39.3 461.3 32.1 50.7 3.2 98.6 15.4 179.1 6.2 7.3 7.9 36.9 32.3 169.4 63.0 39.5 55.4 ITGB2 "CD18, LFA-1, MAC-1, MFI7" ENSG00000160255 "Integrin subunit beta 2" P05107 21 44885953-44931989 "CD markers, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Phagocytosis" "Integrin, Receptor" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 376.2;lymphoid tissue: 175.2" "Group enriched" "Detected in many" 6 "dendritic cells: 417.6;Hofbauer cells: 652.4;Kupffer cells: 485.9;Langerhans cells: 259.1;Macrophages: 527.4;monocytes: 463.8;NK-cells: 959.9;T-cells: 254.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Group enriched" "Detected in many" 6 "THP-1: 812.4;U-937: 615.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008877, HPA016894" Enhanced Supported "Plasma membrane,Rods & Rings" NA NA 3300000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 43: THP-1 - Innate immune response" "Cluster 63: NK-cells & T-cells - Immune response" "Plasma membrane" "Rods & Rings" "HPA008877: AB_1846256, HPA016894: AB_1846257" "unprognostic (1.94e-2)" "unprognostic (7.66e-3)" "unprognostic (1.23e-1)" "unprognostic (6.21e-3)" "unprognostic (2.95e-2)" "unprognostic (9.73e-3)" "unprognostic (2.53e-2)" "unprognostic (1.82e-1)" "unprognostic (1.18e-2)" "unprognostic (1.36e-1)" "unprognostic (1.20e-1)" "unprognostic (6.34e-2)" "unprognostic (1.87e-3)" "unprognostic (1.42e-1)" "unprognostic (4.42e-2)" "unprognostic (2.65e-2)" "unprognostic (4.83e-2)" 54.5 23.2 8.2 175.2 9.5 376.2 15.4 13.1 9.3 15.5 11.7 25.2 23.8 8.5 2.8 16.2 17.0 36.4 11.8 7.7 14.2 8.4 23.4 78.0 169.1 29.5 19.9 7.2 11.3 5.1 4.6 44.4 28.1 8.8 13.9 1.1 19.5 9.2 6.8 9.3 32.8 46.4 23.9 137.2 29.1 5.9 26.2 87.2 7.3 7.6 68.4 46.3 5.9 50.4 1.9 4.8 0.0 0.0 0.0 0.3 1.7 0.0 2.7 0.1 0.0 0.4 0.4 17.9 128.1 0.2 0.6 0.5 0.0 0.2 0.0 1.5 1.4 18.2 0.0 3.2 0.1 106.6 27.5 1.6 0.1 0.5 0.3 0.1 0.3 58.0 0.7 1.4 7.0 4.0 117.8 126.1 0.4 0.4 2.4 1.5 23.2 64.6 4.7 0.0 0.6 1.3 3.4 2.5 1.7 0.0 0.4 812.4 2.5 0.2 6.6 0.4 3.7 0.8 5.9 2.9 0.1 615.0 0.9 186.6 1848.8 1224.1 726.7 1144.9 326.6 86.1 349.7 506.5 1031.4 115.2 233.1 396.5 1386.1 585.5 1183.5 165.5 288.0 3034.2 8.2 9.5 13.1 9.3 7.7 14.2 29.5 19.9 28.1 23.9 26.2 50.4 7.1 16.0 29.6 0.3 81.7 5.5 0.5 9.6 0.6 0.0 4.1 6.5 4.0 14.3 18.6 5.5 0.0 4.0 417.6 0.3 0.0 3.4 1.0 0.6 0.5 16.8 0.0 19.6 0.5 0.4 4.8 5.3 2.6 0.7 24.1 8.2 9.7 8.6 652.4 0.0 0.3 0.2 2.0 485.9 259.1 2.8 0.6 527.4 5.4 27.2 463.8 0.4 959.9 0.0 0.2 0.6 0.1 1.5 50.5 0.6 1.8 4.2 3.6 0.8 6.6 2.1 3.2 0.2 1.0 0.9 5.1 5.6 254.5 0.0 0.3 0.7 ITK "EMT, LYK, PSCTK2" ENSG00000113263 "IL2 inducible T cell kinase" Q08881 5 157142933-157255185 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins" "Adaptive immunity, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "lymphoid tissue: 57.9" "Group enriched" "Detected in some" 6 "dendritic cells: 51.7;granulocytes: 31.8;NK-cells: 42.2;Plasma cells: 34.0;T-cells: 115.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 23 "gdT-cell: 39.6;MAIT T-cell: 26.4;memory CD4 T-cell: 55.6;memory CD8 T-cell: 54.9;naive CD4 T-cell: 78.2;naive CD8 T-cell: 65.0;NK-cell: 29.3;T-reg: 73.2" "Group enriched" "Detected in many" 23 "NK-cells: 29.3;T-cells: 78.2" "Group enriched" "Detected in some" 10 "JURKAT: 62.2;MOLT-4: 23.7" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA043670 Uncertain "Plasma membrane,Cytosol" NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 3: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" "Plasma membrane, Cytosol" "HPA043670: " "unprognostic (2.08e-3)" "unprognostic (6.57e-4)" "unprognostic (5.06e-3)" "unprognostic (4.96e-5)" "unprognostic (1.52e-2)" "unprognostic (1.12e-4)" "unprognostic (8.45e-4)" "unprognostic (1.56e-2)" "unprognostic (1.87e-2)" "unprognostic (5.99e-3)" "unprognostic (1.76e-1)" "unprognostic (2.52e-1)" "unprognostic (4.52e-6)" "unprognostic (3.64e-1)" "unprognostic (4.42e-2)" "unprognostic (1.46e-1)" "unprognostic (3.26e-2)" 1.0 0.3 0.0 15.9 0.0 3.7 0.9 0.0 0.0 1.0 0.0 1.4 0.7 0.4 0.0 1.4 0.4 4.2 0.2 0.0 0.0 0.3 1.6 3.1 29.3 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.4 1.5 0.0 0.3 0.1 0.0 0.2 4.0 0.5 0.0 10.5 3.1 0.5 0.0 57.9 0.5 0.0 24.6 3.9 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 3.9 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.0 62.2 0.0 0.0 0.0 0.0 23.7 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.1 0.0 39.6 0.0 26.4 0.0 55.6 54.9 0.1 0.0 78.2 65.0 1.3 29.3 2.3 0.1 73.2 44.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 6.2 0.0 4.0 2.7 0.6 0.0 0.0 0.0 0.4 0.4 0.9 0.0 0.6 1.8 0.0 0.1 51.7 0.1 0.0 0.1 8.5 0.2 0.3 0.8 0.0 1.7 0.2 0.0 0.0 1.1 7.7 0.4 31.8 0.1 1.8 1.0 0.0 0.0 0.2 0.0 0.0 1.6 5.1 6.7 0.0 2.9 1.8 1.0 2.8 0.0 42.2 0.0 0.1 0.0 0.0 0.0 34.0 0.3 0.0 0.4 0.0 0.0 0.0 1.0 1.0 0.0 0.0 0.2 3.4 0.1 115.7 0.0 0.1 0.6 JAK3 "JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK" ENSG00000105639 "Janus kinase 3" P52333 19 17824780-17848071 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 55.1" "Cell type enhanced" "Detected in many" "B-cells: 27.8;dendritic cells: 20.1;Macrophages: 17.9;NK-cells: 18.6;Plasma cells: 18.4;T-cells: 37.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HDLM-2: 35.7;HEL: 15.9;HMC-1: 15.5;Karpas-707: 40.2;U-266/70: 15.4;U-266/84: 24.7;U-937: 24.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA070314 Enhanced Approved "Plasma membrane,Cytosol" NA NA "Cluster 39: Non-specific - mRNA processing" "Cluster 2: Immune cells - Immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 58: T-cells - T-cell receptor" "Plasma membrane, Cytosol" "HPA070314: AB_2686251" "unprognostic (5.59e-3)" "prognostic favorable (6.42e-5)" "unprognostic (5.71e-2)" "unprognostic (2.34e-1)" "unprognostic (6.13e-3)" "unprognostic (1.11e-3)" "unprognostic (4.21e-2)" "unprognostic (2.60e-1)" "unprognostic (2.38e-2)" "unprognostic (2.36e-1)" "unprognostic (3.58e-2)" "unprognostic (1.94e-1)" "prognostic unfavorable (2.89e-14)" "unprognostic (2.28e-1)" "unprognostic (2.21e-2)" "unprognostic (4.43e-2)" "unprognostic (7.61e-2)" 6.7 2.5 4.0 36.3 4.4 18.6 4.0 3.9 5.6 3.3 3.7 4.0 3.0 2.2 2.4 2.8 5.3 4.8 3.2 4.1 6.7 6.2 2.9 13.1 40.5 7.3 6.1 15.5 1.8 1.9 3.1 5.7 6.4 4.4 3.1 0.6 3.5 1.9 0.7 1.7 15.4 3.5 5.5 55.1 4.6 2.6 6.6 11.3 4.9 0.9 29.7 7.4 3.1 6.1 0.2 0.6 0.5 1.8 0.6 2.4 0.4 0.8 0.0 0.1 0.1 0.0 1.6 0.7 3.3 0.7 0.4 0.2 0.0 0.4 0.0 35.7 0.0 15.9 0.1 1.5 1.2 0.0 15.5 8.4 0.5 0.1 0.0 0.1 0.3 3.6 0.1 40.2 0.0 0.7 6.5 0.0 0.3 0.9 1.3 8.2 0.0 0.7 0.8 0.0 0.0 0.6 0.2 0.4 0.1 0.2 3.5 2.4 0.7 0.0 0.7 0.0 0.0 15.4 24.7 4.3 0.1 24.2 0.3 2.0 7.5 0.3 17.8 14.6 20.2 9.4 21.1 18.6 6.8 10.3 20.2 18.5 25.1 13.4 14.2 5.5 18.0 12.4 4.0 4.4 3.9 5.6 4.1 6.7 7.3 6.1 6.4 5.5 6.6 6.1 5.5 0.0 4.6 2.3 27.8 0.8 0.6 0.5 0.6 0.6 0.5 0.8 1.9 0.0 1.0 1.8 0.0 1.1 20.1 0.0 0.0 0.5 1.0 0.3 2.1 8.0 0.0 6.1 4.3 0.4 0.8 4.6 2.0 0.4 5.1 0.8 9.7 0.4 14.5 0.0 2.6 0.0 0.0 9.2 1.9 2.0 12.5 17.9 3.6 4.7 16.6 0.9 18.6 0.0 0.4 0.5 0.0 14.7 18.4 0.5 0.0 0.3 0.9 0.7 6.6 0.3 2.9 0.3 0.7 0.3 1.0 1.4 37.7 14.8 0.1 0.6 LAMTOR2 "ENDAP, MAPBPIP, MAPKSP1AP, p14, Ragulator2, ROBLD3" ENSG00000116586 "Late endosomal/lysosomal adaptor, MAPK and MTOR activator 2" Q9Y2Q5 1 156054782-156058506 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Proximal tubular cells: 627.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004126 Approved Approved Nucleoplasm,Vesicles No No "Cluster 31: Non-specific - Inflammatory response" "Cluster 35: Non-specific - Unknown function" "Cluster 43: THP-1 - Innate immune response" "Cluster 10: Non-specific - Unknown function" "Nucleoplasm, Vesicles" "HPA004126: AB_1849916" "unprognostic (2.09e-1)" "unprognostic (1.23e-1)" "unprognostic (2.07e-1)" "unprognostic (1.58e-1)" "unprognostic (8.14e-2)" "unprognostic (4.52e-2)" "unprognostic (8.64e-2)" "unprognostic (3.90e-2)" "unprognostic (3.79e-1)" "unprognostic (1.66e-2)" "unprognostic (2.06e-1)" "unprognostic (3.41e-2)" "prognostic unfavorable (1.10e-6)" "unprognostic (2.47e-1)" "unprognostic (1.34e-1)" "unprognostic (8.65e-2)" "unprognostic (1.35e-1)" 64.3 84.4 81.9 41.6 81.4 57.1 57.7 83.9 98.9 44.8 83.0 62.0 51.5 42.3 76.7 75.2 52.1 43.8 96.1 81.6 84.7 91.0 164.3 53.8 56.3 81.6 82.5 26.7 87.8 74.4 44.6 37.5 82.0 50.9 56.5 18.0 59.3 44.0 88.6 57.8 53.7 48.9 82.2 65.7 78.1 26.6 85.8 56.1 44.7 70.2 52.0 53.6 46.7 85.8 63.9 142.3 65.4 90.9 131.9 106.7 72.3 55.7 94.4 68.8 78.1 65.9 106.1 94.0 94.4 108.7 60.0 91.5 67.7 151.1 38.7 78.4 103.0 54.9 96.2 88.6 104.4 78.0 86.5 126.1 93.4 73.1 93.3 94.4 142.6 137.3 50.8 68.1 100.9 128.7 80.6 111.4 69.4 250.9 212.1 67.5 48.7 138.7 152.5 93.2 25.3 145.3 70.4 195.1 116.3 104.1 136.5 227.9 96.6 57.5 52.4 83.4 53.0 101.6 166.5 56.2 102.2 87.3 62.9 281.8 465.8 376.2 172.2 446.9 169.8 290.6 188.2 188.7 537.2 249.4 142.6 152.8 231.8 207.0 363.2 284.1 298.3 389.7 81.9 81.4 83.9 98.9 81.6 84.7 81.6 82.5 82.0 82.2 85.8 85.8 102.5 57.7 46.5 3.6 64.5 48.4 59.5 190.3 43.3 29.4 129.9 123.2 113.5 114.4 120.2 108.5 6.2 146.3 73.9 247.5 387.4 193.0 44.5 113.2 78.7 92.6 126.1 48.0 4.5 179.3 203.1 67.5 68.3 105.0 107.3 56.7 86.7 322.1 416.1 6.7 5.4 164.7 197.4 188.9 150.1 89.0 47.2 165.0 158.3 5.6 297.4 92.8 94.7 4.5 5.8 183.2 267.4 50.8 76.8 80.2 317.8 627.2 144.1 30.5 32.9 38.9 124.6 25.5 33.9 99.4 80.0 77.2 64.2 83.3 166.9 97.7 LCK ENSG00000182866 "LCK proto-oncogene, Src family tyrosine kinase" P06239 1 32251239-32286165 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Host-virus interaction" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 15 "lymphoid tissue: 343.0" "Group enriched" "Detected in many" 9 "dendritic cells: 143.9;NK-cells: 272.9;T-cells: 255.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in all" 12 "gdT-cell: 1109.8;MAIT T-cell: 1034.8;memory CD4 T-cell: 1123.8;memory CD8 T-cell: 1201.7;naive CD4 T-cell: 1260.7;naive CD8 T-cell: 1168.7;NK-cell: 641.5;T-reg: 1682.7" "Group enriched" "Detected in all" 12 "NK-cells: 641.5;T-cells: 1682.7" "Group enriched" "Detected in some" 6 "JURKAT: 365.7;MOLT-4: 536.9;U-698: 302.7" "Low region specificity" "Detected in some" "Low region specificity" "Detected in single" "HPA003494, CAB003816" Enhanced Approved "Golgi apparatus" NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 63: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" "Golgi apparatus" "CAB003816: AB_562158, HPA003494: AB_1852751" "unprognostic (6.38e-3)" "unprognostic (5.45e-3)" "unprognostic (8.39e-2)" "prognostic favorable (2.96e-6)" "unprognostic (2.20e-2)" "prognostic favorable (2.91e-4)" "unprognostic (4.78e-3)" "unprognostic (1.33e-2)" "prognostic favorable (5.65e-5)" "unprognostic (3.07e-2)" "unprognostic (3.80e-2)" "unprognostic (2.83e-1)" "prognostic unfavorable (2.60e-5)" "unprognostic (8.15e-2)" "unprognostic (4.05e-2)" "unprognostic (7.39e-2)" "unprognostic (1.17e-2)" 3.4 2.2 0.4 50.6 0.5 13.7 2.3 0.4 0.5 2.2 0.7 6.9 7.6 1.7 13.0 3.9 2.1 9.4 1.9 0.5 0.4 3.8 3.8 11.4 111.0 0.8 0.5 1.6 0.9 0.5 0.8 1.1 0.6 2.8 6.5 0.0 4.8 1.4 1.3 1.9 23.1 2.3 0.6 39.9 12.1 1.1 0.5 343.0 3.7 1.4 79.6 13.2 2.7 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.6 0.7 64.1 3.5 0.0 0.3 0.1 0.0 0.2 0.0 0.1 0.6 0.0 0.0 1.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 365.7 0.2 0.0 0.0 0.0 536.9 0.2 5.9 4.6 0.3 20.6 0.1 0.3 0.3 0.2 0.1 0.0 0.1 0.3 0.3 0.4 0.6 0.4 0.0 0.0 1.7 0.1 0.1 0.7 0.3 302.7 0.0 0.1 0.0 12.8 5.2 6.0 1109.8 4.9 1034.8 62.0 1123.8 1201.7 5.2 98.9 1260.7 1168.7 33.6 641.5 6.0 7.7 1682.7 1836.9 0.4 0.5 0.4 0.5 0.5 0.4 0.8 0.5 0.6 0.6 0.5 0.6 4.9 0.0 9.3 0.0 23.4 4.6 1.2 0.4 0.0 0.0 3.5 5.2 1.8 4.3 1.6 3.7 0.0 0.3 143.9 0.9 0.0 0.6 0.1 1.0 0.5 3.4 2.4 10.1 0.2 0.5 0.2 3.1 7.7 0.7 5.1 0.0 4.6 1.5 0.3 0.0 0.2 0.3 0.0 7.8 7.3 0.0 0.0 8.1 3.6 0.0 8.7 0.0 272.9 0.5 0.1 4.7 0.0 0.4 15.7 1.0 0.0 1.4 1.8 0.0 0.0 1.5 2.4 4.5 2.0 0.5 3.1 0.4 255.5 2.9 1.3 1.1 LIG1 ENSG00000105486 "DNA ligase 1" P18858 19 48115445-48170603 "Enzymes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, DNA recombination, DNA repair, DNA replication" Ligase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 34.5" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037015, HPA041431, HPA048071" Approved Supported "Nucleoplasm,Golgi apparatus,Vesicles" Yes No "Cluster 15: NK-cells - Transcription" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 24: NB-4 - Immune response" "Cluster 12: Non-specific - Cell cycle regulation" Nucleoplasm "Golgi apparatus, Vesicles" "CAB037015: , HPA041431: AB_2677476, HPA048071: AB_2680248" "unprognostic (1.83e-1)" "unprognostic (1.48e-3)" "unprognostic (6.45e-2)" "unprognostic (9.76e-2)" "unprognostic (9.47e-2)" "unprognostic (9.24e-3)" "unprognostic (1.17e-3)" "unprognostic (2.28e-1)" "unprognostic (6.03e-3)" "unprognostic (4.26e-1)" "unprognostic (1.78e-2)" "unprognostic (1.10e-3)" "prognostic unfavorable (5.75e-5)" "unprognostic (3.59e-2)" "unprognostic (4.09e-2)" "unprognostic (1.59e-2)" "unprognostic (1.55e-2)" 2.8 3.2 3.3 9.0 3.2 34.5 3.6 3.6 3.5 5.5 2.3 6.8 8.6 4.0 2.5 7.4 5.9 2.3 1.6 2.9 3.2 2.9 4.0 3.4 15.6 4.4 2.9 6.0 7.0 4.2 4.8 5.1 4.5 4.0 4.2 2.7 4.8 3.0 3.8 10.4 9.6 2.2 2.6 6.0 5.2 8.2 3.1 20.7 5.1 1.0 9.7 3.5 5.0 3.9 43.4 64.1 57.1 37.6 2.6 4.2 41.7 27.0 19.1 44.1 47.2 35.0 42.9 83.7 15.3 11.2 11.9 30.1 24.7 26.7 16.9 45.2 48.8 56.4 38.7 47.5 1.0 63.0 43.7 5.7 2.5 23.0 3.4 5.0 24.0 51.0 46.3 29.8 23.3 44.0 107.3 123.7 33.6 46.7 15.9 84.1 48.4 43.6 12.3 64.8 36.3 36.5 32.3 33.6 10.1 12.5 22.7 44.5 22.6 31.7 54.3 23.9 40.3 29.3 49.0 83.1 12.7 38.0 33.3 0.0 1.6 2.6 7.8 6.8 7.7 10.9 8.8 8.3 1.6 10.0 11.5 8.2 1.3 12.1 3.3 1.5 10.9 5.7 3.3 3.2 3.6 3.5 2.9 3.2 4.4 2.9 4.5 2.6 3.1 3.9 3.9 3.2 13.6 5.9 16.1 8.3 9.5 8.7 24.5 21.5 7.8 12.3 3.9 7.2 10.3 3.7 10.4 31.1 9.6 10.2 7.9 5.8 19.3 12.0 5.1 8.3 0.0 36.2 4.2 5.2 35.8 6.8 5.1 8.3 6.3 23.1 5.0 5.3 16.4 8.4 5.6 10.0 6.1 3.5 6.8 8.5 2.1 6.6 3.6 3.7 7.2 10.9 11.3 3.5 8.4 3.0 4.4 1.9 23.0 2.8 7.6 4.7 19.5 11.3 13.1 4.5 6.5 13.5 26.1 15.9 9.1 10.0 13.9 6.0 15.3 8.7 LIG4 ENSG00000174405 "DNA ligase 4" P49917 13 108207439-108218368 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, DNA recombination, DNA repair, DNA replication" Ligase "Cancer-related genes, Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001334, HPA057325" Approved Supported "Nucleoplasm,Cytoplasmic bodies" NA NA "Cluster 14: Monocytes - Unknown function" "Cluster 20: Retina & Lymphoid tissues - Unknown function" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 52: Non-specific - Transcription" Nucleoplasm "Cytoplasmic bodies" "HPA001334: AB_1078689, HPA057325: AB_2732608" "unprognostic (9.93e-2)" "unprognostic (1.56e-1)" "unprognostic (2.35e-1)" "unprognostic (2.00e-2)" "unprognostic (1.40e-1)" "unprognostic (1.97e-1)" "unprognostic (1.56e-1)" "unprognostic (7.97e-2)" "unprognostic (2.43e-1)" "unprognostic (4.87e-1)" "unprognostic (1.96e-2)" "unprognostic (4.21e-3)" "unprognostic (1.94e-2)" "unprognostic (3.04e-1)" "unprognostic (1.82e-1)" "unprognostic (1.50e-2)" "unprognostic (9.03e-3)" 7.2 8.3 6.3 8.6 6.5 3.9 5.6 6.1 9.0 4.0 8.7 5.7 7.2 4.4 8.5 4.2 4.5 6.8 6.7 7.1 10.2 8.2 12.0 6.9 11.0 6.8 6.6 5.8 3.8 11.3 5.2 5.8 6.8 5.6 6.6 23.1 4.6 5.2 7.1 5.3 7.0 6.6 6.1 8.3 7.8 9.8 7.1 21.8 7.7 6.5 8.3 6.9 2.3 7.9 15.5 5.8 15.3 10.2 12.4 13.3 5.4 14.9 11.2 11.2 13.3 6.9 6.7 26.0 11.9 9.8 13.7 6.3 10.2 9.9 19.2 15.4 9.8 12.3 13.8 3.6 14.8 16.6 12.5 12.3 16.3 10.8 9.6 10.7 13.5 47.0 4.4 4.7 17.4 8.3 27.7 12.1 3.9 12.6 3.6 25.1 6.0 4.2 14.6 9.7 9.6 9.9 3.3 9.0 11.7 11.7 7.7 25.4 20.1 6.6 7.2 7.5 13.5 12.4 8.7 41.7 25.4 9.4 15.2 0.6 1.6 4.8 1.1 2.5 1.6 1.6 1.2 1.2 1.4 2.2 1.2 1.7 2.2 1.9 8.3 1.0 1.8 1.0 6.3 6.5 6.1 9.0 7.1 10.2 6.8 6.6 6.8 6.1 7.1 7.9 5.6 9.6 9.5 13.4 9.2 2.7 2.8 4.9 3.4 10.7 4.9 2.8 11.6 1.5 10.0 1.8 8.4 2.3 7.3 7.9 9.8 5.3 11.6 8.3 5.7 4.3 9.6 0.4 16.6 7.5 1.0 4.2 7.7 6.0 3.8 3.6 4.6 9.8 5.8 18.5 16.1 5.3 2.0 7.5 3.9 5.1 2.8 7.4 1.8 10.3 9.3 7.3 4.1 13.6 24.9 8.9 6.3 6.0 6.2 2.5 3.5 6.3 21.9 13.6 13.1 4.6 3.8 19.1 4.4 4.0 5.7 1.8 4.1 8.7 2.9 3.7 LRBA "BGL, CDC4L, LAB300, LBA" ENSG00000198589 "LPS responsive beige-like anchor protein" P50851 4 150264435-151015727 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Excitatory neurons: 213.7;Inhibitory neurons: 192.6;Microglial cells: 161.1;Oligodendrocyte precursor cells: 239.8;Oligodendrocytes: 217.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019366, HPA023597" Approved Approved "Golgi apparatus,Cytosol" NA NA 340000 "Cluster 44: Non-specific - Transcription" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 68: Oligodendrocytes - Mixed function" "Golgi apparatus" Cytosol "HPA019366: AB_2138441, HPA023597: AB_1853256" "unprognostic (2.60e-1)" "unprognostic (4.70e-2)" "unprognostic (1.64e-3)" "unprognostic (4.49e-3)" "unprognostic (4.38e-1)" "unprognostic (8.65e-2)" "unprognostic (5.88e-2)" "unprognostic (1.16e-1)" "unprognostic (1.09e-2)" "unprognostic (6.92e-2)" "unprognostic (2.29e-2)" "unprognostic (5.88e-2)" "prognostic favorable (2.22e-16)" "unprognostic (7.15e-2)" "unprognostic (2.36e-1)" "unprognostic (4.79e-1)" "unprognostic (3.00e-1)" 7.3 10.7 3.4 9.3 6.9 11.1 22.7 11.1 3.8 13.1 18.6 16.7 13.3 6.9 14.2 13.9 15.2 9.9 8.3 2.9 2.2 23.5 13.4 11.0 15.8 5.1 4.5 8.9 13.5 34.2 6.5 7.0 6.1 20.0 17.4 14.9 13.8 8.9 7.2 19.3 11.5 6.6 3.4 9.6 17.0 9.4 3.7 18.7 19.1 8.9 17.7 12.3 7.0 6.3 27.6 14.3 11.9 11.1 12.2 18.5 17.0 6.0 15.8 10.9 10.2 30.9 35.6 33.7 7.2 8.6 7.5 13.7 22.1 36.6 15.3 25.9 15.8 20.8 19.8 19.0 7.5 29.0 16.2 14.6 21.1 16.0 24.6 23.9 32.9 14.8 22.4 24.3 12.9 21.9 21.9 7.7 10.7 23.7 10.3 18.4 12.0 12.6 42.0 33.7 39.3 13.0 15.1 32.1 7.4 18.1 32.4 6.1 17.2 16.8 12.2 8.7 11.4 20.9 20.5 20.5 26.2 16.0 6.6 5.7 0.6 1.2 5.0 0.2 3.3 4.9 3.3 4.7 1.0 2.1 2.3 4.0 0.1 3.2 2.1 2.1 4.6 1.8 3.4 6.9 11.1 3.8 2.9 2.2 5.1 4.5 6.1 3.4 3.7 6.3 10.4 16.0 14.9 148.5 42.5 17.5 16.4 21.0 28.5 33.5 30.8 18.2 55.9 21.5 21.5 51.5 148.0 23.7 37.7 19.7 9.8 15.2 25.5 51.2 11.0 13.3 42.0 40.2 213.7 13.5 10.6 12.8 56.6 61.8 6.3 22.4 10.0 20.5 6.1 30.3 192.6 23.8 24.4 11.1 12.8 5.5 9.6 17.7 16.0 161.1 8.2 17.7 46.4 239.8 217.4 17.2 20.2 10.1 38.3 22.4 22.0 15.8 36.7 72.6 6.6 13.7 9.8 16.6 22.3 37.3 23.7 24.2 45.6 25.9 27.2 24.0 LRRC8A "FLJ10337, KIAA1437, LRRC8, SWELL1" ENSG00000136802 "Leucine rich repeat containing 8 VRAC subunit A" Q8IWT6 9 128882133-128918039 "Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Differentiation, Ion transport, Spermatogenesis, Transport" "Ion channel" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Basal prostatic cells: 192.0;Prostatic glandular cells: 207.0;Urothelial cells: 328.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HaCaT: 163.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 27: Brain & Skin - Unknown function" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 22: Epithelial cell types - Mixed function" "unprognostic (6.33e-2)" "unprognostic (3.88e-2)" "unprognostic (1.88e-3)" "unprognostic (2.61e-2)" "unprognostic (1.72e-1)" "unprognostic (4.38e-3)" "unprognostic (4.29e-2)" "unprognostic (1.19e-3)" "unprognostic (2.44e-1)" "unprognostic (4.80e-2)" "prognostic unfavorable (3.83e-4)" "unprognostic (3.53e-1)" "prognostic favorable (5.27e-5)" "unprognostic (3.69e-1)" "unprognostic (8.77e-2)" "unprognostic (3.93e-3)" "unprognostic (1.02e-2)" 31.4 17.4 68.2 16.2 69.4 17.3 27.3 69.4 77.1 30.8 44.6 31.4 9.7 36.3 7.3 71.7 23.5 23.3 32.0 57.2 67.9 18.2 28.9 42.4 9.3 76.7 77.2 18.8 21.2 32.4 13.7 23.1 67.9 29.3 8.5 13.4 28.1 25.5 13.9 35.2 17.3 29.1 63.9 16.2 25.0 11.8 82.6 9.9 25.6 18.4 10.1 32.7 44.2 52.4 35.1 54.2 32.0 27.5 73.6 28.3 40.4 39.8 26.2 24.1 17.1 24.1 73.2 12.8 43.6 43.3 30.1 163.8 19.9 87.5 11.3 13.1 16.4 11.5 33.4 29.2 49.8 13.8 20.3 22.1 60.9 42.7 50.8 48.6 84.1 17.5 25.8 12.4 31.8 30.3 15.6 13.2 95.9 58.3 58.4 21.4 37.0 20.6 37.9 17.3 19.2 39.9 44.4 27.3 15.8 23.9 19.9 10.2 149.4 69.9 30.2 29.9 58.8 14.4 36.5 15.5 38.7 10.3 41.3 0.7 0.7 1.9 3.9 1.1 1.8 1.2 1.9 2.5 1.0 0.9 1.9 1.8 1.4 3.5 0.3 1.6 3.5 1.0 68.2 69.4 69.4 77.1 57.2 67.9 76.7 77.2 67.9 63.9 82.6 52.4 98.8 16.0 15.6 57.1 7.5 105.7 192.0 91.6 113.3 13.1 38.3 29.2 31.3 17.2 73.6 7.3 6.2 13.8 17.4 31.9 0.0 28.9 6.9 22.0 50.5 57.4 16.1 13.7 11.8 21.2 17.6 27.5 24.5 47.0 6.3 35.1 55.6 16.5 6.1 25.2 14.2 28.7 24.4 5.0 17.4 4.5 23.0 9.9 26.6 12.2 5.1 41.3 36.0 8.5 9.7 78.1 23.0 44.4 13.5 207.0 10.9 8.1 33.2 10.2 65.7 38.2 35.2 3.2 8.6 91.6 145.1 20.8 15.5 9.6 14.5 328.5 LRRC8B "KIAA0231, TA-LRRP" ENSG00000197147 "Leucine rich repeat containing 8 VRAC subunit B" Q6P9F7 1 89524829-89597861 "Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Early spermatids: 97.0;Excitatory neurons: 177.4;Inhibitory neurons: 197.3;Oligodendrocytes: 140.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "HAP1: 35.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017950 Uncertain NA NA "Cluster 30: Non-specific - Translation" "Cluster 58: Brain - Synaptic function" "Cluster 1: K-562 - Erythropoiesis" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA017950: AB_1853346" "unprognostic (2.50e-2)" "unprognostic (3.93e-2)" "prognostic favorable (7.15e-4)" "prognostic unfavorable (9.99e-4)" "unprognostic (1.22e-1)" "unprognostic (5.24e-2)" "unprognostic (3.97e-2)" "unprognostic (1.26e-1)" "unprognostic (1.87e-1)" "unprognostic (2.09e-1)" "unprognostic (1.35e-2)" "unprognostic (1.72e-1)" "unprognostic (8.80e-3)" "unprognostic (2.30e-2)" "unprognostic (1.85e-1)" "unprognostic (4.17e-2)" "unprognostic (2.06e-1)" 6.6 14.6 3.9 3.7 8.1 3.0 5.3 0.0 13.5 2.8 0.0 4.4 6.1 1.8 5.5 4.0 3.2 5.0 2.4 13.0 0.0 3.7 3.8 4.7 4.5 0.4 0.4 1.6 6.6 5.3 3.3 1.8 0.8 4.3 5.2 12.9 4.2 1.1 4.0 5.8 4.1 2.7 1.4 3.6 5.2 15.4 0.0 3.8 4.9 3.1 5.0 5.0 2.2 16.0 13.0 4.7 3.8 13.2 18.5 10.8 15.3 0.4 4.0 1.7 2.3 7.9 8.4 1.2 4.8 1.9 5.0 6.7 35.6 2.8 1.9 6.4 6.3 28.9 3.7 7.4 1.9 13.6 17.7 5.6 11.5 1.5 5.6 0.6 18.7 10.6 30.3 9.3 2.1 7.9 5.3 6.2 20.7 6.1 7.1 13.0 1.7 5.3 4.5 16.8 10.6 17.5 7.2 18.3 12.7 4.6 10.7 6.1 6.0 1.5 8.4 3.8 4.1 5.9 4.7 6.7 2.1 3.0 3.3 0.7 0.7 0.5 0.4 0.3 0.3 0.8 0.6 0.4 0.7 0.6 0.9 0.8 0.3 0.3 0.4 0.6 1.0 0.5 3.9 8.1 0.0 13.5 13.0 0.0 0.4 0.4 0.8 1.4 0.0 16.0 5.8 16.0 13.9 15.7 11.4 33.0 12.4 13.6 14.8 32.9 15.2 8.4 7.0 17.2 17.7 7.3 47.9 3.2 2.8 8.9 1.9 13.0 97.0 13.5 1.9 12.7 26.9 3.8 177.4 18.9 18.2 4.4 10.2 8.4 2.5 13.3 16.1 6.7 7.0 0.0 197.3 14.2 8.2 12.8 17.3 72.7 2.5 9.8 1.8 26.2 7.9 5.8 1.0 45.2 140.7 15.4 6.0 2.6 11.1 18.6 4.3 5.7 26.8 22.4 6.6 9.4 14.8 7.3 3.8 13.9 27.6 2.5 8.0 8.0 13.2 12.4 LRRC8C AD158 ENSG00000171488 "Leucine rich repeat containing 8 VRAC subunit C" Q8TDW0 1 89633072-89769903 "Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Adipocytes: 73.5;Excitatory neurons: 73.6;Inhibitory neurons: 99.2;Microglial cells: 185.5;Oligodendrocytes: 85.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Group enriched" "Detected in many" 4 "dendritic cells: 8.9;monocytes: 6.6;T-cells: 11.3" "Cell line enhanced" "Detected in many" "THP-1: 41.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029347 Uncertain Approved "Golgi apparatus" No No "Cluster 12: Non-specific - Basic cellular processes" "Cluster 28: Placenta - Pregnancy" "Cluster 43: THP-1 - Innate immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Golgi apparatus" "HPA029347: AB_10601544" "unprognostic (2.61e-2)" "unprognostic (3.09e-2)" "unprognostic (3.83e-2)" "unprognostic (1.76e-2)" "unprognostic (3.32e-2)" "unprognostic (1.65e-2)" "unprognostic (5.02e-2)" "unprognostic (3.76e-3)" "unprognostic (4.28e-2)" "unprognostic (4.90e-3)" "unprognostic (5.32e-2)" "unprognostic (2.36e-1)" "prognostic unfavorable (3.75e-4)" "unprognostic (2.78e-2)" "unprognostic (4.42e-2)" "unprognostic (1.94e-2)" "unprognostic (3.38e-2)" 14.3 7.6 3.8 9.0 4.5 8.0 7.7 4.5 5.8 3.2 11.4 3.2 3.2 7.3 1.9 2.9 2.8 6.6 6.2 4.1 4.1 2.5 3.3 7.7 12.2 4.6 5.0 5.3 1.8 2.8 2.3 6.6 5.1 2.3 3.7 1.6 2.0 2.0 2.7 6.0 3.8 15.8 4.8 9.2 2.9 4.0 4.7 5.6 3.5 8.0 7.7 6.2 2.0 6.0 0.3 3.8 3.0 2.7 9.1 10.2 1.4 19.3 21.6 8.7 8.0 0.0 1.3 6.0 5.3 8.5 14.9 13.1 10.1 29.0 20.9 14.8 6.1 5.7 2.9 0.3 7.4 26.6 1.9 4.4 5.8 18.8 10.0 5.8 35.6 9.2 3.9 7.9 7.5 0.7 3.9 26.2 3.3 0.1 7.8 26.5 1.4 2.0 1.8 3.2 2.3 10.7 7.1 0.7 16.2 4.7 0.2 41.3 29.9 15.3 7.3 5.3 14.9 2.9 2.6 3.1 4.7 19.6 2.6 0.4 6.0 0.0 3.8 5.2 3.3 0.7 6.1 5.1 8.9 0.5 4.8 4.5 0.8 2.0 6.6 0.7 11.3 3.2 3.8 4.5 4.5 5.8 4.1 4.1 4.6 5.0 5.1 4.8 4.7 6.0 73.5 3.2 3.6 31.3 7.6 45.4 3.8 5.6 3.4 2.3 1.7 2.9 6.3 2.8 2.7 0.0 0.0 0.1 24.6 0.3 0.0 1.7 36.3 0.2 1.9 47.3 1.2 4.8 73.6 2.4 1.1 8.7 2.6 0.6 0.0 58.5 28.9 0.1 13.6 1.7 99.2 0.3 2.0 29.5 36.9 21.3 0.0 27.8 26.6 185.5 21.3 0.5 13.4 22.1 85.2 12.8 1.9 0.7 20.8 2.1 0.3 0.6 2.9 1.2 0.0 2.2 24.2 3.9 2.0 1.3 44.9 0.3 27.1 3.4 0.3 2.5 LRRC8D "FLJ10470, LRRC5" ENSG00000171492 "Leucine rich repeat containing 8 VRAC subunit D" Q7L1W4 1 89821014-89936611 "Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 80.4" "Cell type enhanced" "Detected in many" "Inhibitory neurons: 80.8;Oligodendrocyte precursor cells: 146.8;Oligodendrocytes: 346.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA No "Cluster 20: T-cells - T-cell receptor" "Cluster 70: Brain - Nervous system development" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 42: Oligodendrocytes - Myelin sheath organization" "unprognostic (2.92e-3)" "unprognostic (9.50e-2)" "unprognostic (1.06e-3)" "prognostic unfavorable (3.21e-5)" "unprognostic (4.98e-2)" "unprognostic (7.03e-2)" "unprognostic (7.71e-3)" "unprognostic (7.74e-2)" "unprognostic (9.67e-2)" "unprognostic (1.01e-2)" "unprognostic (1.42e-1)" "unprognostic (2.77e-1)" "unprognostic (4.91e-2)" "unprognostic (9.52e-3)" "unprognostic (1.23e-1)" "unprognostic (2.65e-2)" "unprognostic (9.61e-2)" 5.9 26.9 25.1 15.8 45.2 14.2 12.9 39.2 37.0 12.1 9.6 17.9 19.0 8.8 10.3 7.9 7.8 8.0 7.6 30.6 30.2 25.9 23.5 9.8 24.9 43.3 40.3 5.9 13.0 7.7 16.3 10.3 41.3 5.6 18.2 12.0 24.5 5.8 8.7 5.6 18.0 11.4 39.7 23.9 11.5 10.3 36.5 27.7 15.8 3.4 20.4 11.2 3.3 80.4 73.5 47.0 18.8 44.5 32.9 27.7 63.5 49.1 73.9 27.3 34.1 20.2 18.3 57.7 54.4 82.1 31.0 93.7 43.6 58.9 34.4 45.3 24.1 67.8 40.4 43.2 64.2 78.2 20.5 17.4 48.1 23.3 50.3 37.6 47.1 32.8 37.6 17.7 30.1 22.0 32.5 50.4 32.6 16.4 42.6 43.6 27.3 41.5 69.2 25.7 35.0 24.4 61.0 62.4 137.8 32.4 15.0 76.4 21.0 29.1 9.9 60.0 37.6 21.4 39.5 34.7 11.3 97.0 26.2 0.0 8.9 1.6 7.0 10.4 11.6 6.9 16.0 8.5 8.1 5.6 15.2 11.5 3.5 13.1 8.4 9.4 17.4 10.6 25.1 45.2 39.2 37.0 30.6 30.2 43.3 40.3 41.3 39.7 36.5 80.4 2.9 3.2 1.7 35.3 10.8 6.0 1.4 12.7 15.9 6.6 8.4 7.4 3.0 8.6 6.2 12.9 2.1 4.0 14.8 26.6 7.9 5.7 0.7 3.1 2.9 5.5 7.8 17.0 66.8 8.6 9.9 3.8 6.1 3.4 5.7 7.8 7.9 30.1 11.8 3.3 80.8 10.8 10.2 21.9 5.5 0.8 1.2 19.1 10.6 68.4 36.3 6.3 10.3 146.8 346.4 5.4 11.3 3.8 8.0 4.1 22.5 12.5 7.2 7.6 6.6 10.7 2.9 0.3 1.9 7.1 1.1 1.8 11.0 22.4 11.2 1.8 LRRC8E FLJ23420 ENSG00000171017 "Leucine rich repeat containing 8 VRAC subunit E" Q6NSJ5 19 7888505-7902021 "Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 9.6;Glandular and luminal cells: 13.0;Squamous epithelial cells: 11.6;Suprabasal keratinocytes: 11.2" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-87 MG: 36.4" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA020466 Uncertain NA NA "Cluster 17: Basophils - Unknown function" "Cluster 84: Esophagus - Epithelial cell function" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 44: Endometrium - Transcription" "HPA020466: AB_1853352" "unprognostic (3.79e-2)" "unprognostic (2.85e-1)" "unprognostic (2.30e-1)" "unprognostic (1.33e-1)" "unprognostic (1.10e-3)" "unprognostic (8.28e-3)" "unprognostic (7.64e-2)" "unprognostic (1.71e-2)" "unprognostic (3.36e-1)" "unprognostic (8.38e-2)" "unprognostic (3.98e-6)" "unprognostic (1.11e-1)" "unprognostic (2.30e-2)" "unprognostic (3.29e-2)" "unprognostic (3.21e-1)" "unprognostic (2.84e-1)" "unprognostic (4.07e-1)" 0.6 4.9 0.4 0.8 0.5 1.9 4.6 1.0 0.6 3.3 0.6 1.0 0.9 1.4 6.2 6.4 2.1 2.3 0.9 0.5 0.1 1.9 4.1 4.3 0.7 0.4 0.2 0.3 7.2 3.3 0.5 1.3 0.7 3.5 1.1 0.4 7.7 2.1 0.5 10.6 0.5 0.4 0.0 0.3 3.6 0.7 0.3 0.1 2.0 0.4 2.8 2.9 4.7 1.4 23.5 6.0 0.2 0.6 1.1 5.6 3.5 10.1 8.7 15.8 12.3 7.7 5.3 0.6 7.5 9.8 22.5 18.3 7.7 9.8 14.9 0.4 8.5 0.3 3.1 8.2 4.1 0.3 0.5 9.1 13.9 10.5 7.8 21.2 2.0 4.1 6.5 0.8 1.9 11.9 0.1 0.5 1.7 4.3 21.9 1.4 0.2 0.6 12.0 21.3 0.5 0.4 7.6 9.6 0.3 1.7 12.8 0.5 2.6 4.8 8.7 13.2 5.8 1.5 2.9 0.3 36.4 0.8 1.7 1.7 0.4 0.5 0.5 0.3 0.6 0.6 0.4 0.4 0.1 0.8 0.5 0.6 1.5 1.1 0.4 0.5 0.4 0.2 0.4 0.5 1.0 0.6 0.5 0.1 0.4 0.2 0.7 0.0 0.3 1.4 0.1 3.2 5.5 0.0 0.1 9.6 5.0 1.5 6.2 0.0 8.2 5.7 0.2 1.5 5.4 1.8 0.0 0.7 0.0 1.1 0.0 6.2 0.0 7.7 2.4 0.5 0.0 0.0 0.1 6.0 1.0 1.0 3.6 13.0 1.3 0.4 0.0 3.2 0.1 0.0 0.1 1.2 4.1 0.0 0.7 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.1 0.0 0.0 5.0 0.1 0.5 6.5 0.0 0.0 0.8 0.9 0.0 0.3 11.6 11.2 1.9 0.5 0.1 1.3 5.9 LYST "CHS, CHS1" ENSG00000143669 "Lysosomal trafficking regulator" Q99698 1 235661041-235883640 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Phagocytosis, Protein transport, Transport" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 31.3;retina: 27.9" "Cell type enhanced" "Detected in all" "monocytes: 277.4" "Cancer enhanced" "Detected in all" "melanoma: 11.1" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 12.2" "Group enriched" "Detected in many" 5 "granulocytes: 12.2;monocytes: 6.1" "Cell line enhanced" "Detected in many" "HDLM-2: 30.8;SK-MEL-30: 27.1;THP-1: 99.5;U-937: 38.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA053366, HPA055725" Supported "Nucleoplasm,Plasma membrane,Centriolar satellite" Yes No "Cluster 8: Neutrophils - Inflammatory response" "Cluster 34: Non-specific - Transcription" "Cluster 43: THP-1 - Innate immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" Nucleoplasm "Plasma membrane, Centriolar satellite" "HPA053366: AB_2682129, HPA055725: AB_2682898" "unprognostic (1.56e-2)" "unprognostic (1.54e-1)" "unprognostic (9.92e-2)" "unprognostic (8.85e-2)" "unprognostic (1.96e-2)" "unprognostic (4.32e-2)" "unprognostic (4.11e-2)" "unprognostic (7.79e-2)" "unprognostic (4.08e-2)" "unprognostic (1.95e-1)" "unprognostic (1.55e-1)" "unprognostic (9.31e-2)" "prognostic unfavorable (5.27e-5)" "unprognostic (1.59e-1)" "unprognostic (1.54e-1)" "unprognostic (6.29e-2)" "unprognostic (1.99e-1)" 5.2 2.7 2.0 8.5 2.7 31.3 6.4 10.1 3.3 7.1 9.1 4.5 3.0 4.3 2.7 4.2 3.9 5.1 2.2 2.0 2.5 3.6 5.5 5.5 7.5 2.2 2.6 4.5 2.2 6.2 1.8 4.6 2.5 3.4 4.3 27.9 4.3 3.3 1.7 9.7 3.3 4.4 1.1 10.8 7.7 6.1 3.3 25.7 6.4 3.8 6.5 5.7 5.2 3.4 8.6 1.9 0.9 2.0 12.7 14.4 1.3 3.1 12.5 3.3 3.1 0.0 2.3 1.1 1.2 6.8 7.7 4.1 1.2 1.6 2.9 30.8 2.7 2.8 1.9 0.6 2.3 4.2 3.7 4.8 7.8 4.0 10.0 4.8 2.8 1.3 0.2 1.7 2.6 0.4 5.3 8.7 0.2 1.6 0.9 0.4 1.2 0.0 9.2 9.2 5.4 1.1 3.4 0.2 27.1 1.0 1.2 99.5 5.8 2.4 1.1 2.8 2.8 2.1 0.1 0.2 4.1 38.0 7.0 0.4 2.9 5.7 0.6 3.4 0.8 1.0 0.2 0.7 1.7 1.4 0.2 0.4 12.2 1.7 6.1 0.2 0.2 0.7 2.0 2.7 10.1 3.3 2.0 2.5 2.2 2.6 2.5 1.1 3.3 3.4 66.3 19.2 41.1 71.2 70.9 71.0 89.8 14.6 18.8 67.4 17.6 15.6 11.6 15.7 28.4 11.0 93.8 6.7 77.3 25.0 11.7 6.6 24.6 22.6 23.8 51.2 9.6 21.0 151.5 12.3 5.0 27.0 41.3 22.4 112.5 9.4 26.0 15.4 31.9 52.2 155.9 14.3 28.5 65.6 81.3 17.7 28.0 111.4 120.9 159.3 277.4 25.6 88.6 112.1 81.6 39.6 24.2 21.8 37.3 56.0 12.7 10.9 26.7 162.5 13.1 31.2 22.7 93.3 28.0 18.7 65.1 8.8 71.3 13.6 7.6 98.5 MALT1 "MLT, PCASP1" ENSG00000172175 "MALT1 paracaspase" Q9UDY8 18 58671465-58754477 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins" "Immunity, Ubl conjugation pathway" "Hydrolase, Protease" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "RPTEC TERT1: 88.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004494, HPA048432" Enhanced Approved "Nucleoli fibrillar center,Cytosol" No No "Cluster 21: B-cells - Adaptive immune response" "Cluster 84: Esophagus - Epithelial cell function" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 65: Plasmacytoid DCs - Unknown function" "Nucleoli fibrillar center" Cytosol "CAB004494: AB_627909, HPA048432: AB_2680389" "unprognostic (3.25e-1)" "unprognostic (2.31e-1)" "unprognostic (3.64e-2)" "unprognostic (3.25e-2)" "unprognostic (1.65e-3)" "unprognostic (4.67e-2)" "unprognostic (6.46e-2)" "unprognostic (4.50e-2)" "unprognostic (3.33e-2)" "unprognostic (4.16e-3)" "unprognostic (3.74e-1)" "unprognostic (2.07e-1)" "unprognostic (2.53e-2)" "unprognostic (2.34e-1)" "unprognostic (2.97e-1)" "unprognostic (1.03e-1)" "unprognostic (6.00e-2)" 7.1 2.5 2.9 11.2 2.8 10.5 6.3 4.8 3.6 7.7 4.2 5.1 3.6 5.4 4.2 12.5 5.1 5.8 5.4 3.1 4.1 6.7 6.9 7.3 21.1 3.2 2.6 5.3 4.0 5.3 4.7 4.0 3.0 11.5 5.5 8.7 5.8 3.8 8.3 9.4 7.7 4.2 3.0 11.5 4.6 8.2 4.1 15.6 5.3 2.8 23.1 7.1 9.6 3.6 11.4 16.0 16.8 5.2 3.1 6.7 9.2 19.7 12.1 15.7 12.6 13.8 13.5 27.0 10.3 24.0 11.1 12.0 10.8 7.6 20.8 17.0 6.8 9.7 9.0 21.8 4.0 20.1 11.4 4.0 12.2 11.8 10.4 6.6 3.4 7.7 15.3 42.3 9.6 3.3 4.7 9.7 6.3 4.1 7.1 14.8 11.5 19.7 88.9 2.8 2.5 4.5 11.7 6.0 9.3 12.0 5.1 12.2 5.7 22.6 9.1 7.1 20.8 38.5 54.4 16.3 10.6 15.6 9.9 0.3 0.5 0.2 0.7 0.7 0.6 1.1 1.4 0.8 0.7 2.1 1.0 0.8 0.3 0.5 0.5 1.3 0.8 0.4 2.9 2.8 4.8 3.6 3.1 4.1 3.2 2.6 3.0 3.0 4.1 3.6 35.0 22.4 19.2 24.2 67.8 33.0 32.3 4.8 26.2 14.7 13.6 11.0 14.4 10.0 7.0 11.0 85.5 6.2 53.2 11.1 3.9 16.6 12.7 10.4 17.5 31.1 6.7 0.8 61.3 8.5 6.0 15.7 13.7 24.7 31.7 28.1 10.4 11.1 11.8 55.5 42.9 8.6 8.2 21.0 96.5 8.0 10.2 55.9 12.4 34.7 79.5 26.2 20.6 52.3 11.9 16.2 21.9 7.2 42.2 46.6 8.0 30.7 5.8 18.1 19.7 16.1 12.9 40.1 35.6 25.4 24.7 9.0 55.2 5.7 10.7 38.1 MASP2 MASP1P1 ENSG00000009724 "Mannan binding lectin serine peptidase 2" O00187 1 11026523-11047239 "Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins" "Complement pathway, Immunity, Innate immunity" "Hydrolase, Protease, Serine protease" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 64 "liver: 476.5" "Cell type enriched" "Detected in some" 52 "Hepatocytes: 658.6" "Cancer enriched" "Detected in some" 71 "liver cancer: 41.9" "Region enriched" "Detected in single" 9 "cerebellum: 6.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "Hep G2: 16.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA029313, HPA029314" Uncertain Supported "Golgi apparatus" "Secreted to blood" NA NA 340000000 820000000 "Cluster 62: Liver - Hemostasis" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 2: Hepatocytes - Metabolism" "Golgi apparatus" "HPA029313: AB_10669654, HPA029314: AB_10670029" "unprognostic (7.00e-2)" "unprognostic (8.37e-2)" "unprognostic (2.75e-2)" "unprognostic (2.89e-1)" "unprognostic (1.86e-1)" "unprognostic (3.26e-3)" "prognostic favorable (1.60e-4)" "unprognostic (2.92e-3)" "unprognostic (3.13e-2)" "unprognostic (4.04e-2)" "unprognostic (6.90e-3)" "unprognostic (8.30e-4)" "unprognostic (7.14e-2)" "unprognostic (3.91e-1)" "unprognostic (2.62e-2)" "unprognostic (1.05e-1)" "unprognostic (1.09e-4)" 2.1 1.2 0.0 1.7 0.0 7.4 2.2 6.4 0.7 2.4 0.0 2.7 1.6 2.8 0.0 1.2 2.7 1.2 1.3 0.1 0.0 1.0 476.5 1.8 2.7 0.0 0.0 2.9 2.9 0.0 2.3 0.6 0.2 1.6 0.0 6.9 2.5 0.0 5.1 5.3 3.4 0.0 0.0 2.5 2.4 1.5 0.0 0.0 1.9 0.0 0.0 2.1 1.6 0.4 0.5 0.3 2.6 1.6 0.0 0.1 0.4 0.7 0.0 0.0 0.0 1.2 1.0 2.3 0.6 0.0 0.5 0.7 0.0 0.0 0.0 0.6 2.3 1.3 2.7 16.4 0.0 2.0 1.5 0.0 0.0 0.1 0.0 1.8 0.0 1.7 0.7 0.5 0.0 0.5 0.6 1.1 0.3 0.2 0.7 1.6 0.9 0.6 0.0 1.3 1.7 0.7 0.9 0.4 0.4 1.6 0.6 1.2 1.2 0.9 0.5 0.8 0.5 0.5 0.9 1.5 0.5 1.7 0.4 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 6.4 0.7 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 4.6 1.1 0.9 0.2 0.0 0.6 0.2 0.2 0.0 0.5 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.9 0.0 5.3 9.5 0.0 0.0 0.1 0.0 0.1 1.3 0.0 8.2 658.6 0.1 0.0 8.3 0.0 0.0 12.6 0.3 0.0 0.0 0.0 1.8 1.9 0.0 0.1 0.0 8.0 10.4 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.7 0.4 0.0 0.7 0.2 0.0 0.0 0.4 0.6 0.0 0.8 0.1 0.0 0.1 MBL2 "COLEC1, MBL" ENSG00000165471 "Mannose binding lectin 2" P11226 10 52765380-52772784 "Human disease related genes, Plasma proteins, Predicted secreted proteins" "Complement activation lectin pathway, Complement pathway, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 2810 "liver: 280.9" "Cell type enriched" "Detected in some" 66 "Hepatocytes: 238.5" "Cancer enriched" "Detected in single" 275 "liver cancer: 22.6" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 10 "Hep G2: 2.2" "Not detected" "Not detected" "Region enriched" "Detected in single" 11 "basal ganglia: 1.1" "HPA002027, CAB016782" Enhanced "Secreted to blood" NA NA 1220000000 1900000000 "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 2: Hepatocytes - Metabolism" "CAB016782: , HPA002027: AB_1079324" "unprognostic (1.72e-2)" "unprognostic (3.03e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 280.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 238.5 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.0 0.0 MCM4 "CDC21, CDC54, hCdc21, MGC33310, P1-Cdc21" ENSG00000104738 "Minichromosome maintenance complex component 4" P33991 8 47960185-47978160 "Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, DNA replication" "DNA-binding, Helicase, Hydrolase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 63.2" "Cell type enhanced" "Detected in many" "Early spermatids: 153.2;Erythroid cells: 60.8;Late spermatids: 77.9;Spermatocytes: 65.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004497, HPA004873, HPA031052" Enhanced Enhanced Nucleoplasm NA Yes 140000 "Cluster 4: T-regs - Cell cycle regulation" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Nucleoplasm "CAB004497: AB_627916, HPA004873: AB_1079337, HPA031052: AB_2673712" "unprognostic (4.55e-2)" "unprognostic (3.16e-3)" "prognostic favorable (2.19e-4)" "prognostic unfavorable (2.84e-5)" "unprognostic (7.71e-2)" "unprognostic (1.05e-1)" "prognostic unfavorable (1.23e-4)" "unprognostic (1.12e-3)" "prognostic unfavorable (1.15e-4)" "unprognostic (2.65e-2)" "prognostic unfavorable (2.38e-4)" "unprognostic (5.16e-2)" "prognostic unfavorable (2.61e-4)" "unprognostic (3.53e-2)" "unprognostic (2.90e-1)" "unprognostic (1.70e-2)" "unprognostic (1.40e-1)" 6.5 8.8 4.8 21.7 4.8 63.2 16.0 5.7 5.2 7.7 1.8 17.7 13.3 6.9 4.6 22.4 9.7 5.6 14.5 5.2 3.5 8.2 9.2 6.3 38.7 3.6 4.2 7.1 5.5 7.7 4.1 18.3 3.9 5.6 21.3 12.3 8.8 4.9 13.4 24.2 16.7 9.2 4.2 8.1 10.6 41.6 4.8 47.0 6.5 15.8 41.8 11.8 10.9 5.2 184.0 139.6 188.1 83.2 20.7 36.6 102.8 122.6 99.8 178.5 190.3 156.6 181.1 229.8 70.3 72.1 119.2 143.2 278.7 128.2 199.8 64.2 190.4 371.8 133.3 169.2 5.4 189.7 82.0 20.3 24.1 147.8 54.3 28.6 72.0 136.8 216.2 167.0 129.9 155.6 435.5 141.5 241.2 246.5 54.2 266.6 159.6 139.2 64.9 168.1 209.0 97.8 325.6 133.6 46.3 117.7 154.9 110.5 45.1 138.1 125.4 144.5 131.9 54.7 104.6 347.2 114.8 185.7 131.5 2.3 1.8 1.1 4.0 3.1 2.0 3.9 3.8 5.4 3.9 1.6 3.3 2.7 0.1 4.1 3.5 1.5 10.2 3.6 4.8 4.8 5.7 5.2 5.2 3.5 3.6 4.2 3.9 4.2 4.8 5.2 3.3 0.0 6.3 3.3 6.5 21.7 11.1 9.0 13.6 12.2 9.0 7.7 25.1 1.5 8.4 5.5 10.4 36.7 5.8 12.1 3.9 8.0 153.2 11.0 7.9 6.7 6.7 60.8 5.0 6.0 40.2 10.6 11.2 13.4 1.3 24.9 2.2 3.2 12.3 16.8 5.7 13.9 4.1 2.9 6.5 77.9 5.3 7.9 3.6 1.9 2.4 7.0 3.1 4.0 2.9 4.5 4.8 3.0 22.3 7.7 5.6 3.0 13.1 16.7 0.0 9.5 11.4 65.8 39.9 19.1 19.0 29.8 9.0 11.7 26.2 9.7 MLPH "exophilin-3, l(1)-3Rk, l1Rk3, ln, Slac-2a" ENSG00000115648 Melanophilin Q9BV36 2 237485428-237555322 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "prostate: 135.9;salivary gland: 122.0" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 125.0;Alveolar cells type 2: 389.7;Gastric mucus-secreting cells: 251.8;granulocytes: 187.3;Intestinal goblet cells: 189.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "LHCN-M2: 142.9;MCF7: 255.4;SK-BR-3: 234.5;SK-MEL-30: 182.2;U-87 MG: 236.0" "Low region specificity" "Detected in some" "Not detected" "Not detected" HPA014685 Enhanced NA NA "Cluster 29: Non-specific - Vesicular transport" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 27: Mucus-secreting cells - Mucin production" "HPA014685: AB_1853997" "unprognostic (3.32e-3)" "unprognostic (1.59e-1)" "unprognostic (1.70e-1)" "prognostic favorable (5.14e-6)" "unprognostic (2.26e-4)" "unprognostic (1.36e-2)" "unprognostic (5.44e-2)" "unprognostic (2.66e-1)" "unprognostic (3.74e-3)" "unprognostic (8.16e-2)" "unprognostic (5.73e-2)" "unprognostic (3.16e-2)" "prognostic unfavorable (1.50e-4)" "unprognostic (2.34e-1)" "unprognostic (9.37e-2)" "unprognostic (2.66e-2)" "unprognostic (1.60e-3)" 13.2 1.4 0.6 2.4 0.7 0.1 56.9 0.7 1.6 69.3 1.3 20.4 8.8 18.1 8.9 6.4 18.0 31.0 69.2 1.1 0.7 4.3 39.0 62.7 0.6 1.1 1.0 11.8 16.1 9.0 2.1 1.9 0.8 135.9 21.7 0.3 122.0 13.0 6.6 11.6 15.2 2.8 0.6 0.2 98.1 2.5 0.8 0.9 39.9 2.5 1.2 22.1 21.9 0.9 0.3 133.7 0.3 0.3 58.5 39.5 0.4 26.8 31.5 14.7 18.5 1.1 101.1 0.2 0.1 49.6 51.0 0.3 0.1 0.9 13.0 0.1 0.3 0.1 0.1 0.0 23.3 0.1 0.7 48.1 14.7 43.4 56.2 75.6 0.1 0.0 0.1 0.3 142.9 255.4 0.4 0.6 0.4 105.4 77.1 0.5 0.1 0.2 0.5 3.2 1.5 0.2 0.1 234.5 182.2 0.7 61.5 1.7 26.8 80.1 2.3 0.9 38.0 0.2 0.2 0.2 236.0 0.1 63.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.7 0.7 1.6 1.1 0.7 1.1 1.0 0.8 0.6 0.8 0.9 12.3 125.0 389.7 0.0 0.8 4.1 17.3 6.0 0.0 0.0 95.6 59.7 63.2 52.9 64.2 12.9 0.0 0.4 0.7 34.9 1.9 12.0 0.2 9.5 10.1 10.1 14.4 0.0 0.2 41.3 0.3 4.5 251.8 17.5 187.3 0.2 1.4 28.8 1.2 0.0 0.1 189.0 32.6 0.8 2.9 0.7 8.4 7.4 30.2 5.6 0.6 0.0 0.0 0.0 0.0 58.1 22.4 3.0 0.8 54.4 9.1 0.6 48.5 0.0 0.0 3.1 3.7 0.3 0.6 1.2 2.4 0.7 6.1 0.4 30.5 38.6 MPO ENSG00000005381 Myeloperoxidase P05164 17 58269855-58280935 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Hydrogen peroxide" "Oxidoreductase, Peroxidase" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 61 "bone marrow: 4023.1" "Cell type enriched" "Detected in some" 30 "Erythroid cells: 87.4" "Cancer enhanced" "Detected in single" "stomach cancer: 1.1" "Low region specificity" "Detected in some" "Immune cell enhanced" "Detected in some" "classical monocyte: 6.2" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 94 "HL-60: 3517.4;NB-4: 4589.9" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000059, HPA021147, HPA061464" Enhanced Supported Nucleoplasm,Vesicles "Intracellular and membrane" No NA 576000000 24000000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 24: NB-4 - Immune response" "Cluster 12: Non-specific - Cell cycle regulation" Vesicles Nucleoplasm "CAB000059: AB_2335676, HPA021147: AB_1854083, HPA061464: AB_2684531" "unprognostic (1.91e-1)" "unprognostic (9.08e-2)" "unprognostic (4.62e-2)" "unprognostic (2.90e-2)" "unprognostic (2.13e-3)" "unprognostic (2.78e-1)" "unprognostic (3.23e-1)" "unprognostic (2.91e-1)" "unprognostic (2.56e-1)" "unprognostic (1.68e-1)" "unprognostic (6.92e-2)" "unprognostic (8.34e-3)" "unprognostic (4.91e-2)" "unprognostic (3.07e-3)" "unprognostic (2.83e-1)" "unprognostic (1.14e-2)" "unprognostic (8.05e-2)" 0.5 0.4 0.8 0.6 0.6 4023.1 0.3 0.6 1.1 0.0 0.3 0.2 0.0 0.2 1.1 0.1 0.1 0.3 1.1 0.8 0.7 0.2 1.8 8.4 1.7 0.9 1.0 0.1 0.1 0.0 1.5 1.4 0.9 0.2 0.2 0.4 66.3 0.1 1.1 4.3 0.2 0.3 0.8 21.7 0.1 0.4 0.8 10.9 0.3 0.3 0.2 0.5 0.1 0.7 0.4 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 3517.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4589.9 0.0 0.0 0.0 5.3 3.2 0.6 0.0 0.0 0.0 0.5 1.1 0.0 0.0 0.0 0.0 43.1 0.0 0.0 0.0 1.3 0.0 0.0 0.0 1.1 0.0 4.0 0.0 0.0 6.2 0.0 0.0 3.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 1.4 0.0 0.6 0.0 0.1 7.5 0.8 0.6 0.6 1.1 0.8 0.7 0.9 1.0 0.9 0.8 0.8 0.7 0.0 0.0 0.5 0.7 0.3 0.0 0.0 0.0 0.0 0.4 0.2 0.3 0.4 0.0 0.0 0.0 0.0 0.0 1.8 0.0 1.9 0.0 0.5 0.1 0.0 0.1 0.0 87.4 0.3 0.2 0.9 0.7 0.0 0.0 0.0 0.0 0.7 0.3 0.9 0.0 0.2 0.0 0.0 1.2 0.0 1.3 0.0 2.9 0.0 0.0 2.3 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.2 0.0 1.2 0.1 0.1 0.3 0.1 0.0 0.1 0.6 0.0 0.0 0.0 MRE11 "ATLD, MRE11A" ENSG00000020922 "MRE11 homolog, double strand break repair nuclease" P49959 11 94415570-94493885 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction, Meiosis" "Endonuclease, Exonuclease, Hydrolase, Nuclease" "Cancer-related genes, Ciliopathy, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 28.9;Cytotrophoblasts: 39.2;Granulosa cells: 34.1;Syncytiotrophoblasts: 28.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002691, CAB004081" Supported Enhanced Nucleoplasm NA NA "Cluster 44: Non-specific - Transcription" "Cluster 34: Non-specific - Transcription" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 7: Non-specific - Mitochondria" Nucleoplasm "CAB004081: AB_2145100, HPA002691: AB_1079409" "unprognostic (5.59e-3)" "unprognostic (4.35e-2)" "unprognostic (8.55e-2)" "unprognostic (2.76e-2)" "unprognostic (9.82e-2)" "unprognostic (5.17e-2)" "prognostic unfavorable (7.14e-4)" "unprognostic (2.85e-1)" "unprognostic (1.03e-2)" "unprognostic (1.34e-1)" "unprognostic (8.66e-3)" "unprognostic (6.96e-3)" "unprognostic (1.57e-3)" "unprognostic (1.39e-1)" "unprognostic (1.77e-1)" "unprognostic (1.22e-1)" "unprognostic (8.06e-3)" 9.1 6.1 3.4 11.7 3.7 22.6 13.9 6.8 3.4 8.8 6.0 7.6 6.8 11.7 8.9 7.1 7.9 7.3 5.0 3.3 3.5 6.0 6.4 7.7 12.6 5.1 4.4 11.1 7.5 5.6 3.1 12.1 3.8 9.3 11.5 6.3 7.8 7.3 5.0 15.6 7.7 9.9 4.0 12.7 7.3 8.3 4.4 14.3 7.4 5.4 16.1 8.5 7.4 6.7 21.5 21.5 39.9 5.0 13.1 18.2 22.8 29.4 19.0 25.9 30.6 39.4 43.3 55.8 47.0 15.3 32.5 40.1 33.7 22.1 34.1 37.5 20.0 48.7 31.5 22.7 6.0 32.7 33.6 12.8 13.4 33.7 21.0 11.7 23.0 26.8 34.9 35.6 20.9 15.5 33.2 30.5 13.0 49.3 23.3 29.0 35.3 28.1 16.8 29.6 14.1 19.8 40.6 26.0 8.6 33.2 43.4 19.3 16.9 38.7 28.6 33.9 21.5 8.8 33.2 54.4 10.4 50.3 31.5 5.7 8.0 6.5 8.2 10.0 8.3 6.4 6.0 8.9 11.6 6.9 5.1 8.4 3.8 8.6 8.4 8.7 8.8 6.7 3.4 3.7 6.8 3.4 3.3 3.5 5.1 4.4 3.8 4.0 4.4 6.7 23.6 28.9 14.3 0.0 6.3 0.0 0.0 0.0 0.0 0.0 12.5 13.7 0.0 0.0 9.3 9.2 0.0 39.2 20.8 0.0 3.9 11.4 0.0 19.5 22.2 8.4 0.0 0.0 0.0 8.1 15.8 8.9 0.0 16.3 17.7 34.1 0.0 0.0 14.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.0 9.3 0.0 0.0 0.0 0.0 8.8 0.0 0.0 6.1 0.0 0.0 6.5 11.7 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.0 28.0 7.2 16.8 0.0 0.0 MS4A1 "B1, Bp35, CD20, MS4A2" ENSG00000156738 "Membrane spanning 4-domains A1" P11836 11 60455846-60470752 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "B-cell activation" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 673.3" "Cell type enriched" "Detected in some" 35 "B-cells: 970.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 96 "memory B-cell: 625.4;naive B-cell: 627.0" "Lineage enriched" "Detected in many" 96 "B-cells: 627.0" "Group enriched" "Detected in some" 26 "Daudi: 731.3;U-698: 364.1" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000015, HPA014341, HPA014391" Enhanced Supported "Plasma membrane" NA NA "Cluster 43: B-cells - Humoral immune response" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "Plasma membrane" "CAB000015: AB_2282030, HPA014341: AB_1846265, HPA014391: AB_1846264" "prognostic favorable (4.34e-5)" "unprognostic (4.45e-4)" "unprognostic (1.19e-4)" "unprognostic (2.04e-3)" "unprognostic (1.06e-1)" "unprognostic (5.53e-7)" "unprognostic (2.46e-3)" "unprognostic (1.85e-3)" "unprognostic (3.06e-2)" "unprognostic (2.89e-4)" "unprognostic (6.96e-2)" "unprognostic (2.84e-2)" "unprognostic (3.96e-5)" "unprognostic (2.23e-1)" "unprognostic (8.04e-2)" "unprognostic (1.44e-1)" "unprognostic (1.30e-1)" 3.6 0.4 0.0 149.7 0.0 19.1 0.8 0.0 0.1 0.5 0.1 9.0 3.0 2.2 1.0 4.2 0.5 8.4 1.8 0.0 0.1 3.4 2.1 4.0 500.4 0.2 0.0 0.3 0.2 7.3 0.3 0.9 0.1 5.1 10.6 0.0 8.9 0.3 0.8 0.1 123.5 1.2 0.1 253.8 18.4 1.2 0.1 50.6 6.7 0.1 673.3 16.3 1.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 731.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.3 0.5 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.4 0.0 0.5 0.2 0.0 0.1 0.0 364.1 0.0 0.2 0.0 0.8 0.5 0.3 2.4 0.1 3.7 625.4 2.8 5.5 0.5 627.0 0.5 2.1 2.0 6.5 0.6 0.5 0.8 32.1 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.3 0.0 3.8 0.0 970.5 0.1 0.1 0.0 0.0 0.0 0.4 0.3 0.4 0.0 0.0 0.0 0.0 0.0 14.5 0.3 0.0 0.0 4.5 0.7 0.1 0.3 0.0 7.0 0.0 0.0 0.1 1.8 2.0 0.1 2.5 0.0 1.1 0.3 0.1 0.0 0.0 0.2 0.0 0.6 0.3 2.0 0.0 4.6 7.2 0.0 2.5 0.0 2.1 0.0 0.0 0.0 0.3 0.0 9.1 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.5 0.2 0.1 0.8 0.1 0.0 27.3 0.7 0.2 0.0 MYD88 ENSG00000172936 "MYD88 innate immune signal transduction adaptor" Q99836 3 38138478-38143022 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Immunity, Inflammatory response, Innate immunity" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Kupffer cells: 75.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 172.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009104 Approved Supported Vesicles,Mitochondria,Cytosol NA NA "Cluster 51: Monocytes - Innate immune response" "Cluster 64: Macrophages - Immune response" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 19: Monocytes & Neutrophils - Innate immune response" Cytosol "Vesicles, Mitochondria" "CAB009104: AB_2146724" "prognostic favorable (8.45e-4)" "unprognostic (1.19e-1)" "unprognostic (4.31e-2)" "unprognostic (2.51e-2)" "unprognostic (4.77e-2)" "unprognostic (4.38e-3)" "unprognostic (4.37e-2)" "unprognostic (3.63e-1)" "unprognostic (1.67e-1)" "unprognostic (7.28e-2)" "unprognostic (1.01e-2)" "unprognostic (7.30e-2)" "unprognostic (2.11e-2)" "unprognostic (4.41e-1)" "unprognostic (4.17e-2)" "unprognostic (1.65e-1)" "unprognostic (2.08e-2)" 20.1 14.2 6.9 43.5 7.4 51.8 15.0 7.2 7.5 15.2 8.0 30.3 32.2 12.1 18.6 36.6 14.4 23.5 9.4 6.7 7.7 13.7 61.1 42.6 35.2 9.5 7.5 11.4 11.6 11.6 9.2 22.6 8.0 14.3 31.7 2.1 18.0 12.0 3.2 17.7 32.2 24.5 8.6 40.7 27.6 7.7 9.2 38.3 9.4 8.8 41.6 47.4 20.3 8.5 25.1 34.2 5.9 33.2 25.0 32.0 10.8 23.6 39.0 68.1 72.9 22.7 30.9 52.8 13.8 44.7 15.8 30.9 43.2 24.2 22.1 39.5 8.7 28.5 16.6 36.6 21.4 36.2 72.0 38.4 26.6 39.2 15.3 13.2 39.9 40.3 13.3 22.3 36.8 25.7 61.3 12.2 22.1 52.8 35.7 24.8 7.0 23.1 37.6 58.9 3.0 12.0 33.4 172.1 22.3 4.8 25.8 40.8 35.5 13.8 7.9 60.6 24.0 28.9 32.9 38.5 25.0 63.0 28.9 288.5 236.9 296.9 67.2 333.6 58.1 43.7 60.6 69.3 203.6 35.2 42.1 59.5 284.7 54.6 436.1 99.9 87.4 257.3 6.9 7.4 7.2 7.5 6.7 7.7 9.5 7.5 8.0 8.6 9.2 8.5 13.4 6.4 15.2 2.0 19.5 14.4 13.5 12.7 14.2 1.0 11.3 10.8 1.6 5.7 16.4 5.5 0.0 14.6 35.3 40.8 7.9 24.5 1.4 10.9 30.2 15.9 9.6 9.7 0.2 27.3 24.4 10.8 23.9 18.6 24.1 10.0 10.4 33.2 32.2 0.0 0.4 14.9 10.2 75.4 40.5 0.9 13.7 61.5 3.6 1.9 58.1 4.1 28.8 2.5 0.3 64.0 34.8 10.5 12.9 16.0 28.0 12.2 12.1 0.1 13.1 4.3 7.2 8.6 0.6 15.1 17.2 12.0 19.6 10.2 15.9 49.4 MYO5A "GS1, MYH12, MYO5, MYR12" ENSG00000197535 "Myosin VA" Q9Y4I1 15 52307283-52529050 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Protein transport, Transport" "Actin-binding, Calmodulin-binding, Motor protein, Myosin" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 39.1;parathyroid gland: 47.4" "Cell type enhanced" "Detected in many" "Excitatory neurons: 353.0;Inhibitory neurons: 241.0;Oligodendrocyte precursor cells: 330.8;Oligodendrocytes: 404.2" "Cancer enhanced" "Detected in all" "melanoma: 25.2" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Karpas-707: 201.0;RPMI-8226: 140.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001356 Enhanced Approved "Focal adhesion sites,Centriolar satellite" NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 2: Karpas-707 - Immune response" "Cluster 42: Oligodendrocytes - Myelin sheath organization" "Focal adhesion sites, Centriolar satellite" "HPA001356: AB_1079441" "unprognostic (1.54e-1)" "unprognostic (1.78e-1)" "unprognostic (6.95e-2)" "unprognostic (2.29e-2)" "unprognostic (1.97e-2)" "unprognostic (3.91e-2)" "unprognostic (2.30e-2)" "unprognostic (6.65e-2)" "unprognostic (7.89e-2)" "unprognostic (4.74e-2)" "unprognostic (9.36e-3)" "unprognostic (1.71e-1)" "unprognostic (5.63e-3)" "unprognostic (3.79e-3)" "unprognostic (1.24e-1)" "unprognostic (7.16e-2)" "prognostic unfavorable (4.22e-4)" 10.3 8.3 17.0 12.1 20.8 21.8 6.5 3.0 39.1 6.8 0.0 6.1 3.8 5.0 3.7 5.3 4.0 8.5 5.8 19.0 3.6 5.3 2.9 8.8 15.0 9.6 4.2 5.7 5.2 47.4 8.9 6.3 9.8 5.1 5.9 26.1 5.2 3.5 5.4 11.8 5.0 9.4 0.0 9.5 4.7 5.9 6.6 11.0 8.4 5.0 13.1 9.7 5.3 20.8 19.5 33.7 17.6 21.3 16.2 19.3 19.0 34.7 31.1 18.1 14.0 3.2 7.8 18.7 8.9 41.8 26.5 15.7 40.7 35.6 22.3 105.5 9.6 16.7 8.8 4.2 8.3 9.0 16.3 13.0 21.9 26.6 52.4 17.6 106.8 12.0 0.7 201.0 34.8 34.4 8.2 1.2 8.1 0.5 26.6 14.5 27.8 140.8 15.1 14.0 12.7 7.8 32.3 26.2 59.4 13.1 14.0 9.1 52.0 36.4 15.7 17.1 34.1 20.9 49.9 22.0 39.4 25.1 53.5 0.4 2.4 3.1 1.4 1.7 2.1 1.1 1.3 0.9 2.7 0.7 0.2 0.4 3.0 0.3 1.4 1.5 2.2 1.1 17.0 20.8 3.0 39.1 19.0 3.6 9.6 4.2 9.8 0.0 6.6 20.8 11.2 12.8 11.4 68.2 19.8 20.8 9.3 10.5 7.4 75.1 6.7 5.5 12.1 2.8 19.8 14.7 39.6 0.6 18.4 0.3 0.0 5.4 18.0 9.3 8.0 12.7 1.2 2.5 353.0 6.3 0.4 7.5 3.1 6.7 22.8 5.0 2.5 1.3 24.4 26.9 241.0 0.2 2.0 27.1 28.0 10.8 3.7 50.2 97.8 52.5 36.7 6.0 15.5 330.8 404.2 6.1 2.5 1.9 32.4 10.2 0.0 2.8 11.1 28.7 6.6 16.7 10.8 14.0 9.4 3.9 11.6 1.1 23.7 2.1 0.3 7.3 NBN "AT-V1, AT-V2, ATV, NBS, NBS1" ENSG00000104320 Nibrin O60934 8 89933331-90003228 "Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair, Host-virus interaction, Meiosis" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 265.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001429, CAB003836" Supported Approved "Nucleoplasm,Golgi apparatus" NA NA "Cluster 18: Basophils - Vesicular transport" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 41: Macrophages - Immune response" "Golgi apparatus" Nucleoplasm "CAB003836: AB_562172, HPA001429: AB_1854460" "unprognostic (1.52e-1)" "unprognostic (1.72e-1)" "unprognostic (2.32e-3)" "unprognostic (7.46e-2)" "unprognostic (2.49e-2)" "unprognostic (1.28e-1)" "unprognostic (1.05e-2)" "prognostic unfavorable (5.46e-5)" "unprognostic (5.05e-2)" "unprognostic (4.61e-2)" "prognostic unfavorable (4.20e-4)" "unprognostic (1.15e-1)" "unprognostic (6.68e-2)" "unprognostic (3.14e-2)" "unprognostic (3.28e-1)" "unprognostic (2.84e-2)" "unprognostic (1.03e-1)" 22.5 12.4 9.2 27.8 12.8 54.0 25.4 9.3 10.0 16.9 7.4 18.3 15.1 22.3 11.4 20.0 14.5 22.5 12.1 10.2 12.5 20.7 22.3 18.1 24.3 10.7 8.6 16.9 15.5 15.4 9.0 14.1 9.9 17.5 22.5 9.8 16.6 14.9 10.0 10.3 16.0 24.2 11.0 23.4 12.7 16.4 11.0 19.0 22.7 16.2 26.4 21.8 9.6 15.0 54.8 30.1 29.3 15.6 16.5 38.7 18.9 37.9 49.5 46.6 50.8 17.2 41.8 83.8 42.2 35.5 19.1 17.7 35.7 35.7 59.8 38.0 19.7 67.7 16.8 23.6 30.8 40.0 35.2 30.5 18.3 27.2 57.9 22.8 39.5 33.9 50.6 46.6 55.3 46.9 65.6 26.0 8.5 39.5 31.4 42.3 25.3 47.0 62.8 73.8 8.1 26.6 23.5 265.1 23.1 16.3 49.8 31.4 29.2 40.9 28.0 25.5 38.0 21.2 25.0 45.5 41.3 39.4 39.1 32.4 17.7 32.9 11.9 19.7 12.7 15.2 8.5 8.8 18.9 8.9 8.1 9.0 34.4 16.1 31.5 10.4 5.9 13.1 9.2 12.8 9.3 10.0 10.2 12.5 10.7 8.6 9.9 11.0 11.0 15.0 36.9 48.1 14.2 24.5 39.8 11.9 13.5 20.4 23.9 25.4 29.7 22.9 30.3 14.3 33.7 27.6 2.1 23.0 29.3 11.2 43.0 35.1 17.6 45.4 46.9 22.9 12.1 31.7 45.0 32.0 19.7 36.3 19.9 31.2 79.7 38.3 18.9 30.6 25.9 13.5 39.9 16.9 16.2 29.2 27.1 7.2 19.0 51.1 12.4 32.8 54.7 29.4 36.0 40.7 40.3 24.7 9.9 26.4 38.8 11.6 9.9 40.5 36.4 11.2 6.6 50.3 31.7 20.2 46.0 31.5 13.5 10.8 35.3 68.7 19.4 11.0 NCF1 "NCF1A, NOXO2, p47phox, SH3PXD1A" ENSG00000158517 "Neutrophil cytosolic factor 1" P14598 7 74773962-74789376 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Chronic granulomatous disease, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 86.4;lymphoid tissue: 97.5" "Cell type enhanced" "Detected in many" "B-cells: 293.0;dendritic cells: 157.3;Kupffer cells: 119.9;Macrophages: 153.4;monocytes: 329.9;Plasma cells: 205.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 5 "basophil: 1165.0;classical monocyte: 673.5;eosinophil: 1467.3;neutrophil: 2128.0" "Group enriched" "Detected in all" 5 "granulocytes: 2128.0;monocytes: 673.5" "Group enriched" "Detected in some" 5 "Daudi: 96.2;HMC-1: 130.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004524, HPA047836, HPA052095" Enhanced NA NA "Cluster 5: Granulocytes - Unknown function" "Cluster 2: Immune cells - Immune response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 57: B-cells - Immune response" "CAB004524: AB_627987, HPA047836: AB_2680173, HPA052095: AB_2681721" "unprognostic (4.93e-2)" "unprognostic (8.34e-3)" "unprognostic (1.23e-1)" "unprognostic (1.25e-2)" "unprognostic (8.67e-2)" "unprognostic (3.55e-3)" "unprognostic (7.60e-2)" "unprognostic (4.75e-2)" "unprognostic (6.23e-3)" "unprognostic (9.99e-2)" "unprognostic (6.61e-3)" "unprognostic (1.06e-1)" "unprognostic (2.77e-3)" "unprognostic (3.16e-1)" "unprognostic (4.17e-2)" "unprognostic (3.27e-2)" "unprognostic (2.09e-1)" 7.5 3.8 1.9 38.7 2.2 86.4 2.7 4.6 2.9 1.7 0.9 7.2 7.6 1.3 0.5 3.3 3.2 5.5 3.0 2.8 2.0 2.9 5.0 17.7 56.8 5.0 3.4 1.1 1.5 0.7 1.2 5.0 4.5 2.1 4.5 1.6 4.2 1.4 1.5 1.8 26.6 4.0 2.4 97.5 6.6 0.8 2.3 7.5 2.6 4.8 37.5 7.6 1.8 6.6 0.0 0.0 0.2 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.0 0.1 96.2 0.1 0.0 0.0 0.4 0.0 0.4 0.0 0.5 0.6 2.9 1.4 0.9 0.0 0.8 130.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.9 0.0 0.0 0.1 16.8 0.3 0.0 0.0 1.6 0.0 3.4 0.2 0.4 0.0 0.1 0.0 0.1 0.1 0.1 0.0 20.6 0.2 0.1 0.3 0.2 0.0 0.6 0.3 16.5 0.2 8.1 0.2 1165.0 673.5 1467.3 4.2 242.3 9.8 257.0 10.0 6.7 77.7 276.6 15.4 9.4 2128.0 10.7 60.2 280.9 11.1 514.1 1.9 2.2 4.6 2.9 2.8 2.0 5.0 3.4 4.5 2.4 2.3 6.6 5.0 0.0 2.8 0.0 293.0 3.1 1.1 29.6 5.2 0.2 3.1 3.2 0.6 4.3 10.9 3.7 0.0 0.6 157.3 0.0 0.0 1.3 8.7 0.8 1.0 3.6 0.0 6.1 0.0 0.6 12.2 1.5 10.2 2.5 14.5 0.1 3.9 3.6 39.3 3.3 0.1 0.3 2.0 119.9 23.4 6.4 0.0 153.4 10.6 1.0 329.9 0.3 10.3 0.0 0.1 1.2 4.2 0.4 205.7 1.0 0.4 1.9 17.6 0.5 0.0 1.4 1.5 0.2 0.7 5.0 1.7 4.5 63.6 0.1 0.3 2.2 NCF2 "NOXA2, p67phox" ENSG00000116701 "Neutrophil cytosolic factor 2" P19878 1 183555562-183590876 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Chronic granulomatous disease, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 191.9;lung: 74.6;lymphoid tissue: 78.8" "Group enriched" "Detected in many" 5 "Ductal cells: 68.6;Hofbauer cells: 212.0;Kupffer cells: 137.9;Langerhans cells: 129.5;Macrophages: 194.4;monocytes: 223.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "eosinophil: 1313.6" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 26.4;HMC-1: 21.4;hTERT-HME1: 51.6;RPMI-8226: 20.0;U-2 OS: 50.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA002327, HPA006040, CAB022160" Enhanced Supported Cytosol NA NA 12000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 30: Epithelial cell lines - Translation" "Cluster 19: Monocytes & Neutrophils - Innate immune response" Cytosol "CAB022160: , HPA002327: AB_1079550, HPA006040: AB_1854906" "unprognostic (4.97e-2)" "unprognostic (3.48e-2)" "unprognostic (2.40e-2)" "unprognostic (1.22e-3)" "unprognostic (5.83e-3)" "unprognostic (4.04e-2)" "prognostic unfavorable (7.91e-6)" "unprognostic (1.29e-1)" "unprognostic (2.45e-1)" "unprognostic (2.33e-1)" "unprognostic (5.70e-2)" "unprognostic (2.01e-1)" "unprognostic (1.57e-2)" "unprognostic (1.61e-1)" "unprognostic (1.41e-2)" "unprognostic (8.24e-2)" "unprognostic (2.36e-2)" 29.9 5.8 2.7 76.9 3.0 191.9 7.0 3.2 14.6 9.5 4.5 10.4 8.5 4.1 1.6 7.6 8.0 23.8 5.6 2.3 3.9 3.7 12.7 74.6 17.3 6.2 4.2 2.1 4.6 2.8 2.7 39.7 6.8 2.9 12.5 0.8 6.6 3.5 3.7 15.9 12.4 20.4 4.5 78.8 5.8 2.1 12.0 11.3 3.0 11.5 16.9 24.2 5.9 7.8 26.4 0.8 0.0 0.0 0.0 0.0 0.3 1.9 2.4 3.4 1.6 0.2 0.8 3.2 4.3 0.8 0.6 14.3 0.1 19.0 3.1 16.2 0.0 0.0 7.3 6.0 0.0 2.0 21.4 0.0 4.1 3.4 51.6 2.2 0.0 0.1 0.0 5.6 5.8 0.2 0.2 1.1 0.4 1.5 1.5 7.0 2.2 20.0 0.8 0.2 0.0 0.1 0.3 0.1 0.9 1.7 2.8 9.1 1.2 0.1 50.2 0.0 4.9 0.9 1.4 0.6 0.4 10.3 0.0 199.5 489.2 1313.6 1.0 348.8 1.6 14.1 4.0 1.6 246.0 10.8 2.2 1.3 799.7 2.1 326.1 13.5 11.1 298.9 2.7 3.0 3.2 14.6 2.3 3.9 6.2 4.2 6.8 4.5 12.0 7.8 0.7 9.6 15.7 0.0 8.4 5.5 0.2 13.7 1.8 0.3 0.1 0.3 1.3 7.2 17.3 0.0 0.0 1.0 9.6 0.1 3.9 68.6 1.1 1.9 0.5 3.5 0.0 1.7 0.3 3.9 1.1 2.0 0.5 1.3 7.6 0.0 3.3 1.0 212.0 0.0 0.3 0.2 26.4 137.9 129.5 2.9 0.6 194.4 7.2 3.7 223.6 0.0 6.2 0.0 0.2 27.3 2.6 0.0 3.2 0.6 0.0 0.3 32.0 0.7 13.1 0.7 6.8 0.1 0.6 0.6 4.3 1.9 3.7 0.2 0.0 1.2 NFKB1 "KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50" ENSG00000109320 "Nuclear factor kappa B subunit 1" P19838 4 102501331-102617302 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Langerhans cells: 610.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004031, HPA027305" Enhanced Supported Nucleoplasm,Cytosol NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 41: Macrophages - Immune response" Nucleoplasm Cytosol "CAB004031: AB_330564, HPA027305: AB_1854429" "unprognostic (1.06e-1)" "unprognostic (1.61e-2)" "unprognostic (4.37e-2)" "unprognostic (2.38e-2)" "unprognostic (1.60e-1)" "unprognostic (1.20e-1)" "unprognostic (2.04e-2)" "unprognostic (8.98e-2)" "unprognostic (1.96e-1)" "unprognostic (9.03e-3)" "unprognostic (2.28e-1)" "unprognostic (2.71e-1)" "prognostic favorable (1.76e-4)" "unprognostic (1.84e-2)" "unprognostic (6.75e-3)" "unprognostic (1.74e-1)" "unprognostic (6.92e-3)" 26.7 16.2 3.9 30.3 7.0 34.6 19.8 6.5 5.7 22.0 5.5 20.4 15.2 18.9 2.7 23.0 19.1 20.8 15.8 4.2 5.8 17.4 16.4 25.0 33.1 7.6 6.1 18.8 16.0 11.7 7.7 21.2 7.8 17.3 19.6 4.9 18.9 17.8 20.9 23.7 20.3 17.0 5.6 23.0 17.5 7.6 6.4 37.0 16.3 10.7 35.1 48.5 19.9 10.1 36.8 19.2 11.2 13.6 27.0 28.5 10.9 20.0 64.2 27.7 27.1 21.5 40.8 58.0 17.6 32.6 39.4 29.5 22.0 34.5 35.2 53.6 10.8 22.7 14.5 15.0 20.0 44.3 44.3 19.7 20.2 22.0 34.4 15.0 34.5 18.1 25.8 34.1 17.6 17.7 4.1 9.1 5.0 24.3 15.4 33.4 25.9 24.0 15.3 38.8 7.1 11.8 38.3 37.2 16.3 8.3 8.6 24.2 40.5 32.5 16.6 14.5 26.4 17.0 13.3 52.0 20.8 19.4 44.1 0.0 2.1 2.6 0.9 3.0 1.9 1.9 3.0 1.6 4.8 1.7 4.5 3.2 1.9 3.7 3.1 1.5 0.8 1.6 3.9 7.0 6.5 5.7 4.2 5.8 7.6 6.1 7.8 5.6 6.4 10.1 32.5 41.7 49.4 42.1 90.0 165.4 91.5 57.1 31.3 6.6 41.5 32.6 19.1 24.3 40.8 20.2 6.2 14.4 119.6 41.1 3.9 28.5 7.6 82.5 62.0 47.6 33.6 13.0 78.4 37.3 16.9 63.1 29.6 207.0 111.1 19.8 23.9 23.9 24.8 20.2 77.2 43.2 18.3 56.2 610.3 2.4 23.9 178.3 55.2 59.0 207.9 9.5 23.7 66.9 127.4 46.3 27.1 34.6 56.3 78.5 21.1 24.4 31.5 6.7 0.0 73.7 41.2 2.5 8.1 35.3 150.3 14.2 88.2 16.7 35.4 90.2 NFKB2 "LYT-10, NF-kB2, p105, p49/p100, p52" ENSG00000077150 "Nuclear factor kappa B subunit 2" Q00653 10 102394110-102402524 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Langerhans cells: 122.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 5.6" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "HDLM-2: 168.0;Karpas-707: 157.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008422, CAB022098, HPA023900" Enhanced Approved Nucleoplasm,Cytosol NA NA "Cluster 5: Granulocytes - Unknown function" "Cluster 2: Immune cells - Immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 41: Macrophages - Immune response" Cytosol Nucleoplasm "CAB022098: , HPA008422: AB_1854434, HPA023900: AB_1854435" "unprognostic (1.10e-2)" "unprognostic (1.43e-1)" "prognostic unfavorable (3.86e-4)" "unprognostic (1.53e-2)" "unprognostic (8.08e-3)" "unprognostic (2.15e-1)" "unprognostic (2.38e-3)" "unprognostic (3.98e-2)" "prognostic favorable (8.45e-5)" "unprognostic (4.04e-1)" "unprognostic (8.34e-2)" "unprognostic (4.14e-2)" "prognostic unfavorable (6.69e-12)" "unprognostic (2.37e-3)" "unprognostic (1.63e-1)" "unprognostic (4.90e-2)" "unprognostic (1.56e-1)" 26.5 21.0 7.6 44.4 7.4 69.3 19.6 7.1 9.2 22.9 8.5 39.1 15.5 21.6 2.3 17.7 20.4 18.5 20.6 7.2 7.2 34.6 28.2 41.0 40.7 8.5 7.5 21.4 24.1 6.1 10.8 14.7 8.0 29.0 6.8 1.1 21.3 9.1 18.4 20.0 26.5 12.2 7.5 50.6 22.7 10.0 8.4 16.9 20.1 7.6 25.7 37.0 19.1 8.0 67.9 48.6 7.7 31.7 11.1 16.6 19.3 18.5 61.0 19.6 25.9 28.6 55.2 32.9 43.5 11.9 48.8 40.9 20.5 28.2 6.8 168.0 11.2 7.0 11.7 15.9 30.1 5.1 45.5 22.0 14.6 34.1 32.3 26.5 7.8 16.1 7.6 157.8 7.4 26.4 7.1 22.7 10.3 15.7 16.6 16.8 24.5 27.0 34.3 22.1 1.7 8.2 16.2 36.7 26.3 7.2 29.3 16.4 21.2 19.0 28.9 25.4 47.0 113.1 105.0 32.6 31.1 14.8 10.9 0.0 1.3 0.0 0.7 0.9 0.7 2.6 0.8 0.7 0.7 2.1 0.8 0.8 5.6 0.8 2.1 0.6 1.1 0.5 7.6 7.4 7.1 9.2 7.2 7.2 8.5 7.5 8.0 7.5 8.4 8.0 20.8 9.6 8.8 3.3 88.3 43.5 59.3 41.2 34.7 2.2 17.1 14.5 3.1 25.8 29.9 18.4 16.7 6.3 39.0 33.3 5.9 33.2 1.1 33.7 14.4 26.1 16.3 0.4 0.1 21.0 15.8 26.0 80.0 52.0 71.8 5.5 11.7 3.7 20.9 0.0 0.1 30.4 22.4 19.4 122.9 1.7 7.5 52.5 30.2 1.9 75.1 3.9 12.3 1.5 0.7 44.9 37.4 4.9 49.1 49.3 33.2 8.6 19.9 5.3 0.0 36.4 43.6 4.7 11.1 17.5 44.6 23.1 54.6 8.8 17.9 45.6 NFKBIA "IkappaBalpha, IKBA, MAD-3, NFKBI" ENSG00000100906 "NFKB inhibitor alpha" P25963 14 35401513-35404749 "Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction" "Cancer-related genes, Disease variant, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 1114.7" "Cell type enhanced" "Detected in all" "Basal keratinocytes: 4056.6;Langerhans cells: 4828.7;Suprabasal keratinocytes: 3420.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RT4: 391.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003815, HPA029207" Approved Enhanced Cytosol NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 15: RT4 - Unknown function" "Cluster 41: Macrophages - Immune response" Cytosol "CAB003815: AB_344886, HPA029207: AB_10603122" "prognostic favorable (1.33e-5)" "unprognostic (3.39e-1)" "unprognostic (7.29e-2)" "unprognostic (7.24e-2)" "unprognostic (8.88e-2)" "unprognostic (1.62e-1)" "unprognostic (3.51e-1)" "unprognostic (2.46e-1)" "unprognostic (2.39e-1)" "unprognostic (2.46e-1)" "unprognostic (2.46e-1)" "unprognostic (7.19e-2)" "unprognostic (2.32e-2)" "unprognostic (3.69e-1)" "unprognostic (4.44e-2)" "unprognostic (9.74e-2)" "unprognostic (3.80e-2)" 281.0 171.3 75.6 150.7 78.0 1114.7 171.4 75.4 92.5 123.8 78.3 121.0 61.2 95.5 29.6 151.8 141.2 130.4 145.5 71.4 75.9 104.5 208.1 366.0 122.6 90.1 76.2 255.7 101.9 68.8 92.4 92.7 81.6 112.6 80.9 18.7 118.3 110.0 139.7 260.5 148.5 92.7 77.0 226.2 130.7 31.7 84.9 123.2 111.9 138.3 181.4 366.2 166.8 79.8 62.5 54.1 20.1 18.2 114.7 75.9 71.1 25.2 240.7 53.3 47.3 16.9 36.5 37.5 66.1 40.2 125.2 79.5 38.3 104.9 76.1 229.2 14.9 18.6 39.9 101.4 68.6 29.9 15.0 83.1 103.5 36.4 92.2 35.5 48.6 18.4 15.9 58.4 38.6 73.0 39.2 71.0 18.6 60.0 33.1 87.8 23.1 31.6 92.8 391.7 17.9 31.2 67.2 115.9 29.7 41.0 66.1 62.2 91.7 72.8 26.5 21.3 41.0 70.9 77.7 64.5 60.8 22.0 15.3 322.0 444.9 301.4 175.3 267.2 264.0 258.4 207.1 182.5 428.9 329.7 178.1 153.0 942.9 285.9 183.7 233.0 154.9 506.4 75.6 78.0 75.4 92.5 71.4 75.9 90.1 76.2 81.6 77.0 84.9 79.8 802.9 535.2 914.0 14.4 505.6 4056.6 1862.8 2061.4 1729.6 27.0 430.7 414.0 188.6 367.4 719.2 62.5 12.5 196.4 762.2 447.8 195.6 875.0 4.3 703.8 935.6 1079.8 203.5 87.8 7.1 394.8 174.9 1145.1 333.8 1440.1 906.1 68.2 313.4 147.2 791.2 48.8 5.1 453.0 634.7 491.4 4828.7 14.7 153.1 1609.0 1085.1 39.4 428.1 95.2 97.9 6.6 8.6 383.5 511.5 116.2 1039.4 1412.0 1051.6 115.9 298.2 37.4 203.8 956.9 847.2 3.3 26.4 1544.6 3420.6 660.0 838.4 91.8 346.0 1004.6 NHEJ1 "Cernunnos, FLJ12610, XLF" ENSG00000187736 "Non-homologous end joining factor 1" Q9H9Q4 2 219069357-219160865 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" DNA-binding "Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Distal enterocytes: 7.8;Microglial cells: 11.2;Oligodendrocytes: 8.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012334, HPA043869" Approved Supported "Nucleoplasm,Nucleoli fibrillar center" NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 71: Testis - DNA repair" "Cluster 39: CACO-2 - Unknown function" "Cluster 59: Non-specific - Transcription" Nucleoplasm "Nucleoli fibrillar center" "CAB012334: , HPA043869: AB_2678707" "unprognostic (5.66e-2)" "unprognostic (3.01e-2)" "unprognostic (3.16e-1)" "unprognostic (2.73e-2)" "unprognostic (2.28e-1)" "unprognostic (1.06e-2)" "unprognostic (5.92e-2)" "unprognostic (5.16e-2)" "unprognostic (6.04e-2)" "unprognostic (3.51e-2)" "unprognostic (6.87e-2)" "unprognostic (1.58e-3)" "unprognostic (4.52e-2)" "unprognostic (1.65e-1)" "unprognostic (1.82e-1)" "unprognostic (8.90e-2)" "unprognostic (8.29e-2)" 10.2 8.4 2.4 4.4 2.5 4.5 8.5 3.8 3.8 9.4 2.2 14.0 6.9 8.7 4.3 7.2 7.4 4.8 6.2 2.4 2.9 12.8 8.1 6.9 6.1 3.3 2.5 9.1 8.4 3.4 2.8 4.6 3.2 6.7 8.4 3.4 5.7 4.3 17.1 8.4 12.2 8.1 2.7 6.9 9.0 18.7 2.7 6.1 4.6 7.6 5.8 10.4 8.7 3.5 5.5 8.2 13.9 12.6 15.6 17.9 8.0 10.9 9.6 13.2 15.4 25.4 5.9 12.2 8.4 11.4 13.4 7.2 20.5 10.9 11.8 13.8 9.0 18.1 10.0 17.5 12.5 8.5 13.9 15.5 21.2 10.5 12.5 8.9 11.1 7.8 22.3 11.8 10.7 4.6 11.5 10.3 15.9 5.1 8.0 14.6 10.2 9.8 10.5 8.2 10.2 11.4 5.0 7.1 15.8 15.6 6.4 8.0 9.9 10.0 9.3 4.4 9.1 6.3 8.0 13.2 6.1 16.2 10.3 6.3 11.9 6.6 7.0 17.7 12.2 12.0 11.4 9.3 8.7 9.0 14.1 10.4 3.3 11.6 15.6 4.8 12.8 9.1 2.4 2.5 3.8 3.8 2.4 2.9 3.3 2.5 3.2 2.7 2.7 3.5 0.3 0.0 0.0 5.9 3.5 0.4 0.0 0.2 5.7 0.0 0.2 0.1 0.1 0.0 0.7 0.0 0.0 0.2 1.7 7.8 0.0 1.6 0.7 0.1 0.3 1.0 2.4 3.8 4.7 1.9 0.3 0.6 5.6 0.2 0.0 0.0 0.0 0.3 0.3 0.0 5.1 3.4 0.0 0.0 0.0 0.2 0.3 2.1 0.0 11.2 3.1 0.0 0.0 5.0 8.1 1.0 2.9 0.0 6.1 0.2 3.4 0.4 0.0 0.0 0.0 0.1 1.3 0.2 0.5 5.9 0.0 0.3 2.6 0.2 3.1 0.0 NRAS N-ras ENSG00000213281 "NRAS proto-oncogene, GTPase" P01111 1 114704469-114716771 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Disease variant, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010157, HPA049830, CAB079912" Uncertain Supported "Plasma membrane" NA NA "Cluster 38: Basophils - Unknown function" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 16: Pancreatic endocrine cells - Mixed function" "Plasma membrane" "CAB010157: AB_632073, CAB079912: AB_2784586, HPA049830: AB_2680903" "unprognostic (4.75e-2)" "unprognostic (2.81e-1)" "unprognostic (1.09e-3)" "unprognostic (2.11e-2)" "unprognostic (8.59e-3)" "unprognostic (1.14e-1)" "prognostic unfavorable (3.03e-7)" "unprognostic (7.76e-3)" "unprognostic (1.57e-2)" "unprognostic (1.01e-3)" "prognostic unfavorable (1.36e-4)" "unprognostic (6.60e-3)" "prognostic unfavorable (7.87e-4)" "unprognostic (2.68e-1)" "unprognostic (1.30e-1)" "unprognostic (1.16e-1)" "unprognostic (3.33e-2)" 19.0 9.1 10.3 25.7 11.2 58.5 18.0 11.5 12.3 12.5 8.6 27.8 21.5 12.4 7.8 20.7 10.3 17.2 8.3 10.2 12.2 20.9 24.9 18.5 30.4 12.3 12.1 9.6 11.4 9.0 4.3 28.3 12.3 11.4 26.6 6.6 10.9 7.1 7.7 19.8 22.5 14.1 11.7 18.6 21.8 9.6 11.4 39.0 16.1 7.8 29.7 22.2 8.6 13.4 93.7 24.9 65.2 24.9 26.4 56.3 46.5 43.5 48.4 79.5 89.0 50.4 33.9 70.4 56.3 58.9 55.4 26.0 88.2 70.6 113.4 96.5 34.2 47.8 34.5 60.2 52.3 120.0 71.0 51.1 56.1 91.5 66.2 25.0 102.8 54.6 77.3 78.5 71.0 248.9 83.5 46.4 111.0 30.2 17.9 62.9 116.0 44.1 70.6 49.5 39.4 59.0 44.7 36.4 107.1 75.4 31.9 96.2 79.2 43.3 82.2 81.5 90.3 137.7 101.6 81.6 86.4 64.6 159.0 38.7 12.8 12.6 11.7 19.2 10.5 12.8 9.3 11.6 12.6 10.5 9.9 12.9 3.4 15.5 17.6 9.6 13.4 13.1 10.3 11.2 11.5 12.3 10.2 12.2 12.3 12.1 12.3 11.7 11.4 13.4 22.7 16.0 16.5 8.1 25.9 30.7 31.2 23.1 15.4 5.2 18.5 13.6 5.6 18.6 19.3 22.0 8.4 22.4 27.7 49.2 13.7 34.1 3.9 22.9 24.7 29.2 24.6 31.6 5.8 31.5 50.4 16.1 29.0 38.0 31.1 22.2 33.2 29.7 49.2 5.0 5.2 28.1 30.5 44.9 30.7 5.9 8.1 30.4 23.2 9.4 41.6 7.8 22.6 5.0 8.1 51.4 32.9 6.4 39.6 30.6 28.1 39.4 23.1 3.3 6.6 12.8 15.3 7.3 15.4 24.6 36.2 31.2 21.9 13.8 28.8 40.2 ORAI1 "CRACM1, FLJ14466, TMEM142A" ENSG00000276045 "ORAI calcium release-activated calcium modulator 1" Q96D31 12 121626550-121642677 "Disease related genes, Human disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Adaptive immunity, Calcium transport, Immunity, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 60.1" "Cell type enhanced" "Detected in many" "dendritic cells: 92.3;NK-cells: 88.6;Theca cells: 86.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NB-4: 81.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA016583 Approved NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 59: Non-specific - Translation" "Cluster 24: NB-4 - Immune response" "Cluster 24: Non-specific - Transcription regulation" "HPA016583: AB_1848720" "unprognostic (2.22e-2)" "unprognostic (3.78e-3)" "unprognostic (7.82e-3)" "unprognostic (8.83e-2)" "unprognostic (3.20e-1)" "unprognostic (1.99e-3)" "unprognostic (4.25e-3)" "unprognostic (1.92e-1)" "unprognostic (2.00e-2)" "prognostic favorable (4.30e-4)" "unprognostic (1.41e-1)" "unprognostic (2.59e-1)" "unprognostic (6.84e-2)" "unprognostic (1.95e-1)" "unprognostic (1.83e-1)" "unprognostic (2.04e-1)" "unprognostic (1.57e-2)" 10.8 5.4 4.4 9.6 4.6 8.8 10.9 5.2 6.8 7.3 22.1 10.6 20.8 7.6 0.0 8.7 7.7 3.3 9.3 3.8 4.9 11.2 12.3 15.5 12.0 5.5 4.9 6.7 8.1 8.7 2.6 4.5 5.5 6.4 0.3 0.0 15.6 2.6 60.1 46.6 13.8 2.2 5.4 23.1 12.5 11.5 5.1 6.1 10.4 14.0 2.8 11.1 7.8 5.1 18.3 42.0 3.4 16.9 4.0 4.9 18.4 20.5 2.9 8.8 4.7 33.1 16.2 13.3 31.4 3.1 11.8 30.2 3.4 13.7 0.0 41.9 7.8 23.9 6.8 16.6 10.1 18.5 43.7 2.0 5.1 14.4 0.9 4.9 12.9 30.0 16.8 6.9 2.3 41.4 46.1 81.7 19.6 10.3 35.7 16.8 7.9 20.5 5.0 13.4 16.4 3.3 10.7 11.7 17.5 0.2 29.3 11.6 23.5 21.0 8.4 28.6 15.9 9.4 8.7 5.6 15.7 25.9 19.1 9.4 6.3 8.2 18.6 5.4 13.9 6.3 15.4 18.8 7.5 9.0 14.3 12.5 6.9 7.5 5.2 1.9 13.7 7.6 4.4 4.6 5.2 6.8 3.8 4.9 5.5 4.9 5.5 5.4 5.1 5.1 32.0 28.9 16.4 1.0 41.0 22.6 10.1 3.4 6.8 2.1 48.4 22.9 4.2 18.6 10.3 1.8 4.2 3.7 92.3 8.4 1.9 13.3 3.4 14.1 11.1 40.6 2.4 23.8 0.3 19.5 15.2 9.5 8.6 17.4 7.0 24.0 43.2 17.9 38.6 0.0 0.5 9.3 2.0 28.2 65.0 11.8 13.4 42.8 21.4 4.7 27.2 5.8 88.6 3.0 1.5 29.5 6.3 9.4 30.5 14.8 17.2 12.1 6.3 6.9 0.0 6.3 10.8 1.7 6.0 6.9 37.4 7.8 70.3 86.0 20.1 10.7 PGM3 "AGM1, DKFZP434B187, PAGM" ENSG00000013375 "Phosphoglucomutase 3" O95394 6 83161150-83193936 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins" "Carbohydrate metabolism" Isomerase "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004998, HPA029759, HPA029760" Enhanced Approved Nucleoplasm,Cytosol NA NA 220000 "Cluster 34: Basophils - Unknown function" "Cluster 29: Non-specific - Vesicular transport" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 55: Plasma cells - Humoral immune response" "Nucleoplasm, Cytosol" "CAB004998: AB_425591, HPA029759: AB_10600305, HPA029760: AB_10601109" "prognostic unfavorable (8.78e-4)" "prognostic unfavorable (5.67e-4)" "unprognostic (1.45e-2)" "unprognostic (3.03e-2)" "unprognostic (1.51e-2)" "unprognostic (4.04e-2)" "unprognostic (1.09e-3)" "unprognostic (6.72e-3)" "unprognostic (3.11e-1)" "prognostic favorable (9.96e-4)" "unprognostic (4.00e-1)" "unprognostic (1.30e-1)" "prognostic unfavorable (2.39e-7)" "unprognostic (2.21e-1)" "unprognostic (7.98e-2)" "unprognostic (1.22e-1)" "unprognostic (4.22e-3)" 23.6 21.0 12.0 18.1 12.9 9.3 18.0 20.2 15.2 24.4 19.6 18.0 15.8 17.1 34.5 12.3 13.4 24.6 14.3 9.7 10.5 13.6 38.3 16.8 11.2 10.9 10.2 22.7 46.1 13.3 28.2 47.5 13.1 51.0 23.4 26.8 35.8 20.3 6.7 10.9 18.2 18.5 6.6 11.5 24.9 32.3 11.1 8.2 25.6 8.6 15.2 19.0 12.3 15.9 35.1 23.4 41.8 51.0 68.9 72.9 48.9 118.1 82.9 55.2 83.3 60.1 16.1 18.3 24.7 112.3 53.0 20.1 38.4 49.5 104.6 14.6 37.8 22.7 41.9 105.0 77.6 22.6 11.2 46.2 40.1 96.6 120.0 55.5 64.6 12.1 74.9 19.6 61.0 39.1 3.7 14.7 18.8 31.8 31.6 16.2 92.5 11.3 42.0 36.0 16.9 26.3 34.8 28.5 20.9 61.8 27.0 25.5 94.2 38.3 21.2 74.9 60.5 36.5 16.1 13.0 29.7 17.7 58.4 10.8 4.1 2.7 2.6 3.5 3.9 4.6 2.8 3.4 3.6 2.5 4.5 4.7 1.8 3.5 4.5 4.2 2.1 2.3 12.0 12.9 20.2 15.2 9.7 10.5 10.9 10.2 13.1 6.6 11.1 15.9 14.3 28.9 27.7 14.4 13.0 15.8 29.2 28.5 5.7 16.4 19.9 15.0 6.8 15.7 36.1 11.0 10.4 32.4 12.7 15.9 7.9 31.7 67.7 17.0 35.1 13.8 16.1 6.9 25.1 49.6 71.1 46.1 23.9 36.4 5.1 25.4 14.3 32.6 17.6 8.4 29.4 35.5 18.3 6.0 8.7 20.9 33.5 8.6 10.6 15.9 10.1 25.9 2.1 41.2 36.8 37.9 19.7 18.4 44.1 56.5 16.1 23.2 22.2 21.1 6.6 22.1 26.6 75.5 34.2 11.6 15.6 64.4 10.1 12.2 17.6 25.6 PIK3CD p110D ENSG00000171608 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta" O00329 1 9651731-9729114 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Adaptive immunity, Chemotaxis, Differentiation, Immunity, Inflammatory response, Innate immunity" "Kinase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 60.9;lymphoid tissue: 50.4" "Cell type enhanced" "Detected in many" "dendritic cells: 44.0;granulocytes: 25.3;Kupffer cells: 35.2;Microglial cells: 29.0;NK-cells: 29.9;T-cells: 37.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 153.3;NB-4: 65.9;REH: 68.9;THP-1: 65.4;U-937: 78.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015420, HPA044953" Enhanced Approved "Vesicles,Cytokinetic bridge" Yes No "Cluster 8: Neutrophils - Inflammatory response" "Cluster 2: Immune cells - Immune response" "Cluster 43: THP-1 - Innate immune response" "Cluster 63: NK-cells & T-cells - Immune response" Vesicles "Cytokinetic bridge" "CAB015420: AB_831654, HPA044953: AB_2679153" "unprognostic (5.73e-3)" "unprognostic (2.75e-3)" "unprognostic (8.93e-2)" "unprognostic (4.05e-2)" "unprognostic (4.71e-2)" "unprognostic (1.40e-2)" "unprognostic (2.13e-1)" "unprognostic (7.42e-2)" "unprognostic (2.78e-2)" "unprognostic (1.54e-2)" "unprognostic (3.46e-2)" "unprognostic (6.75e-2)" "unprognostic (8.65e-3)" "unprognostic (2.09e-1)" "unprognostic (1.34e-1)" "unprognostic (2.04e-1)" "unprognostic (6.78e-2)" 7.2 3.1 6.8 33.4 6.3 60.9 3.9 6.1 7.5 6.2 6.4 5.4 5.2 4.9 1.7 4.9 6.1 7.0 3.3 7.0 5.3 6.4 3.5 12.0 46.9 7.3 6.6 7.0 3.0 2.9 2.8 4.2 7.8 4.6 3.4 0.6 5.1 2.7 1.2 3.0 17.2 4.7 6.6 50.4 5.7 4.0 9.3 24.3 5.5 3.5 32.0 7.4 5.1 8.5 8.1 5.2 0.4 1.4 1.3 1.1 0.7 12.1 24.5 26.0 21.1 0.3 3.3 21.5 4.9 9.8 12.4 2.4 2.0 11.0 16.2 153.3 0.4 2.4 1.3 9.0 5.1 56.0 18.7 4.3 4.5 29.2 9.8 11.4 3.8 14.9 8.0 0.1 15.0 0.6 5.4 65.9 2.2 0.3 1.4 68.9 13.0 0.7 10.9 0.0 1.7 1.5 2.7 4.9 11.9 6.8 0.8 65.4 9.8 7.7 7.9 0.2 11.5 4.9 4.9 30.1 16.7 78.6 4.4 18.0 23.5 40.2 21.6 23.0 22.6 12.8 16.3 19.9 22.5 13.6 20.9 23.1 63.2 25.9 29.2 25.7 13.3 38.3 6.8 6.3 6.1 7.5 7.0 5.3 7.3 6.6 7.8 6.6 9.3 8.5 1.7 9.6 13.4 2.0 22.2 1.5 2.2 1.8 4.0 0.7 2.0 1.7 3.1 0.0 1.1 0.0 2.1 0.3 44.0 0.1 1.9 3.9 3.0 2.0 1.7 2.7 0.0 10.3 6.7 2.0 0.5 2.9 0.0 1.0 25.3 4.2 3.6 0.0 14.7 0.0 13.4 0.1 0.0 35.2 6.0 2.8 1.2 23.1 3.6 29.0 19.3 2.5 29.9 1.0 1.1 11.3 0.0 1.5 8.2 4.1 0.2 3.8 3.3 1.3 6.6 2.0 4.7 1.5 3.4 2.9 1.1 0.3 37.1 1.5 0.2 2.1 PNP "NP, PUNP" ENSG00000198805 "Purine nucleoside phosphorylase" P00491 14 20468954-20477089 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Purine salvage" "Glycosyltransferase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 333.9;epididymis: 594.8" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 360.6;Erythroid cells: 227.3;Syncytiotrophoblasts: 646.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HL-60: 531.3;U-937: 593.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA001625 Enhanced Supported Cytosol NA NA 58000000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 68: Epididymis - Unknown function" "Cluster 32: U-937 - Innate immune response" "Cluster 47: Cytotrophoblasts - Unknown function" Cytosol "HPA001625: AB_1854577" "unprognostic (1.20e-3)" "unprognostic (2.68e-2)" "unprognostic (1.04e-2)" "unprognostic (1.70e-1)" "unprognostic (3.10e-1)" "unprognostic (7.06e-2)" "prognostic unfavorable (4.43e-4)" "unprognostic (4.94e-3)" "unprognostic (3.87e-2)" "unprognostic (7.45e-2)" "unprognostic (1.85e-2)" "unprognostic (2.21e-1)" "prognostic favorable (2.24e-4)" "unprognostic (1.69e-1)" "unprognostic (7.54e-2)" "unprognostic (2.46e-1)" "unprognostic (1.64e-3)" 78.6 24.8 16.1 46.8 16.6 333.9 34.6 22.6 22.7 25.3 18.9 52.2 120.3 14.2 594.8 87.4 18.2 56.8 29.0 17.7 19.6 206.8 98.0 48.6 46.7 20.3 18.1 5.0 23.2 32.0 19.8 132.6 20.1 15.0 61.8 27.1 22.6 27.4 7.3 29.6 60.3 38.7 23.1 44.5 50.6 7.4 21.1 33.5 17.8 10.0 64.4 100.4 41.5 20.1 86.1 113.4 24.0 53.9 26.0 21.0 71.8 85.2 40.3 68.2 67.0 66.1 76.5 227.1 96.8 45.5 81.5 89.9 125.2 159.8 89.5 75.0 109.6 189.1 89.9 109.3 24.2 531.3 94.7 14.4 57.4 206.0 91.0 37.8 295.9 141.0 95.4 137.4 86.7 79.1 157.6 311.3 67.5 215.7 186.1 130.2 35.9 88.3 243.7 79.6 101.9 22.6 163.4 205.0 13.2 32.6 75.5 92.5 240.0 46.1 62.6 105.1 148.4 63.1 113.3 258.9 39.3 593.0 4.6 12.0 30.6 10.3 39.8 27.3 73.6 25.7 44.2 45.0 48.1 28.8 27.6 35.9 3.7 38.5 26.6 27.3 16.7 31.1 16.1 16.6 22.6 22.7 17.7 19.6 20.3 18.1 20.1 23.1 21.1 20.1 149.6 0.0 23.5 5.9 50.3 84.6 67.4 12.6 112.7 4.7 56.3 62.6 3.5 27.1 13.4 82.8 14.6 360.6 45.2 61.1 39.2 43.2 1.3 36.0 12.7 139.4 46.4 227.3 0.6 51.5 41.8 32.4 106.5 65.3 57.7 5.0 24.3 30.6 70.9 16.8 1.1 51.3 18.3 18.1 58.4 0.8 0.3 83.3 30.2 3.7 13.2 78.8 29.9 3.0 0.9 130.8 83.9 0.7 88.6 27.5 41.2 118.9 10.5 18.1 0.0 23.9 41.3 0.4 0.7 114.7 63.9 646.2 62.3 3.1 51.4 77.1 PRF1 "HPLH2, P1, PFP" ENSG00000180644 "Perforin 1" P14222 10 70597348-70602759 "Cancer-related genes, Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters" Cytolysis "Cancer-related genes, Disease variant, Familial hemophagocytic lymphohistiocytosis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "bone marrow: 28.6;lung: 16.5;lymphoid tissue: 49.4" "Cell type enhanced" "Detected in some" "dendritic cells: 542.1;NK-cells: 1231.7;T-cells: 265.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "gdT-cell: 900.4;MAIT T-cell: 628.8;memory CD8 T-cell: 499.1;naive CD8 T-cell: 313.0;NK-cell: 656.8" "Group enriched" "Detected in all" 50 "NK-cells: 656.8;T-cells: 900.4" "Cell line enriched" "Detected in some" 11 "HDLM-2: 240.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB002436, HPA037940" Approved Approved Cytosol "Intracellular and membrane" NA NA 2100000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 2: Immune cells - Immune response" "Cluster 44: HDLM-2 - Immune response" "Cluster 63: NK-cells & T-cells - Immune response" Cytosol "CAB002436: AB_563955, HPA037940: AB_2675747" "unprognostic (6.11e-3)" "unprognostic (1.26e-2)" "unprognostic (1.71e-1)" "prognostic favorable (2.09e-4)" "unprognostic (1.87e-2)" "prognostic favorable (3.54e-4)" "unprognostic (6.98e-3)" "unprognostic (2.62e-1)" "unprognostic (1.44e-3)" "unprognostic (1.69e-2)" "unprognostic (5.22e-2)" "unprognostic (1.45e-1)" "prognostic unfavorable (1.08e-5)" "unprognostic (7.38e-2)" "unprognostic (2.70e-1)" "unprognostic (7.97e-3)" "unprognostic (5.22e-3)" 5.0 2.0 0.7 7.6 0.7 28.6 2.7 0.7 1.3 1.3 1.3 2.2 2.3 3.5 1.1 1.9 1.9 4.2 2.2 0.6 0.6 1.7 6.3 16.5 20.3 1.4 0.7 1.0 1.0 0.5 0.9 2.7 1.0 1.5 1.4 0.0 2.3 1.2 2.6 0.9 5.2 2.0 1.3 49.4 4.7 0.6 1.0 5.8 2.6 1.5 4.9 3.8 1.9 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 240.1 0.0 1.4 0.0 7.4 0.0 0.3 11.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.1 22.2 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.2 0.0 0.1 0.0 5.2 1.9 0.9 900.4 1.7 628.8 4.0 125.8 499.1 2.0 3.5 52.1 313.0 15.4 656.8 2.6 2.9 108.8 587.5 0.7 0.7 0.7 1.3 0.6 0.6 1.4 0.7 1.0 1.3 1.0 1.0 3.1 3.2 13.6 0.0 4.4 0.4 0.1 0.0 0.6 0.0 0.5 0.5 0.8 1.5 2.5 0.0 0.0 0.2 542.1 0.1 0.0 0.3 0.0 0.2 0.3 1.9 0.0 19.0 0.0 0.0 0.1 2.1 7.7 0.4 8.8 0.0 10.8 2.7 0.1 0.0 0.0 0.0 0.0 7.8 2.3 0.0 0.0 5.7 0.0 1.9 7.4 0.0 1231.7 0.0 0.1 0.0 0.0 0.0 88.5 0.1 0.1 1.6 1.5 0.0 0.0 1.1 0.8 0.0 0.0 0.5 0.9 0.7 265.4 0.0 0.1 0.0 PRKCD ENSG00000163932 "Protein kinase C delta" Q05655 3 53156009-53192717 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Apoptosis, Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Late spermatids: 75.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Group enriched" "Detected in all" 7 "dendritic cells: 57.0;granulocytes: 52.9;monocytes: 73.7" "Cell line enhanced" "Detected in all" "SK-BR-3: 267.7;THP-1: 194.0" "Group enriched" "Detected in all" 5 "basal ganglia: 121.4;thalamus: 334.6" "Low region specificity" "Detected in all" "HPA001863, HPA001890, CAB010469, CAB013225" Enhanced Enhanced "Endoplasmic reticulum,Golgi apparatus,Cytosol" NA NA 30000 "Cluster 52: Eosinophils - Transcription" "Cluster 64: Macrophages - Immune response" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 53: Intestinal epithelial cells - Unknown function" Cytosol "Endoplasmic reticulum, Golgi apparatus" "CAB010469: AB_632229, CAB013225: , HPA001863: AB_1079627, HPA001890: AB_1079628" "unprognostic (3.59e-1)" "unprognostic (4.85e-2)" "unprognostic (2.66e-2)" "unprognostic (1.90e-1)" "unprognostic (1.17e-1)" "unprognostic (6.97e-2)" "prognostic unfavorable (2.24e-4)" "prognostic favorable (9.01e-4)" "unprognostic (1.95e-2)" "unprognostic (1.42e-1)" "unprognostic (1.79e-1)" "unprognostic (2.89e-1)" "unprognostic (2.05e-1)" "unprognostic (1.73e-1)" "unprognostic (2.48e-2)" "unprognostic (2.06e-3)" "unprognostic (2.95e-3)" 46.1 59.7 10.4 45.4 11.1 90.3 28.9 4.4 11.7 25.9 7.3 43.5 54.8 9.1 39.1 32.7 42.3 32.8 19.6 12.8 11.0 25.6 8.8 44.3 46.8 9.9 8.5 13.6 33.2 20.7 8.2 20.5 7.5 39.3 41.5 2.2 25.9 31.9 6.8 34.0 55.7 16.2 9.5 54.2 65.1 20.8 9.0 16.3 41.8 9.2 62.1 44.2 23.2 12.3 33.5 14.4 5.2 8.7 35.9 21.6 46.2 20.4 25.7 24.5 23.7 34.4 31.9 86.5 8.3 45.6 42.9 14.5 34.1 49.8 20.6 75.2 23.6 50.1 18.3 32.0 23.6 64.8 103.4 17.1 35.8 25.6 23.2 21.8 22.4 9.3 9.7 11.8 36.1 85.0 7.0 81.0 13.0 51.5 23.0 7.6 13.6 20.6 25.5 72.8 8.3 6.5 15.4 267.7 39.6 24.0 22.6 194.0 31.5 11.7 14.4 15.4 19.2 18.1 33.6 45.9 27.6 116.4 22.6 51.8 73.7 50.1 3.6 71.3 2.2 6.2 2.1 2.5 57.0 8.2 2.2 2.0 52.9 6.9 47.7 16.3 2.6 24.1 10.4 11.1 4.4 11.7 12.8 11.0 9.9 8.5 7.5 9.5 9.0 12.3 4.3 3.2 23.5 2.0 25.7 29.2 26.3 8.0 23.9 0.3 11.8 4.3 6.4 14.3 16.1 14.7 0.0 3.1 24.7 61.8 3.9 8.9 34.5 18.5 4.4 2.7 26.5 5.2 3.4 10.7 16.0 6.7 54.0 17.8 5.7 8.9 3.3 2.3 44.8 1.7 4.2 37.1 4.1 47.4 43.0 75.6 9.0 41.5 10.6 20.6 44.9 2.0 8.2 1.0 0.5 13.2 55.4 6.8 25.8 19.7 64.5 13.1 16.5 0.2 6.6 6.5 12.1 23.1 3.7 23.9 27.8 8.8 10.0 10.4 23.0 34.6 PRKDC "DNA-PKC, DNA-PKcs, DNAPK, DNAPKc, DNPK1, HYRC, HYRC1, p350, p460, XRCC7" ENSG00000253729 "Protein kinase, DNA-activated, catalytic subunit" P78527 8 47773111-47960178 "Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, Ribosome biogenesis" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005167, HPA035174" Supported Enhanced Nucleoplasm NA NA 250000 "Cluster 6: Non-specific - Transcription" "Cluster 59: Non-specific - Translation" "Cluster 36: HEL - Hemostasis" "Cluster 36: Stromal cells - Cell proliferation" Nucleoplasm "CAB005167: AB_2172845, HPA035174: AB_2674504" "unprognostic (3.14e-2)" "unprognostic (3.02e-3)" "unprognostic (1.56e-2)" "prognostic unfavorable (1.03e-4)" "unprognostic (8.95e-2)" "unprognostic (1.34e-1)" "unprognostic (7.70e-3)" "unprognostic (5.74e-2)" "unprognostic (1.12e-2)" "unprognostic (1.60e-2)" "unprognostic (7.76e-3)" "unprognostic (7.77e-2)" "unprognostic (2.84e-2)" "unprognostic (2.32e-1)" "unprognostic (2.20e-1)" "unprognostic (6.76e-3)" "unprognostic (2.15e-2)" 17.3 16.8 8.6 14.1 10.7 19.2 16.1 9.8 11.9 18.2 10.8 16.2 7.0 20.1 8.0 24.0 18.3 7.4 16.7 10.6 9.3 14.8 14.0 14.8 17.9 10.4 10.0 19.8 18.0 14.0 16.3 10.9 9.8 13.5 11.6 23.8 16.0 9.2 26.4 19.8 17.2 12.1 10.6 18.8 16.6 18.3 9.6 27.8 13.4 15.0 17.1 18.7 17.5 14.3 123.5 103.4 98.4 93.9 59.9 63.0 41.6 51.2 49.9 70.3 68.9 68.0 39.6 117.1 43.1 63.3 52.3 68.5 131.3 70.2 109.3 26.3 81.8 230.2 92.1 83.7 25.8 88.6 46.0 45.9 22.5 111.3 115.3 27.1 73.4 79.5 156.6 48.0 78.8 57.7 125.8 72.3 108.6 85.6 31.2 60.8 77.3 41.2 35.5 104.4 49.2 62.5 158.1 50.6 51.1 60.2 72.6 60.1 86.2 91.5 78.0 73.0 104.2 41.3 56.7 162.8 51.7 97.9 75.6 11.4 8.1 4.1 8.7 6.8 11.0 13.1 10.8 9.2 6.5 16.7 11.2 10.3 7.7 12.8 13.7 15.3 8.3 2.9 8.6 10.7 9.8 11.9 10.6 9.3 10.4 10.0 9.8 10.6 9.6 14.3 73.4 38.5 36.1 56.8 67.9 38.4 48.3 59.7 77.4 103.4 63.1 64.0 82.1 22.8 44.1 42.3 125.1 61.1 81.9 17.5 17.6 41.9 29.0 66.0 166.5 59.7 25.8 147.6 85.5 36.0 60.6 73.2 55.0 72.6 45.6 105.1 32.5 41.2 35.9 104.3 77.1 31.2 38.7 45.5 20.1 15.5 56.8 54.6 19.6 61.8 63.6 73.1 57.7 82.0 76.0 34.9 16.6 69.6 69.3 57.1 13.2 23.5 50.1 111.6 52.6 91.2 69.3 100.7 106.3 85.3 40.6 33.0 71.0 143.2 55.2 36.4 PTPRC "CD45, GP180, LCA, T200" ENSG00000081237 "Protein tyrosine phosphatase receptor type C" P08575 1 198638457-198757476 "Cancer-related genes, CD markers, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Host-virus interaction" "Hydrolase, Protein phosphatase" "Cancer-related genes, Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 208.6;lymphoid tissue: 329.9" "Cell type enhanced" "Detected in many" "B-cells: 525.2;dendritic cells: 1026.4;Macrophages: 534.1;monocytes: 554.9;NK-cells: 769.3;Plasma cells: 474.2;T-cells: 1049.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 209.9;HEL: 118.0;HL-60: 108.1;JURKAT: 266.4;MOLT-4: 161.1;THP-1: 87.0;U-266/70: 93.7;U-266/84: 91.2;U-698: 123.4;U-937: 94.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000052, HPA000440, CAB002800, CAB056154, CAB068221" Enhanced Uncertain Nucleoplasm,Vesicles "Intracellular and membrane" NA NA 24000000 "Cluster 14: Monocytes - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" "Nucleoplasm, Vesicles" "CAB000052: AB_2314143, CAB002800: AB_2237910, CAB056154: AB_2665572, CAB068221: AB_2665571, HPA000440: AB_611377" "unprognostic (1.51e-2)" "unprognostic (1.24e-2)" "unprognostic (5.10e-3)" "unprognostic (2.33e-3)" "unprognostic (1.30e-1)" "unprognostic (2.40e-3)" "unprognostic (1.62e-1)" "unprognostic (3.17e-2)" "unprognostic (1.25e-1)" "unprognostic (3.18e-2)" "unprognostic (8.08e-2)" "unprognostic (3.95e-1)" "prognostic unfavorable (2.42e-4)" "unprognostic (2.31e-1)" "unprognostic (3.43e-2)" "unprognostic (6.41e-2)" "unprognostic (7.06e-2)" 32.8 11.6 3.8 248.5 3.3 208.6 13.9 4.4 4.3 14.9 6.9 26.4 27.4 11.3 5.6 15.1 8.4 45.7 7.3 3.5 5.6 7.0 29.6 68.6 329.9 12.9 8.6 5.7 5.6 4.0 2.9 23.5 11.5 11.6 30.5 2.0 13.8 6.6 4.6 5.7 42.9 25.3 7.9 202.5 37.9 5.5 6.9 306.9 7.0 7.6 251.2 62.1 5.2 14.7 0.4 0.0 0.2 0.2 0.0 0.0 0.8 0.3 0.3 0.1 0.0 0.0 0.1 209.9 0.3 0.7 0.2 0.3 0.0 0.2 0.4 0.6 0.0 118.0 0.2 0.1 0.0 108.1 0.7 0.0 0.0 0.3 0.0 0.4 0.5 266.4 2.4 3.3 0.3 0.1 161.1 65.0 0.5 0.2 0.2 4.6 0.4 0.3 0.1 0.1 1.2 1.8 0.1 0.4 0.5 0.2 0.3 87.0 1.3 0.0 0.8 0.8 0.4 93.7 91.2 123.4 0.1 94.5 0.4 226.1 480.0 521.4 634.4 885.8 541.8 249.0 437.0 618.1 385.8 245.8 489.8 494.1 844.3 506.9 1015.8 57.4 508.6 1340.6 3.8 3.3 4.4 4.3 3.5 5.6 12.9 8.6 11.5 7.9 6.9 14.7 12.6 44.8 62.3 0.7 525.2 15.8 0.9 0.0 4.0 0.3 6.0 9.3 4.6 5.7 14.2 1.8 0.0 0.6 1026.4 1.0 0.0 0.7 2.4 2.3 2.3 15.1 1.2 58.8 0.7 0.0 0.9 17.2 46.9 2.7 246.5 0.1 14.6 6.9 96.0 0.0 1.7 0.4 0.0 334.9 214.5 3.5 1.2 534.1 21.4 201.4 554.9 0.1 769.3 2.5 0.7 0.1 0.8 0.0 474.2 1.1 0.1 2.5 11.7 0.2 6.6 7.4 6.7 0.3 0.6 1.8 15.2 0.8 1049.1 5.4 0.9 0.8 RAB27A "GS2, HsT18676, RAB27, RAM" ENSG00000069974 "RAB27A, member RAS oncogene family" P51159 15 55202966-55319113 "Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins" Exocytosis Hydrolase "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "stomach 1: 119.9" "Cell type enhanced" "Detected in many" "Alveolar cells type 2: 147.1;Intestinal goblet cells: 252.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "basophil: 261.3" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HL-60: 208.7;K-562: 238.0;Karpas-707: 179.4;SK-MEL-30: 188.3;U-937: 185.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001333, CAB034046" Enhanced NA NA "Cluster 46: Basophils - DNA binding" "Cluster 37: Intestine - Unknown function" "Cluster 1: K-562 - Erythropoiesis" "Cluster 27: Mucus-secreting cells - Mucin production" "CAB034046: AB_2176724, HPA001333: AB_1079730" "prognostic favorable (2.56e-4)" "unprognostic (9.75e-2)" "unprognostic (2.01e-2)" "unprognostic (1.81e-1)" "unprognostic (1.08e-1)" "unprognostic (1.79e-1)" "unprognostic (1.73e-1)" "unprognostic (2.32e-1)" "unprognostic (2.62e-1)" "unprognostic (2.77e-1)" "unprognostic (6.24e-2)" "unprognostic (1.47e-1)" "prognostic unfavorable (1.67e-4)" "unprognostic (4.23e-2)" "unprognostic (4.34e-1)" "unprognostic (7.95e-3)" "unprognostic (4.32e-1)" 17.5 27.8 3.5 40.2 3.9 100.2 13.9 4.4 4.4 12.9 5.6 53.0 30.0 12.8 5.0 20.6 12.3 17.6 7.7 3.4 6.7 19.2 43.6 42.4 46.0 5.8 5.0 8.0 29.2 11.4 31.4 17.6 5.9 61.2 66.1 4.2 18.3 11.8 3.2 12.8 40.9 25.8 5.0 30.8 119.9 10.0 5.9 19.3 30.5 7.0 46.2 37.5 13.9 5.7 23.0 10.0 9.7 11.3 8.3 38.8 9.5 29.4 32.5 19.2 26.4 7.0 15.6 0.9 22.3 16.0 38.9 16.0 15.7 27.0 18.3 84.9 9.7 5.4 37.6 18.1 56.0 208.7 26.5 34.3 44.2 29.0 71.6 80.7 46.9 26.4 238.0 179.4 20.7 27.7 1.5 57.6 3.6 38.9 14.7 32.4 27.3 50.3 28.7 17.7 14.9 7.1 31.4 15.2 188.3 24.3 13.3 162.2 25.3 52.5 20.3 33.1 33.6 72.0 88.2 6.0 70.2 185.1 19.0 261.3 72.4 99.8 59.2 30.1 58.2 8.0 28.6 61.9 39.0 13.4 13.9 37.4 114.9 34.1 24.0 2.1 36.2 48.9 3.5 3.9 4.4 4.4 3.4 6.7 5.8 5.0 5.9 5.0 5.9 5.7 27.5 76.9 147.1 12.7 18.6 14.1 25.7 19.2 6.2 3.0 16.3 18.3 7.4 15.7 50.1 11.0 2.1 6.3 81.0 18.5 13.7 24.6 2.8 10.1 15.6 32.1 74.3 12.8 12.5 87.6 18.7 16.9 93.3 16.7 31.7 8.8 41.7 41.7 15.6 0.0 12.2 252.0 12.2 33.3 15.2 2.2 7.5 31.1 71.2 10.3 71.9 2.4 104.0 10.1 7.1 62.9 15.9 13.9 38.6 32.3 14.6 6.7 31.3 4.4 19.7 9.4 15.8 9.3 4.6 7.1 15.5 7.5 81.4 4.6 18.4 23.4 RAC2 EN-7 ENSG00000128340 "Rac family small GTPase 2" P15153 22 37225270-37244448 "Disease related genes, Human disease related genes, Predicted intracellular proteins, RAS pathway related proteins" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "bone marrow: 411.9;lymphoid tissue: 387.9" "Cell type enhanced" "Detected in many" "B-cells: 329.0;dendritic cells: 381.4;granulocytes: 520.5;NK-cells: 717.9;Plasma cells: 287.8;T-cells: 419.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 522.5;HL-60: 734.5;HMC-1: 1427.9;Karpas-707: 684.5;U-87 MG: 618.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022946, HPA047820" Enhanced NA Yes 3300000 "Cluster 5: Granulocytes - Unknown function" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 3: HMC-1 - Innate immune response" "Cluster 63: NK-cells & T-cells - Immune response" "CAB022946: , HPA047820: AB_2680167" "prognostic favorable (1.03e-5)" "unprognostic (2.91e-1)" "unprognostic (3.21e-2)" "unprognostic (1.82e-3)" "unprognostic (6.74e-2)" "unprognostic (7.78e-2)" "unprognostic (3.47e-1)" "unprognostic (5.00e-2)" "unprognostic (8.52e-3)" "unprognostic (2.65e-1)" "unprognostic (7.65e-2)" "unprognostic (3.81e-1)" "prognostic unfavorable (1.06e-6)" "unprognostic (1.45e-1)" "unprognostic (1.75e-1)" "unprognostic (6.21e-2)" "unprognostic (1.50e-2)" 24.7 8.4 3.6 207.2 3.8 411.9 11.4 3.9 8.0 12.2 4.4 34.8 35.3 10.1 4.7 15.9 11.7 37.1 6.5 3.8 4.7 10.9 19.3 63.4 387.9 6.5 5.3 5.5 5.3 2.1 3.4 12.4 7.1 10.9 33.9 0.4 21.5 8.3 4.9 7.6 96.9 19.6 5.2 299.9 42.7 3.5 6.1 323.9 9.5 7.2 309.1 54.0 9.9 7.2 136.6 0.2 0.0 0.0 14.3 130.5 0.6 17.9 41.1 14.2 28.8 0.3 44.8 167.4 19.8 52.9 0.8 33.3 1.0 231.6 15.6 522.5 0.6 209.6 3.6 0.6 35.8 734.5 1427.9 96.4 32.3 25.1 84.3 0.9 239.7 159.1 50.5 684.5 1.9 0.2 218.9 291.2 2.8 13.1 87.2 72.3 0.7 193.8 22.6 0.1 2.0 0.6 0.9 23.0 2.7 0.8 9.7 391.8 258.7 0.6 23.5 1.0 2.0 307.0 171.4 176.6 618.6 316.5 35.1 1319.9 519.8 1602.2 972.1 695.5 731.5 761.7 768.6 858.9 494.0 672.8 584.3 759.8 1336.4 972.2 879.5 728.7 1163.4 1566.2 3.6 3.8 3.9 8.0 3.8 4.7 6.5 5.3 7.1 5.2 6.1 7.2 4.4 16.0 47.7 0.0 329.0 5.4 2.2 26.0 16.5 0.0 8.6 9.5 1.1 2.8 12.6 1.8 0.0 0.8 381.4 3.4 0.0 13.6 0.2 1.1 0.8 5.6 4.2 109.7 0.4 2.2 1.5 9.2 33.6 1.0 520.5 0.3 13.6 3.4 150.8 0.0 0.1 6.3 0.0 129.9 63.9 0.9 0.3 147.9 30.2 3.7 125.9 0.0 717.9 0.5 0.0 18.2 18.1 0.0 287.8 0.5 0.6 1.5 4.4 0.0 13.1 2.4 4.5 0.0 1.0 5.1 4.0 2.9 419.6 3.7 11.2 3.6 RAD50 "hRad50, RAD50-2" ENSG00000113522 "RAD50 double strand break repair protein" Q92878 5 132556019-132646349 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair, Host-virus interaction, Meiosis" Hydrolase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022103, CAB024979, HPA052291" Supported Supported Nucleoplasm NA NA 12000 "Cluster 15: NK-cells - Transcription" "Cluster 72: Non-specific - Transcription" "Cluster 30: Epithelial cell lines - Translation" "Cluster 50: Fibroblasts - ECM organization" Nucleoplasm "CAB022103: , CAB024979: , HPA052291: AB_2681786" "unprognostic (3.46e-3)" "prognostic unfavorable (3.77e-4)" "unprognostic (7.50e-3)" "unprognostic (4.22e-3)" "unprognostic (6.71e-2)" "unprognostic (5.98e-2)" "unprognostic (2.76e-2)" "unprognostic (1.06e-1)" "unprognostic (6.84e-2)" "unprognostic (2.55e-1)" "unprognostic (5.40e-3)" "unprognostic (1.62e-1)" "prognostic favorable (1.95e-4)" "unprognostic (1.86e-1)" "unprognostic (1.36e-1)" "unprognostic (2.49e-2)" "unprognostic (2.40e-1)" 6.3 8.0 5.8 2.8 6.9 5.9 6.6 7.6 8.6 6.9 4.0 8.7 2.5 8.1 10.3 7.6 7.3 3.5 7.1 6.8 4.9 6.1 6.2 5.0 2.5 5.0 4.4 9.2 9.2 8.8 8.1 3.6 5.7 6.2 4.6 8.5 7.1 4.2 11.3 10.4 8.0 3.8 3.4 5.4 8.6 5.5 5.4 4.0 6.0 4.7 3.5 7.9 6.9 8.6 9.1 22.8 2.1 12.1 13.3 20.0 9.8 6.3 11.2 11.0 12.8 20.4 14.8 20.6 3.7 10.3 19.7 8.8 17.6 14.2 16.5 11.7 13.4 9.5 13.3 12.5 10.8 10.2 7.6 10.8 24.1 13.4 36.7 7.2 5.4 6.5 17.9 3.2 10.1 8.6 7.7 13.9 11.7 9.0 6.8 7.2 3.7 10.1 8.8 16.9 11.5 14.9 11.7 4.7 2.8 5.6 11.5 7.0 9.5 4.7 5.5 14.5 8.3 5.7 7.7 24.2 8.4 12.5 6.7 7.0 3.3 1.1 4.1 3.8 5.6 7.0 5.4 5.4 3.6 5.8 4.9 4.5 0.3 9.3 4.8 2.5 4.0 2.7 5.8 6.9 7.6 8.6 6.8 4.9 5.0 4.4 5.7 3.4 5.4 8.6 3.5 38.5 27.1 65.6 34.6 26.0 37.3 33.7 31.9 56.8 6.6 4.8 130.0 44.3 31.6 7.3 89.6 69.6 22.9 31.0 1.9 6.3 26.4 8.2 15.8 16.6 37.1 38.5 65.9 6.0 49.2 37.6 37.2 7.6 30.4 8.5 22.1 38.5 37.4 37.0 79.7 44.1 18.3 27.2 12.2 12.6 60.6 16.5 16.0 49.6 22.4 38.0 48.4 65.9 92.4 4.8 35.6 53.4 33.0 32.1 53.7 4.4 40.8 60.8 32.9 50.9 39.9 108.4 87.2 39.2 26.7 33.1 25.2 11.5 52.3 25.1 RAG1 "MGC43321, RNF74" ENSG00000166349 "Recombination activating 1" P15918 11 36510709-36593156 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA recombination, Ubl conjugation pathway" "Chromatin regulator, DNA-binding, Endonuclease, Hydrolase, Multifunctional enzyme, Nuclease, Transferase" "Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 92 "lymphoid tissue: 395.0" "Cell type enhanced" "Detected in some" "Distal tubular cells: 3.9;Hepatic stellate cells: 8.2" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "MOLT-4: 283.5;REH: 266.4" "Not detected" "Not detected" "Low region specificity" "Detected in some" HPA043939 Supported Nucleoplasm NA NA "Cluster 63: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Nucleoplasm "HPA043939: AB_2732512" "unprognostic (7.35e-2)" "unprognostic (1.57e-3)" "unprognostic (8.75e-2)" "unprognostic (3.44e-1)" "unprognostic (2.14e-1)" "unprognostic (1.46e-2)" "unprognostic (2.30e-1)" "unprognostic (1.70e-2)" "unprognostic (1.43e-1)" "unprognostic (1.54e-2)" "unprognostic (5.98e-3)" "unprognostic (1.28e-1)" "unprognostic (1.16e-9)" "unprognostic (2.16e-2)" "unprognostic (1.04e-1)" "unprognostic (2.53e-4)" "unprognostic (1.53e-1)" 0.4 0.5 0.1 0.2 0.1 4.3 0.2 0.1 0.2 0.4 0.2 0.4 0.8 0.2 0.8 0.1 0.3 0.4 0.3 0.1 0.1 1.3 0.8 0.6 0.1 0.1 0.1 0.3 0.3 0.6 0.1 0.6 0.1 0.3 0.3 0.6 0.4 0.3 0.1 0.1 1.0 0.1 0.1 2.6 0.5 0.3 0.1 395.0 2.4 0.3 0.6 0.3 0.1 0.1 0.4 0.0 0.5 0.1 0.2 0.6 0.0 0.3 0.3 0.1 0.5 0.0 0.4 0.5 0.0 0.0 0.1 0.2 0.0 0.4 0.4 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.3 0.4 0.0 0.3 0.2 0.5 54.0 0.2 0.0 0.5 0.0 283.5 0.0 2.2 0.2 0.0 266.4 0.0 1.3 0.9 0.0 0.1 0.3 0.1 0.7 0.1 1.2 1.0 0.1 1.0 0.2 0.2 0.2 0.1 2.3 1.9 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 1.5 0.0 0.0 0.0 0.1 0.1 1.4 0.7 0.0 1.0 1.0 0.8 0.9 0.0 0.4 1.8 0.0 0.2 0.5 1.3 3.9 0.8 2.3 0.3 0.3 1.6 0.0 0.4 1.8 0.5 0.1 0.7 0.0 0.4 0.0 0.3 8.2 2.1 0.4 0.0 1.7 0.8 0.0 0.6 0.7 1.7 0.0 0.1 0.0 1.0 1.1 0.5 2.1 1.0 1.3 1.1 0.4 0.0 0.0 0.5 3.0 2.9 0.4 0.9 0.0 0.2 0.7 1.0 1.0 0.2 0.4 0.4 0.4 0.5 0.6 0.6 RAG2 ENSG00000175097 "Recombination activating 2" P55895 11 36575574-36598279 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "DNA recombination" "Chromatin regulator" "Disease variant, SCID" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "lymphoid tissue: 152.3" "Group enriched" "Detected in some" 19 "Astrocytes: 1.3;Early spermatids: 2.3;Excitatory neurons: 2.9;Inhibitory neurons: 1.5;Oligodendrocyte precursor cells: 2.5;Oligodendrocytes: 1.3;Spermatocytes: 1.5" "Cancer enriched" "Detected in single" 21 "thyroid cancer: 1.0" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "JURKAT: 40.0;MOLT-4: 46.8;REH: 183.8" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA065704 Approved Nucleoplasm NA NA "Cluster 63: T-cells - Adaptive immune response" "Cluster 14: REH - Unknown function" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" Nucleoplasm "HPA065704: AB_2732737" "unprognostic (4.30e-2)" "unprognostic (9.09e-2)" "unprognostic (1.21e-1)" "unprognostic (1.77e-1)" "unprognostic (4.58e-2)" "unprognostic (2.17e-1)" "unprognostic (8.11e-2)" "unprognostic (1.68e-3)" 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 152.3 23.9 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 40.0 0.0 0.0 0.0 0.0 46.8 0.0 0.1 0.0 0.0 183.8 0.0 0.6 0.0 0.0 0.1 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 RFX5 ENSG00000143390 "Regulatory factor X5" P48382 1 151340640-151347326 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "monocytes: 40.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018519, HPA079241" Supported Supported Nucleoplasm,Vesicles NA NA "Cluster 23: Antigen presenting cells - Antigen presentation" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" Nucleoplasm Vesicles "HPA018519: AB_1856209, HPA079241: " "unprognostic (1.17e-3)" "unprognostic (1.62e-1)" "unprognostic (2.61e-1)" "unprognostic (3.21e-2)" "unprognostic (2.68e-2)" "unprognostic (2.49e-2)" "unprognostic (3.73e-2)" "unprognostic (2.09e-3)" "unprognostic (2.99e-2)" "unprognostic (1.96e-1)" "unprognostic (8.29e-2)" "unprognostic (4.42e-2)" "unprognostic (5.66e-3)" "unprognostic (2.00e-3)" "unprognostic (3.43e-2)" "unprognostic (4.03e-2)" "unprognostic (3.05e-2)" 18.4 25.6 13.3 43.3 13.7 24.0 14.9 17.8 13.2 18.2 11.7 22.7 31.6 22.0 13.1 18.3 18.4 23.4 18.3 12.3 16.8 18.3 13.1 27.9 67.7 17.1 17.6 10.1 9.6 22.1 18.1 12.4 18.5 20.4 28.1 14.6 16.0 25.1 17.0 13.1 26.1 31.8 15.4 50.7 19.6 15.5 15.7 50.5 23.7 23.8 71.8 26.5 11.4 13.3 37.7 41.8 57.6 32.8 27.6 24.0 12.6 17.8 30.0 43.6 57.7 13.7 50.9 145.2 63.9 21.5 42.6 59.5 24.9 34.4 31.9 177.4 39.7 54.8 89.4 23.0 17.7 48.9 59.4 25.2 18.8 28.8 13.2 35.7 39.9 92.0 26.8 88.3 33.8 34.2 78.7 36.2 41.9 30.5 21.2 97.1 32.3 80.1 42.0 49.1 20.4 60.0 35.7 55.0 52.8 69.2 51.6 114.3 39.9 23.8 25.1 11.8 33.7 110.9 118.2 168.6 37.8 26.4 31.3 5.6 22.6 11.5 17.4 28.2 15.3 47.9 13.9 17.4 47.4 53.3 10.9 12.2 3.1 31.4 30.8 25.1 28.5 21.5 13.3 13.7 17.8 13.2 12.3 16.8 17.1 17.6 18.5 15.4 15.7 13.3 8.4 9.6 7.5 4.9 32.0 6.6 12.5 11.4 14.2 7.6 9.4 6.5 5.1 8.6 12.1 7.3 0.0 8.8 16.9 3.8 9.8 15.7 8.4 7.5 6.3 9.9 4.2 16.6 3.2 9.2 3.4 6.1 5.6 12.8 24.1 9.4 10.8 7.3 12.4 1.7 7.0 5.1 10.2 18.5 15.7 17.9 5.0 13.3 5.4 8.4 40.8 7.2 21.6 3.0 2.4 8.6 2.7 9.8 9.5 14.1 11.2 10.7 7.4 2.7 6.6 5.3 5.7 15.5 7.5 14.2 6.1 3.4 13.7 15.7 7.3 14.6 RFXANK "ANKRA1, BLS, F14150_1, MGC138628, RFX-B" ENSG00000064490 "Regulatory factor X associated ankyrin containing protein" O14593 19 19192229-19201869 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049157, HPA053330" Approved Enhanced Nucleoplasm NA NA "Cluster 26: Non-specific - Mitochondria" "Cluster 18: Non-specific - Mitochondria" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 39: Non-specific - Basic cellular processes" Nucleoplasm "HPA049157: AB_2680658, HPA053330: AB_2682114" "unprognostic (3.16e-2)" "unprognostic (6.39e-3)" "unprognostic (1.47e-2)" "unprognostic (1.22e-1)" "unprognostic (5.23e-2)" "unprognostic (4.46e-2)" "unprognostic (1.25e-3)" "unprognostic (3.40e-2)" "unprognostic (3.89e-1)" "unprognostic (1.57e-1)" "unprognostic (2.71e-1)" "unprognostic (1.97e-1)" "unprognostic (1.31e-2)" "unprognostic (3.62e-2)" "unprognostic (3.52e-1)" "unprognostic (2.73e-2)" "unprognostic (2.04e-3)" 30.2 20.2 27.3 21.4 30.2 41.1 29.6 29.4 34.8 28.6 25.8 30.5 21.4 28.4 14.1 40.2 34.8 13.6 27.4 27.1 29.3 36.6 20.6 25.8 31.1 31.1 28.1 27.1 29.6 23.1 24.3 18.2 29.0 32.3 11.1 8.7 34.1 14.2 31.6 34.9 27.6 13.0 28.6 38.9 31.8 12.7 28.7 28.4 38.0 15.0 22.1 26.1 27.1 29.9 60.0 36.6 25.6 50.2 8.7 24.2 64.5 29.0 30.3 48.8 47.7 30.7 121.4 58.2 72.9 30.2 20.8 43.6 21.9 56.2 21.5 40.4 33.7 46.7 36.7 45.1 89.4 66.8 94.6 44.7 32.4 42.8 31.0 29.8 49.1 56.8 94.4 64.2 27.1 119.3 88.0 88.3 30.7 62.6 82.0 73.5 26.1 101.9 41.5 39.8 21.0 43.6 30.3 38.2 70.4 17.1 54.1 134.8 49.1 25.4 27.9 63.3 47.6 73.5 86.9 87.7 37.6 82.3 52.2 48.5 29.4 52.2 23.9 32.7 20.4 41.7 27.2 26.5 34.2 41.4 27.1 26.6 13.4 33.3 24.6 54.2 40.5 29.0 27.3 30.2 29.4 34.8 27.1 29.3 31.1 28.1 29.0 28.6 28.7 29.9 33.4 32.1 36.9 6.5 28.9 22.0 33.8 77.9 28.5 10.0 30.5 33.5 3.4 31.5 39.5 31.3 2.1 63.5 24.9 46.2 76.3 44.0 6.4 48.4 29.7 35.7 37.2 45.8 1.2 57.4 61.3 26.8 35.2 37.7 31.8 31.4 33.2 16.7 63.1 15.2 1.4 40.0 40.7 44.5 27.8 11.1 30.4 34.1 21.4 8.4 57.8 27.6 36.0 3.5 3.3 59.3 44.4 19.2 27.9 27.0 56.5 70.7 57.6 12.3 39.5 14.6 37.5 6.3 20.1 35.4 24.6 45.6 29.4 28.5 46.9 27.1 RFXAP ENSG00000133111 "Regulatory factor X associated protein" O00287 13 36819222-36829104 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" DNA-binding SCID "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA032035 Approved "Nuclear speckles" NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 34: Non-specific - Transcription" "Cluster 32: U-937 - Innate immune response" "Cluster 52: Non-specific - Transcription" "Nuclear speckles" "HPA032035: AB_2674120" "unprognostic (2.03e-1)" "unprognostic (9.69e-2)" "unprognostic (7.40e-2)" "unprognostic (3.13e-1)" "unprognostic (5.14e-3)" "unprognostic (4.45e-3)" "unprognostic (1.15e-2)" "prognostic favorable (2.26e-5)" "unprognostic (1.45e-1)" "unprognostic (2.94e-1)" "prognostic favorable (4.18e-4)" "unprognostic (1.43e-1)" "unprognostic (1.15e-1)" "prognostic favorable (4.91e-4)" "unprognostic (2.81e-2)" "unprognostic (4.09e-1)" "unprognostic (5.99e-3)" 4.3 3.4 3.8 5.0 4.2 6.0 4.7 6.8 5.2 6.3 2.5 5.1 3.1 6.8 5.1 3.0 5.8 4.1 3.5 3.9 3.5 3.3 2.6 4.3 6.7 3.3 3.7 7.0 4.6 6.2 4.6 3.7 3.5 5.2 4.1 5.5 4.8 3.8 4.3 3.5 4.4 5.8 4.0 5.1 4.2 6.5 3.4 8.3 5.8 3.0 5.4 4.0 3.8 4.3 7.4 1.8 10.4 14.7 3.8 5.2 6.7 5.9 6.2 10.9 6.7 5.2 5.9 32.3 4.8 5.4 9.6 6.7 10.8 3.6 12.2 24.4 17.9 15.5 8.6 10.2 6.9 28.7 10.9 4.8 6.3 5.3 4.0 3.1 8.3 24.4 9.0 6.4 3.3 3.6 28.8 20.5 11.1 6.4 3.2 24.9 19.3 9.8 4.6 4.5 8.5 10.6 5.7 3.8 4.7 6.3 3.9 16.9 6.5 2.8 6.1 9.8 5.5 6.0 5.3 24.2 7.9 19.6 4.5 0.0 0.0 0.5 0.2 0.0 0.1 0.3 0.1 0.2 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.3 0.2 0.0 3.8 4.2 6.8 5.2 3.9 3.5 3.3 3.7 3.5 4.0 3.4 4.3 6.6 3.2 3.9 11.1 10.4 3.6 3.3 2.5 7.4 14.5 4.9 4.4 3.6 1.5 2.7 3.7 2.1 6.4 11.1 2.0 15.6 4.2 5.3 4.3 7.5 7.0 7.2 16.0 26.4 5.5 2.8 9.8 4.6 3.0 10.2 10.9 7.9 2.2 3.1 23.5 27.5 2.8 2.0 1.9 7.4 4.1 11.1 4.1 7.2 7.5 5.5 20.8 17.5 11.1 23.9 2.8 2.5 10.9 6.4 1.5 3.3 1.4 2.2 18.0 6.6 13.1 10.0 20.1 25.8 2.8 2.0 1.2 11.7 8.2 3.6 0.8 RNF168 FLJ35794 ENSG00000163961 "Ring finger protein 168" Q8IYW5 3 196468783-196503768 "Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" "Chromatin regulator, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Early spermatids: 199.9;Late spermatids: 459.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA046109 Enhanced "Nucleoplasm,Nuclear bodies" NA NA "Cluster 38: Basophils - Unknown function" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 25: Spermatids - Spermatogenesis" "Nucleoplasm, Nuclear bodies" "HPA046109: AB_2679540" "unprognostic (6.15e-3)" "prognostic favorable (8.21e-4)" "unprognostic (3.11e-1)" "unprognostic (1.11e-2)" "unprognostic (4.22e-1)" "unprognostic (5.04e-2)" "prognostic unfavorable (2.29e-4)" "unprognostic (6.81e-3)" "unprognostic (5.30e-2)" "unprognostic (1.63e-1)" "prognostic unfavorable (8.31e-4)" "unprognostic (4.83e-3)" "unprognostic (2.80e-3)" "unprognostic (5.98e-2)" "unprognostic (1.45e-1)" "unprognostic (1.95e-2)" "unprognostic (6.65e-2)" 8.6 4.8 3.9 6.0 4.2 20.6 6.8 5.9 4.3 9.3 4.4 6.1 6.1 6.0 4.0 7.9 5.9 4.5 6.8 3.2 6.3 4.7 10.4 8.1 7.2 6.1 5.2 7.4 4.8 4.0 3.5 5.4 6.5 5.3 5.7 4.9 5.8 4.1 13.1 11.5 5.6 5.3 4.9 6.8 5.8 10.7 6.0 7.7 4.9 8.3 8.7 6.7 9.3 6.0 21.6 8.5 14.8 19.5 13.6 9.8 21.1 12.9 8.1 8.5 13.3 16.6 10.4 22.7 29.1 10.8 11.9 21.3 21.0 15.4 13.0 10.9 10.3 43.0 22.2 20.7 7.0 13.3 10.3 9.8 5.8 13.3 11.7 6.0 12.6 18.4 13.1 23.1 8.7 36.4 44.6 7.8 17.6 11.6 10.8 19.7 17.2 18.4 7.2 29.2 12.3 12.4 14.6 17.7 11.1 10.9 26.8 11.7 12.4 14.6 11.4 15.7 17.2 19.6 19.7 33.2 14.3 15.8 11.9 30.0 7.3 8.8 12.2 8.0 10.9 6.3 10.1 8.8 6.6 6.6 8.8 9.4 8.0 8.7 12.2 6.2 7.0 7.5 3.9 4.2 5.9 4.3 3.2 6.3 6.1 5.2 6.5 4.9 6.0 6.0 34.4 16.0 37.5 16.0 37.7 100.1 49.8 30.8 52.3 36.0 17.3 15.0 21.7 12.8 20.0 14.7 60.5 14.6 76.4 25.3 17.6 14.0 199.9 17.0 20.8 33.3 14.4 14.1 33.5 8.9 26.6 27.9 23.9 24.0 50.1 24.0 24.3 25.9 17.9 15.2 36.0 18.5 28.5 32.4 98.8 459.7 20.2 33.9 26.6 28.1 38.2 12.7 42.2 25.1 27.4 10.5 17.3 20.7 37.9 27.7 11.4 10.3 17.1 39.8 13.1 23.6 25.7 13.8 54.9 55.5 126.6 10.7 63.7 20.3 22.4 50.3 RORC "NR1F3, RORG, RZRG, TOR" ENSG00000143365 "RAR related orphan receptor C" P51449 1 151806071-151831845 "Disease related genes, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Receptor" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 86.2;skeletal muscle: 128.0" "Cell type enhanced" "Detected in many" "Distal tubular cells: 35.2;Hepatocytes: 47.8;Proximal enterocytes: 32.9" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in some" "cerebellum: 4.1" "Immune cell enriched" "Detected in many" 6 "MAIT T-cell: 50.3" "Lineage enriched" "Detected in many" 44 "T-cells: 50.3" "Cell line enhanced" "Detected in some" "HDLM-2: 23.8;Karpas-707: 11.5;MOLT-4: 6.3;RPMI-8226: 6.0;SK-BR-3: 5.7;T-47d: 9.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA065620 Supported "Nuclear bodies" NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 59: Non-specific - Translation" "Cluster 44: HDLM-2 - Immune response" "Cluster 30: Mammary glandular cells - Lactation" "Nuclear bodies" "HPA065620: AB_2685521" "unprognostic (6.51e-2)" "unprognostic (7.78e-2)" "prognostic favorable (1.83e-4)" "unprognostic (9.20e-2)" "unprognostic (3.05e-4)" "unprognostic (6.29e-5)" "unprognostic (1.13e-3)" "unprognostic (8.94e-2)" "unprognostic (1.67e-1)" "unprognostic (7.88e-2)" "unprognostic (3.78e-2)" "unprognostic (2.42e-1)" "prognostic favorable (2.94e-5)" "unprognostic (2.13e-1)" "unprognostic (3.22e-1)" "unprognostic (1.82e-2)" "unprognostic (1.80e-2)" 2.9 4.9 0.2 1.8 0.1 0.4 7.5 4.1 0.3 6.5 5.2 9.3 11.6 1.9 4.6 5.4 21.2 3.7 11.6 0.2 0.4 18.8 86.2 12.7 0.9 0.9 1.6 0.3 59.2 33.5 18.3 0.0 0.7 15.8 9.2 0.0 41.0 11.0 128.0 24.7 13.9 0.3 0.8 1.3 19.8 10.7 0.4 52.7 26.4 58.8 2.4 3.0 3.4 0.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.3 0.1 0.0 0.0 0.0 23.8 0.0 0.0 2.5 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 11.5 0.0 0.3 6.3 0.0 0.0 0.0 0.0 0.0 0.1 6.0 0.1 0.0 0.0 0.2 0.1 5.7 0.0 0.0 9.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 3.4 0.0 50.3 0.0 8.0 7.5 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.4 5.8 1.2 0.2 0.1 4.1 0.3 0.2 0.4 0.9 1.6 0.7 0.8 0.4 0.4 0.1 6.4 6.0 0.3 0.8 2.0 4.4 3.1 3.4 0.0 18.4 9.8 5.9 21.5 5.3 16.5 0.0 0.0 1.8 12.0 35.2 8.3 0.4 15.3 2.6 0.7 9.6 5.3 0.1 7.0 0.0 0.3 17.3 18.9 0.0 0.3 1.8 47.8 0.1 0.0 0.0 20.0 16.2 2.7 0.3 0.9 0.6 0.6 3.6 0.0 0.2 0.0 0.0 0.0 0.0 3.2 16.0 0.4 0.3 5.0 32.9 17.1 10.5 0.0 0.0 4.2 0.5 0.2 0.0 5.0 3.0 0.0 6.8 0.1 15.3 3.5 SBDS "CGI-97, FLJ10917, SDS, SWDS" ENSG00000126524 "SBDS ribosome maturation factor" Q9Y3A5 7 66987680-66995587 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Ribosome biogenesis" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Late spermatids: 2042.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028891 Approved Supported Nucleoplasm,Cytosol NA NA 190000 "Cluster 44: Non-specific - Transcription" "Cluster 80: Striated muscle - Unknown function" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 31: Spermatids - Spermatogenesis" "Nucleoplasm, Cytosol" "HPA028891: AB_10601500" "prognostic unfavorable (1.49e-4)" "unprognostic (1.87e-2)" "unprognostic (5.73e-2)" "unprognostic (1.71e-3)" "unprognostic (8.06e-3)" "prognostic unfavorable (3.65e-4)" "unprognostic (1.07e-1)" "unprognostic (2.22e-2)" "unprognostic (1.44e-1)" "unprognostic (6.99e-2)" "unprognostic (7.84e-3)" "unprognostic (4.59e-1)" "unprognostic (1.04e-2)" "unprognostic (9.38e-3)" "unprognostic (1.83e-1)" "unprognostic (2.30e-1)" "unprognostic (5.06e-3)" 139.1 107.5 136.1 57.9 152.1 157.2 113.7 151.2 168.3 97.3 115.8 143.6 127.8 117.2 83.3 128.6 99.2 84.9 238.0 133.1 148.4 117.8 126.8 113.8 43.8 156.2 142.3 90.1 89.3 145.0 87.4 106.2 155.0 107.9 111.6 90.3 80.7 122.6 374.0 92.0 114.2 128.2 152.6 57.3 104.6 60.9 143.4 38.8 107.0 263.3 52.5 113.9 90.7 169.7 168.3 68.9 59.9 54.6 212.7 157.9 67.0 281.4 225.4 206.1 157.1 143.1 83.0 62.2 209.7 253.5 136.3 80.1 101.7 164.3 219.4 59.8 136.4 31.1 125.9 86.6 188.9 78.1 40.8 144.0 215.1 157.0 269.8 105.9 129.2 39.7 227.2 65.0 324.2 100.0 41.8 112.4 67.2 227.3 165.9 31.3 132.6 129.3 218.1 73.6 91.7 63.7 142.3 235.5 194.3 131.0 176.2 64.8 176.4 276.5 96.7 142.5 205.4 40.6 51.4 141.0 95.7 125.5 157.4 75.5 33.2 61.4 64.7 37.7 81.7 62.8 82.7 75.2 33.4 59.9 104.4 85.7 13.0 51.8 35.1 45.4 80.2 62.2 136.1 152.1 151.2 168.3 133.1 148.4 156.2 142.3 155.0 152.6 143.4 169.7 169.9 304.5 128.0 10.7 101.6 464.2 466.2 213.2 145.7 73.7 118.5 154.0 286.6 108.7 160.3 92.0 12.5 130.5 98.0 270.9 262.2 177.4 583.0 93.0 131.2 153.2 101.9 51.3 12.5 165.7 232.1 197.7 96.8 128.2 150.0 29.7 138.5 102.1 107.0 58.9 15.3 221.9 142.4 47.2 238.1 2042.9 127.1 74.8 256.1 11.2 66.5 161.9 30.9 7.5 36.0 300.0 242.2 168.5 117.5 267.2 359.3 264.6 75.6 56.8 164.3 512.9 266.2 86.3 47.9 129.9 430.0 398.5 144.5 132.2 165.4 318.5 SERPING1 "C1-INH, C1IN, C1INH, C1NH, HAE1, HAE2" ENSG00000149131 "Serpin family G member 1" P05155 11 57597387-57619171 "Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Complement pathway, Fibrinolysis, Hemostasis, Immunity, Innate immunity" "Protease inhibitor, Serine protease inhibitor" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 2622.4" "Cell type enhanced" "Detected in many" "Cholangiocytes: 726.4;Ductal cells: 604.0;Fibroblasts: 793.6;Hepatocytes: 2530.0;Leydig cells: 735.3" "Cancer enhanced" "Detected in all" "liver cancer: 609.9" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 65.2;plasmacytoid DC: 60.6" "Group enriched" "Detected in many" 243 "dendritic cells: 60.6;granulocytes: 65.2;monocytes: 25.7" "Group enriched" "Detected in many" 6 "ASC diff: 1372.2;ASC TERT1: 694.9;HSkMC: 1159.0" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "spinal cord: 194.1" "CAB026161, HPA048738" Supported "Secreted to blood" NA NA 28000000000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 85: Liver - Metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 2: Hepatocytes - Metabolism" "CAB026161: , HPA048738: AB_2680505" "unprognostic (1.35e-2)" "unprognostic (2.24e-1)" "prognostic unfavorable (9.96e-4)" "unprognostic (4.26e-2)" "unprognostic (4.38e-2)" "unprognostic (2.32e-1)" "unprognostic (4.12e-3)" "unprognostic (2.13e-1)" "unprognostic (8.95e-2)" "prognostic favorable (8.03e-4)" "unprognostic (5.92e-3)" "unprognostic (3.76e-2)" "prognostic unfavorable (1.55e-4)" "unprognostic (2.60e-2)" "unprognostic (4.14e-2)" "unprognostic (2.56e-1)" "unprognostic (1.17e-1)" 971.5 144.2 27.4 90.0 27.5 10.9 733.0 27.1 36.0 629.4 53.4 358.7 52.0 616.7 163.3 162.0 793.2 533.0 547.1 26.2 34.8 337.3 2622.4 785.0 147.6 67.4 34.7 918.3 267.5 55.2 138.2 198.9 34.2 329.3 97.0 34.5 250.5 258.1 151.8 293.5 283.5 226.8 42.3 240.7 344.8 50.6 37.2 36.1 338.2 173.4 64.4 555.9 519.8 35.1 0.0 0.0 48.2 0.0 1372.2 694.9 7.3 74.2 57.0 16.8 30.7 2.5 0.0 0.0 96.7 42.1 0.0 0.0 0.4 4.7 9.4 0.0 0.1 33.7 0.0 1.7 170.3 0.9 5.4 1159.0 15.5 5.7 0.2 6.0 0.0 0.0 1.0 0.0 1.0 0.0 0.0 1.3 46.6 0.0 0.0 4.3 4.0 0.7 7.4 0.0 0.2 14.4 0.3 0.0 0.9 41.8 0.2 3.3 0.0 0.8 21.2 0.7 0.0 0.2 0.4 0.6 0.2 0.5 0.0 0.0 18.3 0.3 0.0 25.7 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 65.2 0.2 11.5 60.6 0.0 5.7 27.4 27.5 27.1 36.0 26.2 34.8 67.4 34.7 34.2 42.3 37.2 35.1 162.1 118.6 110.8 5.5 8.0 75.8 61.2 7.1 24.5 0.8 24.2 57.7 28.7 726.4 57.5 158.2 0.0 37.1 15.3 0.0 43.0 604.0 4.8 76.0 297.4 150.5 0.0 69.2 3.6 44.0 93.4 793.6 8.6 69.6 7.6 8.3 260.5 2530.0 43.6 0.0 6.2 0.1 2.0 118.9 94.2 25.6 735.3 46.9 90.7 15.9 10.4 57.2 0.0 3.5 0.5 41.4 0.0 228.7 4.5 32.4 0.0 53.5 23.1 4.5 269.5 143.6 259.6 2.5 10.4 9.0 59.5 25.2 16.8 3.4 0.0 37.4 SH2D1A "DSHP, EBVS, IMD5, LYP, MTCP1, SAP, XLP, XLPD" ENSG00000183918 "SH2 domain containing 1A" O60880 X 124227868-124373197 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 48 "lymphoid tissue: 262.5" "Group enriched" "Detected in some" 7 "dendritic cells: 77.6;NK-cells: 138.0;T-cells: 108.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 54 "gdT-cell: 120.2;MAIT T-cell: 162.9;memory CD4 T-cell: 90.4;memory CD8 T-cell: 175.8;naive CD4 T-cell: 91.2;naive CD8 T-cell: 108.3;NK-cell: 162.2;T-reg: 125.3" "Group enriched" "Detected in many" 70 "NK-cells: 162.2;T-cells: 175.8" "Group enriched" "Detected in some" 6 "HDLM-2: 101.1;JURKAT: 193.0;Karpas-707: 201.3;MOLT-4: 257.2" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA072265 Approved Cytosol NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 63: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" Cytosol "HPA072265: " "prognostic favorable (2.03e-4)" "unprognostic (1.18e-3)" "unprognostic (4.35e-3)" "unprognostic (9.66e-5)" "unprognostic (1.60e-1)" "unprognostic (1.86e-3)" "unprognostic (9.25e-3)" "unprognostic (3.34e-2)" "unprognostic (1.88e-2)" "unprognostic (2.80e-3)" "unprognostic (9.33e-2)" "unprognostic (1.05e-1)" "prognostic unfavorable (4.94e-6)" "unprognostic (1.27e-1)" "unprognostic (9.00e-2)" "unprognostic (2.36e-1)" "unprognostic (3.14e-3)" 1.4 1.1 0.0 10.8 0.1 5.4 1.2 0.1 0.2 0.9 0.1 1.6 1.5 0.6 0.6 1.1 0.5 4.1 0.3 0.1 0.1 0.4 2.8 3.2 38.4 0.2 0.1 0.4 0.2 0.2 0.2 0.3 0.1 1.1 1.5 0.0 1.3 0.3 0.3 0.4 2.5 0.6 0.2 14.7 2.7 0.2 0.1 262.5 0.7 1.2 16.6 5.0 0.5 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 15.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 101.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 193.0 0.0 201.3 0.0 0.0 257.2 4.6 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 32.7 33.3 0.0 0.2 0.0 0.0 1.4 0.6 0.1 120.2 0.5 162.9 1.1 90.4 175.8 0.5 0.2 91.2 108.3 2.4 162.2 1.2 0.8 125.3 91.3 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 1.1 3.2 4.7 0.0 3.0 1.5 0.1 0.0 0.0 0.0 0.7 0.8 0.2 1.5 0.0 0.0 0.0 0.1 77.6 0.0 0.0 0.0 0.0 0.5 0.2 0.7 0.0 7.4 0.1 0.0 0.0 2.0 1.1 0.2 3.8 0.0 3.6 0.9 0.1 0.0 0.0 0.0 0.0 5.6 4.4 0.0 0.0 4.3 5.4 0.0 2.3 0.0 138.0 0.5 0.2 0.0 0.0 0.0 14.1 0.2 0.0 0.5 0.0 0.0 0.0 0.7 0.6 0.0 0.0 0.2 1.0 0.1 108.9 0.0 0.0 0.0 SLC35C1 "FLJ11320, FUCT1" ENSG00000181830 "Solute carrier family 35 member C1" Q96A29 11 45804072-45813016 "Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Sugar transport, Transport" "Congenital disorder of glycosylation, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 84.5" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 50.6;Distal enterocytes: 54.6;Pancreatic endocrine cells: 50.6;Paneth cells: 54.0;Proximal enterocytes: 58.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA064001 Enhanced Supported "Golgi apparatus" NA NA "Cluster 44: Non-specific - Transcription" "Cluster 37: Intestine - Unknown function" "Cluster 18: U-2197 - ECM organization" "Cluster 27: Mucus-secreting cells - Mucin production" "Golgi apparatus" "HPA064001: AB_2685171" "unprognostic (2.62e-2)" "unprognostic (5.16e-2)" "unprognostic (7.82e-2)" "unprognostic (1.57e-2)" "prognostic unfavorable (9.68e-4)" "unprognostic (8.22e-2)" "unprognostic (9.40e-2)" "unprognostic (1.56e-2)" "unprognostic (2.83e-2)" "unprognostic (1.28e-1)" "unprognostic (4.09e-2)" "unprognostic (2.73e-1)" "unprognostic (7.68e-2)" "unprognostic (1.83e-3)" "unprognostic (2.18e-1)" "prognostic favorable (3.64e-4)" "unprognostic (2.30e-2)" 28.2 7.3 6.6 10.7 6.3 2.4 19.8 7.0 7.0 9.6 6.1 19.8 24.4 8.8 2.3 41.5 7.3 12.2 9.0 6.2 7.2 7.0 84.5 10.2 6.6 8.2 7.9 6.3 13.4 5.6 10.4 15.0 7.7 9.9 14.3 1.6 26.1 5.9 6.8 5.1 24.1 9.9 6.5 8.4 18.5 5.2 8.8 4.5 6.6 6.9 10.0 13.8 14.9 6.3 10.3 25.8 6.3 16.3 19.9 19.8 19.5 22.1 20.1 13.3 14.4 10.7 15.2 10.4 9.9 27.3 19.4 26.0 13.4 13.6 6.5 24.8 14.5 5.9 20.4 20.6 42.6 11.4 16.2 23.8 16.3 9.2 11.1 16.2 17.6 10.3 13.3 13.8 14.4 21.8 5.9 9.0 27.5 39.9 34.6 7.2 10.5 21.5 15.1 25.4 6.0 8.6 16.6 16.3 9.5 6.6 13.7 6.0 25.7 25.0 14.7 46.1 15.6 9.8 26.9 4.9 18.5 14.4 14.2 9.7 11.6 12.5 11.0 11.9 12.3 5.0 18.0 14.7 9.6 3.7 9.3 8.0 1.8 5.6 8.7 8.2 13.0 10.1 6.6 6.3 7.0 7.0 6.2 7.2 8.2 7.9 7.7 6.5 8.8 6.3 5.5 0.0 11.2 2.6 6.2 3.6 8.9 12.7 3.4 1.9 11.1 3.0 50.6 22.8 26.7 5.5 2.1 13.8 6.4 54.6 0.0 18.4 4.9 7.3 6.7 10.6 9.6 3.6 2.0 41.9 14.0 10.5 23.4 11.4 2.5 5.2 6.8 42.2 14.7 3.3 2.1 40.6 4.1 9.3 4.8 6.0 6.5 6.3 1.8 2.8 9.5 2.8 7.2 1.0 2.1 50.6 54.0 5.7 13.6 11.8 58.0 4.7 11.4 1.1 0.0 3.6 9.7 4.0 4.3 12.7 2.4 15.3 6.5 5.7 26.4 20.1 SMARCD2 "BAF60B, CRACD2, PRO2451, Rsc6p" ENSG00000108604 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2" Q92925 17 63832081-63843065 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Theca cells: 101.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA059934, HPA061348" Enhanced Nucleoplasm NA NA "Cluster 12: Non-specific - Basic cellular processes" "Cluster 24: Salivary gland - Salivary secretion" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 40: Granulosa cells - Unknown function" Nucleoplasm "HPA059934: AB_2684170, HPA061348: AB_2684486" "unprognostic (1.70e-1)" "unprognostic (2.17e-2)" "unprognostic (8.04e-2)" "unprognostic (3.84e-2)" "unprognostic (1.59e-1)" "unprognostic (2.00e-2)" "unprognostic (7.84e-2)" "unprognostic (4.79e-1)" "prognostic unfavorable (3.51e-4)" "unprognostic (4.75e-1)" "unprognostic (1.26e-1)" "unprognostic (1.93e-1)" "prognostic unfavorable (9.94e-4)" "unprognostic (1.81e-2)" "unprognostic (1.26e-1)" "unprognostic (1.79e-3)" "unprognostic (6.80e-2)" 53.8 55.2 23.3 44.6 28.1 71.6 65.9 35.5 28.5 48.0 29.1 49.9 51.1 37.4 58.5 71.3 52.9 33.1 31.2 22.9 23.2 26.4 54.9 46.7 66.0 27.7 26.7 38.3 89.5 42.8 36.7 47.8 27.0 52.7 46.6 17.6 78.0 49.0 25.3 97.0 49.8 32.4 25.5 60.6 68.2 42.7 25.6 70.2 33.8 34.2 70.1 52.3 55.9 31.7 142.9 87.9 21.3 93.0 133.6 196.1 139.7 52.5 64.1 97.5 61.7 101.7 76.8 163.0 32.5 79.0 43.9 99.4 65.7 99.1 57.3 61.1 169.5 109.3 40.3 141.7 102.3 159.5 128.9 154.3 122.0 55.3 42.1 56.4 78.3 110.8 89.5 101.7 57.2 279.1 203.8 132.3 51.3 202.0 96.9 195.0 77.8 185.0 66.9 96.0 80.2 145.9 79.2 228.4 97.1 69.3 212.2 121.7 58.4 67.7 52.5 61.4 90.7 119.8 113.2 113.5 54.1 129.6 50.4 4.2 9.1 8.8 9.4 8.4 5.6 7.2 9.9 9.8 12.1 9.5 6.3 8.5 10.8 8.0 10.0 10.1 11.5 6.0 23.3 28.1 35.5 28.5 22.9 23.2 27.7 26.7 27.0 25.5 25.6 31.7 14.8 28.9 42.4 19.9 18.2 22.9 23.6 14.3 26.2 9.7 47.1 41.0 5.9 30.0 25.2 16.5 6.2 54.9 21.1 36.0 3.9 16.9 1.0 17.6 25.3 17.4 33.0 12.6 7.2 19.6 38.2 25.8 18.8 20.7 14.0 88.1 25.7 83.3 22.0 11.8 5.8 42.0 12.2 36.9 19.6 5.4 49.4 23.1 14.2 8.4 31.9 16.9 15.5 6.6 10.7 21.0 26.2 30.9 12.6 19.0 30.0 11.6 23.8 12.4 32.9 21.9 14.6 12.3 22.4 29.7 31.1 52.9 16.7 101.7 40.8 24.1 STAT1 "ISGF-3, STAT91" ENSG00000115415 "Signal transducer and activator of transcription 1" P42224 2 190908460-191020960 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Antiviral defense, Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "BJ hTERT+ SV40 Large T+: 533.6;BJ hTERT+ SV40 Large T+ RasG12V: 595.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000931, HPA000982, CAB004049" Approved Enhanced Nucleoplasm,Cytosol NA NA 92000 "Cluster 31: Non-specific - Inflammatory response" "Cluster 16: Immune cells - Immune response" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 58: T-cells - T-cell receptor" Nucleoplasm Cytosol "CAB004049: AB_2197984, HPA000931: AB_1080100, HPA000982: AB_1080099" "unprognostic (6.90e-2)" "unprognostic (6.47e-2)" "unprognostic (4.27e-2)" "unprognostic (2.47e-2)" "unprognostic (2.51e-1)" "unprognostic (2.91e-2)" "unprognostic (8.50e-2)" "unprognostic (1.02e-2)" "unprognostic (1.35e-1)" "prognostic favorable (1.75e-4)" "prognostic unfavorable (4.23e-4)" "unprognostic (1.35e-1)" "prognostic unfavorable (1.22e-5)" "unprognostic (2.43e-1)" "unprognostic (4.17e-2)" "unprognostic (3.35e-3)" "unprognostic (3.93e-2)" 41.2 35.6 8.0 113.3 7.7 35.1 27.1 5.1 10.2 33.9 5.6 43.4 51.3 27.5 15.1 35.8 25.1 66.6 35.6 11.1 14.7 45.3 66.0 69.1 145.6 18.8 9.4 33.0 40.7 39.0 23.8 28.9 13.4 34.8 40.6 20.0 107.4 24.2 29.8 24.9 41.8 47.5 27.3 114.5 55.7 31.2 17.4 104.3 33.4 29.7 59.0 62.2 25.1 13.2 54.8 58.6 26.8 41.4 105.7 158.8 79.3 82.4 257.1 533.6 595.5 95.1 62.8 21.7 48.1 180.8 173.9 45.9 29.8 62.0 108.6 179.6 24.6 99.0 43.8 47.3 72.2 48.4 58.3 94.7 36.8 100.4 31.0 56.5 63.5 38.4 56.8 103.9 93.6 42.5 38.0 41.1 36.6 34.2 95.3 31.4 71.4 27.9 58.9 70.1 37.9 35.0 100.3 35.7 236.5 37.5 38.6 59.9 56.2 105.1 57.5 90.0 51.4 202.1 330.7 21.0 80.8 40.3 47.8 50.0 143.9 104.9 51.6 191.1 71.4 38.3 129.3 77.4 61.4 31.7 128.2 94.2 203.9 77.3 117.3 28.9 227.8 210.2 8.0 7.7 5.1 10.2 11.1 14.7 18.8 9.4 13.4 27.3 17.4 13.2 46.8 73.7 34.3 14.0 48.8 22.2 17.5 32.3 22.2 13.3 27.6 26.0 44.6 51.5 40.3 53.3 25.0 13.6 48.0 44.4 7.9 47.5 18.5 30.9 43.9 42.1 21.0 15.5 9.0 37.8 53.9 44.1 51.5 39.3 51.4 38.5 28.5 54.1 92.6 3.3 12.2 26.7 16.2 72.0 26.2 5.2 21.8 96.9 17.8 31.9 107.3 13.7 62.8 25.1 11.9 36.0 21.7 29.7 69.4 26.7 24.7 44.0 47.7 19.3 39.5 35.4 31.1 25.4 24.6 28.8 31.3 8.3 78.1 37.9 29.2 26.9 STAT3 APRF ENSG00000168610 "Signal transducer and activator of transcription 3" P40763 17 42313324-42388540 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Diabetes mellitus, Disease variant, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001671, CAB003859, HPA058603, CAB068241, CAB068242" Supported Supported Nucleoplasm,Cytosol NA NA 55000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 55: Non-specific - Mitochondria & Proteasome" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 46: Photoreceptor cells - Phototransduction" "Nucleoplasm, Cytosol" "CAB003859: AB_347629, CAB068241: AB_2665663, CAB068242: AB_2665662, HPA001671: AB_1080102, HPA058603: AB_2683772" "unprognostic (1.83e-2)" "unprognostic (2.42e-1)" "unprognostic (9.23e-3)" "unprognostic (2.91e-1)" "unprognostic (5.59e-3)" "unprognostic (1.78e-2)" "unprognostic (8.26e-2)" "unprognostic (1.51e-1)" "unprognostic (1.32e-1)" "unprognostic (1.77e-1)" "unprognostic (2.21e-1)" "unprognostic (1.26e-1)" "unprognostic (6.47e-3)" "unprognostic (7.75e-3)" "unprognostic (2.21e-2)" "unprognostic (7.63e-2)" "unprognostic (1.61e-1)" 105.6 68.1 32.4 78.5 34.5 63.2 84.4 38.7 30.2 62.6 32.4 76.9 45.9 71.6 28.2 81.6 74.0 71.7 101.2 28.6 44.6 77.2 143.1 106.0 55.3 48.4 40.7 65.4 67.3 35.3 53.3 55.6 43.4 62.9 46.5 29.9 63.5 48.2 123.9 66.8 68.1 72.1 43.9 68.0 62.3 24.6 43.0 50.5 61.9 92.1 65.2 88.6 64.3 43.1 61.5 116.0 47.4 48.2 103.7 97.6 35.4 66.5 89.7 59.6 58.3 30.3 55.8 18.5 68.2 71.2 90.3 89.2 45.8 72.6 47.7 160.6 31.4 131.2 60.4 62.4 77.3 31.8 79.0 152.1 69.8 47.4 68.9 62.2 81.1 33.4 80.1 56.4 40.1 43.8 118.7 31.3 28.5 63.4 0.0 26.6 133.8 28.1 91.3 77.2 45.2 29.8 81.4 184.9 29.2 57.2 100.5 49.1 68.7 88.9 44.9 54.8 56.5 82.9 75.3 16.4 56.1 32.8 41.6 121.1 78.4 100.0 79.5 79.9 64.4 40.2 57.5 62.6 54.3 36.6 58.7 56.5 262.6 58.3 80.8 29.3 47.9 124.5 32.4 34.5 38.7 30.2 28.6 44.6 48.4 40.7 43.4 43.9 43.0 43.1 216.0 93.0 173.7 46.0 111.6 129.5 105.3 76.8 138.3 92.6 147.1 113.0 59.7 54.3 103.2 134.3 281.5 25.2 115.1 148.9 17.6 83.2 33.5 129.3 187.0 164.7 124.0 54.3 24.2 96.8 38.2 154.0 109.1 153.9 142.0 86.3 115.3 115.7 69.1 25.2 35.8 97.8 69.2 71.0 121.7 13.7 71.7 111.7 72.9 51.5 94.1 131.3 78.2 30.7 41.7 82.9 94.5 60.9 104.6 147.9 206.4 46.3 88.5 406.7 65.7 189.5 169.7 31.5 15.3 93.4 160.1 31.2 170.2 102.3 117.5 90.6 STAT5B ENSG00000173757 "Signal transducer and activator of transcription 5B" P51692 17 42199177-42276707 "Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease variant, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Early spermatids: 100.5;Late spermatids: 188.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 121.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004298, CAB005418, HPA042128, HPA049883, HPA051156" Approved Approved Cytosol NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 59: Non-specific - Translation" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 31: Spermatids - Spermatogenesis" Cytosol "CAB004298: AB_2197067, CAB005418: AB_632445, HPA042128: AB_2677864, HPA049883: AB_2680931, HPA051156: AB_2681366" "unprognostic (1.49e-1)" "unprognostic (3.60e-2)" "unprognostic (4.06e-2)" "prognostic favorable (9.37e-4)" "unprognostic (2.68e-1)" "unprognostic (4.29e-1)" "unprognostic (2.23e-1)" "unprognostic (1.03e-1)" "unprognostic (3.06e-2)" "unprognostic (7.98e-2)" "prognostic favorable (1.63e-4)" "unprognostic (1.36e-1)" "prognostic favorable (2.39e-5)" "unprognostic (9.19e-2)" "unprognostic (2.95e-1)" "unprognostic (1.54e-1)" "unprognostic (2.13e-1)" 45.9 45.7 26.4 35.1 26.5 42.4 36.7 33.4 29.0 43.6 24.6 45.3 14.8 59.1 19.3 19.2 50.8 23.6 24.5 23.5 42.9 24.3 24.4 32.5 43.6 32.8 33.9 55.9 22.8 21.1 40.8 31.5 32.9 29.2 17.0 18.7 22.8 34.2 73.3 25.3 30.7 42.7 27.4 42.3 27.6 23.5 49.9 37.6 22.7 46.5 34.7 43.4 31.5 26.1 15.0 22.9 33.3 9.0 40.6 20.4 15.9 15.0 26.5 21.0 18.2 10.1 12.3 48.1 21.8 17.2 41.3 18.7 19.9 13.0 16.6 121.8 23.0 47.1 44.5 15.6 22.3 20.9 72.7 25.1 19.6 15.9 19.9 18.0 33.6 31.9 86.5 10.1 8.8 14.6 99.2 54.9 8.3 34.3 0.2 42.0 20.9 16.8 13.3 23.5 24.5 14.4 27.3 34.4 21.2 7.4 24.3 24.3 26.0 29.2 10.2 15.2 21.2 19.8 9.8 23.9 11.6 21.7 15.5 11.5 3.3 5.9 6.6 3.0 7.1 2.9 9.3 7.6 2.9 2.9 6.5 5.5 22.5 4.2 3.7 2.1 8.4 4.7 26.4 26.5 33.4 29.0 23.5 42.9 32.8 33.9 32.9 27.4 49.9 26.1 30.2 6.4 19.5 41.8 12.9 8.9 5.7 4.5 2.8 21.2 25.1 22.7 20.7 5.7 7.8 3.7 20.9 8.0 31.2 8.4 5.9 8.2 100.5 10.1 22.4 26.0 10.2 12.4 23.7 11.8 6.1 18.8 13.3 15.0 16.4 16.1 20.0 11.2 9.4 10.1 61.2 6.1 8.2 13.3 17.1 188.5 47.2 16.9 10.6 51.5 23.7 9.5 26.8 69.4 60.8 12.2 6.2 74.4 13.6 11.9 7.9 9.8 6.3 13.3 39.5 20.0 23.0 4.3 7.3 5.9 9.8 12.7 34.4 15.5 7.5 7.7 STIM1 "D11S4896E, GOK" ENSG00000167323 "Stromal interaction molecule 1" Q13586 11 3854527-4093210 "Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Oligodendrocyte precursor cells: 77.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011088, HPA012123, CAB037128, CAB037288" Enhanced Enhanced "Endoplasmic reticulum" NA NA 1900000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 59: Non-specific - Translation" "Cluster 30: Epithelial cell lines - Translation" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Endoplasmic reticulum" "CAB037128: AB_1079007, CAB037288: AB_1079008, HPA011088: AB_1849884, HPA012123: AB_1849882" "unprognostic (2.06e-1)" "unprognostic (9.75e-2)" "unprognostic (1.34e-1)" "unprognostic (3.85e-3)" "unprognostic (3.13e-2)" "unprognostic (4.12e-1)" "unprognostic (3.43e-1)" "unprognostic (1.59e-1)" "unprognostic (2.25e-1)" "unprognostic (7.41e-2)" "unprognostic (1.86e-1)" "unprognostic (2.88e-2)" "unprognostic (9.35e-2)" "unprognostic (1.40e-1)" "unprognostic (2.73e-1)" "unprognostic (3.48e-2)" "unprognostic (1.39e-2)" 40.6 18.4 32.9 22.3 31.5 46.4 33.1 18.1 34.5 40.4 30.5 33.7 18.1 39.3 18.2 65.6 39.0 25.1 24.0 30.5 23.1 20.0 38.0 26.8 29.8 17.4 22.9 41.2 30.1 43.7 18.0 17.5 18.9 26.0 24.6 11.4 61.1 24.3 111.9 47.1 31.3 34.3 18.6 31.5 32.2 25.4 26.9 68.6 40.9 49.7 29.7 32.2 40.4 22.4 42.4 48.5 14.1 23.5 60.9 55.4 22.2 31.1 31.0 22.6 28.5 24.3 13.8 44.7 35.4 46.2 50.9 74.3 20.1 21.5 19.3 36.7 30.5 70.1 19.2 36.0 53.0 58.9 40.1 56.8 53.2 32.0 90.7 28.2 31.7 59.6 44.2 80.1 24.7 9.8 55.8 20.7 5.4 23.3 18.1 13.8 22.1 41.7 38.2 23.7 3.4 14.2 51.2 33.5 19.2 22.5 12.7 32.4 34.0 40.2 13.8 42.2 25.1 88.0 71.9 22.5 33.4 24.0 26.0 16.6 11.2 20.0 17.8 14.8 14.5 7.9 13.1 19.5 9.6 11.4 14.8 13.3 16.7 20.8 25.5 8.3 14.7 17.1 32.9 31.5 18.1 34.5 30.5 23.1 17.4 22.9 18.9 18.6 26.9 22.4 20.1 16.0 8.2 53.8 22.2 16.4 7.4 9.5 17.6 5.3 16.5 13.2 4.6 18.6 10.5 5.5 14.6 27.3 35.2 27.9 1.9 12.4 4.9 17.5 35.5 12.6 9.1 18.1 63.5 14.5 13.5 20.2 10.7 24.0 29.8 4.7 20.3 32.6 15.7 16.8 56.3 13.0 12.2 22.2 15.2 9.2 27.4 18.7 17.8 57.1 11.0 16.5 36.0 77.4 5.1 12.3 6.7 11.3 14.8 11.2 7.9 3.6 14.2 3.9 26.3 17.1 18.4 21.4 13.5 50.6 22.3 17.4 28.5 1.6 11.8 11.9 STX11 ENSG00000135604 "Syntaxin 11" O75558 6 144150517-144191939 "Disease related genes, Human disease related genes, Predicted intracellular proteins" "Protein transport, Transport" "Familial hemophagocytic lymphohistiocytosis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 25.1;bone marrow: 56.5" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 85.0;granulocytes: 90.3;Langerhans cells: 271.6;Macrophages: 158.0;monocytes: 85.5;Suprabasal keratinocytes: 154.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Group enriched" "Detected in all" 7 "basophil: 22.6;classical monocyte: 68.4;eosinophil: 43.5;intermediate monocyte: 81.1;myeloid DC: 25.4;neutrophil: 81.7;non-classical monocyte: 87.0" "Group enriched" "Detected in all" 8 "dendritic cells: 25.4;granulocytes: 81.7;monocytes: 87.0" "Cell line enhanced" "Detected in some" "HDLM-2: 17.2;Karpas-707: 10.1;RH-30: 6.9;TIME: 8.3;U-266/70: 11.6" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA007992 Approved NA NA 1100000 "Cluster 7: Monocytes - Unknown function" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 44: HDLM-2 - Immune response" "Cluster 41: Macrophages - Immune response" "HPA007992: AB_1857620" "unprognostic (1.30e-3)" "unprognostic (1.19e-1)" "unprognostic (1.68e-1)" "unprognostic (2.62e-2)" "unprognostic (3.73e-2)" "unprognostic (8.96e-2)" "unprognostic (3.04e-2)" "unprognostic (1.74e-1)" "unprognostic (2.85e-1)" "unprognostic (1.03e-2)" "unprognostic (8.65e-2)" "unprognostic (1.36e-1)" "unprognostic (4.47e-3)" "unprognostic (7.07e-2)" "unprognostic (3.91e-2)" "unprognostic (8.50e-3)" "unprognostic (1.07e-1)" 25.1 4.4 0.6 5.8 0.6 56.5 14.5 0.6 1.1 1.9 0.7 2.8 1.0 1.4 0.3 5.1 2.6 2.1 7.3 0.7 0.8 3.6 3.1 21.3 5.5 1.0 0.7 0.9 1.1 0.6 2.1 2.4 0.9 1.3 0.9 0.2 2.1 0.3 2.5 8.2 3.3 1.9 0.8 14.1 2.0 1.1 0.9 1.8 7.5 0.9 3.5 4.0 3.2 1.1 0.4 0.1 0.1 3.9 0.2 0.3 0.6 0.4 0.3 0.4 0.7 0.1 0.4 0.1 0.4 0.6 0.7 0.6 0.0 0.1 0.2 17.2 0.6 3.0 0.6 0.1 1.0 0.9 0.5 0.0 0.0 0.2 0.1 0.2 4.3 0.8 0.1 10.1 0.5 0.2 0.4 0.9 0.0 0.0 0.3 0.1 6.9 0.6 0.0 1.9 0.2 0.1 1.2 0.1 1.7 0.3 0.1 3.8 8.3 0.2 1.0 0.4 0.3 11.6 4.6 0.1 0.2 2.1 0.4 22.6 68.4 43.5 6.0 81.1 3.8 1.4 2.7 5.1 25.4 2.4 1.0 3.0 81.7 3.2 87.0 2.7 8.3 43.9 0.6 0.6 0.6 1.1 0.7 0.8 1.0 0.7 0.9 0.8 0.9 1.1 41.9 54.5 10.7 0.0 16.6 85.0 11.3 6.3 3.4 0.0 11.1 4.6 4.5 4.3 6.6 1.8 0.0 0.9 38.1 0.1 0.0 6.4 0.4 3.7 0.7 23.7 3.5 6.1 0.1 2.6 5.7 11.2 0.5 5.0 90.3 0.2 8.2 1.4 30.1 0.0 0.1 0.4 2.0 73.7 271.6 1.2 0.6 158.0 44.4 2.8 85.5 0.0 21.6 0.0 0.1 6.1 3.3 0.0 63.1 14.4 0.0 0.1 10.7 0.1 0.0 46.6 9.7 3.0 3.8 11.2 154.6 28.0 36.6 3.2 0.6 33.3 TAP1 "ABCB2, D6S114E, PSF1, RING4" ENSG00000168394 "Transporter 1, ATP binding cassette subfamily B member" Q03518 6 32845209-32853816 "Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Adaptive immunity, Host-virus interaction, Immunity, Peptide transport, Protein transport, Transport" Translocase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 126.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009516, HPA072354" Approved Approved "Endoplasmic reticulum,Centriolar satellite" NA NA "Cluster 5: Granulocytes - Unknown function" "Cluster 64: Macrophages - Immune response" "Cluster 28: BEWO - Transcription regulation" "Cluster 63: NK-cells & T-cells - Immune response" "Endoplasmic reticulum, Centriolar satellite" "CAB009516: AB_2303048, HPA072354: AB_2686513" "unprognostic (3.59e-2)" "unprognostic (1.06e-1)" "prognostic favorable (9.01e-4)" "unprognostic (1.33e-1)" "unprognostic (1.84e-1)" "unprognostic (3.22e-2)" "unprognostic (4.92e-2)" "unprognostic (6.16e-3)" "unprognostic (2.56e-2)" "prognostic favorable (4.07e-4)" "unprognostic (3.02e-3)" "unprognostic (2.37e-1)" "prognostic unfavorable (6.58e-5)" "unprognostic (2.07e-2)" "unprognostic (4.69e-2)" "unprognostic (2.42e-2)" "unprognostic (2.21e-2)" 28.4 24.9 16.1 50.1 16.2 13.7 20.7 15.8 20.3 21.6 16.2 30.3 36.0 20.5 2.5 31.6 17.8 12.7 25.4 14.7 16.2 21.8 19.3 52.7 50.0 24.0 16.1 12.1 14.5 7.0 11.6 12.1 21.2 21.9 12.5 1.7 25.9 7.0 16.3 51.2 42.6 11.5 18.6 73.0 33.4 11.5 19.4 25.5 17.0 7.4 21.3 23.9 24.4 17.4 22.9 13.7 0.1 16.1 8.8 11.4 126.2 8.1 34.3 59.3 86.5 2.0 27.3 41.8 25.0 12.6 48.9 45.8 4.5 20.6 5.3 81.0 6.1 26.5 4.1 10.8 42.3 0.1 17.5 15.0 17.9 17.1 10.4 8.6 15.4 8.4 1.9 55.0 10.6 10.5 17.7 27.4 0.8 3.1 11.1 47.6 5.2 32.8 25.0 10.5 0.2 1.2 6.7 38.0 33.4 1.7 30.9 37.4 9.7 21.5 8.1 53.1 11.4 59.9 82.6 12.6 16.6 16.6 16.4 176.8 99.5 270.1 155.8 101.6 133.8 137.3 125.2 153.7 95.0 107.5 120.9 124.6 295.6 132.9 94.6 94.8 213.8 221.2 16.1 16.2 15.8 20.3 14.7 16.2 24.0 16.1 21.2 18.6 19.4 17.4 72.1 25.6 24.0 9.1 62.1 74.7 47.1 54.5 27.3 4.8 21.5 15.9 7.3 24.3 33.1 5.5 0.0 5.6 108.0 78.8 5.9 81.6 0.5 31.3 39.3 63.6 16.8 12.6 1.1 75.3 95.0 26.9 42.8 77.9 26.6 13.8 27.1 11.1 45.9 15.2 1.9 55.9 57.0 31.9 90.6 0.3 13.1 43.9 23.2 16.9 115.9 25.1 149.3 12.1 3.6 91.3 38.8 10.5 84.8 70.2 84.6 6.9 29.4 2.8 6.6 18.1 27.8 1.0 1.3 20.4 76.4 4.8 92.3 18.2 54.5 52.1 TAP2 "ABCB3, D6S217E, PSF2, RING11" ENSG00000204267 "Transporter 2, ATP binding cassette subfamily B member" Q03519 6 32821833-32838770 "Disease related genes, Human disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Adaptive immunity, Host-virus interaction, Immunity, Peptide transport, Protein transport, Transport" Translocase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "monocytes: 69.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HBEC3-KT: 61.4;U-251 MG: 52.0" HPA001312 Approved Supported "Nuclear speckles,Endoplasmic reticulum" NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 64: Macrophages - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" "Endoplasmic reticulum" "Nuclear speckles" "HPA001312: AB_1080206" "unprognostic (2.95e-3)" "unprognostic (2.35e-1)" "unprognostic (3.77e-2)" "unprognostic (1.12e-1)" "unprognostic (1.39e-1)" "unprognostic (3.46e-1)" "unprognostic (8.04e-2)" "unprognostic (1.28e-2)" "unprognostic (1.68e-1)" "unprognostic (1.51e-2)" "prognostic unfavorable (1.51e-4)" "unprognostic (1.90e-1)" "prognostic unfavorable (5.22e-8)" "unprognostic (5.32e-1)" "unprognostic (4.17e-2)" "unprognostic (2.35e-1)" "unprognostic (4.71e-2)" 17.1 11.7 1.0 4.3 1.0 8.8 14.7 0.8 1.2 16.3 0.5 14.6 10.2 13.7 1.1 26.0 11.9 1.1 14.4 1.2 2.0 12.4 11.5 25.7 7.9 1.6 1.1 9.2 9.0 3.7 8.2 3.1 1.5 9.9 5.5 2.5 11.2 2.1 8.6 14.5 25.2 4.1 0.8 29.8 11.4 2.5 1.8 9.7 12.3 5.8 8.1 10.6 17.2 1.7 4.4 2.0 0.5 5.0 6.1 6.5 0.0 2.3 3.3 13.1 17.7 3.9 41.0 36.5 7.5 9.1 37.1 38.8 15.8 61.4 6.9 43.8 1.9 20.3 11.6 1.3 8.5 0.0 29.5 0.6 2.6 10.3 24.8 0.0 12.1 0.0 20.0 12.2 0.4 1.6 5.8 2.4 0.5 0.0 11.7 25.8 0.0 12.8 10.9 1.1 0.0 0.0 16.0 37.3 4.1 1.0 7.4 1.9 5.7 25.7 6.9 3.9 52.0 17.9 31.4 33.3 19.5 25.7 10.9 1.8 1.3 1.6 3.0 3.2 1.7 0.4 0.8 1.7 0.8 0.3 0.6 0.7 3.8 1.9 2.8 1.3 1.2 0.8 1.0 1.0 0.8 1.2 1.2 2.0 1.6 1.1 1.5 0.8 1.8 1.7 48.2 0.0 7.5 7.5 20.7 0.0 15.6 0.0 3.4 5.0 9.2 8.0 3.5 4.3 3.7 14.7 2.1 1.9 37.9 21.0 1.9 34.1 0.1 18.0 19.4 32.0 3.6 4.0 6.6 33.4 45.8 8.0 10.7 41.9 5.1 8.7 16.4 8.3 23.9 18.5 14.6 14.9 0.0 18.9 0.0 0.0 5.6 20.3 0.0 14.0 69.3 17.7 47.4 10.6 6.5 35.1 12.6 6.0 18.0 29.7 55.9 4.8 1.5 5.8 0.0 8.6 10.3 0.7 2.5 11.1 0.0 1.6 24.0 20.3 14.3 16.7 TAPBP TAPA ENSG00000231925 "TAP binding protein" O15533 6 33299694-33314387 "Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 168.7;Karpas-707: 140.8;U-266/70: 140.5" "Low region specificity" "Detected in all" HPA007066 Approved NA NA 20000 "Cluster 49: Eosinophils - Unknown function" "Cluster 18: Non-specific - Mitochondria" "Cluster 2: Karpas-707 - Immune response" "Cluster 1: Pancreatic cells - Digestion" "HPA007066: AB_1857769" "prognostic favorable (2.76e-4)" "unprognostic (1.43e-2)" "unprognostic (7.01e-2)" "unprognostic (1.98e-2)" "unprognostic (1.59e-3)" "unprognostic (2.03e-1)" "unprognostic (1.37e-1)" "unprognostic (8.21e-2)" "prognostic favorable (6.29e-4)" "unprognostic (1.67e-2)" "unprognostic (2.37e-1)" "unprognostic (3.63e-1)" "unprognostic (1.61e-2)" "unprognostic (3.82e-1)" "unprognostic (1.19e-2)" "unprognostic (1.21e-1)" "unprognostic (6.54e-3)" 47.3 73.1 2.4 28.5 4.8 25.0 43.1 1.9 2.8 40.1 1.2 66.7 52.3 38.2 13.3 57.3 43.8 10.5 63.7 2.9 1.8 67.4 107.5 82.1 21.2 2.7 3.2 33.3 48.2 14.9 38.8 18.7 2.0 64.3 19.6 4.1 61.9 17.2 26.7 54.0 81.9 23.1 1.9 129.0 52.1 16.2 2.0 24.4 59.1 6.5 36.7 45.0 43.4 2.4 3.3 1.2 6.3 26.1 20.3 25.6 92.9 18.5 88.1 42.5 57.1 0.1 168.7 48.1 38.1 41.3 92.2 2.9 0.3 30.3 15.8 125.5 4.1 19.1 9.9 24.8 0.2 20.4 63.0 51.7 20.6 0.8 8.2 37.8 0.4 16.0 1.5 140.8 14.7 19.6 51.9 44.1 0.5 0.0 6.3 2.8 0.4 1.3 35.5 1.2 8.6 0.6 0.6 2.4 23.7 3.7 1.4 0.9 45.5 89.4 18.6 1.3 2.0 140.5 117.4 46.2 58.6 38.8 58.8 159.7 87.9 172.1 137.3 121.6 117.0 97.1 99.7 114.3 90.0 86.0 76.2 109.9 151.3 159.6 139.0 102.9 85.9 150.5 2.4 4.8 1.9 2.8 2.9 1.8 2.7 3.2 2.0 1.9 2.0 2.4 116.8 125.0 102.1 22.5 186.6 77.0 93.3 148.2 66.6 34.7 82.0 64.1 73.9 84.4 105.8 71.7 33.3 46.9 223.7 259.6 13.7 256.4 1.9 64.0 52.4 99.1 84.6 58.0 25.9 282.9 85.9 63.9 105.5 78.4 91.9 65.9 75.0 143.7 119.7 20.2 15.0 174.6 83.4 124.3 128.0 9.2 33.2 131.9 119.2 30.9 229.3 34.7 195.7 23.6 8.7 215.5 172.4 32.0 194.9 130.4 283.2 33.1 113.3 30.4 32.9 39.3 57.6 1.2 0.6 53.6 56.3 49.1 163.7 66.4 162.3 141.0 TBX1 "CATCH22, VCF" ENSG00000184058 "T-box transcription factor 1" O43435 22 19756703-19783593 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 61.5;tongue: 36.5" "Cell type enriched" "Detected in many" 4 "Late spermatids: 181.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HEK 293: 24.6;K-562: 121.6;NB-4: 28.6;TIME: 40.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA029330 Approved "Nuclear bodies,Cytoplasmic bodies" NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 33: Striated muscle - Muscle contraction" "Cluster 1: K-562 - Erythropoiesis" "Cluster 25: Spermatids - Spermatogenesis" "Nuclear bodies, Cytoplasmic bodies" "HPA029330: AB_2673002" "unprognostic (2.54e-1)" "unprognostic (4.28e-3)" "unprognostic (7.53e-3)" "unprognostic (1.59e-1)" "unprognostic (4.03e-2)" "unprognostic (2.63e-3)" "unprognostic (1.16e-1)" "unprognostic (2.53e-1)" "unprognostic (5.48e-2)" "unprognostic (1.18e-1)" "unprognostic (4.42e-2)" "unprognostic (2.25e-2)" "unprognostic (8.30e-3)" "unprognostic (9.14e-2)" "unprognostic (4.44e-1)" "unprognostic (8.31e-2)" "prognostic favorable (8.90e-4)" 4.0 0.6 0.5 1.0 0.7 0.1 8.0 0.6 0.8 7.4 0.8 1.8 0.7 2.6 0.2 3.0 7.7 0.4 0.8 0.2 0.2 0.4 0.4 4.3 2.9 0.6 0.2 2.2 0.3 7.6 0.7 0.1 0.5 5.2 0.3 0.0 8.1 0.5 61.5 10.6 3.0 0.6 0.0 0.6 1.2 16.8 0.9 0.0 11.2 36.5 1.2 2.7 7.1 1.0 15.3 1.4 0.2 10.7 0.0 0.0 2.1 0.2 0.0 0.0 0.0 1.1 0.1 0.3 0.3 0.3 1.5 0.8 12.0 10.4 0.0 0.6 24.6 0.2 2.9 0.0 0.0 0.1 0.1 0.1 0.1 2.4 0.0 0.0 0.0 0.5 121.6 0.0 7.7 2.8 0.3 28.6 1.7 0.0 16.8 0.3 10.6 0.1 0.0 0.0 1.5 0.4 0.0 0.2 0.0 3.1 5.1 7.7 40.0 0.1 0.4 0.2 0.2 0.3 0.5 0.1 0.0 0.2 0.0 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.7 0.6 0.8 0.2 0.2 0.6 0.2 0.5 0.0 0.9 1.0 11.4 0.0 2.8 0.0 0.3 2.4 1.6 3.3 0.0 0.6 1.1 0.9 2.4 0.0 1.6 0.0 0.0 0.2 0.6 0.1 0.0 0.0 43.3 0.2 0.1 7.5 0.0 0.0 0.3 0.2 1.7 1.5 0.0 0.2 2.5 0.1 2.5 0.0 2.0 0.0 0.9 1.0 6.1 1.3 3.6 181.9 2.5 1.0 0.0 0.0 0.1 0.3 2.1 0.0 0.0 0.1 0.0 2.2 0.0 1.0 0.1 0.0 2.3 0.1 0.0 1.1 0.8 1.9 12.8 0.3 2.4 0.1 0.7 0.0 0.2 2.0 TNFRSF13B "CD267, IGAD2, TACI" ENSG00000240505 "TNF receptor superfamily member 13B" O14836 17 16929816-16972118 "CD markers, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "intestine: 18.9;lymphoid tissue: 33.0;skeletal muscle: 62.9" "Group enriched" "Detected in some" 4 "B-cells: 117.3;Plasma cells: 143.2" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 41 "memory B-cell: 130.9;naive B-cell: 51.8" "Lineage enriched" "Detected in many" 59 "B-cells: 130.9" "Group enriched" "Detected in some" 9 "Karpas-707: 167.2;RPMI-8226: 106.7;U-266/70: 72.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA030453 Uncertain NA NA "Cluster 19: B-cells - Humoral immune response" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 2: Karpas-707 - Immune response" "Cluster 57: B-cells - Immune response" "HPA030453: AB_10601700" "unprognostic (3.94e-5)" "unprognostic (1.11e-3)" "unprognostic (4.88e-2)" "unprognostic (4.30e-3)" "unprognostic (1.23e-4)" "unprognostic (2.16e-1)" "unprognostic (1.62e-3)" "unprognostic (1.47e-2)" "unprognostic (1.61e-4)" "unprognostic (2.22e-1)" "unprognostic (9.78e-2)" "unprognostic (1.59e-5)" "unprognostic (1.20e-1)" "unprognostic (4.49e-1)" "unprognostic (1.39e-1)" "unprognostic (2.05e-1)" 0.4 0.1 0.3 8.9 0.4 1.1 0.7 0.0 0.5 0.3 0.0 3.4 4.1 0.1 0.0 1.3 0.4 0.5 5.3 0.1 0.3 0.3 0.3 0.8 17.3 0.4 0.3 0.4 0.0 0.0 0.0 0.0 0.9 0.4 2.5 0.3 2.1 0.3 62.9 0.0 18.9 0.1 0.2 33.0 5.2 0.1 0.4 2.0 0.5 0.0 21.6 2.6 0.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 167.2 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.4 0.2 106.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 72.6 0.0 13.5 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 130.9 0.0 0.0 0.0 51.8 0.0 0.1 0.5 0.0 0.0 0.0 2.2 2.7 0.3 0.4 0.0 0.5 0.1 0.3 0.4 0.3 0.9 0.2 0.4 1.2 0.0 0.0 0.0 0.0 117.3 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.7 0.1 0.0 0.0 0.4 1.1 0.0 0.0 0.0 1.1 0.8 0.0 0.0 0.1 0.0 0.0 0.3 0.4 0.0 0.0 0.5 32.0 0.0 0.2 0.0 1.0 0.0 0.1 0.0 0.0 0.0 143.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.6 0.0 6.2 0.0 0.0 0.0 TNFRSF13C "BAFFR, CD268" ENSG00000159958 "TNF receptor superfamily member 13C" Q96RJ3 22 41922032-41926806 "CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "intestine: 33.8;lymphoid tissue: 58.1" "Cell type enriched" "Detected in some" 10 "B-cells: 194.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 36 "memory B-cell: 22.5;naive B-cell: 29.1" "Lineage enriched" "Detected in single" 40 "B-cells: 29.1" "Group enriched" "Detected in some" 6 "REH: 21.0;U-698: 10.9" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "HPA003246, CAB008380" Enhanced NA NA "Cluster 21: B-cells - Adaptive immune response" "Cluster 16: Immune cells - Immune response" "Cluster 14: REH - Unknown function" "Cluster 57: B-cells - Immune response" "CAB008380: AB_590602, HPA003246: AB_1078264" "unprognostic (3.43e-4)" "prognostic favorable (4.44e-7)" "unprognostic (6.52e-2)" "unprognostic (9.10e-2)" "unprognostic (7.64e-3)" "unprognostic (4.83e-3)" "unprognostic (2.89e-2)" "unprognostic (3.78e-3)" "unprognostic (1.95e-1)" "unprognostic (1.27e-1)" "unprognostic (2.51e-2)" "unprognostic (1.66e-1)" "unprognostic (4.79e-8)" "unprognostic (2.21e-1)" "unprognostic (1.89e-1)" "unprognostic (1.77e-1)" "unprognostic (9.44e-2)" 0.8 0.8 2.1 17.7 1.3 6.0 0.5 1.6 1.9 0.2 0.6 2.1 1.2 0.3 0.3 1.5 0.4 1.0 0.4 1.9 2.0 0.8 0.3 1.0 39.0 3.6 2.1 0.1 0.1 0.1 0.2 0.3 2.2 0.5 1.1 0.4 1.7 0.1 2.3 3.3 33.8 0.1 2.7 58.1 2.5 0.7 2.1 3.4 1.1 0.5 54.6 1.8 0.5 2.0 0.3 0.2 1.1 2.3 0.0 0.0 0.4 0.2 0.1 0.2 0.8 0.9 0.5 1.9 0.4 0.2 0.2 0.4 0.7 0.0 0.3 0.4 2.3 0.2 0.4 0.2 0.1 1.7 0.4 0.1 0.0 0.4 0.1 0.1 0.0 0.7 0.4 1.9 0.2 0.7 1.6 1.8 0.7 0.1 0.1 21.0 2.4 1.6 0.0 0.2 1.3 0.3 0.1 0.4 0.3 0.2 0.4 2.2 0.2 0.5 2.5 0.9 0.3 2.0 1.1 10.9 0.1 1.8 0.5 0.7 0.1 0.2 0.2 0.2 0.3 22.5 0.3 0.2 0.1 29.1 0.4 0.4 0.3 0.3 0.3 0.4 0.2 1.1 2.1 1.3 1.6 1.9 1.9 2.0 3.6 2.1 2.2 2.7 2.1 2.0 0.1 0.0 1.1 0.0 194.5 0.1 0.4 0.0 1.2 1.0 1.6 1.3 1.4 0.0 0.0 0.0 0.0 0.2 2.6 0.3 0.0 0.0 0.1 2.6 0.5 0.3 1.2 0.4 0.0 0.0 0.2 0.7 0.5 4.3 0.0 1.5 0.0 0.2 0.1 8.4 0.1 0.1 0.0 0.6 0.0 0.0 0.0 1.3 0.0 6.5 0.3 0.0 0.0 0.0 0.0 0.1 0.3 0.0 18.0 0.3 0.1 0.2 0.0 0.4 0.0 0.5 0.4 1.5 1.4 0.3 0.0 0.1 3.4 0.2 0.4 0.2 TNFRSF4 "ACT35, CD134, OX40, TXGP1L" ENSG00000186827 "TNF receptor superfamily member 4" P43489 1 1211340-1214153 "Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins" "Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 10.3;lymphoid tissue: 13.3" "Cell type enhanced" "Detected in many" "Adipocytes: 112.3;Endothelial cells: 58.0;granulocytes: 67.4;Ionocytes: 40.7;Langerhans cells: 128.1;T-cells: 43.6" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 7 "basophil: 9.7;memory CD4 T-cell: 26.6;NK-cell: 14.7;T-reg: 35.3" "Group enriched" "Detected in many" 17 "granulocytes: 9.7;NK-cells: 14.7;T-cells: 35.3" "Group enriched" "Detected in some" 10 "MOLT-4: 6.2;NB-4: 12.1" "Low region specificity" "Detected in some" "Not detected" "Not detected" CAB016128 Enhanced NA NA "Cluster 35: T-regs - Unknown function" "Cluster 64: Macrophages - Immune response" "Cluster 24: NB-4 - Immune response" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "CAB016128: AB_626897" "unprognostic (2.24e-1)" "unprognostic (8.69e-3)" "unprognostic (1.36e-1)" "unprognostic (8.55e-3)" "unprognostic (1.02e-1)" "prognostic favorable (3.50e-6)" "prognostic unfavorable (6.03e-4)" "unprognostic (3.30e-1)" "unprognostic (1.48e-2)" "unprognostic (7.04e-3)" "unprognostic (1.04e-2)" "unprognostic (1.47e-1)" "prognostic unfavorable (4.52e-6)" "unprognostic (1.61e-1)" "unprognostic (5.46e-2)" "unprognostic (2.42e-1)" "unprognostic (5.91e-2)" 10.2 0.5 0.5 6.2 0.1 0.6 6.7 0.6 0.9 1.9 0.2 3.3 1.7 1.1 0.0 1.0 1.2 0.5 10.3 0.5 0.2 4.1 0.7 6.3 6.5 0.3 0.2 0.8 1.2 0.2 1.6 1.8 0.3 3.7 0.2 0.0 1.8 0.7 2.1 1.1 5.2 0.2 0.3 13.3 2.6 0.3 0.5 1.8 4.6 0.4 1.5 1.7 1.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.2 12.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.7 0.0 0.3 0.4 0.0 3.0 0.0 26.6 2.8 0.0 0.0 2.3 0.1 0.3 14.7 0.0 1.1 35.3 2.8 0.5 0.1 0.6 0.9 0.5 0.2 0.3 0.2 0.3 0.3 0.5 0.4 112.3 0.0 0.0 0.3 11.1 9.1 0.3 0.9 0.0 0.3 1.0 2.4 1.7 0.0 0.1 0.0 0.0 0.0 25.6 0.0 0.0 0.9 0.0 0.6 3.8 58.0 0.0 2.7 0.7 0.2 0.4 7.7 0.0 0.6 67.4 0.0 13.9 0.4 1.9 0.0 0.1 0.3 40.7 1.9 128.1 0.0 0.3 9.6 10.6 1.0 18.4 0.0 8.2 1.5 0.1 0.0 0.0 0.4 26.2 0.4 0.0 0.2 0.1 0.2 0.0 17.8 2.0 0.0 0.2 0.1 8.4 0.1 43.6 2.5 0.1 0.2 TYK2 JTK1 ENSG00000105397 "Tyrosine kinase 2" P29597 19 10350529-10380572 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Distal tubular cells: 52.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "NB-4: 206.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005157 Uncertain Approved Cytosol NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 24: NB-4 - Immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" Cytosol "HPA005157: AB_1858480" "unprognostic (1.60e-2)" "unprognostic (6.12e-3)" "unprognostic (3.67e-2)" "prognostic favorable (9.62e-4)" "unprognostic (7.61e-2)" "prognostic favorable (1.05e-5)" "unprognostic (1.20e-2)" "unprognostic (6.16e-3)" "unprognostic (4.93e-2)" "unprognostic (1.90e-2)" "prognostic favorable (1.02e-4)" "unprognostic (1.24e-2)" "prognostic unfavorable (4.43e-4)" "unprognostic (2.10e-3)" "unprognostic (1.78e-1)" "unprognostic (4.19e-1)" "prognostic favorable (4.16e-4)" 53.0 60.5 69.9 37.0 71.9 82.6 52.5 70.7 82.3 55.8 72.2 51.5 29.4 44.8 22.6 46.2 49.0 26.2 65.0 69.6 68.8 77.3 111.2 72.6 51.5 75.1 71.4 56.4 65.1 28.6 66.2 20.1 71.5 64.5 25.7 25.2 50.8 20.6 41.3 51.1 73.9 23.5 70.2 140.8 54.6 16.6 71.8 54.4 60.2 33.7 51.8 49.3 46.0 76.4 29.1 41.1 24.1 38.0 31.9 44.2 23.5 38.9 39.1 48.1 52.2 31.5 18.7 44.5 44.5 43.4 32.8 28.4 29.4 45.5 24.2 78.0 45.5 81.4 90.5 80.2 49.4 34.4 89.4 43.2 31.3 54.5 32.2 29.9 46.5 56.6 35.0 116.1 42.3 90.1 50.7 206.9 7.7 28.4 71.8 49.9 21.1 45.1 40.0 90.1 22.4 28.0 37.6 38.6 28.1 18.4 21.5 57.2 41.1 61.7 22.7 74.1 45.9 97.2 81.4 40.2 32.4 70.8 36.6 9.8 20.8 27.2 12.8 15.2 7.9 7.5 7.6 11.6 23.5 8.0 5.0 7.1 33.0 8.6 15.7 13.0 10.1 13.0 69.9 71.9 70.7 82.3 69.6 68.8 75.1 71.4 71.5 70.2 71.8 76.4 18.6 12.8 17.9 13.1 17.5 6.6 5.4 7.6 13.1 9.2 10.3 11.0 25.7 11.5 11.1 9.2 4.2 7.0 23.2 14.6 52.8 7.6 2.1 10.2 12.6 12.8 4.8 8.6 10.4 11.1 9.7 11.1 27.0 12.0 19.6 17.1 15.4 27.1 14.6 0.0 9.2 8.7 8.2 28.2 14.6 8.8 7.5 30.8 16.0 12.2 25.3 8.7 17.5 11.1 11.1 11.8 12.9 9.8 19.5 5.9 12.1 29.0 11.2 11.0 0.0 10.5 12.6 1.5 4.5 8.8 7.2 6.7 19.4 13.6 11.1 6.3 UNC13D Munc13-4 ENSG00000092929 "Unc-13 homolog D" Q70J99 17 75827225-75844552 "Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins" Exocytosis "Familial hemophagocytic lymphohistiocytosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 58.9;lymphoid tissue: 66.2" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 68.3;Hofbauer cells: 58.5;NK-cells: 61.8;Pancreatic endocrine cells: 47.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 245.7;HeLa: 136.3;HMC-1: 245.9;SK-BR-3: 189.7" "Region enriched" "Detected in single" 6 "cerebellum: 5.0" "Low region specificity" "Detected in many" "HPA067117, HPA073525" Enhanced Supported Vesicles,Cytosol NA NA 1500000 "Cluster 38: Basophils - Unknown function" "Cluster 2: Immune cells - Immune response" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 63: NK-cells & T-cells - Immune response" Cytosol Vesicles "HPA067117: AB_2685784, HPA073525: AB_2686615" "unprognostic (6.79e-3)" "unprognostic (4.36e-2)" "unprognostic (1.73e-1)" "prognostic unfavorable (3.62e-4)" "unprognostic (2.98e-2)" "unprognostic (1.42e-3)" "unprognostic (3.93e-1)" "unprognostic (1.37e-2)" "unprognostic (2.74e-1)" "unprognostic (1.31e-2)" "prognostic unfavorable (6.01e-4)" "unprognostic (1.89e-1)" "prognostic unfavorable (5.28e-12)" "unprognostic (3.27e-2)" "unprognostic (5.58e-2)" "unprognostic (1.56e-1)" "unprognostic (8.59e-2)" 7.7 7.3 5.6 23.5 6.8 58.9 7.8 5.8 7.3 18.6 5.0 10.7 8.0 8.6 2.0 23.6 13.8 6.5 14.3 5.0 5.6 6.6 12.6 38.1 25.9 7.9 6.5 19.3 8.8 0.5 11.6 9.0 7.5 8.1 4.5 5.5 7.7 5.1 8.5 6.0 18.5 4.9 6.2 66.2 13.8 6.1 8.2 20.7 5.9 1.5 17.6 10.7 19.6 8.7 44.0 18.7 0.4 0.3 0.5 1.0 47.6 0.1 0.0 0.0 0.1 41.4 97.0 3.4 46.4 0.0 7.5 15.4 0.0 2.2 0.0 0.4 0.5 245.7 136.3 24.2 3.9 94.1 245.9 0.6 2.0 0.5 2.1 2.3 17.9 42.5 87.1 1.1 0.0 71.2 100.9 50.8 0.9 69.9 1.7 32.8 1.0 1.5 1.6 17.7 0.3 66.7 19.2 189.7 0.9 0.5 47.1 56.5 48.1 0.8 65.9 0.5 0.5 1.3 5.9 4.0 0.6 31.3 0.2 59.1 16.0 31.2 19.3 16.9 17.4 6.7 11.4 13.6 12.3 3.6 8.8 11.9 40.1 14.7 25.6 7.2 10.8 18.1 5.6 6.8 5.8 7.3 5.0 5.6 7.9 6.5 7.5 6.2 8.2 8.7 3.8 44.8 8.3 6.8 16.6 1.1 1.7 1.0 0.6 12.0 4.9 2.4 68.3 7.2 4.4 3.7 20.9 4.7 27.0 40.9 0.0 7.2 5.3 1.3 3.3 6.6 6.0 14.9 1.2 6.0 11.6 2.2 2.0 2.3 45.0 9.9 7.9 1.2 58.5 5.0 1.5 3.6 2.0 21.6 8.2 0.5 2.8 22.2 1.8 5.6 22.5 4.5 61.8 3.0 7.9 47.3 30.7 1.5 27.4 1.6 5.5 0.7 1.6 16.2 0.0 4.5 2.6 1.2 1.4 1.5 1.4 25.9 30.9 2.0 6.3 2.3 UNG "DGU, HIGM4, UDG, UNG1, UNG2" ENSG00000076248 "Uracil DNA glycosylase" P13051 12 109097597-109110992 "Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction" Hydrolase "Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 64.9;Spermatogonia: 74.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB011605 Uncertain Approved Cytosol NA Yes "Cluster 16: MAIT-cells - Unknown function" "Cluster 39: Non-specific - Mitochondria" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Cytosol "CAB011605: AB_778737" "unprognostic (4.38e-2)" "unprognostic (3.82e-3)" "unprognostic (1.03e-2)" "unprognostic (1.33e-2)" "unprognostic (4.64e-1)" "unprognostic (4.10e-2)" "prognostic unfavorable (6.40e-4)" "unprognostic (5.68e-3)" "prognostic unfavorable (3.06e-4)" "unprognostic (4.66e-2)" "unprognostic (8.78e-3)" "unprognostic (1.91e-1)" "unprognostic (1.35e-3)" "unprognostic (2.57e-2)" "unprognostic (4.50e-1)" "unprognostic (1.40e-2)" "unprognostic (6.89e-2)" 19.8 56.7 32.4 14.7 32.4 16.0 23.1 30.1 34.8 16.6 27.7 28.0 17.1 14.5 12.7 29.7 15.6 10.4 21.1 29.2 34.9 27.5 32.2 9.6 18.0 32.2 31.4 15.7 12.4 33.2 10.9 17.8 34.1 13.6 29.3 6.8 17.7 17.6 43.0 32.7 18.8 14.5 31.6 16.1 17.7 24.3 33.5 22.8 22.2 33.5 27.0 13.5 20.1 30.8 77.1 77.5 72.8 66.6 118.6 33.8 69.5 44.4 30.1 68.6 52.3 61.7 51.6 100.3 65.1 40.2 35.9 47.6 81.4 46.0 66.4 85.6 150.9 98.1 41.1 105.5 17.7 147.6 58.2 30.7 41.6 33.0 18.3 54.6 50.4 117.8 80.9 32.5 47.0 96.2 136.8 173.6 130.0 124.2 117.7 123.9 109.8 85.9 43.4 95.6 103.3 57.4 79.6 67.8 39.5 94.2 126.2 68.2 26.0 59.1 52.7 39.3 62.5 62.6 145.0 190.5 44.8 97.7 73.8 12.9 2.7 5.0 22.4 5.3 31.6 16.0 25.5 25.6 6.8 17.2 16.4 18.4 0.0 16.5 5.5 4.9 25.5 14.4 32.4 32.4 30.1 34.8 29.2 34.9 32.2 31.4 34.1 31.6 33.5 30.8 26.6 0.0 4.8 16.0 9.2 18.0 11.0 13.2 25.0 2.6 21.7 14.1 12.4 7.2 5.0 42.3 4.2 64.9 12.5 14.7 19.6 14.4 3.4 7.6 15.0 17.7 8.4 32.4 7.0 6.2 38.1 12.6 14.3 9.9 7.6 24.8 20.3 20.8 18.3 5.0 6.2 21.4 10.2 3.8 5.4 4.2 14.0 5.5 14.2 6.5 3.8 15.8 7.2 6.6 4.0 5.0 10.3 14.7 16.7 6.8 9.3 20.2 3.2 3.5 6.6 10.2 11.5 21.9 74.6 37.8 20.9 20.4 15.3 25.7 40.4 9.7 WAS "IMD2, THC, WASP, WASPA" ENSG00000015285 "WASP actin nucleation promoting factor" P42768 X 48676596-48691427 "Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease variant" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 58.4;lymphoid tissue: 83.0" "Cell type enhanced" "Detected in many" "B-cells: 83.2;dendritic cells: 91.7;Hofbauer cells: 111.5;Kupffer cells: 110.7;Macrophages: 118.1;monocytes: 88.2;NK-cells: 84.5;Plasma cells: 57.8;T-cells: 99.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "eosinophil: 37.4" "Group enriched" "Detected in all" 4 "granulocytes: 37.4;monocytes: 9.5" "Cell line enhanced" "Detected in some" "Daudi: 76.5;HEL: 67.6;HMC-1: 157.0;MOLT-4: 70.8;NB-4: 75.7;RPMI-8226: 94.0;THP-1: 68.8;U-266/70: 83.1;U-937: 87.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002022, CAB004290" Enhanced Approved "Plasma membrane,Cytosol" NA NA 600000 "Cluster 52: Eosinophils - Transcription" "Cluster 2: Immune cells - Immune response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" "Plasma membrane" Cytosol "CAB004290: AB_628445, HPA002022: AB_1080581" "unprognostic (1.43e-3)" "unprognostic (2.09e-3)" "unprognostic (2.36e-2)" "prognostic favorable (4.95e-4)" "unprognostic (9.89e-2)" "prognostic favorable (3.78e-4)" "unprognostic (5.12e-3)" "unprognostic (7.60e-2)" "unprognostic (1.54e-2)" "unprognostic (2.86e-1)" "unprognostic (7.40e-2)" "unprognostic (3.60e-1)" "prognostic unfavorable (5.58e-6)" "unprognostic (2.24e-1)" "unprognostic (2.37e-2)" "unprognostic (3.55e-2)" "unprognostic (1.71e-1)" 10.2 5.2 6.3 52.2 5.8 58.4 4.4 5.9 8.1 3.3 6.3 6.4 8.0 2.8 3.0 3.5 5.6 6.9 3.5 6.0 8.0 4.4 7.2 19.1 54.2 11.1 8.2 1.8 2.4 1.4 2.9 9.0 8.6 4.2 5.0 0.4 4.9 2.8 1.4 2.8 23.0 6.1 8.0 83.0 7.0 1.9 8.6 42.0 3.5 3.4 36.2 10.3 3.0 10.8 0.8 0.2 0.4 1.0 0.0 0.0 0.2 0.0 0.0 0.2 0.2 0.6 0.9 76.5 0.3 0.0 0.3 2.0 0.3 0.2 0.0 44.2 0.4 67.6 0.9 0.0 0.8 34.9 157.0 0.3 0.1 0.1 0.0 0.0 0.0 40.3 0.7 45.7 0.0 7.6 70.8 75.7 0.4 1.1 0.4 61.1 0.3 94.0 0.1 0.0 0.5 0.9 1.0 0.7 0.5 0.2 0.4 68.8 0.5 0.1 0.4 1.2 0.1 83.1 43.6 53.7 0.5 87.4 0.2 3.3 7.6 37.4 4.6 8.4 3.4 3.0 3.5 3.9 5.7 3.3 3.1 3.5 29.2 3.6 9.5 3.1 5.4 4.0 6.3 5.8 5.9 8.1 6.0 8.0 11.1 8.2 8.6 8.0 8.6 10.8 1.5 3.2 14.3 0.7 83.2 2.4 0.2 0.2 2.2 0.2 1.1 1.8 1.1 0.0 0.1 0.0 0.0 0.9 91.7 0.3 1.9 0.4 0.6 0.4 0.4 2.6 1.2 14.1 0.3 0.4 1.1 1.5 5.6 0.3 48.1 0.2 3.9 1.6 111.5 0.0 0.3 0.2 0.0 110.7 54.5 1.1 0.0 118.1 3.6 4.7 88.2 0.2 84.5 0.5 0.0 0.1 0.1 0.0 57.8 0.2 0.1 1.8 1.6 0.2 0.0 1.0 1.3 1.3 1.1 0.8 1.4 1.4 99.3 0.4 0.1 0.2 WIPF1 "WASPIP, WIP" ENSG00000115935 "WAS/WASL interacting protein family member 1" O43516 2 174559572-174682916 "Disease related genes, Human disease related genes, Predicted intracellular proteins" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 126.9" "Cell type enhanced" "Detected in many" "dendritic cells: 172.7;monocytes: 187.2;NK-cells: 245.1;Oligodendrocytes: 217.2;Plasma cells: 162.8;T-cells: 208.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 209.1;Karpas-707: 296.8;U-266/70: 233.0" "Low region specificity" "Detected in all" "HPA003739, CAB009737, HPA070706" Enhanced Approved "Plasma membrane,Cytosol" No No 520000 "Cluster 5: Granulocytes - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 63: NK-cells & T-cells - Immune response" Cytosol "Plasma membrane" "CAB009737: AB_2288577, HPA003739: AB_1858783, HPA070706: AB_2686300" "unprognostic (4.76e-2)" "unprognostic (4.80e-2)" "unprognostic (1.49e-1)" "unprognostic (9.88e-2)" "unprognostic (1.87e-1)" "unprognostic (2.27e-3)" "unprognostic (2.05e-1)" "unprognostic (1.21e-1)" "unprognostic (7.22e-2)" "unprognostic (1.26e-1)" "unprognostic (3.25e-2)" "unprognostic (1.46e-1)" "prognostic unfavorable (1.14e-4)" "unprognostic (3.65e-2)" "unprognostic (5.43e-2)" "unprognostic (1.58e-1)" "unprognostic (2.50e-2)" 31.0 14.7 14.2 93.0 37.2 56.8 21.0 36.1 20.5 30.6 11.1 26.0 18.2 22.4 11.5 14.2 14.4 34.8 16.0 14.9 28.8 13.0 16.4 31.8 126.9 46.2 38.6 12.3 7.3 12.9 4.8 33.5 42.3 14.9 20.8 3.4 17.7 23.0 5.9 9.9 32.5 29.1 27.9 89.7 21.8 4.7 35.1 66.4 15.4 11.5 110.5 31.5 17.0 53.8 0.7 7.0 16.3 0.2 40.4 70.9 16.9 31.1 26.4 12.1 18.7 1.9 1.4 209.1 9.2 47.0 15.6 0.5 2.8 0.0 15.1 144.8 4.1 106.5 26.9 0.0 15.1 94.9 167.2 29.6 5.1 27.7 2.6 16.0 25.0 18.7 3.3 296.8 34.4 0.1 106.6 87.1 19.1 0.0 1.4 90.0 6.6 37.9 11.3 0.7 2.6 33.8 0.3 8.8 18.7 30.4 0.4 46.8 21.2 41.0 11.5 30.1 29.9 233.0 165.2 113.7 60.4 64.7 111.7 41.5 35.4 87.2 71.6 37.3 59.4 35.1 47.6 71.1 26.1 28.6 38.0 51.4 166.1 57.4 43.7 11.2 57.7 54.7 14.2 37.2 36.1 20.5 14.9 28.8 46.2 38.6 42.3 27.9 35.1 53.8 32.1 19.2 21.7 27.7 134.5 12.5 6.3 0.9 2.8 2.1 3.3 4.3 10.5 1.5 4.6 3.7 25.0 2.0 172.7 0.3 5.9 1.7 40.2 3.3 21.9 30.8 4.9 30.1 5.3 11.6 82.5 40.5 9.7 2.1 67.2 2.1 36.8 3.7 86.2 0.0 7.2 1.6 0.0 142.2 128.0 96.9 25.1 139.8 26.6 98.4 187.2 1.2 245.1 120.6 217.2 16.8 0.8 18.0 162.8 5.0 0.2 35.9 0.1 3.4 13.1 15.7 21.4 4.4 4.1 1.2 11.1 4.1 208.1 8.8 2.1 3.1 XIAP "API3, BIRC4, hILP, ILP-1" ENSG00000101966 "X-linked inhibitor of apoptosis" P98170 X 123859724-123913976 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway, Wnt signaling pathway" "Protease inhibitor, Thiol protease inhibitor, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009203, HPA042428" Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Cluster 38: Basophils - Unknown function" "Cluster 8: Non-specific - Mitochondria" "Cluster 18: U-2197 - ECM organization" "Cluster 53: Intestinal epithelial cells - Unknown function" "Nucleoplasm, Cytosol" "Plasma membrane" "CAB009203: AB_2257167, HPA042428: AB_2677993" "prognostic unfavorable (9.21e-4)" "unprognostic (8.43e-2)" "unprognostic (1.50e-2)" "unprognostic (2.14e-1)" "unprognostic (1.40e-1)" "unprognostic (9.41e-2)" "unprognostic (1.95e-2)" "unprognostic (8.51e-2)" "unprognostic (9.17e-2)" "unprognostic (3.90e-2)" "unprognostic (7.50e-2)" "unprognostic (4.41e-2)" "unprognostic (3.15e-3)" "unprognostic (8.21e-3)" "unprognostic (2.26e-1)" "unprognostic (4.99e-2)" "unprognostic (4.65e-2)" 9.2 7.7 6.5 9.2 7.5 8.3 9.7 6.8 7.0 9.6 12.9 12.4 10.1 8.4 10.0 11.5 7.4 8.6 7.8 5.8 8.2 11.8 12.1 8.5 10.4 7.6 8.1 7.5 8.3 18.4 6.3 8.6 7.3 8.5 10.1 21.4 8.6 7.4 10.3 8.8 10.1 7.4 8.5 10.4 10.2 4.2 8.1 8.9 14.9 11.9 8.6 9.6 6.1 10.3 15.8 13.2 10.2 8.8 11.8 15.0 13.3 16.9 12.4 8.9 7.7 5.9 17.9 14.7 24.3 14.4 17.1 5.6 15.3 10.5 16.3 15.5 8.3 9.9 11.1 9.2 14.9 18.1 19.7 10.4 16.0 14.9 19.0 10.2 12.7 10.8 15.9 16.4 17.6 16.5 10.2 8.8 8.4 15.6 10.3 10.8 11.9 15.6 13.4 22.6 6.8 10.0 22.9 13.0 13.5 9.0 8.0 8.7 15.7 0.5 6.0 27.0 18.9 13.8 14.9 15.8 18.3 12.7 11.5 9.3 1.8 2.6 3.3 1.5 3.0 3.1 2.4 3.6 1.0 4.0 2.7 1.9 5.6 2.4 2.9 2.9 1.8 1.5 6.5 7.5 6.8 7.0 5.8 8.2 7.6 8.1 7.3 8.5 8.1 10.3 50.0 80.1 91.6 26.4 42.1 26.6 36.3 35.0 28.5 72.1 29.7 19.9 44.5 44.3 55.2 53.3 95.9 17.9 41.7 122.9 27.4 36.0 2.7 38.4 44.9 55.0 47.4 23.5 30.0 54.0 30.0 38.4 39.8 50.4 60.7 30.9 64.2 85.8 29.0 75.7 34.9 62.2 26.4 43.6 33.0 4.1 42.6 44.2 8.8 29.0 45.8 45.8 55.6 32.6 41.9 65.4 53.5 51.6 39.5 53.0 59.2 59.8 50.6 133.7 65.7 43.6 34.9 15.2 21.0 30.8 35.5 38.0 40.8 30.0 48.0 68.1 ZAP70 "SRK, STD, ZAP-70" ENSG00000115085 "Zeta chain of T cell receptor associated protein kinase 70" P43403 2 97713576-97739862 "Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Adaptive immunity, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Disease variant, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 24.8;lymphoid tissue: 79.9" "Group enriched" "Detected in many" 4 "dendritic cells: 101.0;NK-cells: 155.5;T-cells: 105.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 41 "gdT-cell: 137.4;MAIT T-cell: 93.2;memory CD4 T-cell: 71.7;memory CD8 T-cell: 108.3;naive CD4 T-cell: 50.8;naive CD8 T-cell: 79.8;NK-cell: 112.2;T-reg: 80.1" "Group enriched" "Detected in many" 56 "NK-cells: 112.2;T-cells: 137.4" "Group enriched" "Detected in some" 11 "JURKAT: 121.0;MOLT-4: 183.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002625, HPA003134" Enhanced NA NA 14000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 3: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" "CAB002625: , HPA003134: AB_1080629" "unprognostic (4.11e-3)" "prognostic favorable (6.89e-5)" "unprognostic (3.82e-3)" "prognostic favorable (9.66e-8)" "unprognostic (5.78e-2)" "prognostic favorable (3.93e-6)" "unprognostic (2.30e-3)" "unprognostic (1.09e-3)" "unprognostic (3.30e-1)" "unprognostic (1.37e-2)" "unprognostic (9.23e-3)" "unprognostic (2.70e-1)" "prognostic unfavorable (3.02e-8)" "unprognostic (1.29e-1)" "unprognostic (1.65e-1)" "unprognostic (6.40e-2)" "unprognostic (5.83e-3)" 3.3 1.3 0.5 28.0 0.6 24.8 1.9 0.5 0.9 1.7 0.7 4.0 5.8 1.4 0.5 2.3 2.2 5.4 1.4 0.5 0.7 2.8 3.9 8.7 57.0 0.8 1.3 0.8 1.0 0.4 1.1 0.9 0.7 2.5 1.5 0.0 2.3 0.8 2.0 2.4 18.5 0.5 0.6 35.5 6.7 2.7 1.2 79.9 3.5 2.8 17.7 4.9 2.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.1 0.0 121.0 0.0 0.7 0.0 0.0 183.4 0.5 0.1 0.0 0.0 7.2 0.1 9.1 0.0 0.0 0.2 0.2 0.0 0.2 0.1 0.6 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 14.1 0.1 0.0 0.0 0.3 0.3 0.5 137.4 0.4 93.2 0.2 71.7 108.3 0.3 1.6 50.8 79.8 2.2 112.2 1.0 0.9 80.1 64.2 0.5 0.6 0.5 0.9 0.5 0.7 0.8 1.3 0.7 0.6 1.2 0.6 0.8 9.6 13.6 0.3 3.9 1.5 0.0 0.0 0.0 0.0 0.8 0.5 3.0 0.0 0.0 0.0 0.0 0.1 101.0 0.2 1.9 0.2 1.0 1.6 0.5 0.8 0.0 8.8 0.2 0.0 0.0 1.8 4.6 0.4 2.5 0.1 2.5 0.7 2.2 0.0 0.2 0.0 0.0 2.8 2.2 0.7 0.0 3.4 1.8 2.8 5.0 0.0 155.5 0.0 0.1 0.0 0.0 0.0 28.0 0.1 0.0 0.5 0.0 0.0 0.0 14.3 0.6 1.3 2.1 0.2 1.4 0.0 105.6 0.1 0.1 0.2 ZBTB24 "BIF1, KIAA0441, PATZ2, ZNF450" ENSG00000112365 "Zinc finger and BTB domain containing 24" O43167 6 109462594-109483219 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Rod photoreceptor cells: 65.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017872, HPA049003" Uncertain Approved "Nucleoplasm,Cytokinetic bridge,Centrosome" Yes No "Cluster 37: B-cells - Transcription" "Cluster 34: Non-specific - Transcription" "Cluster 30: Epithelial cell lines - Translation" "Cluster 46: Photoreceptor cells - Phototransduction" Nucleoplasm "Cytokinetic bridge, Centrosome" "HPA017872: AB_2669673, HPA049003: AB_2680596" "unprognostic (8.15e-2)" "unprognostic (1.56e-1)" "unprognostic (1.03e-1)" "unprognostic (1.41e-1)" "unprognostic (4.80e-2)" "unprognostic (1.98e-2)" "prognostic unfavorable (3.15e-4)" "unprognostic (4.53e-2)" "unprognostic (5.09e-2)" "unprognostic (3.31e-2)" "unprognostic (1.22e-3)" "unprognostic (1.37e-1)" "unprognostic (1.75e-3)" "unprognostic (1.26e-1)" "unprognostic (2.69e-1)" "unprognostic (2.60e-1)" "unprognostic (6.77e-2)" 3.1 2.2 1.5 5.4 2.4 8.9 4.6 2.4 2.4 4.0 1.0 3.5 3.6 3.1 3.2 3.0 2.9 2.5 2.2 1.6 1.9 3.9 2.6 3.9 8.7 1.5 1.2 3.4 3.5 7.4 1.8 3.2 1.6 3.5 3.8 10.1 4.4 3.3 3.2 4.7 3.7 2.8 1.3 5.5 4.1 4.3 1.6 6.9 4.9 2.9 7.3 3.5 2.7 2.9 4.7 4.8 4.3 10.8 6.8 6.9 7.0 5.3 7.3 6.5 7.4 6.7 3.6 20.0 6.7 6.7 7.8 6.0 10.9 8.3 9.8 12.4 10.7 16.2 6.5 5.1 5.0 13.3 8.0 7.0 6.7 6.6 11.4 4.6 5.5 9.3 13.8 11.0 6.8 8.0 19.2 9.0 10.7 4.7 5.3 11.9 6.1 8.3 8.0 8.0 7.3 6.4 6.8 7.1 16.9 5.9 5.0 14.5 5.4 5.3 5.3 4.4 11.5 5.3 4.4 20.2 7.0 10.4 9.0 0.1 0.6 0.9 0.7 0.6 0.4 3.4 1.5 0.9 0.7 2.8 1.9 1.1 0.4 1.3 0.8 1.1 2.9 0.5 1.5 2.4 2.4 2.4 1.6 1.9 1.5 1.2 1.6 1.3 1.6 2.9 8.4 12.8 9.1 2.6 32.8 10.1 11.2 5.3 7.4 21.7 8.6 7.4 3.8 7.2 5.2 3.7 31.3 8.5 16.8 4.5 3.9 6.6 1.4 7.3 14.3 6.6 9.6 12.0 3.3 9.1 9.9 8.6 12.8 10.7 9.5 14.1 3.6 7.3 7.7 10.1 2.8 11.0 6.1 12.5 12.1 1.8 7.2 10.3 8.8 5.6 20.5 10.0 14.4 1.0 5.4 6.4 5.1 6.4 16.8 8.2 7.4 6.4 6.0 65.2 0.0 13.2 7.4 6.2 27.8 9.3 9.7 7.8 17.8 15.0 8.5 7.3 ZNF341 dJ553F4.3 ENSG00000131061 "Zinc finger protein 341" Q9BYN7 20 33731657-33792269 "Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Disease variant" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Excitatory neurons: 11.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023240, HPA024607, HPA067108" Uncertain Approved "Nucleoplasm,Nuclear bodies,Vesicles" Yes No "Cluster 34: Basophils - Unknown function" "Cluster 59: Non-specific - Translation" "Cluster 28: BEWO - Transcription regulation" "Cluster 53: Intestinal epithelial cells - Unknown function" "Nucleoplasm, Vesicles" "Nuclear bodies" "HPA023240: AB_1859207, HPA024607: AB_1859208, HPA067108: AB_2685780" "unprognostic (1.74e-1)" "unprognostic (2.18e-1)" "unprognostic (3.73e-1)" "unprognostic (2.10e-1)" "unprognostic (9.31e-2)" "prognostic favorable (3.93e-4)" "prognostic unfavorable (1.87e-4)" "unprognostic (2.44e-1)" "unprognostic (1.70e-1)" "unprognostic (1.80e-1)" "unprognostic (7.38e-2)" "unprognostic (9.31e-2)" "unprognostic (8.17e-5)" "unprognostic (4.84e-2)" "unprognostic (2.90e-1)" "unprognostic (8.67e-3)" "unprognostic (3.68e-2)" 1.2 0.9 1.0 1.9 1.1 2.4 0.9 0.8 2.2 1.1 0.0 1.5 1.4 1.3 1.0 1.3 1.3 0.9 1.0 1.6 0.2 0.6 0.6 1.1 1.9 0.3 0.1 1.3 1.6 0.9 0.6 1.4 0.4 1.3 1.1 0.7 1.5 1.0 3.3 2.1 1.0 1.2 0.2 1.9 1.4 1.5 0.5 1.8 0.9 3.3 1.2 1.2 1.1 1.3 2.4 6.4 2.2 4.7 2.1 1.7 9.5 2.3 1.2 1.9 1.2 4.6 5.4 3.7 3.8 1.7 2.2 3.7 2.4 4.1 0.8 3.3 2.2 3.6 3.6 3.7 1.2 2.1 4.3 1.4 3.0 1.6 1.0 1.7 2.3 3.4 1.9 1.7 2.0 2.9 1.9 1.6 3.0 3.5 3.1 2.4 1.4 2.1 1.3 5.2 1.9 2.1 6.1 5.6 1.4 1.7 5.0 1.7 2.9 3.4 1.4 2.5 2.2 1.3 1.9 3.4 3.3 1.7 2.4 2.6 1.3 2.9 1.1 1.8 1.0 2.2 0.8 0.7 1.0 1.2 0.5 1.5 2.5 1.3 1.2 0.7 0.6 0.9 1.0 1.1 0.8 2.2 1.6 0.2 0.3 0.1 0.4 0.2 0.5 1.3 1.8 3.2 5.1 5.5 2.9 0.4 1.0 1.5 0.6 2.2 1.9 1.4 2.7 2.8 4.7 1.8 2.1 2.6 0.9 7.0 0.0 1.5 0.6 1.6 1.4 1.4 1.2 0.8 11.3 1.4 3.3 1.6 6.6 2.1 2.5 1.8 1.4 1.0 1.4 1.7 8.0 2.0 2.0 1.6 2.0 0.1 0.6 2.4 0.0 3.7 1.2 0.6 2.1 6.0 7.7 1.7 2.5 0.4 2.6 2.5 4.2 0.4 4.6 2.3 0.0 1.9 1.1 1.6 2.4 1.6 1.0 2.1 1.9 1.5 2.4 2.5